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“Do not go where the path may lead, go where there is no 
path and leave a trail.”  








 “The value of an idea lies in the using of it.”  








 “Success consists of going from failure to failure without 
loss of enthusiasm.”  
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Chemotherapy has grown, from chemotherapeutic agents discovered in the 1940s still 
used today, such as vincristine, to antibody therapies developed in the 1990s such as 
trastuzumab. Antibody drug conjugates (ADCs) are a class of drug that have been 
theorized about since the turn of the 20th century, they are a potent cytotoxic drug and 
an antibody combined. Trastuzumab emtansine, licensed in 2013, has broken headlines, 
as it outperforms current gold standard therapies, but costs £90K per patient a year.  
 
Stability studies performed on aseptically prepared biopharmaceuticals, conforming to 
the requirements set out in the NHS’s ‘A Standard Protocol for Deriving and Assessment 
of Stability. Part 2’ allow the shelf life of products prepared under a Section 10 
exemption or a Specials License to be extended beyond their summary of products 
characteristics shelf life (typically 24-48 hours). Shelf life extensions have many benefits 
e.g. reducing logistics issues for product storage and transportation, a safety net of time 
in case a product cannot be administered, batch production minimising drug wastage, 
which allows prices of medicines to be reduced. 
 
The work herein details research dedicated to enabling a stability study to be performed 
on the ADC, trastuzumab emtansine. We identified and validated many techniques for 
characterisation of the biopharmaceutical infliximab and published an NHS compliant 
stability study. A 7-day shelf life can be applied to infliximab by all UK hospitals. These 
techniques were then evaluated by their ability to characterise trastuzumab emtansine 
and if they remained stability indicating, a minimum requirement for a stability study. 
Where necessary, methods were optimised or developed anew, to enable full 
characterisation of the ADC trastuzumab emtansine. This involved validation of a new 
chromatography method, the design, construction and validation of an infrared 
spectroscopy method, and creative thinking to overcome low sensitivity of intact LC-MS. 
This allowed a stability study to be performed and a shelf life extension for trastuzumab 
emtansine was achieved. Furthermore, some preliminary work regarding ADC in use 
safety and the applicability of the developed methods regarding differently designed 
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Chapter 1. Introduction 
1  
1.1  Cytotoxic Chemotherapy 
 
1.1.1 The development of cytotoxic chemotherapy 
 
During World War 2, an American ship secretly carrying bombs containing 100 
tons of chlormethine (1) was destroyed while docked in Bari, Italy during a German air 
raid on the city. Chlormethine, is a nitrogen mustard and survivors of the attack 
exhibited unusual symptoms for a simple air strike. Dr Stewart Alexander was sent to 
aid their treatment and investigate the cause of their unusual symptoms. He found 
evidence of the mustard gas bombs in the wreckage of the American ship and noted 
that the people affected by the mustard gas had reduced white blood cell counts, 
suggesting nitrogen mustards were toxic to white blood cells.1 Based on Dr Alexander’s 
observations, Dr Alfred Gilman and Dr Louis Goodman hypothesised nitrogen mustards 
would also kill cancerous white blood cells.  They performed a single patient experiment 
on a man with advanced lymphoma, a cancer of white blood cells. He agreed to an 
experimental treatment that involved having intravenous injections of a nitrogen 
mustard.2 The patient responded to this therapy and his tumours decreased in size 
allowing him to swallow, eat and sleep. This trial is considered the first recorded use of 
cytotoxic chemotherapy.2 
 
In 1948 Dr Sydney Farber published a paper documenting the first complete 
remission of leukaemia using the chemotherapeutic agent aminopterin (2).3 This paved 
the way for Farber’s subsequent work on chemotherapeutic agents, many of which are 
still used today. For example vincristine (3), which increased leukaemia remission rates 
above 80% 4 and methotrexate (4),5 (Figure 1.1). Faber’s work on methotrexate 
identified that the chemotherapy dosing regimen must be designed to limit the toxic 
side effects. He proposed shorter infusions with a more concentrated solution to be 
administered once every three weeks to lessen the side effects while retaining the 
2 
 
therapeutic activity.5  The general public perceived chemotherapy as very dangerous, 
this is because many patients died while suffering from chemotherapy’s extreme side 
effects and very few had sustained remission. Farber’s work increased the survivability 
of patients receiving chemotherapy and improved its public perception.  
 
Most early research was directed at blood cell cancers, as intravenous infusions 
allowed the drugs to readily reach their targets. Solid tumours, such as breast cancer 
and stomach carcinomas, are harder for drugs to reach and therefore harder to treat. 
Nonetheless, work undertaken by Roy Hertz demonstrated how methotrexate could 
affect choriocarcinomas (cancers of the uterus).6 William Wilson demonstrated how 5-
fluorouracil (5-FU, 5) could be used to treat solid cancers as a monotherapy (Figure 1.2).7  
In addition, some people began experimenting with adjuvant therapy, administering 5-
FU (5) following surgical removal of tumour tissue.8  Adjuvant therapy drastically 
improved solid tumours remission rates and many tumours became more treatable than 
ever before. 
 
Figure 1.1. The chemical structures of the cytotoxic chemotherapy agents Chlormethine (1), 


















































While in 1957 Dr Ellison had been investigating combination therapy,9 the co-
administration of two or more chemotherapeutic agents, following a publication by Dr 
Law regarding the effectiveness of combination therapy on drug resistant cancers, 10  it 
was in the 1960’s when combination therapy really took off, with the introduction of 
two particular chemotherapy regimens. The first regimen used vincristine (3), 
methotrexate (4), 6-mercaptopurine (6-MP, 6), and prednisone (7) and was referred to 
as VAMP. 11,12  The second regimen used mechlorethamine (1), vincristine (3), 
prednisone (7) and procarbazine (8) and was referred to as MOPP. 13,14  The VAMP 
regime managed to achieve a remission rate over 50%,15 while the MOPP regimen was 
reported to produce substantial durations of remission in patients compared to the 
standard treatments at the time.14 Combination therapy is still used today, due to 
superior clinical outcomes over monotherapy. This is partly because combination 
therapy slows the development of drug resistance.16 It was well known about bacterial 
cells developing drug resistance during the 1960’s and this served as a good model for 
understanding how combination therapy prevented the development of drug resistance 
in cancer.16 
 
     
(5)      (6) 
  
(7)       (8) 
 
Figure 1.2. Chemical structures of the chemotherapy drugs 5-Fluorouracil (5), 6-Mercaptopurine (6), 































Between 1960 and 1970, Dr Harold Skipper published many papers on 
chemotherapy and made some important advances. These included: the development 
of animal models of cancer which he used to study cancer treatment 17, based on that 
research he proposed a theory that drugs don’t kill a specific number or mass of cancer 
cells but a specific percentage of cancer cells present. 18 Finally he applied the knowledge 
he had gained from his animal models to design chemotherapy regimens to kill the 
entire cancer cell population before it could grow back. 19 
 
Between the period of 1940 and 1970 the treatment of cancer evolved from 
simple surgery or radiation therapy, to adjuvant combination therapies with well-
designed dosing regimens to spare the patient but kill the cancer. However, even with 
these advances, patient mortality remained almost unchanged.20   
 
1.1.2 The drawbacks of cytotoxic chemotherapy 
 
A major problem with traditional chemotherapy was that patients could not 
tolerate higher doses of these non-selective cytotoxic drugs, without suffering from 
potentially fatal side effects. 20 As small molecule cytotoxic chemotherapy lacks 
targeting, it is limited by the side effects of the drugs that act on all cells of a body not 
just cancerous cells. Especially as some cancers do not exhibit increased growth rates 
via evading growth suppressors or sustaining proliferative growth signals, instead 
satisfying other hallmarks of cancer, such as avoiding immune destruction, tumor-
promoting inflammation, genome instability and mutation, resisting cell death. 244 
 
Cytotoxic drugs are still used to treat cancer, even though they have numerous awful 
side effects including: hair loss, nausea, damage to the mouth and pharynx, diarrhoea, 
damage to bone marrow as well as long term effects such as cardiac toxicity, lung 




1.2 Non-cytotoxic Chemotherapy 
 
1.2.1  Emergence of non-cytotoxic chemotherapy 
 
Tamoxifen (9) is a drug that was initially developed as a contraceptive during the 
1960’s. It acts as a prodrug, having to be metabolised into a more active compound 
known as 4-hydroxy-tamoxifen (10), which binds to the oestrogen receptor as a partial 
agonist and this reduces cell growth and division (Figure 1.3). Tamoxifen was trialled in 
breast cancer which was known to be associated with the oestrogen receptors, and this 
study found that most patients responded. Furthermore, at higher doses the response 
rate increased while the side effects remained negligible. 21 Tamoxifen soon became a 
gold standard drug for treating breast cancer when used alongside cytotoxic 
chemotherapy drugs. 22  
 
Our understanding of growth factors and cellular signalling pathways was 
expanded in 1986 with the work of Goustin et al. 23 They demonstrated that cancerous 
cells can have different growth requirements, such as constituently active receptors and 
upregulated expression of growth receptors. They identified this was due to proto-
oncogenes such as human epidermal growth factor receptor 2 (HER2, Figure 1.4) 24 25 
and the colony stimulating factor 1 receptor (Figure 1.5). 23 26 They proposed proteins in 
these signalling pathways that would make good targets for anticancer drugs, as they 
could selectively affect aberrant cells, while having minimal effect on normal cells. 
Goustin’s ideas were realized when imatinib (11), an inhibitor of a tumour specific 
antigen (TSA), was successfully tested.27 Imatinib was able to inhibit the growth and 
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Figure 1.5.  Colony stimulating factor receptor 1 intracellular signalling pathways. Figure taken from 
Achkova and Mahar 29 
 
Over time many small molecule drugs that targeted molecular pathways were 
discovered and tested, including inhibitors of many kinases involved in cancer as well as 
proteasome and VEGF inhibitors. 27, 246, 247, 248 
 
1.2.2 Drawbacks of non-cytotoxic chemotherapy 
Non-cytotoxic drugs have much better side effect profiles than more traditional 
cytotoxic drugs. 27 However these molecular pathway inhibitors do not work indefinitely, 
with resistance often developing due to mutations. Resistance to imatinib developed in 
patients with advances chronic myeloid leukaemia due to mutations in the target kinase 
that made the kinase resistant to imatinib. 247 Mutations that cause resistance are 
diverse, using kinase inhibitors as an example, resistance can develop via over 
expression of the kinases, mutation of the kinase inhibitor binding site, kinase receptor 
mutations, drug transporter mutations and mutations to drug-metabolizing pathways. 
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246 Furthermore, these non-cytotoxic drugs may have less aggressive side effects, but 
they do still have adverse effects for patients taking them, such as diarrhoea, skin 
toxicity and hypertension. 247 Clinical trials and pharmacoepidemiological reviews have 
revealed, that while molecular targeted therapies such as imatinib are important in 
cancer therapy there are numerous complications such as: an improved response rate 
and progression free survival improvements but no improvement to overall survival in 
clinical trials, issues of patient section due to the development of resistance or specific 
population groups that do not benefit from the drug due to genetic differences, as well 
as higher cost compared to traditional chemotherapeutic agents. 248 Additionally, these 
non-cytotoxic drugs are typically used alongside cytotoxic chemotherapy as cancerous 
cell death is a desired outcome of cancer therapy, as well as slowing their growth and 
metastasis, however in some indications co-therapy of a traditional-cytotoxic drug and 
a molecular targeted small molecule does not lead to an improvement in survival rates. 
248 Fortunately, research on a class of biological molecules also able to interact with 
molecular targets, known as antibodies, had been taking place for almost 100 years and 
was about to revolutionize cancer therapy. 
 
1.3 Antibodies as drugs 
 
1.3.1 Foundational antibody research 
 
At the turn of the 20th century, Dr Paul Ehrlich proposed the theory that cells 
interacted with nutrients and toxins through side chains that were specific for certain 
toxins and nutrients (Figure 1.6).30 He later coined the term receptor to describe these 
side chains. He also hypothesised that the body would produce blood soluble receptors 
specific to toxins in response to an infection. He speculated this would prevent toxins 
from interacting with the receptors on cells. He described these hypothetical soluble 
receptors as ‘antibodies’. Ehrlich was a visionary and unfortunately his theory was not 
readily accepted before he died in 1915. 31, 30 However, the receptor theory became a 





Figure 1.6.  Dr Paul Ehrlich and diagrams of his receptor theory, including receptors and antibodies.32 
 
The structure of antibodies, also known as immunoglobulins, was initially solved 
by Gerald Edelman and Rodney Porter. Both scientists experimented with antibodies by 
denaturing them with chemicals. Edelman managed to reduce an antibody into two 
pairs of protein fragments. 33 These were the heavy and light chains as we know them 
today (Figure 1.7).34 At the same time, Rodney Porter had performed experiments on 
antibodies, using the enzyme papain, which created two fragments that retained their 
antigen binding properties and one fragment that crystallized at low temperatures. 
These became known as the fragment antigen binding (Fab) and fragment crystallisable 
(Fc) (Figure 1.8). 35 The Nobel Prize in Physiology or Medicine 1972 was awarded jointly 
to Gerald M. Edelman and Rodney R. Porter for “their discoveries concerning the 
chemical structure of antibodies." 
                                   
Figure 1.7. Simple diagram of an antibody, with the heavy chains coloured grey and the light chains 




Figure 1.8. Simple diagram of an antibody, with both Fab regions colour purple and the Fc region 
coloured green. 37 
 
While we had an understanding of the structure and purpose of antibodies, we 
still did not know how they managed to be so specific while having such similar 
structures. In 1970 Dr Wu and Dr Kabat published their work on what they termed the 
“complementary determining regions” or CDRs.38  These were short regions on the 
heavy and light chains of the Fab regions which controlled the antigen specificity 
through different amino acid sequences (Figure 1.9). 38 
 
 
Figure 1.9. Simple diagram of an antibody, with the CDRs coloured red. 39 
 
Putting all of this information together we now understand an antibody is a 
protein that forms part of the mammalian adaptive immune system. Antibodies are 
proteins that have a quaternary structure, meaning they are constructed of more than 
one sequence of amino acids. More specifically, IgG antibodies are made of two pairs of 
amino acid sequences (four polypeptide chains in total). These four proteins are known 
as the heavy and light chains. Heavy chains have a molecular weight of about 50 kDa 
each, while the light chains are about 25 kDa each (Figure 1.10). The heavy and light 
chains are held together by disulphide bonds. Therapeutic antibodies typically contain 
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four inter-chain disulphide bonds, two between the heavy chains and one between each 
pair of heavy and light chains (Figure 1.10). This gives antibodies a flexible “Y” shaped 
quaternary structure. The structure is flexible as the heavy chains contain “hinge 
regions” (Figure 1.10). 
 
The Fc domain is located on the tail or trunk of the antibody, close to where the 
two heavy chains are attached through disulphide bonds (Figure 1.10). This domain is 
constant between antibodies of the same isotype and controls the activation of the 
immune system. The ‘arms’ of the antibody where the light and heavy chains are 
attached are known as Fab domains. These Fab domains contain variable sections that 
confer the antibodies selectivity. The variable sections contain complementary 
determining regions or CDRs (Figure 1.10). The CDRs are responsible for the selective 
binding to the target antigen. The heavy and light chain CDRs form an antigen binding 
site, also known as a paratope, and the specific complementary sequence found on the 
antibody is known as the epitope. Some antibodies that bind to the same target antigen, 
such as trastuzumab and pertuzumab, bind to different epitopes on the same antigen. 
 
There are 5 known classes of antibodies, also known as immunoglobulins: IgA, 
IgD, IgE, IgG and IgM. 249 Each class is differentiated and defined by their conserved 
heavy chain domains. IgA, IgD and IgG each have the conserved domains known as CH1, 
CH2 and CH3, while IgE and IgM have an additional region, CH4. 249 Furthermore, while 
IgD, IgE and IgG are monomeric (Figure 1.7 - 1.9), IgA is dimeric, and IgM is pentameric. 
249 Antibodies expressed on the surface of B cells are IgD, while secreted antibodies tend 
to be IgG. 249 The other classes of antibodies won’t be discussed in this thesis. 
 
Figure 1.10 shows an IgG1 antibody with important features highlighted. The 
heavy chains are blue with the three conserved subunits in dark blue, labelled CH1-3, 
while the variable subunit is a pale blue and labelled VH. You can see the hinge regions 
located between CH2 and CH1 on each heavy chain. The light chains are coloured green, 
with the conserved light subunit in darker green, labelled CL and the variable light 
subunit in paler green labelled VL. The CDRs are represented as the tips of orange 
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antigen binding sites; these are labelled L1-3 and H1-3 depending on if they are from the 
light or heavy chain. The antigen binding region, also known as the paratope, is orange. 
Lastly the 12 disulphide bonds are shown in red. The VL, CL, VH and CH1 subunits all 
contain intra-chain disulphide bonds, these account for 8 of the disulphide bonds. There 
are 4 inter-chain disulphide bonds that hold the chains together, these are located 
between the CL and CH1 subunits and two disulphide bonds are between the heavy chain 
hinge regions. 
 
         
 
 
Figure 1.10.  Highly detailed diagram of an IgG1 antibody.  
Taken from Janeway, Travers, Walport and Schlomchik. 64 
 
The mammalian immune system contains cells known as B cells which through 
complex mechanism produce antibodies with specific CDR regions, conferring each 
antigen they produce with the same antigen specify. 250 These antigen specific 
antibodies are fixed to the plasma membrane of the B-cells which can then bind to 
antigens. B cells can then process the antigen and present it on major histocompatibility 
complex 2 molecules. 250 T helper cells can interact with the presented antigen via their 
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T cell receptors, which then activate the B-cells via an interaction of the CD40, expressed 
on B-cells and CD40 ligand expressed on T cells. 250 The B cell is now activated and will 
proliferate as an effector cell which will secrete the same antibodies that originally 
bound the antigen. 250 Effector B cells will progress to large plasma cells which can 
secrete 2000 antibodies a second, however large plasma cells sacrifice their ability to 
grow or divide, lasting only a matter of days, though some will persist in bone marrow 
for months. 250 Once secreted, antibodies typically circulate in the blood and lymph until 
they find and bind their target antigen. Once bound to an antigen, typically a foreign 
protein, the immune system can take further steps to remove the entity, most often a 
virus or bacteria. 250 
 
The Fc region of an antibody can activate various immune pathways including 
the complement system which can drive histamine release via C3a, phagocytosis via 
opsonin (C3b) coating of microorganisms, promotes chemotaxis and activates white 
blood cells via C5a and bacterial lysis via C5-9. 251 This is known as complement 
dependent cytotoxicity (CDC) 
 
The Fc region can also promote phagocytosis of the antibody bound target via 
interactions with neutrophils and macrophages, this occurs without the need for 
opsonin from the complement cascade. Once ingested via phagocytosis the neutrophils 
and macrophages assault the antibody bound target with proteolytic enzymes and 
reactive oxygen species which damage the bacteria or virus. 251 This is known as antibody 
dependent cellular phagocytosis (ADCP) 
 
Another mechanism mediated through the FC region is antibody dependent 
cellular cytotoxicity (ADCC). This is a mechanism through which the FC region of the 
antibodies interacts with specific effector cells, most commonly natural killer (NK) cells, 
which are white blood cells that express FC receptors. Once bound to an FC region of an 
antibody, the NK cells release granzyme and perforin, which create pores in plasma 





IgG antibodies come in a variety of subclasses (Figure 1.11). 59 Although all IgG 
subclasses share over 90% of the same amino acid sequence, there are significant 
differences between IgG subclass effector functions.  The structural difference between 
IgG subclasses is primarily at the CH2 and hinge domains. Both of these domains are 
involved with Fc receptor and complement protein interaction, which is what controls 
CDC, ADCP and ADCC.  IgG1, IgG2, and IgG4 isotypes are used as therapeutic antibodies. 
IgG1 antibodies elicit stronger ADCC and CDC promotion than IgG2 and IgG4 isotypes. 60 
IgG2 antibodies tend to have very little CDC activity and only promote ADCC at very high 
cell binding densities. 60 The IgG4 isotype has less ADCC activation but is able to promote 
CDC using the same glycan structures as IgG1 antibodies. 61 
 
 





While the protein structure of antibodies is critical for their binding and affects 
effector function, so too does the glycosylation of the antibody. 57 Glycosylation is a 
post-translational modification of an antibody, through which glycans are attached to 
the antibody. These glycans are large monosaccharide chains, often containing: 
mannose, N-acetylglucosamine, N-glycolylneuraminic, galactose, sialic acid, xylose 
and/or fucose. 57 The glycosylation of antibodies is heterogenous, with at least 36 
potential chain structures. 254 Some glycan modifications have been associated with 
adjustments in effector function, which are described below (Figure 1.12). 
 
Fucosylation, the attachment of fucose to glycans, can affect the binding of 
antibodies to types of Fc receptors. More specifically, core-afucosylation, the lack of a 
fucose on the molecules of the glycan chain, causes a tighter binding to a type of Fc 
receptor which increases ADCC and ADCP. 57, 254 Galactosylation, the attachment of galactose to 
glycans, is reported to confer anti-inflammatory activity to IgG antibodies. 57 Sialyation, the 
attachment of sialic acid, has been shown to decrease ADCC but only if the antibody was core-
fucosylated, and had no effect on core-afucosylated antibodies. 254 Sialyation has also been 
shown to increase anti-inflammatory activity. 57 
 
 
Figure 1.12.  Examples of different Fc region glycosylation chains and the observed cellular effects. 
Taken from Lauc, Pezer, Rudan and Campbell. 57 
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Antibodies that target upregulated proteins expressed on cancer cells, would 
direct the immune system to conduct CDC, ADCP and ADCC against the cancerous cells, 
as well as binding to and blocking receptors that may be involved in cancer related signal 
propagation, such as growth signalling. However, although we now had a clearer 
understanding of antibody structure, we could not make antibodies very well, with the 
key limitations being specificity and quantity. In 1975 César Milstein and Georges Köhler 
published a paper which explained how to use their hybridoma technique to make a cell 
capable of producing large quantities of antibodies that were specific towards a single 
target (Figure 1.13). 40  The Nobel Prize in Physiology or Medicine 1984 was awarded 
jointly to Niels K. Jerne, Georges J.F. Köhler and César Milstein "for theories concerning 
the specificity in development and control of the immune system and the discovery of 
the principle for production of monoclonal antibodies.".  
 
Their method worked by harvesting splenocytes from mice already primed 
against a specific antigen via intravenous immunization. Some of the spleenocytes 
harvested should be B cells that have antigens expressed against the antigen used during 
the immunization. These cells are then fused with immortal b cell cancers cells that don’t 
have the hypoxanthine-guanine phosphoribosyltransferase (HGPRT) gene, using either 
electrofusion or polyethylene glycol. This procedure should produce a mixture of cells 
that are immortal myelomas that lack HGPRT, harvested B cells that secrete the antibody 
and immortal fusion cells that secrete the antibody and have the HGPRT gene. This 
mixture of cells is grown on hypoxanthine-aminopterin-thymidine medium for up to two 
weeks. The unfused myeloma cells lack HGPRT and as the aminopterin blocks nucleotide 
synthesis they die. The unfused B cells die due to their short lifespan. The remaining cells 
must all be hybridoma cells, which will produce antibodies towards the same target, 
hence ‘monoclonal’ antibodies. 41 The hybridomas can be cultivated and the secreted 
antibody purified from the media they are grown in typically via affinity 
chromatography. Protein A or G coated resin can be used to bind the antibodies via their 
Fc regions, this binding will occur at neutral pHs (7.5). Once the resin is at capacity, the 
chromatographic conditions can be adjusted to lower the pH to around pH 2.5, which 
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washes the bound antibody off the resin. 41 This enables the isolation and purification 
of monoclonal antibodies from the supernatant taken from the hybridoma cell cultures. 
 
 
Figure 1.13. Diagram of method for production of a monoclonal antibody using hybridoma cells. Figure 
taken from Sgro 41 
 
Following Köhler and Milstein’s methods, monoclonal antibodies (mAbs) could 
then be made against a specific target. This allowed mAbs to be made as drugs against 
extracellularly expressed disease associated proteins, something which is common in 
many cancers. 
 
1.3.2 Early therapeutic antibodies 
 
Ideally a therapeutic antibody would be targeted to a protein that is expressed 
exclusively on or over expressed on cancerous cells. This would enable the specific or 
selective activation of the immune system via CDC, ADCP and ADCC against cancerous 
cells. Antibodies can also bind to receptors antagonistically and prevent activation of 
cancer associated receptors, such as over-expressed growth receptors. However, with 
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antibodies being produced in murine hybridoma cells, immunogenicity soon became a 
problem. 40,41 Early clinical trials with murine antibodies such as Muromonab-CD3, failed 
mainly due to potentially fatal immune system activation and development of anti-
mouse antibodies which reduced the effectiveness of the drug after repeated 
administrations. 43 
 
To overcome the issue of immunogenicity, scientists began working on 
minimising the murine content of the antibody (Figure 1.14). Chimeric antibodies were 
first developed by Vernon Oi who developed a method of combining the constant region 
of a human antibody with the variable antigen binding domain of a murine antibody.44 
These chimeric antibodies were approximately 66% human and demonstrated a more 
tolerable side effect profile than fully murine antibodies.45 Taking this even further was 
Greg Winter who developed a method of producing “humanised” antibodies, which are 
human antibodies with only the CDRs transplanted in from murine antibodies.46 
Humanised antibodies are over 80% human and exhibit the least amount of immune 
activation and anti-drug antibody production upon administration.45 
 
 
Figure 1.14.  Simple diagram of antibodies, with murine protein in blue and human protein in orange. 47 
 
In 1997, a chimeric antibody called rituximab was the first monoclonal antibody 
approved for cancer treatment. Rituximab targets CD20, a protein expressed on B-cells. 
Once bound to CD20, rituximab promotes ADCC and CDC (Figure 1.15). Rituximab in 
combination with cytotoxic chemotherapy improved response rates and progression 
free survival. 48 CD20 has no known function and Rituximab’s therapeutic effect is solely 





Figure 1.15.  Rituximab’s mechanisms of action, including CDC, direct apoptosis, antibody (Ab) 
dependent cellular cytotoxicity and ADCC. Figure taken from Falduto. 49  
 
In 1998, Trastuzumab was the first humanized antibody licensed for use to treat 
cancer. Trastuzumab targets the HER2 receptor, a protein overexpressed in about 20% 
of breast cancers. 24 Once bound to HER2, trastuzumab promotes ADCC, CDC and direct 
apoptosis much like rituximab does when bound to CD20 (Figure 1.15). However, as 
HER2 is a functional receptor, trastuzumab also downregulates HER2 signalling. HER2 
activation promotes cell growth, which is why overexpression is typically associated with 
cancer (Figure 1.4). While trastuzumab initially inhibits HER2 signalling, it is found that 
within 1 year most cancers will have developed resistance. 51 As such, trastuzumab is 
often administered in combination with cytotoxic chemotherapy drugs which extends 
the duration of its use before drug resistance develops and improves the rate of 
remission and clinical outcomes. 52,53   
 
1.3.3 Current clinical use of antibodies in cancer therapy 
 
Antibodies are used in a variety of ways to treat cancer. Many antibodies act as 
anticancer agents through ADCC and CDC and scientists have engineered antibodies to 
exhibit increased levels of ADCC and CDC promotion.54,55 These second generation 
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antibodies demonstrate how we can modify Fc region glycosylation of antibody directed 
to the same targets as first generation antibodies, but now with greater efficacy and 
improved tolerability.56 For example, ocrelizumab targets CD20 like rituximab, but is 
humanised and has been glycoengineered to increase effector function at the Fc region 
(Figure 1.12). This means ocrelizumab produces milder adverse effects and up to 5 times 
the level of ADCC.56 
 
Alternatively, some antibodies do not treat cancer by targeting the cancer itself 
but target the immune system. So-called ‘immune checkpoint blockers’ inhibit signals 
that dampen down a human’s immune system. For example, ipilimumab antagonizes 
the inhibitory receptor of CTLA-4, resulting in T-cells with increased activity. 255 
Combined administration of ipilimumab with a cytotoxic drug called dacarbazine causes 
a significant improvement in survival compared to patients only administered with 
dacarbazine. 255 There are also antibodies that antagonise PD-1 and PD-L1 such as 
pembrolizumab and atezolizumab respectively. 255 PD-1, expressed on activated T and B 
cells, when bound with PD-L1 propagates an inhibitory signal to the immune cells. 255 
 
Monoclonal antibodies have proven to be a revolutionary tool in the treatment 
and management of cancer. A study in 2014, found addition of trastuzumab to HER2+ 
breast cancer therapy caused a 37 % improvement in overall survival. The 10-year 
disease free survival rate for HER2 positive breast cancer was over 73 % and overall 
survival was at 84 %. 52,53 When rituximab was added to combination chemotherapy 
treatments for B-cell lymphoma the duration of response increased from 14 months to 
38 months, and the objective response rate increased from 75 % to 92 %. 49 Second-
generation antibodies, such as obinituzumab have been shown to outperform their first-
generation equivalents, for example progression free survival increased 9 % comparing 
rituximab with obinituzumab chemotherapy in the GALLIUM trial. 256 However, there are 
still many issues with antibody therapies in current clinical use, such as side effects, 





1.3.4 Problems with antibodies in cancer therapy 
 
Paul Ehrlich is famous for having described “The Magic Bullet”.30 He proposed 
antibodies were magic bullets, able to kill microbes in the body without harming the 
host. However he gave up on this concept when he discovered antibodies could not 
always kill microbes.30 Since then numerous issues with antibodies have been 
identified, which are described below. 
 
Most antibodies have unpleasant side effects such as nausea, vomiting, 
dizziness, headaches, fevers, and rigors as well as potential drug specific adverse 
events such as anti-CD-20 infusion reactions, anti-EGFR antibodies skin, lung, and 
gastro intestinal toxicity, anti-HER2 antibodies cardiotoxicity, anti-VEGF delayed 
wound healing, and immune -checkpoint blocker autoimmune effects. 255 
 
Compared to small molecule drugs, antibodies have a high cost, especially 
second-generation antibodies. According to the online British National Formulary, 257 
the small molecule cytotoxic drug doxorubicin costs ~£20 per mL, rituximab costs 
~£350 per mL, and ocrelizumab costs ~£4800 per mL. These high costs are especially 
problematic for the NHS, due to limited funding requiring resource allocation to 
maximise the cost effectiveness of care, while the main effect on private healthcare is 
rapidly rising costs of cancer treatment and a willingness to pay these costs if possible, 
thus resulting in an ever-widening health care gap between the richer and poorer of 
society. 259, 260 
 
Additionally, cancers are known to development resistance to antibody therapy 
via a number of mechanisms. 258 For example trastuzumab therapy of HER2 positive 
breast cancer often only works for 18 months before resistance emerges. 258 The 
resistant to trastuzumab can be due to: over expression of a membrane associated 
glycoprotein that sterically hinders binding of trastuzumab to HER2, increased 
signalling activity of insulin-like growth factor recptor-1, mutation of HER2 into a 
truncated form that does not have an extra-cellular domain for trastuzumab to bind to, 
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and mutation of signalling proteins downstream of HER2 that increased activity or 
reduce signalling inhibition, making inhibition of HER2 less effective. 258 While these 
are examples of resistance to trastuzumab, similar mechanisms of resistance affect 
other antibodies such as rituximab along with other such as down regulation of CD20. 
258 
Lastly while co-administration of antibodies has been shown to improve patient 
outcome with better overall objective response, longer progression free survival and 
higher 10-year survival rates, 52, 53 some patients to not respond to therapy, resistance 
develops, cancer often eventually progresses, and patients die. 258 Ideally the therapies 
to treat cancer would have a 100 % response rate and indefinite progression free 
survival, but that is not the reality of modern cancer therapy. Furthermore, second-
generation antibodies are not living up to their original promise, for example in some 
clinical trials ocrelizumab has failed to demonstrate any difference regarding disease 
progression compared with rituximab, although there were some statistically 
significant improvements in the number and severity of adverse events and side 
effects. 261 
 
Like Ehrlich before us, we must conclude that antibodies are not the magic 
bullets that he had envisioned and they are also not a perfect answer to cancer, even 
with all the advances we have, such as glycoengineered antibodies and co-
administration with immune modulators and cytotoxic drugs, for example in the phase 
2 trial GALEN, which combines atezolizumab, obinituzumab and lenalidomide to treat 
lymphomas metastasised into the central nervous system. 262 The GALEN trial had a 90 
% response rate, but a mean response rate of only 9 months. 262 Clearly new tools are 









1.4 Antibody drug conjugates 
 
1.4.1 A brief history 
 
The idea to link (or conjugate) potent cytotoxic small molecules to an antibody 
had been around for decades before it was technically possible, going as far back as 
Ehrlich himself. In 1993 a paper was published, demonstrating a conjugate of 
doxorubicin and a chimeric monoclonal antibody targeted to a tumour associated 
protein. This antibody drug conjugate was called BR96-Doxorubicin and it cured 94 % of 
rats with lung cancer.66 Once bound to the target protein, the conjugate was internalized 
into the cell, where the doxorubicin, a topoisomerase II inhibitor, is cleaved from the 
antibody and can cause DNA cleavage (Figure 1.16).66  Following this finding, there was 
a surge in the number of antibodies conjugated to different cytotoxic drugs that were 
investigated.67  These new drugs fall under the wide drug class of immunoconjugates, 
which covers any antibody, fragment of antibody, or targeted protein, conjugated to 
cytotoxic drugs, bacterial toxins, radionuclides, cytokines, enzymes etc. More 
specifically, the type of immunoconjugate that will be discussed in this thesis is known 
as an antibody-drug conjugate (ADC). 
 
Unfortunately, BR96-doxorubicin did not perform well in human clinical trials. 68 
A major problem identified was the difference between targeting tumour associated 
antigens (TAA) and tumour specific antigens (TSA), as targeting TAA can lead to off target 
toxicity and reduced therapeutic capacity.69 For example, BR96-doxorubicin was found 
to have severe gastric side effects due to the expression of the target antigen in gastric 
mucosal cells.70 Another tragedy occurred when, an ADC in phase one clinical trials 
caused the death of one of its seven patients and caused major adverse skin reactions 
in other patients.71 The ADC was immediately discontinued, with unexpected off target 
toxicity to blame for the fatality. 
 
ADCs use extremely potent cytotoxic drugs or “warheads”. If the target antigen 
is not tumour specific it must be upregulated, by a significant degree, in the cancerous 
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cells. If the antigen is also upregulated in a non-target cell population, severe off target 
toxicity will be dose limiting and preclude therapeutic activity. 69 The issue of antigen 
distribution is confounded by xenograft cancer models where human tumours are 
cultivated in non-human hosts. This means the target antigen could only be expressed 
in the tumour and not elsewhere in the host, which does not help identify off target 
toxicity.72 More modern genetically engineered tumour models have proven more 
predictive of human response.72 
 
 
Figure 1.16.  Mechanism of ADC internalisation and drug release.  
Taken from Bouchard, Viskov and Garcia-Escheverria. 73 
 
In 2001, an ADC known as gemtuzumab ozagamicin was given accelerated 
approval to market. While it had overcome many hurdles that other ADCs could not, it 
was subsequently withdrawn from the market in 2010. An ongoing clinical trial had 
revealed that gemtuzumab ozagamicin actually increased the rate of mortality from 
1.4% to 5.7% and had equivalent therapeutic outcomes compared to conventional 
therapies. 75 Gemtuzumab ozagamicin was reintroduced in 2017 at a third of its original 
dose (3mg/mL), in a revised dosing regimen (three administrations for the first induction 
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only, then one administration per consolidation course, as opposed to every 14 days) 
and a different patient group (Co-administration with daunorubicin or cytarabine) . 76 
This was after it was demonstrated in another clinical trial that gemtuzumab ozagamicin 
could increase overall survival compared to conventional therapies. 76 
 
In 2011, brentuximab vedotin was the second ADC approved to market, closely 
followed by trastuzumab emtansine in 2013. In 2017, inotozumab ozagamicin became 
the fourth and most recently approved ADC. 
 
1.4.2 The target protein 
 
The target protein should ideally be a tumour specific, extracellularly expressed, 
internalising protein. But if the target antigen is only highly upregulated in the cancerous 
cells, a tumour associated target can work. All market approved ADCs currently target 
tumour associated proteins and not tumour specific ones. Gemtuzumab ozagamicin 
targets CD33 77,  a receptor often overexpressed in leukaemia (Figure 1.17)78, while 
brentuximab vedotin  targets CD30 79, a receptor expressed in activated B and T cells 
that is associated with lymphoma (Figure 1.18).80 Trastuzumab emtansine targets 
HER2,81 a receptor overexpressed in 20% of breast cancers (Figure 1.19).24 
 




Figure 1.18. Brentuximab vedotin's mechanism of drug release and action. Taken from Eyre, Khan, Hall 




Figure 1.19. Trastuzumab emtansine's mechanism of drug release. Taken from Gogia et al. 84 
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1.4.3 Antibody species 
 
The antibody species is referring to whether it is murine, chimeric, humanized or 
even fully human (Figure 1.14). Ideally, fully human antibodies would be the starting 
point for any new ADC, however the technology to create fully human antibodies is 
expensive and so many new antibodies and ADCs are humanized, as they still work, and 
the final product is less costly and so more likely to be available. Over time, the 
technology to create fully human antibodies will become common place. Currently: 
gemtuzumab ozagamicin is humanized, brentuximab vedotin is chimeric, trastuzumab 
emtansine is humanized and inotozumab ozagamicin is humanized. Additionally, there 
are chimeric, humanized and fully human ADCs currently in development. 85 
 
 
1.4.4 Linker chemistry 
 
The linkers in ADCs are responsible for holding the warhead and antibody 
together. This means the linker controls the site of attachment to the antibody and the 
conjugation chemistry to the warhead. The linker is an extremely important aspect of 
ADCs as it effects payload distribution, drug to antibody ratio (DAR), warhead release 
and warhead potency. 
 
Linkers currently used in ADCs target either nitrogen or sulphur atoms on the 
surface of the antibody. These atoms are found in lysine and cysteine amino acid 
residues respectively (Figure 1.20). There are between 30 and 40 externally accessible 
lysine residues on an IgG1 antibody 85,86 and linker attachment to the lysine residues 
typically varies between 1 and 8 payload attachments per antibody. This allows a 
staggering 8.65 million potential regional-isomers across all the DARs. 87 Alternatively, 
there are only 8 externally accessible cysteine residues on an IgG1 antibody, which are 
the cysteine residues responsible for the inter-chain disulphide bonds (Figure 1.10). 
While the DAR for ADC’s utilising cysteine reactive linkers can still vary from 1 to 8, the 
potential positional-isomers across all DARs is only 255. 87 Furthermore, the attachment 
28 
 
typically occurs at both cysteines that form a disulphide bond, leading to predominantly 
2, 4 and 6 DARs being most abundant. This reduces the number of cysteine linked 
positional-isomers down to 126, resulting in a significant difference in overall ADC 
heterogeneity. 
                
                       
           (12)       (13) 
 
Figure 1.20. The chemical structures of amino acids lysine (12) and cysteine (13). 
 
Trastuzumab emtansine utilizes the linker succinimidyl 4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate (SMCC, 14). 274 The SMCC linker forms an amide bond to a 
lysine residue on the antibody via its amine reactive NHS-ester and a thioether bond to 
the DM-1 warhead via a sulphur reactive maleimide, (Figure 1.21). 274 The SMCC linker 
is described as non-cleavable, however the thioether bond is susceptible to retro-
michael reactions, liberating the warhead. It is mainly inside a lysosome, where enzymes 
can digest the antibody, that the lysine-linker-DM1 conjugates are released and able to 
affect tubulin dimers (Figure 1.19).  
 
   













Gemtuzumab ozagamicin and inotozumab ozagamicin both use 4-(4-
acetylphenoxy)-butanoic acid (15) as a linker, to form an amide bond with a lysine 
residue on the antibody (Figure 1.22). 274 Both gemtuzumab ozagamicin and inotozumab 
ozagamicin also use a calicheamicin molecule which is modified using 3-mercapto-3-
methylbutyryl hydrazide (16) through a disulphide bond. 274 The 4-(4-
acetylphenoxy)butanoic acid can then form a hydrazone bond with the 3-mercapto-3-
methylbutyryl hydrazide to attach the warhead to the antibody (Figure 1.22). 274 While 
the disulphide bond is relatively stable in the body, the hydrazone is rapidly hydrolysed 
in acidic environments such as the lysosome. This liberates the cytotoxic calicheamicin, 




       
Figure 1.22. Chemical structures of linker components 4-(4-acetylphenoxy)-butanoic acid (15) and 3-
mercapto-3-methylbutyryl hydrazide (16) and their incorporation within the ADC’s gemtuzumab 
ozagamicin and inotozumab ozagamicin. 
 
Brentuximab vedotin utilizes a more complex linker with multiple components 
(Figure 1.23). Connecting the antibody to the linker structure is 6-maleimidohexanoic 
acid (17) which forms a thioether with the sulphur atom of cysteine residues on the 
antibody. 274 Compound (17) is then connected to a valine-citrulline group composed of 
(18) and (19), which is in turn is connected to the 4-aminobenzyl carbamate (20) (Figure 
1.22). The bonds between each component of this linker are stable amide bonds and 
the linker to antibody bond is a thioether (Figure 1.25). However, an enzyme known as 
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cathepsin B recognises the valine-citrulline amide bond and then selectively cleaves the 
amide bond between the citrulline group and 4-aminobenzyl carbamate. 274 This creates 
an MMAE-4-aminobenzyl carbamate conjugate that rapidly undergoes a spontaneous 
1,6-elimination, resulting in the free MMAE cytotoxic. 
 
 
Figure 1.23. The chemical structure of the linker used in brentuximab vedotin. 
 
 
Figure 1.24. The chemical structures of 6-maleimidohexanoic acid (17), Valine (18), Citrulline (19) and 4-
aminobenzyl carbamate (20). 
 
When attaching the linker to the antibody the duration of reaction and ratio of 
reagents will control how many linkers become chemically attached to each antibody. 
However, the chemistry for cysteine and lysine attachment is not precise enough to yield 
only antibodies with the same number of linkers bound. The number of linkers bound 
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will be heterogeneous with a mean average being the best way of quantifying the 
number of drugs that will subsequently bind to the linkers. Gemtuzumab ozagamicin is 
reported to have an average drug to antibody ratio (DAR) of 3, but it is as mixture 
containing naked gemtuzumab and gemtuzumab ozagamicin with a DAR of up to 6. 88 
Brentuximab vedotin is reported to have a mean DAR of 4 89 but is predominantly 
present with DARs of 2, 4 and 6 due to its cysteine attachment. 89 Trastuzumab 
emtansine has a mean DAR of 3.5, but is present with DARs of 0 to 8. 89 ADCs with DARs 
below 3 have lower therapeutic activity than those with DAR 3 and above, assuming only 
the DAR is changed. 90 ADCs with DARs of 7 and 8 are cleared from the body much faster 
resulting in reduced therapeutic activity, assuming only the DAR is changed. 91 Ideally 
the mean DAR will be 4, with most of the drug present at DARs of 3-6, this should yield 
the best balance of therapeutic activity, rate of clearance, and chemical stability. 90,91 
 
 
Figure 1.25. Chemical structure of brentuximab vedotin's linker and cytotoxic drug. 
 
Linker chemistry between the linker and the drug is broadly classed as cleavable 
or non-cleavable. 90 Essentially, cleavable linkers allow the cytotoxic drug or “warhead” 
to be released without the linker or additional amino acids remaining attached. Typically 
cleavable linkers are acid labile such as the hydrazone linkers used in gemtuzumab 
ozagamicin and inotozumab ozagamicin (Figure 1.22), or are enzymatically cleavable 
such as the citrulline-valine linker that is cleaved by the protease ‘cathepsin B’ in 
brentuximab vedotin (Figure 1.25). 90 Trastuzumab emtansine uses a non-cleavable 
linker, so the warhead is not released on its own. Once trastuzumab emtansine has been 
internalised, the entire ADC is degraded inside a lysosome generating amino acid-drug 





Figure 1.26. Chemical structure of the lysine-maleimidocaproyl-DM1 conjugate. 
 
 
1.4.5 The warheads 
 
In relation to ADC’s, the term warhead refers to the cytotoxic drug attached to 
the antibody. ADCs typically use cytotoxic drugs that act via one of two mechanisms, 
DNA synthesis inhibitors or tubulin inhibitors. 91 The maytansinoid derivative DM-1 is 
used in trastuzumab emtansine while DM-4 is used in many other ADCs in clinical trials. 
73 Maytansinoids are sourced from the bark of the Mayentus ovatus shrub. 92 These 
molecules bind to tubulin, a protein that composes the dynamic microtubules used in 
the cell cycle. By binding to the tubulin on microtubules Maytansinoids inhibit the 
tubulin depolymerisation and microtubule reorganisation. The cytoskeleton becomes 
static, stalling the cell cycle between the G2 phase and M phase, leading to apoptosis. 73 
DM-1 is drawn and labelled in Figure 1.26. 
 
The auristatins, MMAE and MMAF, are also tubulin inhibitors. MMAE is used in 
brentuximab vedotin  while MMAF is used many other ADCs in clinical trials. Auristatins 
are derivatives of dolastatins originally found in the sea hare Dolabella auricularia. 73 
Auristatins bind to free tubulin and prevent it from polymerizing. This means new 
microtubules can’t form and the cytoskeleton fails to assemble, leading to apoptosis. 73 




Calicheamicin is a DNA synthesis inhibitor used in gemtuzumab ozagamicon, 
inotozumab ozagamicin and other ADCs in clinical trials. It was originally found to be 
produced in the bacteria Micromonospora echinospora ssp. Calichensis.73 Calicheamicin 
binds to DNA and generates a double free radical on the DNA. The diradical DNA is 
extremely unstable and rapidly reacts with oxygen in its immediate environments 
leading to double strand scission. This DNA disruption then initiates apoptosis. 73 
Calicheamicin is drawn and labelled in Figure 1.22. 
 
The warheads for ADCs are chosen on the basis of their extreme cytotoxic 
potency. To put this into perspective, Doxorubicin is a cytotoxic chemotherapeutic drug 
which was also used in early ADCs that failed in the clinic. Calicheamicin is 4000 times 
more potent than doxorubicin,93 and cannot be used without attachment to a targeting 
motif. DM1 and MMAE are also significantly more toxic than licensed cytotoxic drugs 
that act via similar mechanisms. 81,94 The reason why warheads must be so potent is that 
only a small percentage of the ADC will reach the cancerous cells,95 so the warheads 
must be potent enough to initiate apoptosis at very low intracellular concentrations.95,96 
 
1.4.6 ADC summary 
In summary, while an ADC is defined as an antibody linked to a cytotoxic drug, 
ADCs are more than just the sum of their parts. There are seven key choices to make 
when designing an effective ADC: 
 
1) Antibody target 
2) Antibody isotype 
3) Antibody species 
4) Antibody to linker conjugation chemistry 
5) Drug to antibody ratio 
6) Linker to drug conjugation chemistry 




Most of the original issues with ADCs have been overcome or identified, for 
example: the antibody host species raising an immune response, has been solved by 
using humanized or fully human antibodies, where human antibody content is over 80%. 
Drug heterogeneity with regards to DAR and positional-isomers has been improved by 
linking via cysteine residues, (and more recently engineered amino acid residues) which 
drastically reduces DAR and isomer variability. 
 
ADCs are close to Paul Ehrlich’s concept of a magic bullet and are in high demand 
by patients around the world. There are four licensed ADCs; brentuximab vedotin which 
treats Hodgkin’s lymphoma, trastuzumab emtansine which treats HER2+ breast cancer, 
gemtuzumab ozagamicin which treats acute myeloid leukaemia and inotozumab 
ozagamicin which treats acute lymphoblastic leukaemia. While gemtuzumab ozagamicin 
had some issues regarding in vivo linker stability, all licensed ADCs have been 
demonstrated as better than the pre-existing gold standard therapies in at least one 
indication each. Furthermore, there are over 65 ADCs in clinical trials, with 10 of these 
in phase three trials. 97 
 
 
1.5 Biopharmaceuticals in clinical practice 
 
Most drugs for infusion or injection, which includes all antibodies and ADCs, 
come as concentrated solutions or lyophilized (freeze dried) powders for reconstitution 
into concentrated solutions. These are stored in vials, which usually have a 1 to 3 year 
shelf-life. For administration to the patient, the concentrated solutions first need to be 
transferred into a delivery device, such as a syringe, infusion bag or ambulatory infusion 
pump. A volume of diluent such as water for injection, 0.9% w/v NaCl solution for 
injection, or 5% w/v glucose solution for injection, is usually added to the device to dilute 
the concentrated drug solution. The process of combining drug, diluent and/or devices 




Compounding is very important as it allows the use of concentrated drug 
solutions or if it is required, lyophilised powders. These have much greater stability than 
products at ready to use concentrations, where the concentrations of excipients such as 
buffering agents or detergents like polysorbate 80 would be limited. This makes 
concentrated drug vials more convenient for pharmaceutical companies to manufacture 
and sell and for healthcare providers to store and use, limiting the risk of purchased 
stock going out of date. Compounding also allows drugs to be used in a great variety of 
devices, such as different brands or sizes of infusion bag, or syringes. Furthermore, 
patient specific products can be made when standardized dosing is not applicable. 
 
Compounding is performed in many places, such as hospital pharmacies, aseptic 
pharmacy units, or even on a hospital ward. For example, a nurse may withdraw and 
administer a drug as per a doctor’s instructions via a syringe. A pharmacy technician may 
reconstitute a lyophilised drug powder, and then add a specific volume of the 
reconstituted drug to a saline infusion bag that had previously had a specific volume of 
saline withdrawn, thus creating a defined concentration of a drug in a defined volume, 
this is often done to create ‘patient specific’ products. Once the sterile drug solution or 
lyophilized powder has been compromised, typically the airtight rubber septum has 
been breached, the product must be discarded within 4-48 hours, as specified in each 
drugs summary of product characteristics (SPC).  
 
Aseptic compounding is simply compounding but performed in an aseptic 
environment to prevent microbial contamination of the products. This is typically 
performed in a class 2 biological safety cabinet or laminar flow cabinet, which meet or 
exceed all grade A conditions for environmental sterility, as specified in the “Rules and 
Guidance for Pharmaceutical Manufacturers and Distributors 2017.98 By preventing 
microbial contamination of the product, the inherent stability of the specific 
combination of container, drug and diluent can be used to determine the maximum 
shelf-life of the new product. In the UK, pharmacists supervising aseptic compounding 
can apply up to seven days of shelf life according to available stability data. This is known 
as the ‘Medicines Act 1968 Section 10 Exemption’ allowing pharmacists that are 
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following an official prescription to make products and apply up to short extensions. To 
extend beyond seven days requires a Medicines Health Regulatory Agency (MHRA) 
Specials license. ‘Specials’ are any unlicensed medicinal products, such as patient 
specific products, which require specific concentrations, volumes or administration 
devices or more broadly require special manufacturing for the individual patient. An 
extended shelf-life of at least seven days makes the logistics of compounding and then 
administering the products much easier. 
 
Most large hospitals have an aseptic compounding unit. These units are costly to 
build and run. The number of products requiring aseptic compounding is increasing, 
indicated by an annual 4.8% increase in chemotherapy product production, furthermore 
the complexity of products has increased resulting in an even greater rate of increase in 
NHS aseptic service workload. 223 A compounding unit’s production capacity limit can be 
increased by extending the operating hours of the unit or physically expanding the 
compounding unit. Otherwise more products will be prepared in non-aseptic 
environments, by less practiced staff and with no operator protection. It has been 
advised since 1976  by multiple advisory bodies that products for parenteral 
administration are manufactured and assembled under aseptic conditions. 99 Reports 
have shown increased risk to patients and staff when products are assembled in wards, 
theatres, clinics and in the patient’s home compared to aseptic preparation areas. 100 
 
The Department of Health, National Patient Safety Agency and multiple 
independent researchers have been trying to get assembly of high risk products out of 
clinical areas and into aseptic manufacturing units for over three decades. Support for 
this idea has only grown stronger as more evidence is compiled explaining why this 
should happen. This is for the safety of the patients and as such should be a priority for 
all hospitals and staff. No identified risks should be accepted as part of patient treatment 
when there are alternatives like outsourcing for ready to use products. And with 
research showing that moving assembly of these products out of clinical areas will 
increase the workload on the in-house units by 50%, major changes will have to be made 
with regards to the supply and manufacture of high risk medicinal products. In 2003 the 
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UK Department of Health identified working with industry and creating commercial 
partnerships as a positive action and one of the 4 central pillars of modernising the NHS 
manufacturing service. 
 
Aseptic compounding allows more effective allocation of staff skill sets, reducing 
the time a nurse or doctor spends compounding on a ward or theatre allowing them to 
focus on nursing or diagnosing patients. Rather than using a section 10 exemption, most 
commercial manufacturers have an MHRA specials license. A key difference is that with 
a specials license is that you can apply a shelf life over 7 days. The longer the shelf life 
extension the more likely costs can be saved by reducing wastage, capitalising on batch 
production and the easier it is logistically to manufacture, transport, store and then 
administer the product. Furthermore, commercial manufacturers typically have purpose 
built aseptic compounding units with an infrastructure built solely around them, this 
keeps overheads low and often allows expansion if close to the capacity limit of the unit. 
Hospital pharmacy units tend to be built inside pre-existing hospitals meaning space is 
usually not available for expansion into, and the infrastructure isn’t designed around the 
compounding unit which leads to increased overheads, furthermore, an internal 
hospital unit will supply to a much smaller customer base (almost exclusively the 
hospital it is based in) than an external commercial unit, therefore downtime can also 
be an issue of unnecessary running costs. External commercial aseptic compounding 
units offer UK hospitals a way of sourcing ‘Special’ products at a better price than they 
could make for themselves and with a longer and more useful shelf life than they would 
normally be able to apply (some UK hospital compounding pharmacies do have specials 
licenses). The main benefits are only apparent when extended stability can be applied 
to products, and to this end the NHS has published guidance regarding the assessment 








1.6 The stability and degradation of antibodies 
 
1.6.1 Mechanisms of degradation 
 
Antibodies can be degraded via a number of different mechanisms, including: 
elevated temperatures (thermal stress), physical agitation (mechanical stress), light 
(photolytic stress), exposure to air and O2 (oxidative stress), changes in pH (acidic or 
basic stress), interface interaction / adhesion (air-liquid, air-solid, solid-liquid). 263 
 
 Thermal stress can cause changes to an antibodies structure, resulting in 
unfolding of the higher order structure. 263 Increased temperature will also increase 
the kinetic energy of the antibodies, resulting in more frequent and more energetic 
protein-protein interaction and protein-interface interactions. 263, 264 Lastly, when 
unfolded hydrophobic amino acid residues that would usually be inaccessible, can 
be exposed. The exposed hydrophobic residues can react with each other, container 
surfaces, lubricant or dissolved oxygen. 263 Thus, thermal stress is highly damaging 
to antibodies, and will drive aggregation resulting in aggregates that can range from 
dimers to visible aggregates. 263, 264 Interestingly antibodies Fab and Fc regions will 
unfold at different temperatures, 63–71 °C and 73–82 °C respectively. 263 
 
 Mechanical stress can be applied to antibodies during their manufacturing 
process, but more relevant to aseptic compounding is dilution/reconstitution, 
mixing, withdrawal into a syringe and addition to a device, such as an infusion bag, 
followed by transportation of the device. Reconstitution allows the antibodies to 
move around and interact with other antibodies, excipients, surfaces and air 
interfaces. This will be followed by a mixing step, typically in a swirling motion, to 
ensure all the drug is dissolved and the mixture is homogenous. Swirling however 
results in mechanical stress as well as exposure to a variety of interfaces at which 
adhesion may occur, leading to aggregation. 263, 264 Once the concentrate is 
satisfactorily mixed, it will be drawn up into a syringe using a metal needle. The 
needles have narrow internal diameters and the rate at which the drug is withdrawn 
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can cause shear stress to affect the antibodies, which has been associated with 
antibody aggregation. 264 The antibody may then be injected into another device 
such as an infusion bag or ambulatory pump, containing a diluent such as 5 % w/v 
glucose or 0.9 % w/v NaCl. This addition to a large volume of diluent dramatically 
dilutes the excipients that the antibody was originally stored in, as well as altering 
the pH and is followed by another mixing step, during which mechanical stress, 
exposure to air-liquid and air-solid interfaces can cause further aggregation and 
unfolding. 263, 264 Finally, bags will need to be transported, it is understood devices 
should contain as little headspace as possible to limit mechanical stress, limit the 
dissolving of oxygen into the drug solution and limit the air-surface and air-liquid 
interaction. 263 
 
 Many drugs are stored in amber vials or wrapped in light proof bags. This is to 
protect the drugs from UV rays, which can cause photolytic degradation. 263, 264 UV 
light can provide the energy required to cross-link sulphides, tyrosine residues and 
induce non-covalent aggregation. 263, 264 Furthermore, UV radiation can drive 
oxidation of methionine and histidine residues. 263 Photolytic degradation is often 
associated with discolouration of antibody solutions as well as loss of functional 
activity. 263 
 
 Oxidation of histidine and methionine residues is most common in antibodies 
with oxidation also possible at other amino acids such as cysteine and tyrosine. 263 
Oxidation of key residues on antibodies have been linked to impaired Fc effector 
function and an increased propensity to aggregate. pH is known to affect the solvent 
accessibility of a number of oxidizable residues, thus extreme pHs can drive 
oxidation. 263 
 
 High and low pH stress can cause conformational changes to a protein, which 
can result in exposure of hydrophobic regions as well as reactive residues that 
previously were not solvent accessible. 263 Furthermore, high and low pH stress can 
cause hydrolysis. Hydrolysis can lead to deamidation. 263 Hydrolysis of amino acids 
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can result in isomerisation, the transition of naturally occurring L form amino acids 
to the D forms. 268 Isomerisation in the CDR regions of an antibody have been found 
to negatively affect antigen-antibody interaction, reducing binding efficacy. 270 
 
 Solvent accessible asparagine and glutamine residues can be deamidated into 
aspartic acid. 263-266 Deamidation of asparagine residues in the CDR regions of IgG 
antibodies have been reported to affect antigen binding 265 and deamidation has 
also been associated with changes to Fc receptor dissociation. 266 
 
 Protein can become adsorbed onto liquid-solid and liquid-air interfaces such as 
the plastic containers material via hydrophobic interaction. 263, 264, 267 While 
adsorbed onto surfaces antibodies have an increased chance of further aggregating 
due to stabilising atypical conformations. 264, 267  
 
Glycation is the attachment of a sugar molecule to a protein without enzymatic 
regulation. Reports on the effect of glycation of antibodies is mixed, with some 
studies showing no effect, while others have found loss of antigen affinity and 
mannose receptor activity. 272 At 2-8 °C glycation was found to be negligible for at 
least 21 months, while at 40 °C glycation was significant within 1 week, although no 
difference in aggregation was found between glycated and control mAb at 40 °C. 272 
 
Glycosylation is also important for antibody stability, studies have found that 
deglycosylation of an antibody significantly increases the rate of unfolding and 
aggregation, however deglycosylation of an antibody typically requires enzymes 
such as PNGase F, rather than occurring naturally. 273 
 
Biopharmaceutical formulations often contain protective excipients, described 






1.6.2 Protective excipients 
 
 To help reduce the level of degradation to antibodies, excipients are added to 
the medicinal formulations. These excipient mixtures commonly include non-ionic 
surfactants, such as polysorbate 20 and 80; 263, 264, 268 pH stabilisers such as sodium 
citrate buffer, sodium phosphate buffer and L-histidine buffers; 263, 268, 268 and sugars 
such as sucrose or trehalose. 269 
 
 Non-ionic surfactants are believed to form protein-surfactant complexes and 
surface-surfactant complexes, thus inhibiting the formation of protein-surface 
complexes. 126, 150, 238, 240, 263, 264, 267 Surfactants have been shown to reduce the rate 
of antibody aggregation and dilution will reduce the stabilising effect of the 
surfactant. 126, 150, 238, 240, 267 
 
 Antibodies are typically most stable between pH 6.5 and 7.5. 148, 149 Use of pH 
buffers helps ensure the pH remains in this optimum zone during prolonged storage 
and upon dilution. 268 
 
 Sugars are sometimes added to antibody formulations as they can form 
interactions with the proteins and reduce their mobility, thus reducing their 
reactivity with other proteins and surfaces. 268, 269 Addition of sugars to antibody 
formulations has been shown to reduce the rate of oxidation and deamidation. 268 
Studies have shown that relative to other sugars such as glucose, trehalose has a 
much lower propensity for glycating antibodies. 271   
 
 While mechanisms of degradation and protective excipients overlap for 
antibodies and ADCs, there are some antibody specific stability issues, discussed in 






1.6.3 ADC specific stability issues 
 
 ADCs have additional stability concerns over antibodies, as the linker and 
warheads could detach as well as the conjugation reactions affecting the stability of 
the antibody. ADCs, such as brentuximab vedotin, utilize a Michael addition reaction 
between a free thiol of cysteine residues, with a maleimide group on the linker. 273, 
274  This causes an addition on a double bond of the maleimide. However, to generate 
solvent accessible cysteines, the intermolecular disulphide ridges are reduced, and 
the addition of a linker reduces the number of disulphide bridges holding the ADC’s 
antibody together. 273 High DAR brentuximab vedotin has a much lower stability than 
low DAR brentuximab vedotin, for example, the rate of aggregation is higher, and 
the melting temperature is much lower. 90, 91 
 
 Trastuzumab emtansine does not use cysteine to attach it’s linkers, and instead 
uses the solvent accessible thiols of lysine residues. 273 The linker SMCC contains an 
NHS ester group which reacts with free thiols on lysines, to form an amide bond. 273 
This means that there is no need to reduce the disulphide bridges that hold the ADC 
together and thus ADCs that attach their linkers via lysines have improved stability 
compared to ADCs that utilise conjugation via cysteines. 273 
 
 The attachment sites of linker to thiol are both prone to retro-Michael reactions. 
273, 275 Where present, free thiols found on glutathione, albumin or free amino acids 
such as cysteine exchange with the linker-warhead species. 273, 275 This phenomenon 
is reported to be responsible for in vivo premature payload release from ADCs such 
as trastuzumab emtansine and brentuximab vedotin. 273 However, during prolonged 
storage free thiols containing compounds should not be present to facilitate 
maleimide exchange/retro-Michael reactions. 
 
 The payloads of ADCs are also known to be hydrophobic, as discussed previously, 
hydrophobic interactions are key to antibody aggregation, which is why partial 
unfolding, stabilisation of partially unfolded antibody and hydrophobic surface 
43 
 
interaction, such as air-liquid and liquid-solid, have such significant impacts on 
biopharmaceutical aggregation. 274 The addition of up to eight hydrophobic payloads 
increases the rate of aggregation compared to the naked antibody, for example 
model ADCs aggregate faster than their parent antibodies. 90, 91, 274 
 
 Scientists have already been testing alternative linkers which are hydrophilic, 
which reduces payload hydrophobicity and cysteine re-bridging, such as the 
THIOMAB linker, which prevents loss of disulphide structural integrity when using 
cysteine thiols to conjugate to. 274 Additionally, experimentation with self-
hydrolysing maleimides in linkers has found that retro-Michael reactions can be 
prevented, improving the in vivo stability of ADCs and reducing premature payload 
release via retro-Michael reactions. 275 However, currently licensed ADCs do not yet 
use these technologies. 
  
 ADCs clearly have some additional stability issues compared to antibodies, with 
evidence pointing towards an increased propensity for aggregation via hydrophobic 
protein-protein and protein-surface interactions. 
    
 
1.7 The high cost of modern medicines 
 
Cancer therapy has come a long way since the 1940’s. The advent of chemotherapy 
and the discovery that combination therapy improved patient outcomes made 
untreatable diseases treatable. In the 1960’s non-cytotoxic small molecule drugs such 
as tamoxifen saw use alongside cytotoxic chemotherapy agents. In the 1990’s 
monoclonal antibodies emerged and revolutionized not only cancer therapy but also 
many immune disorders too. Trastuzumab, marketed as Herceptin made headlines as it 
helped treat HER2 positive breast cancers and had a much less severe side effect profile. 
Trastuzumab was found to work best when combined with traditional chemotherapy 
and is still a very popular drug when used alongside lapatinib or capecitabine for treating 
HER2 positive breast cancer. However, data from the clinical trials TH3RESA and EMILIA 
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have shown the new antibody drug therapies such as trastuzumab emtansine 
outperform gold standard therapies such as trastuzumab combined with lapatinib 103,104. 
 
Cancer therapy has also become more expensive since the 1940’s. Trastuzumab 
emtansine’s problem is its £90,000 price tag per patient. The national institute for health 
care excellence informs the NHS if a therapy is cost effective and has struggled to justify 
trastuzumab emtansine, which even after multiple “special deal” between the NHS and 
Roche, is above the top of the extended range of cost effectiveness.  
 
As previously mentioned, anticancer therapies are getting more and more 
expensive. According to the online British National Formulary, 257 the small molecule 
cytotoxic drug doxorubicin costs ~£20 per mL, rituximab costs ~£350 per mL, and 
ocrelizumab costs ~£4800 per mL. With limited funding, getting approval from the 
national institute for health care excellence is harder which makes it harder from 
patients to benefit from these ground-breaking new drugs. 
 
As already mentioned, vial wastage is a big problem, which can cost the NHS 
hundreds of thousands a year. The problem is when a drug is dosed according to 
patient weight, it is very likely that not all of the drug in a vial will eb needed, thus 
extremely valuable drug is discarded due to the short, typically 24-hour, shelf life if the 
manipulated drug. This wastes money that could be spent on funding more cancer 
therapy. A 2016 report on USA hospital overspending due to biopharmaceutical drug 
wastage reported, that over $23 million is spend on unused trastuzumab emtansine, 
$29 million is spent on unused brentuximab vedotin. 278 The authors state drug 
wastage could vary between 1% and 33% for the 10 most expensive drugs used in 
oncology. 278 The authors also suggest vial sharing as a practice that could reduce 
wastage. 278   
 
A key way to reduce the level of wastage is to manufacture multiple patients 
doses simultaneously, to reduce the amount of left over, thus wasted drug per patient, 
this is known as vial sharing. As most drugs have an SPC stipulated shelf life of only 24 
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hours once manipulated, the practice of batch manufacturing is hard to facilitate, and 
potential cost savings can be hard to achieve. However, if the shelf life was extended 
to at least a week, this would reduce the difficulty in timing the manufacture of 
multiple patients’ medicines within 7 days of their administration date, thus increase 
cost savings. Even better is to increase the shelf life to at least one dose cycle, this 
enables the manufacture of at least two products, both for the same patient which can 
enable cost savings even if only one patient exists. Furthermore, outsourcing this work 
to external aseptic compounders enables the manufacture and supply to multiple 
hospitals thus increasing the chance of having multiple patients requiring the same 
drug. 
 
Shelf life extensions bring a wealth of non-financial benefits too such as: driving costs 
per dose down due to batch manufacturing benefits and improving logistical and supply 
issues as the time limit for manufacture, shipping and administration is not as restrictive 
as 24 hours, with some drugs having three-month shelf lives, enabling hospitals to be 
stocked up and prepared for their patients. Additionally, stability can be demonstrated 
in environments previously not investigated, such as room temperature stability. Room 
temperature stability data can save the NHS and aseptic manufacturers a lot of money 
if stock is left out of the cold-chain. Anecdotal evidence from Bath ASU and NHS 
employees highlights how power cuts, fridge failures, absent minded staff and errors 
during delivery of stock can happen surprisingly often. Evidence of stability for 24-96 
hours at 25 °C can save tens of thousands of pounds per event. Furthermore, with long 
enough room temperature stability, for example seven days, some drugs can be moved 
from high cost hospital administration settings to low cost home healthcare 
administration, this also has the benefit of improving a patients quality of life as they do 
not need to travel to a hospital to receive their healthcare, 276 studies have reported 
improved clinical outcomes for patients who receive the same antibody therapy via 
home infusion services vs traditional hospital clinic services. 276, 277 
 
Due to the reasons described above, the NHS desires shelf life extensions, where 
possible and places product shelf life as a high priority when considering working with 
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external compounding units, such as Bath ASU. However, to ensure that the shelf lives 
applied to pharmaceuticals are just and proper, they have created and published their 
own guidance on deriving and assessing stability of small molecule and biopharmauticals 
drugs. 101, 102 These are described in the next section. 
 
1.8 NHS stability guidance 
 
The NHS has published two documents called “Standard Protocol for Deriving 
and Assessment of Stability, Part 1: Aseptic Preparations (Small Molecules), Edition 4, 
April 2017 (Yellow Cover)” 101 and “Standard Protocol for Deriving and Assessment of 
Stability, Part 2: Aseptic Preparations (Biopharmaceuticals), Edition 4, April 2017 (Yellow 
Cover)” 102. Yellow Cover part 1 deals only with non-peptide drugs with a molecular 
weight (MW) less than 2000 Dalton, and the Yellow cover part 2 covers 
biopharmaceuticals such as peptides, antibodies and fusion proteins. 
 
The yellow cover documents were written by the R&D subgroup of the NHS 
Pharmaceutical Aseptic Services Group, the NHS Pharmaceutical Quality Assurance 
Committee and the NHS Pharmaceutical Production Committee, and subsequently 
updated by the NHS Pharmaceutical Research and Development Working Group. The 
NHS state “Published stability data may be of limited value because of inappropriate or 
inadequate analytical methodology, limited study duration, or improper processing of 
analytical data”, this is as the standards to satisfy the NHS stability documents are higher 
than in pre-existing stability assessments of pharmaceuticals. 101,102 The documents then 
list a range of key considerations when assessing or designing a study such as: relevant 
storage conditions, sample numbers, sampling frequency and minimum required 
sampling timepoints, as well as 10 critical quality attributes of a biopharmaceutical 
product: Visible changes, pH, chemical degradation, active pharmaceutical ingredient 
concentration, sub-visible particulates, Higher order structure, degradant product 
concentration, biological activity, active excipient concentrations, moisture loss and 





These documents enable assessment of stability data to ensure that NHS staff, 
such as pharmaceutical quality assurance officers for hospitals, are able to adequately 
review stability data and determine if it is of sufficient quality to be used to justify an 
extended shelf-life for a product. Conversely, the guidance documents can be used to 
ensure stability studies can be appropriately designed to justify shelf life extensions. 
Many published stability studies do not meet all the criteria, though this has improved 
with time.  For example, a 2011 paper title “Physiochemical stability of diluted 
Trastuzumab infusion solutions in polypropylene infusion bags” fails on a great number 
of point, such as not characterising: higher order structure, levels of sub-visible 
particulates or changes to functional activity. The NHS guidance documents set a level 
of scientific rigour that must be met, otherwise no shelf life extension can be applied to 
products sold to NHS hospitals. 
 
It should be noted that that it is the customer, typically a chief hospital 
pharmacist, who is ultimately responsible for the products shelf life, however they come 
to their own conclusions based on the research and data provided by companies such 
as Bath ASU or those found in published literature of a suitable quality, hence the 
importance of the NHS part 1 and 2 guidance. 
 
Both NHS stability guidance documents draw heavily from pre-existing 
documentation written by the International council for harmonization of technical 
requirements for   Pharmaceuticals for human use (ICH). These are covered in the next 
section. 
 
1.9 ICH guidance documents 
 
ICH is project that brings together the regulatory authorities of Europe, Japan 
and the Unites States, as experts of pharmaceuticals. The purpose of this council is to 
discuss scientific and technical aspects of pharmaceutical product registration, which 
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cover quality, safety, efficacy and multidisciplinary guidance.  Multiple documents about 
stability study requirements they produced are of interest. 
  
The ICH have released numerous documents since the 1990’s that have shaped 
the NHS yellow cover documents. However, the ICH guidance is less detailed and 
focussed than the NHS guidance, and much older. Important documents such as Q2 (R1) 
are over 20 years old and the most recently published document that applies to stability 
research, Q1E, is over 15 years old. The NHS yellow cover documents are more recent 
and have been strongly influenced by the ICH guidance, specifically: Q1A (R2) “Stability 
Testing of New Drug Substances”, Q1B “Stability testing: Photostability of New Drug 
Products and Substances”, Q5C “Stability Testing of Biotechnological/Biological 
Products”, Q6B “Specification: Test Procedures and Acceptance Criteria for 
Biotechnological/Biological Products” and Q1E “Evaluation and Stability Data”. The NHS 
yellow cover documents collate most relevant information from the five 
aforementioned ICH documents. 
 
A sixth document Q2 (R1) “Validation of Analytical Procedures: Text and 
Methodology” is referenced by the NHS yellow cover documents but Q2 (R1) is not 
encompassed by them. Both NHS yellow cover documents state that analytical 
techniques should be validated to the standard set out in Q2 (R1). ICH Q2 (R1) covers 
how to perform tests of linearity, precision, specificity, accuracy, robustness, and limits 
of detection and quantitation. 
 
Following the NHS stability guidance documents and the ICH Q2 (R1) guidance 
enables the design and validation of studies to investigate the stability of small molecule 
and biological drugs to performed to a standard enabling shelf life extensions for the 







1.10 Aims and objectives 
 
ADCs have unique structural characteristics unlike conventional biopharmaceuticals 
and stability studies of ADCs are not covered by any existing guidance, though many 
similarities do exist between antibodies and ADCs. The NHS part 2 guidance states 
“Currently this group of products is outside of the scope of this document, although the 
principles may be relevant in assessing the antibody component of the conjugate”. 102 
 
The overall aim of this thesis was to develop methods for the characterisation of an 
ADC trastuzumab emtansine product. These methods must be stability indicating and 
must encompass all 10 stated critical characteristics of biopharmaceuticals in the NHS 
guidance, 102 as well as any additional critical quality attributes that ADCs have. These 
methods would then enable a stability study to be performed on trastuzumab 
emtansine, for the purpose of applying an extended shelf-life, beyond its current 24 
hours. 
 
An extended shelf life trastuzumab emtansine product would have several benefits, 
such as enabling batch production of trastuzumab emtansine which will save thousands 
of pounds per patient, as well as loosening the logistical constraints between 
manufacturing and administration of the product. Ideally the shelf life would be 
extended beyond 21 days, which is a full dose cycle for trastuzumab emtansine, thus 
enabling cost savings on a single patient basis. Remember that trastuzumab emtansine 
drug wastage is estimated to cost the USA over $23 and it is estimated that on average 
8 mg of trastuzumab emtansine is wasted per dose, which is worth £1312, 278 
furthermore each patient receives an average of 40 doses. 103, 104 Therefore the average 
cost of drug wastage per patient is £52,480. 
 
It would be beneficial for sufferers of HER2 positive breast cancer, the NHS, private 
UK hospitals and Bath ASU to be able to extend the shelf life of trastuzumab emtansine. 
Extended shelf life trastuzumab emtansine will provide Bath ASU with a competitive 
edge in the aseptic manufacturing business, increasing their chance of sales to hospitals 
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and reducing their own waste costs. The NHS and private hospitals will benefit due to 
reduced cost per patient due to reduced wastage and reduced risk to staff, as 
concentrated trastuzumab emtansine will not need to be handled by their staff. Both 
Bath ASU, and hospitals will benefit due to the increased window of time available 
between manufacture and administration, greatly reducing scheduling conflicts and the 
cost burden of missed deliveries or missed administrations due to sickness. A 2015 study 
found 13% of chemotherapy infusions were cancelled late, causing high cost drug 
wastage. 279 
 
This stability study cannot be easily performed, as ADCs are not covered by current 
stability guidance, and it is already known that some current characterisation techniques 
used for antibodies are affected when applied to ADCs. 173  
 
Chapter 2 of this thesis describes the methods and materials used during the project, 
though some experimental detail is also presented in subsequent chapters, especially 
where method optimisation is involved. 
 
Chapter 3 describes work carried out towards identifying critical characteristics that 
must be assessed during an ADC stability study, selection of appropriate methods for 
assessing each characteristic, validation of these methods on the standard therapeutic 
antibody infliximab, and results from a published stability study using these methods. 
The published stability study was performed on a mAb (infliximab) as an easy starter 
project, to practice validating methods that ought to work and to get a publication. This 
involved literature research, focussing on the NHS yellow cover documents Part 1 101 
and Part 2 102 as well as research papers that have fully or partially characterised a mAb 
or ADC. This is critical for the project as it is known that the structure of ADCs makes 
them unsuitable for frequently used antibody characterisation techniques. 
Furthermore, the structure of ADCs means there are additional characteristics, such as 
the DAR that may be vital to assess during a stability study that could have implications 




Chapter 4 details the work carried out to validate the developed methods described 
in Chapter 3 towards application on trastuzumab emtansine, as well as developing 
methods using mass spectrometry for characterising characteristics unique to ADCs, 
such as using mass spectrometry to assess payload binding on reduced ADCs. This 
chapter also includes results from a full stability study carried out on trastuzumab 
emtansine. 
 
Chapter 5 describes an investigation into the effect that container (infusion bag) 
material and construction has on biopharmaceutical stability. Three biopharmaceuticals 
are subjected to extended storage in three different types of infusion bags, and the 
impact on stability are investigated. This work was an outcome of Bath ASU’s customer 
feedback, requesting products with extended stability be stored in containers different 
to those which had been used during the stability study. 
 
Chapter 6 describes some preliminary investigations carried out into the in-use 
environmental safety of trastuzumab emtansine. Theoretically, the cytotoxic warheads 
of an ADC could become detached upon prolonged storage, or upon exposure to certain 
handling conditions such as spill clean-up. This poses a potential health risk as the 
warheads cytotoxic activity is typically kept in check by being bound to the antibody, but 
once detached it has implications for the safety of any persons involved in compounding, 
transporting, or administrating the final product. 
 
Chapter 7 describes preliminary work carried out in determining the compatibilities 
of methods developed for trastuzumab emtansine towards brentuximab vedotin. Both 
trastuzumab emtansine and brentuximab vedotin share the overall design of an ADC, 
however the specific sites of attachment and linker chemistry of the two drugs are 
significantly are different and affect method suitability. This work is important as it will 
inform the next steps taken for a potential stability study on brentuximab vedotin. 
 
Chapter 8 presents a conclusion to the thesis, summarising the main achievements 
to come out of this project, as well as a discussion about possible future work. 
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Chapter 2. Materials and methods 
2  
2.1 General reagents 
Ultrapure Water with a resistivity of > 10 MΩ/cm was produced onsite by a 
Direct-Q 3 water purification machine (Merck Millipore, Massachusetts, USA). Analytical 
grade; Tris(2-carboxyethyl)phosphine (TCEP), sodium monophosphate, sodium 
diphosphate, potassium monophosphate, potassium diphosphate, sodium azide and 
sodium chloride were purchased from Sigma Aldrich (Sigma Aldrich, Dorset, UK). Amicon 
ultra 0.5 mL 100 kDa centrifugal filters, Bos taurus albumin, Bos taurus catalase, Bos 
taurus RNase A, Homo sapien Haemoglobin, Equus ferrus Myoglobin, Amoracia 
rusticana Peroxidase I, Gallus gallus domesticus Lysozome, Leporidae Aldolase, Glycine 
max Lipoxidase, Pichia Pastoris Alcohol Oxidase, Aspergillus niger Glucose Oxidase, 
Saccharomyces cerivisae  Alcohol Dehydrogenase I, Sus Trypsin, and Canavalia 
enisformis  Concanvalin A were purchased from Sigma Aldrich (Sigma Aldrich, Dorset, 
UK). 
 
MAbPac HIC-10 LC columns, Fisherbrand 0.5 mL, 0.6 mL and 1.5 mL 
microcentrifuge tubes, Fisherbrand 15 mL and 50 mL centrifuge tubes, Roswell Park 
Memorial Institute (RPMI)-1640 cell media, Dulbecco’s modified eagle media (DMEM) 
cell media, cell culture grade penicillin 10,000 units/mL, cell culture grade streptomycin 
10 mg/mL, cell culture grade heat inactivated foetal calf serum, pH 7.4 Phosphate 
Buffered Saline, HyQTase cell detachment solution, desiccated MTT powder, 
Hellmannex III cuvette cleaning solution and Fisherbrand T75 cell culture treated flasks 
were purchased from (ThermoFisher Scientific, Massachusetts, USA). Analytical grade 
Hipersolv CHROMANORM brand isopropanol, methanol and acetonitrile were 
purchased from VWR Scientific (VWR Scientific, Fontenay, France). 
 
 Injekt BBraun syringes (1 mL, 5 mL and 10 mL) were obtained BBraun (BBraun, 
Sheffield, UK). Brentuximab vedotin (Adcetris) 50 mg vials and Vedolizumab (Entyvio) 
300 mg vials were obtained from Takeda (Takeda UK Ltd, High Wycombe, UK). 
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Natalizumab (Tysabri) 300 mg vials were obtained from Biogen (Biogen Idec Ltd, 
Maidenhead UK). Ofatumumab (Arzerra) 100 mg vials were obtained from Novartis 
(Novartis Pharmacuticals UK Ltd, Camberley, UK). Nivolumab (Opdivo) 40 mg vials were 
obtained from Bristol-Myers Squibb (Bristol-Myers Squibb Pharmaceuticals limited, 
Uxbridge, UK). Bevacizumab (Avastin) 100 mg vials, Obinituzumab (Gazyvaro) 1000 mg 
vials, Pertuzumab (Perjeta) 420 mg vials, Rituximab (Mabthera) 100 mg vials, 
Trastuzumab (Herceptin) 150 mg vials and Trastuzumab emtansine (Kadcyla) 100 mg 
vials were obtained from Roche (Roche Products Limited, Hertfordshire, UK).  Abatacept 
(Orencia) 250 mg vials were obtained from Bristol-Myers Squibb Pharma EEIG (Uxbridge, 
Greater London, UK).  Infliximab (Remsima) 100 mg vials were obtained from Napp 
(Napp Pharmaceuticals, Cambridge, UK). Cetuximab (Erbitux) 100 mg vials were 
obtained from Merck (Merck Serono Ltd, Middlesex, UK). Denosomab (Prolia) 60 mg 
vials were obtained from Amgen (Amgen Ltd, Cambridge, UK). 
 
Viaflo infusion bags of sodium chloride 0.9% sterile solution for infusion were 
obtained from Baxter (Thetford, Norfolk, UK). Freeflex infusion bags of sodium chloride 
0.9% sterile solution for infusion were obtained from Fresenius Kabi (Runcorn, Cheshire, 
UK). Macoflex-N infusion bags of sodium chloride 0.9% sterile solution for infusion were 
obtained from MacoPharma (Tourcoing, Nord, France). 
 
Tosoh TSKgel G3000SWxl size exclusion HPLC columns, Tosoh TSKgel Butyl-NPR 
columns, BIA Separations CIM r-Protein G DISKs, BIA Separations CIM r-Protein A DISKs 
and BIA Separations CIM C4 DISKs were purchased from Hichrom (Hichrom Ltd, Reading, 
UK). BioSep-SEC-s3000 columns and Yarra-SEC-s3000 columns were purchased from 
Phenomenex (Phenomenex, Cheshire, UK). 
 
PNGase F and PNGase F Rapid were purchased from New England Biolabs (New 
England BioLabs, Massachusetts, USA). 
 
BT-474 human mammary gland epithelial cells, HaCaT human keratinocyte 
epidermal cells, HepG2 human liver epithelial cells and WEHI 164 murine fibroblast cells 
54 
 
were purchased from ATCC via LGC (LGC Standards, Middlesex, UK). GCT-27 human 
testicular germ cell tumour cells were purchased from DSMZ (Leibniz-Institut DSMZ-
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, 
Germany). Recombinant human TNF-alpha protein (97%) and  actinomycin-D (98%) 
were purchased from R&D Systems (R&D Systems Inc, Minneapolis, Cananda). 
 
Lidl brand cotton buds were purchased from Lidl (Lidl UK, Wimbledon, UK). 
Klercide 70|30 Denatured Ethanol (Ecolab Ltd, Northwich, UK), Actichlor Chlorine 
disinfectant (Ecolab ltd, Northwich, UK) Sterile Prochlor stabilised hypochlorous acid 
spray (Contec, Vannes, France), InSpec N10 non-sterile prediluted detergent solution 
(Redditch Medical, County Durham, UK) were purchased via CleanRoomShop (Connect 
2 Cleanrooms Ltd, Lancaster, UK). 
 
2.2 General methods for analysis 
 
2.2.1 Moisture loss  
 
During both stability studies carried out for this thesis, the infusion bag masses 
were recorded for each sample before and after sampling at each time point to check 
for moisture loss upon storage. This was performed using an Ohaus Adventure Pro 
laboratory balance (Ohaus, Greifensee, Switzerland). The masses were recorded by 
contemporaneous printouts via an Ohaus SF40A printer (Ohaus, Greifensee, 
Switzerland). The balance was zeroed, and a measurement taken before placing a bag 
and taking a reading once the mass was stable. 
 
2.2.2 Visual inspection  
 
Prior to any analytical methods being performed, samples were checked 
according to ‘Method 2.9.20 Appendix XIII B. Particulate Contamination’ from the British 
Pharmacopeia. 110 The method detects visible particulates distinguished by the unaided 
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eye under normal laboratory fluorescent light against dark and white backgrounds as 
well as changes in colour and/or turbidity.   Digital photographs of test sample syringes 
(e.g. after sampling from storage bag containers) were collected at each timepoint using 
a Canon Ixus 230 HS camera (Canon, Middlesex, UK).  
 
2.2.3 pH analysis  
 
Samples were tested using a Mettler-Toledo Seven Compact pH Meter equipped 
with a Mettler Toledo InLab Micro electrode (Mettler-Toledo, Leicestershire, UK). These 
were calibrated with Certipur® pH 4.00, 7.00 and 10.00 25 °C buffers, (Merck KGaA, 
Darmstadt, Germany) immediately prior to the first analysis of everyday. The calibration 
standards are purchased from Sigma Aldrich (Gillingham, Dorset, UK). The electrode 
were stored in a 15 mL centrifuge tube containing 10 mL of Mettler-Toledo KCL 3 mol/L 
Electrolyte Solution (Mettler-Toledo, Leicestershire, UK). Sample measurements are 
recorded using the Mettler Toledo LabX Direct software (Mettler-Toledo, Leicestershire, 
UK). The electrode was rinsed with ultrapure water before being dipped into the sample 
ensuring the electrode did not touch the centrifuge tube. The electrode was agitated 
until the pH reading stabilises, then a reading was taken and recorded by LabX Direct. 
 
2.2.4 Dynamic light scattering analysis of subvisible particles 
 
Each sample (0.2 mL) was analysed on a Zetasizer Nano-S instrument (Malvern 
Instruments, Worcestershire, UK) using a red laser at a wavelength of 633 nm and a 
Hellma Quartz-Suprasil cuvette, Type 105.251.005-QS, Light path 3 x 3 mm, Centre 9.65 
mm (Hellma Analytics, Essex, UK).  Samples were tested in triplicate at 20 °C.  All data 
was recorded based on intensity and converted to relative percentage by volume using 
Zetasizer software v.6.20 and cumulants fit analysis. The cuvettes were filled with and 
soaked in a 5% w/v Hellmannex cuvette cleaning solution (Hellma Analytics, Essex, UK) 
for two minutes, before being rinsed out with ultrapure water. The cuvette was rinsed 
out with ultrapure water between each sample. A mean was calculated from the three 




2.2.5 Nanoparticle tracking analysis 
 
Nanoparticle tracking analysis was performed using a Nanosight-LM10 (Malvern 
Instruments, Worcestershire, UK), set up with the version C red laser unit.  The detection 
threshold was set at 30.  Samples were analysed in triplicate, and measurements were 
recorded from runs of 60 seconds in duration. The camera level was optimised manually 
for each concentration on Day 0. It was then kept fixed at that level for the duration of 
the study to ensure no change in the image contrast. A mean average was calculated 
from the three repeated measurements taken. 
 
2.2.6 Microflow imaging analysis of microparticles  
 
Microflow imaging (MFI) was performed with a Fluid Imaging Technologies 
FlowCAM VS instrument (Fluid Imaging Technologies, Massachusetts, USA) fitted with 
an FC100 flow cell. The FC100 width is 2000 μm and the depth is 100 μm. The FC100’s 
tubing is cut to the following specified dimensions, length above flow cell = 105 mm, 
length below tubing = 175 mm.  The flow rate was set at 0.15 mL/min, with an imaging 
rate of 20 frames/second, a volume of analysis of 250 μL and a calculated efficiency of 
34.5 %. Visual focus calibration was manually performed with 10 µm polystyrene beads 
and data analysed using Visual Spreadsheet software version 4.2.  All samples were 
measured in triplicate and a mean average is calculated from the three repeated 
measurements taken. 
 
Results were binned using digital filters into three categories sequentially. These 
were as follows, ‘Total Reading’ which has no filters, effectively generating a raw total 
reading. ‘>10 μm’ which only includes particles from the ‘Total Reading’ which conform 
to the following three filters: an aspect ratio between 0.0 and 0.8, a circle fit between 
0.0 and 0.8 and a length of 10 μm to 1000. ‘>25 μm’ which only includes particles from 
the ‘>10 μm’ which conform to the following three filters: an aspect ratio between 0.0 - 
0.8, a circle fit between 0.0 and 0.8 and a length of 25 μm to 1000. While these filters 
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reduce the number of oil droplets and air bubbles, as well as rapidly removing particles 
less than 10 or 25 μm, often manual particle removal is required. This was done via visual 
inspection of the data from the ‘>10 μm’ bin and ‘>25 μm’ bin. 
 
2.2.7 Gel Electrophoresis 
 
Gel electrophoresis was performed with an Agilent 2200 series TapeStation 
system (Agilent Technologies, Waldbronn, Germany), in combination with the Agilent 
Screen Tape P200 Protein Standard Kit Part number: 5067-5371 (Agilent Technologies, 
Waldbronn, Germany).  Samples were analysed under reducing and non-reducing 
conditions using P200 Reagents (Part number: 5067-5372). These were used according 
to the manufacturer’s instructions.  The pre-stained reagent P200 Marker was used as a 
molecular marker (Agilent Technologies, Waldbronn, Germany).  
 
Samples were diluted to a concentration of 0.5 mg/mL with sodium chloride 
0.9%. 2 μL of diluted sample was mixed with 2 μL of P200 stain reagent. This resultant 
mixture was centrifuged for 10 seconds with a Heathrow benchtop ‘Sprout’ centrifuge 
(Heathrow Scientific LLC, Illinois, USA). Then transferred to an IKA MS 3 Vortexer (IKA 
England LTD, Oxford, UK), the sample was vortexed for 15 seconds, then transferred to 
a ‘PRO-LAB Benchmark myBlock Mini Dry Bath’ (PRO-LAB, Toronto, Canada) preheated 
to 70 °C. After 7 minutes the samples were removed from the dry block and spun in the 
sprout centrifuge for another 10 seconds. The sample then had 4 μL of either P200 
reducing sample buffer or P200 non-reducing sample buffer added, depending on if the 
sample was to be reduced or not. This resultant mixture was then centrifuged for 10 
seconds with the sprout centrifuge, then transferred to the vortexer and vortexed for 
15 seconds, then transferred to the dry bath. After 7 minutes the samples were removed 
from the dry block and spun in the sprout centrifuge for another 10 seconds. Then 2 μL 
of pre-stained reagent P200 Marker was added. This resultant mixture was then 
centrifuged for 10 seconds with the sprout centrifuge, then transferred to the vortexer 
and vortexed for 30 seconds, then centrifuged for 10 seconds with the sprout centrifuge. 
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This final mixture is what was run on the Tapestation and this process is in accordance 
to the manufacturer’s instructions. 
 
2.2.8 Circular dichroism analysis of secondary structure 
 
Circular dichroism analysis was performed using a Chirascan spectrophotometer 
(Applied Photophysics Ltd, Surrey, UK) in conjunction with the software ‘Chirascan’ and 
‘Pro-Data Viewer‘ (Applied Photophysics Ltd, Surrey, UK). 250 μL of each sample from a 
single concentration were pooled and diluted to a concentration of 0.3 mg/mL with 
sodium chloride 0.9%. 400 μL was transferred to a Quartz Suprasil Cuvette (Hellma 
Analytics, Essex, UK) with a pathlength 0.1 cm. The cuvettes were filled with and soaked 
in a 5% w/v Hellmannex cuvette cleaning solution (Hellma Analytics, Essex, UK) for two 
minutes, before being washed and rinsed out with ultrapure water, prior to being used 
to measure any sample.  CD spectra were collected in the far-UV region (205 to 260 nm) 
over a temperature range of 25-90 °C in steps of 1 °C at a rate of 1 °C / minute.  Final CD 
spectra had blank subtraction using the diluent NaCl 0.9% w/v as the blank. The spectra 
were then smoothed using the Pro-Data viewer. The smoothed data was then converted 
from a dsx file to a txt file using ‘APL Data Converter’ (Applied Photophysics Ltd, Surrey, 
UK). This txt file cold then be analysed by the CDNN software version 2.1 (Gerald Bohm, 
Magderburg, Germany). CDNN estimates secondary protein structure composition using 
the accurate mass of the protein, the number of amino acids, the CD spectrometers path 
length and the sample’s concentration. CDNN was set to use the 33-base spectra library 
during the deconvolution process. 
 
2.2.9 Infrared spectroscopy secondary structure determination 
 
The secondary structure of the trastuzumab emtansine protein was measured 
using a Tensor II Fourier Transform Infrared Spectrophotometer (Bruker, Coventry, UK) 
fitted with a supercooled HgCdTe photovoltaic detector and BioATR II sample interface 
device. These are controlled using the OPUS software version (Bruker, Coventry, UK). 
The instrument is purged with purified, dried air using a CleanAIR pump (Aariac, Italy), 
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maintained at 25 °C using a Ministat-125 water-circulation thermostat (Huber, 
Offenburg, Germany) and the HgCdTe detector reservoir has been filled with 300 mL of 
liquid nitrogen, for at least 30 minutes before analysis. Sample volume was 20 μL, 
applied using a pipette to the sample well.   120 scans were run between 4000-900 cm-
1 with a resolution of 4 cm-1 and a scanning duration of 55 seconds. The sample well was 
rinsed with sodium chloride 0.9% solution, and the well physically dried and cleaned 
with a cotton bud between each sample.  Sodium chloride 0.9% was used as a 
background sample, and five replicate measurements of each sample were made, with 
a fresh background reading taken between each sample measurement. Spectra are 
compared to a pre-processed quantitative data set to estimate the alpha helix and beta 
sheet structural content. The mean average is calculated for alpha helix and beta sheet 
for the quintuplicate measurements. The QDS was generated as part of this PhD project 
and design, construction and validation of the QDS is described in section 4.3. 
 
2.2.10 UV Spectrophotometry  
 
Total UV absorbance was measured using a FLUOStar plate reader (BMG Labs, 
Aylesbury, UK). Spectra (220-400 nm) were obtained to monitor for the accumulation of 
leachable substances. Absorbance at 280 nm was also recorded as a measure of protein 
concentration throughout the study period (single analysis only for each concentration).  
Samples were run undiluted and corrected for sodium chloride 0.9% absorbance which 
was run as a blank. 10 μL of each sample was transferred to a BMG UV-VIS microplate 
for UV plate analysis. 
 
2.2.11 Cellular activity assay using MTT 
 
This refers to the reading of a 96 well plate regardless of which experimental set 
up was used. The assay plates were removed from the incubator after incubation for 96 
hours at 37 °C. Using a Fisherbrand FB70155 vacuum pump (ThermoFisher Scientific, 
Massachusetts, USA) the cell media and diluted drug were aspirated out of each well. 
100 μL of 1 mg/mL Dimethylthiazol-2-yl diphenyltetrazolium bromide (MTT) (Sigma 
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Aldrich, Dorset, UK) and 10% foetal calf serum (ThermoFisher Scientific, Massachusetts, 
USA) in colourless cell medium was added to each well. The plates were then returned 
to the incubator for a further 4 hours. The plates were removed from the incubator and 
the MTT solution aspirated off. 100 μL of dimethyl sulfoxide (ThermoFisher Scientific, 
Massachusetts, USA) was added to each well and the plate then gently rocked on the 
IKA MS3 vortexer, before reading the plates absorbance at 540 nm in a FLUOStar 
OMEGA plate reader (BMG Labs, Aylesbury, UK. Percent cell viability was then calculated 
as (A540 sample/A540 negative control) × 100. Values were then indexed against values 
obtained for control samples, to control for inter-assay variability. Each sample was 
tested in quintuplicate and the mean and standard deviation calculated. 
 
2.2.12 LC-MS sample preparation  
 
Aliquots of samples (600 μL) were individually frozen in 0.6 mL microcentrifuge 
tubes at minus 80 °C until the day of analysis. Samples were thawed at room 
temperature over 1 hour.  Samples were pooled by combining 125 µl of each sample 
from a single concentration group to give a total of 500 µL per concentration. This was 
transferred to an AMICON ultra® 100 kDa centrifugal filter tube (Merck KGaA, 
Darmstadt, Germany) which was subsequently spun at 14000 G for 10 minutes in a 
Heraeus Fresco 17 Microcentrifuge (ThermoFisher Scientific, Massachusetts, USA). The 
filtrate was discarded and 500 µL of ultrapure water was added to each sample. This 
removes 95% of salt in the sample and is repeated a further two times, removing 99.99% 
of the NaCl and excipients. The sample is then spun once more to concentrate the 
sample by 20x. The desalted and concentrated samples were then reduced by the 
addition 1 µL - 10 µL of tris-carboxyethylphosphine (TCEP) 10 mg/mL solution (Sigma 
Aldrich, Dorset, UK) , depending on drug concentration to achieve a 80 fold molar excess 







2.2.13 LC-MS measurement and data collection  
 
Chip-based analysis was conducted using a HPLC-Chip Cube system coupled to a 
6520-quadrupole time-of-flight (QTOF) mass spectrometer (Agilent Technologies, 
California, USA) operated in electrospray ionization positive-ion mode. Liquid 
chromatography was performed using a Protein-Chip (II) with a 40 nL enrichment 
column and analytical column of 43 mm x 75 µM with Zorbax 300SB-C8 packing material 
at 5 µm (Agilent Technologies, California, USA). The ChipCube source was operated at 
365 °C with 5 L/min N2 drying gas, the capillary voltage set to 2100 V and fragmentor at 
400 V. The Time of flight MS scan range was from 100 – 4000 mass-to-charge ratio (m/z) 
at an acquisition rate of 1 spectrum per second. The source was interfaced with an 
Agilent 1260/1200 series HPLC system consisting of a 1260 Cap pump, 1200 Nano pump, 
1200 Micro WPS and 1290 Infinity Thermostat (Agilent Technologies, California, USA). 
Between 0.2 and 1 µL sample was loaded on the enrichment column using the capillary 
pump flow with H2O + 0.1 % formic acid (FA) at a flow rate of 4 µL/min. The sample was 
eluted onto the analytical column using the nanopump at a flow rate of 0.6 µL/min. 
Solvent A and B consisted of H2O + 0.1 % formic acid (FA) and MeCN : H2O 90:10 with 
0.1 % formic acid. Gradient step were as follows: 0-4 min from 3 %B to 50 %B, 4-5 min 
to 100 %B, 5-11 min 100%B, 11-12 min from 100 % to 3 %B.  Internal lock mass 
calibration during the run was done using one calibrant reference mass at 1221.9906 
m/z. 
 
2.2.14 LC-MS data processing 
 
Data processing was performed using the MassHunter Workstation software 
version B.50.00 (Agilent, California, USA). LC-MS spectra (10-100 kDa) were generated 
at various timepoints and visually compared to spectra obtained on day zero or controls 





2.2.15 Hydrophobic interaction chromatography 
 
A ThermoFisher MAbPac HIC-10 (ThermoFisher Scientific, Massachusetts, USA), 
column dimensions 4.6 × 100 mm and particle size 5 μm was used for HIC analysis.  The 
HIC-10 final method used a UV detection was set to 280 nm, flow rate was 0.5 mL/min, 
injection volume was 25 μL, column oven temperature was set to 30 °C, the method was 
a gradient from 100% 3M ammonium sulphate dissolved in 100 mM potassium 
phosphate + 15mM NaN3 (pH 7.0) to 50 mM potassium phosphate + 15mM NaN3 (pH 
7.0). The gradient was over 180 minutes, the column was re-equilibrated for 10 minutes 
before the next injection at the starting conditions. 
 
2.2.16 Size exclusion chromatography – mAb 
 
Size Exclusion Chromatography (SEC) was performed on performed on Dionex 
Ultimate 3000 HPLC System (Dionex, Sunnyvale, California, USA). HPLC System 1 (HS1) 
consisted of an LPG-3400BM pump, a WPS-3000TBFC analytical autosampler, a TCC-
3000SD column oven and a VWD-3100 detector. HS1 was operated via the Dionex 
Chromeleon software version 6.8. Detection was set at 280 nm, flow was isocratic, 
injection volume was 20 μL and sample trays were thermostated at 7 °C. The sample 
was eluted on a TSKGel G4000 SWXL column with the dimensions 7.8 × 300 mm and 
particle size 8 μm, pore size 450 Å.  The mobile phase was 300 mM NaCl + 50 mM Na3PO4 
buffer at pH 6.8 in HPLC water. Samples were analysed in triplicate and a mean average 
including a standard deviation calculated from the three replicate measurements. Drug 
concentration was obtained from peak signal area using a linear regression curve of drug 
concentration vs absorption generated during drug specific method validations, see 







2.2.17 Size Exclusion Chromatography – ADC 
 
Size Exclusion Chromatography (SEC) was performed on performed on Dionex 
Ultimate 3000 HPLC System (Dionex, Sunnyvale, California, USA). HPLC System 3 (HS3) 
consisted of an HPG-3200RS pump, a WPS-3000TSL analytical autosampler, a TCC-
3100SD column oven and a DAD-3000RS detector. HS3 was operated via the Dionex 
Chromeleon software version 7.2. Sample trays were thermostated at 7 °C. a BioSep-
SEC-s4000 with dimensions 300 mm × 7.8 mm, particle size 5 μm and pore size 500 Å 
fitted with a guard column. Isocratic elution was performed with the mobile phase being 
a 16:84 mix of propan-2-ol / 100 mM potassium phosphate buffer (pH 6.80) containing 
15mM NaN3 as an anti-microbial agent.  The column temperature was 30 °C, the 
injection volume was 20 μL and UV detection was set at 280 nm.  The flow rate was 0.75 
mL/min and the run time was 25 min, with the monomer peak eluting at 12.5 minutes 
(Figure 4.19). Samples were analysed in triplicate and a mean average including a 
standard deviation calculated from the three replicate measurements. Drug 
concentration was obtained from peak signal area using a linear regression curve of drug 
concentration vs absorption generated during drug specific method validations, see 
sections 4.3 & Appendix I-III.  
 
2.2.18 Forced degradation by acid  
 
25 μL of 100 mM hydrochloric acid was mixed with 475 μL of sample. This is 
repeated three times. After 1, 2 & 3 hours at 25 °C, a sample is neutralised with 25 μL of 
100 mM sodium hydroxide. The concentration of acid during degradation is 5mM. 
 
2.2.19 Forced degradation by base  
 
25 μL of 100 mM sodium hydroxide was mixed with 475 μL of sample. This is 
repeated three times. After 1, 2 & 3 hours at 25 °C, a sample is neutralised with 25 μL of 




2.2.20 Forced degradation by oxidation 
 
200 μL of a 30% w/v aqueous hydrogen peroxide solution was mixed with 400 μL 
of sample. The sample was stored at 25 °C, until testing. The concentration of hydrogen 
peroxide is 10% w/v, during degradation. 
 
2.2.21 Forced degradation by photolysis 
 
Sample was placed in an Adelphi Apollo 1 Lightbox (Adelphi Instruments, 
Haywards Heath, UK), exposing the sample to 20,000 lux. The sample was removed after 
72 hours. 
 
2.2.22 Forced degradation by thermolysis 
  
Sample was placed in a myBlock Mini Dry Bath, at 60 °C. The sample was 
removed and sampled after 96 hours. 
 
2.2.23 Unpaired students t-test  
 
Data was assessed using a two tailed, unpaired, students t-test, performed using 
Graphpad Prism version 5.04. The confidence interval was set at 95%. 
 
2.2.24 One-way ANOVA with post hoc Bonferroni  
 
Data was assessed using a one-way analysis of variance (ANOVA) with a post hoc 
Bonferroni comparing all groups to D0 and D1 groups, this was performed using 




2.2.25 Validation of SEC HPLC method  
 
Validation of SEC methods were performed as follows: 
To demonstrate linearity, 5 concentrations of sample were tested covering the range of 
at least 20% below the lowest study concentration to at least 20% above the highest 
study concentration. These samples would be tested in triplicate and means taken. This 
is as defined in the ICH Q2 (R1) document. 103 
 
To calculate the limit of detection the mean standard deviation of the y-intercept 
was divided by the mean slope then multiplied by 3.3. This is as defined in the ICH Q2 
(R1) document. 103 
 
To calculate the limit of quantification the mean standard deviation of the y-
intercept was divided by the mean slope then multiplied by 10, this must be smaller than 
20% less than the lowest study concentration. This is as defined in the ICH Q2 (R1) 
document. 103 
 
To calculate the precision, 3 measurements of 3 samples at each test 
concentration were made, the relative standard deviation was calculated and had to be 
less than 2% for each test concentration. This is as defined in the ICH Q2 (R1) document. 
103 
As no standards exist for our drug samples, accuracy can be inferred if linearity, 
precision and selectivity have been demonstrated, as per ICH Q2 (R1). 103 
 
Selectivity can be demonstrated by forced degradation of samples to generate 
degraded samples for comparison to. According to ICH Q2 (R1), “As appropriate, this 
should include samples stored under relevant stress conditions: light, heat, humidity, 
acid/base hydrolysis and oxidation”. Thus, samples were subjected to light using method 
2.1.20, heat using method 2.1.21, acid hydrolysis using method 2.1.17, base hydrolysis 




2.3 Experimental for Chapter 3 
 
2.3.1 Preparation of infliximab validation samples 
 
Remsima brand infliximab vials were reconstituted using validated pharmacy 
procedures and in full accordance with instructions outlined within the ‘Summary of 
manufacturers Product Characteristics’ for Remsima. The 10mg/mL stock solution was 
diluted 1/10, by adding 150 μL to 1350 μL of 0.9% NaCl for injection.  The samples were 
then inverted several times to ensure good mixing, without over agitating the samples. 
This produces a 1.5 mL 1mg/mL sample of Remsima branded infliximab.  
 
2.3.2 Infliximab 96 well plate set-up 
 
Biological activity of infliximab was assessed by measuring the infliximab 
mediated ‘rescue’ of WEHI-164 cells grown in the presence of TNF-α and actinomycin D. 
WEHI-164 cells were grown in RPMI-1640 supplemented with 10% foetal calf serum with 
100 U/mL penicillin and 0.1 mg/mL streptomycin. WEHI cells were harvested from 
culture and seeded in a Nunclon, cell culture treated, 96 well, flat bottomed, clear 
plastic, plate (ThermoFisher Scientific, Massachusetts, USA) at 1.5 x 104 cells/well and 
incubated for 2 hours at 37 °C in a Heraeus BBD 6220 incubator (ThermoFisher Scientific, 
Massachusetts, USA). To assess inhibition of TNF-α induced cell death, infliximab was 
diluted to 3 μg/mL in a 10 pg/mL solution of TNF-α. This solution was incubated in a 
Heraeus BBD 6220 incubator (ThermoFisher Scientific, Massachusetts, USA) at 37 °C for 
30 minutes before adding 10 μL/well for a final well concentration of 1 μg/mL μg/mL. 
Finally, 10 μL of a 20 μg/mL actinomycin-D solution was added to each well, yielding a 
final concentration of 2 μg/mL actinomycin-D. The cell line, and concentrations of TNF-
α and actinomycin-D are the same as those used in three published studies investigating 
activity of infliximab. 106-108 The actinomycin D induces a higher level of apoptosis, 




2.3.3  Preparation of Remsima study devices 
 
Remsima products under study were prepared under aseptic conditions in line 
with Good Manufacturing Practice, using validated pharmacy procedures and in full 
accordance with instructions outlined within the Summary of manufacturers Product 
Characteristics for Remsima. Products were prepared at a clinically high, common and 
low concentration by reconstituting the vials with water for injection to give a 10 mL 
concentrated stock solution.  The stock solution was added to a Freeflex polyolefin 
infusion bag of sodium chloride 0.9 % w/v and stored at 2-8˚C in light-protective bags.  
On the day of analysis, samples were removed from each test product bag using aseptic 
technique by withdrawing 4 mL into a lubricant-free syringe, which was capped and 
stored at 2-8˚C during the analysis period.  All test products were prepared in 
quadruplicate thus a total of 4 bags at each test concentration were compounded and 
used for analysis. 
 
2.3.4  Remsima sampling schedule 
 
Samples were analysed on the day of test product preparation (Day 0) and then 
at days 1, 2, 4 and 7 for batches at the high and low concentration.  Samples were 
analysed on the day of test product preparation (Day 0) and then at days 1, 2, 3 and 7 
for the batch at the common concentration mg/mL. Test product samples were analysed 
using the listed range of physico-chemical and biological techniques to assess the 
physical, chemical and functional stability profiles of Remsima at each time point. 
  
2.4 Experimental for Chapter 4 
 
2.4.1  Preparation of validation samples 
 
Kadcyla brand trastuzumab emtansine vials were reconstituted using validated 
pharmacy procedures and in full accordance with instructions outlined within the 
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‘Summary of manufacturers Product Characteristics’ for Kadcyla. The 20mg/mL stock 
solution was diluted 1/20, by adding 75 μL to 1425 μL of 0.9% NaCl for injection.  The 
samples were then inverted several times to ensure good mixing, without over agitating 





2.4.2 Trastuzumab emtansine 96 well plate set up 
 
Biological activity of trastuzumab emtansine was assessed by measuring the 
trastuzumab emtansine mediated growth inhibition of three different cell lines. The cell 
line used for on-target toxicity was BT-474 cells, grown in RPMI-1640 supplemented with 
10% foetal calf serum with 100 U/mL penicillin and 0.1 mg/mL streptomycin. The cell 
lines used to assess off-target toxicity were HepG2 and HaCaT, grown in DMEM 
supplemented with 10% foetal calf serum with 100 U/mL penicillin and 0.1 mg/mL 
streptomycin. Cells were harvested from culture and seeded in a Nunclon, cell culture 
treated, 96 well, flat bottomed, clear plastic, plate (ThermoFisher Scientific, 
Massachusetts, USA) at 1.5 x 104 cells/well and incubated for 4 hours at 37 °C in a 
Heraeus BBD 6220 incubator (ThermoFisher Scientific, Massachusetts, USA). 
Trastuzumab emtansine samples were diluted to 3000 μg/mL, 1000 μg/mL and 30 μg/mL 
in NaCl 0.9% for injection. 10 μL of these trastuzumab emtansine solutions were added 
to wells of HepG2 cells, HaCaT cells, and BT-474 cells, respectively. The final well 
concentration of trastuzumab emtansine was 300 μg/mL, 100 μg/mL and 3 μg/mL for 
HepG2 cells, HaCaT cells, and BT-474 cells, respectively. Assay plates were incubated for 
96 hours at 37 °C before assessment via an MTT assay according to method 2.2.11. 
 
2.4.3 Size exclusion chromatography – Yarra-SEC-3000 
 
This was performed on HS3, using a Phenomenex Yarra 3 μm SEC-3000 column, 
with dimension 300 x 4.6 mm. Detection was at 280 nm, flow rate was 0.35 mL/min for 
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20 minutes, injection volume was 2 μL, Mobile phase was 0.1 M sodium phosphate 
buffer (pH 6.8) + 0.3 M sodium chloride + 0.25% sodium azide. Autosampler thermostat 
was set at 7 °C. Column oven temperature 25 °C. 
 
2.4.4  Size exclusion chromatography – Organic modifier 
 
This is method 2.2.17 except, the mobile phase was a ratio of 0.1 M sodium 
phosphate buffer (pH 6.8) + 0.3M NaCl + 0.25% sodium azide to 5, 10, 15 and 20% 
ethanol, acetonitrile or propan-2-ol. 
 
2.4.5  Size exclusion chromatography – Potassium vs sodium 
 
This is method 2.2.17 except, the mobile phase was adjusted as part of this 
experiment. The mobile phase was 90% 0.1M sodium or potassium phosphate buffer 
(pH 6.8) + 0.3M NaCl + 0.25% sodium azide to 10% propan-2-ol. 
 
2.4.6  Size exclusion chromatography - Alkali chloride concentration 
 
This is method 2.2.17 except, the mobile phase was adjusted as part of this 
experiment. The mobile phase was 90% 0.1M potassium phosphate buffer (pH 6.8) + 0.3 
or 0.0 M NaCl + 0.25% sodium azide to 10% propan-2-ol. 
 
2.4.7  Size Exclusion Chromatography – Buffer concentration 
 
This is method 2.2.17 except, the mobile phase was adjusted as part of this 
experiment. The mobile phase was 90-25% 0.1M potassium phosphate buffer (pH 6.8) 






2.4.8  Size exclusion chromatography – Isopropanol 0-30% 
 
This is method 2.2.17 except, the mobile phase was adjusted as part of this 
experiment. The mobile phase was 85% -70% 0.1M potassium phosphate buffer (pH 6.8) 
+ 0.25% sodium to 15-0% ultrapure water azide to 0-30% propan-2-ol. Exact 
combinations of propan-2-ol : water : buffer are below. 0:15:85, 5:10:85, 10:5:85, 
15:0:85, 20:0:80, 25:0:75, 30:0:70. 
 
2.4.9  Size exclusion chromatography – Isopropanol 14-17% 
 
This is method 2.2.17 except, the mobile phase was adjusted as part of this 
experiment. The mobile phase was 85% -83% 0.1M potassium phosphate buffer (pH 6.8) 
+ 0.25% sodium to 1-0% ultrapure water azide to 14-17% propan-2-ol. Exact 
combinations of propna-2-ol : water : buffer are below. 14:1:85, 15:0:85, 16:0:84, 
16.5:0:83.5, 17:0:83. 
 
2.4.10 Size exclusion chromatography – Column temperature 
 
This is method 2.2.17 except, the column oven temperature was tested at 25 °C, 
30 °C, 35 °C and 40 °C. 
 
2.4.11 Size exclusion chromatography – Flow rate 
 
This is method 2.2.17 except, the flow rate was tested at 0.5, 0.75, 1.0, 1.25 and 
1.5 mL/min over 30 min, and UV absorbance measured at 280 nm. 
 
2.4.12 Infrared spectroscopy QDS initial protein acquisitions 
 
10 mg ± 0.1 mg of each of the 15 proteins was weighed out into a 10 mL 
volumetric flask. This was then reconstituted in 0.9% NaCl for injection to make a final 
71 
 
concentration of 1 mg/mL. The Tensor 2, with the BioATR fitted, was purged for 30 
minutes before the sample well was cleaned using 5% v/v Hellmannex III solution. The 
well was rinsed out with ultrapure water and dried with soft cotton buds (Lidl, London, 
UK). 20 μL of 0.9% NaCl for injection was pipetted into the sample well, then a 
background reading was taken. The full settings for each sample measurement are 
described in (Table 4.6). Once the background had been fully acquired, the NaCl was 
completely drawn up and discarded using a 100 μL pipette (Gilson, Bedforshire, UK). 
Then 20 μL of a protein solution would be pipetted into the well. A measurement would 
be recorded, then the sample drawn up and discarded, the cell rinsed with ultrapure 
water, dried with a cotton bud then 20 μL of 0.9% NaCl for injection was pipetted into 
the sample well, then a background reading was taken. This was repeated until three 
spectra had been recorded for each protein solution. These 42 spectra were used to 
create the QDS. 
 
2.4.13 Infrared spectroscopy vs Circular dichroism spectroscopy 
 
Vials of bevacizumab, cetuximab, denosumab, infliximab, natalizumab, 
nivolumab, obinituzumab, ofatumumab, pertuzumab, rituximab, trastuzumab, 
vedolizumab and trastuzumab emtansine were reconstituted according to their 
individual summary of product characteristics, using sterile water for injection. These 
concentrated solutions were diluted in triplicate to 1 mg/mL and 0.3 mg/mL in 0.9% w/v 
NaCl for injection. The 0.3mg /mL samples were measured using circular dichroism 
 
2.4.14 Infrared spectroscopy structure determination validation 
 
A vial of obinituzumab and a vial trastuzumab emtansine were reconstituted 
according to their individual summary of product characteristics, using sterile water for 
injection. These concentrated solutions were diluted in triplicate to 1 mg/mL in 0.9% 




2.4.15 Hydrophobic interaction chromatography – TSKGel Butyl NPR 
 
HIC was performed using HS2. HS2 consisted of an LPG-3400SD pump, WPS-3000 
analytical autosampler, TCC-3000 column oven and DAD-3000 multiple-wavelength 
detector. The column used was a TSKgel Butyl-NPR (TOSOH BioScience, Stuttgart, 
Germany), column dimensions 4.6 × 35 mm and particle size 2.5 μm. The TSKgel final 
method used a UV detection was set to 280 nm, flow rate was 1 mL/min, injection 
volume was 25 μL, column oven temperature was set to 30 °C, the method was a 
gradient from 100% 1.5M ammonium sulphate dissolved in 100 mM potassium 
phosphate + 15mM NaN3 (pH 6.80) to 100 mM potassium phosphate + 15mM NaN3 (pH 
6.80). The gradient was over 150 seconds and was held for 30 seconds before returning 
in 30 seconds to the starting conditions which were held to re-equilibrate for 150 
seconds before the next injection. 
 
2.4.16 Hydrophobic interaction chromatography - CIM r-Protein & C4 
 
Dual HIC & Affinity chromatography using CIM r-Protein G/A Disks in 
combination with the CIM C4 A Disk. CIM disks were found unsuitable. No final method 
was achieved. However, the following method was used during early experimentation. 
 
HIC was performed using HS2. HS2 consisted of an LPG-3400SD pump, WPS-3000 
analytical autosampler, TCC-3000 column oven and DAD-3000 multiple-wavelength 
detector.  UV detection was set to 280 nm, flow rate was 1.0 mL/min, injection volume 
was 50 μL, column oven temperature was set to 20 °C, the method was a gradient from 
100% 2M ammonium sulphate dissolved in 100 mM sodium citrate buffer (pH 2.0) to 
2M ammonium sulphate dissolved in 100 mM potassium phosphate (pH 7.0) to 100 mM 
potassium phosphate (pH 7.0). The gradient was over 60 minutes, the column was re-






2.4.17 Intact LC-MS sample preparation 
 
500 μL of sample was aliquoted into a 1.5 mL centrifuge tube and processed 
according to method 2.2.12, except no TCEP is added. 
 
2.4.18 PNGase F deglycosylation protocol 
 
425 μL of 1 mg/mL trastuzumab emtansine was mixed with 50 μL of the provided 
‘GlycoBuffer’ and 125 μL of NEB PNGase F in a 1.5mL centrifuge tube. This sample was 
kept at 37 °C using a heat block for 24 hours. The sample would be removed and 
processed via experimental method 2.4.30. 
 
2.4.19 PNGase F Rapid deglycosylation protocol 
 
400 μL of 1.25 mg/mL trastuzumab emtansine was mixed with 200 μL of the 5X 
RAPID PNGase F in a 1.5mL centrifuge tube. This sample was kept at 75 °C using a heat 
block for 5 minutes. The sample would be removed and 50 μL of the Rapid PNGase F 
added and the sample placed at 50 °C for a further 10 minutes before being removed 
and processed via experimental method 2.4.30. 
 
2.4.20 pH 9-11 at 50 °C buffer degradation of trastuzumab emtansine 
 
75 μL of 100 mM Dipotassium phosphate adjusted to pH 9 with 1M hydrochloric 
acid or 10 or 11 with 5M potassium hydroxide was mixed with 25 μL of sample. After 
180 minutes in the myBlock Mini Dry Bath at 50 °C, the samples were neutralised with 






2.4.21 pH 7-9 at 40 °C buffer degradation of trastuzumab emtansine 
 
75 μL of 100 mM Dipotassium phosphate adjusted to pH 7, 8 or 9 with 1M 
hydrochloric acid was mixed with 25 μL of sample. After 90 minutes in the myBlock Mini 
Dry Bath at 40 °C, the samples were neutralised with 900 μL of 100 mM dipotassium 
phosphate, pH adjusted to 5.5 with 1M hydrochloric acid. 
 
2.4.22 pH 9 at 45 °C buffer degradation of trastuzumab emtansine 
 
75 μL of 100 mM Dipotassium phosphate adjusted to pH 9 with 1M hydrochloric 
acid was mixed with 25 μL of sample. After 60, 90, 120 and 180 minutes in the myBlock 
Mini Dry Bath at 45 °C, the samples were neutralised with 900 μL of 100 mM dipotassium 
phosphate, pH adjusted to 5.5 with 1M hydrochloric acid. 
 
2.4.23 Assessing DAR via heavy and light chain relative TICs  
 
LC-MS was also used to evaluate the stability of cytotoxic ‘payload’ attachments 
to the trastuzumab antibody portion of the trastuzumab emtansine ADC.  Total ion 
counts (TICs) per mass were exported at 1 Da resolution for each sample in the form of 
an XY plot (mass v abundance).  Each XY plot was manually processed to sum all TICs 
related to a light or heavy chain bound to zero, one or two payloads.  This produced 6 
values: 3 describing the distribution of payloads on the light chain and 3 describing the 
distribution of payloads on the heavy chain.  To improve data comparability the TICs 
pertaining to each chain are converted to TICs relative to the sum of all TICs pertaining 
to heavy or light chains respectively, these are then then expressed as a percentage. The 
mass range for TICs corresponding to naked light chains was 23422-23472 daltons. The 
mass range for TICs corresponding to single payload light chains was 24370-24440 
daltons. The mass range for TICs corresponding to double payload light chains was 
25324-25386 daltons. The mass range for TICs corresponding to naked heavy chains was 
50525-50679 daltons. The mass range for TICs corresponding to single payload heavy 
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chains was 51483-51637 daltons. The mass range for TICs corresponding to double 
payload heavy chains was 52447-52577 daltons. 
 
2.4.24 Preparation of study devices 
 
Kadcyla products were prepared under aseptic conditions in line with Good 
Manufacturing Practice, using validated pharmacy procedures and in full accordance 
with instructions outlined within the Summary of manufacturers Product Characteristics 
for Kadcyla. Products were prepared at a clinically high, common and low concentration 
by reconstituting the vials with water for injection to give a 5 mL concentrated stock 
solution.  The stock solution was added to a Freeflex polyolefin infusion bag of sodium 
chloride 0.9% and stored at 2-8˚C in light-protective bags.  On each day of analysis, 
samples were removed from each test product bag using aseptic technique by 
withdrawing 5 mL into a lubricant-free syringe, which was capped and stored at 2-8˚C 
during the analysis period.  All test products were prepared in quadruplicate thus a total 
of 4 bags at each test concentration were compounded and used for analysis. 
 
2.4.25 Sampling schedule 
 
Samples were analysed on the day of test product preparation (Day 0) and then 
at days 1, 4, 7, 11, 14, 18 and 20.  After Day 20 samples were placed in a 25 °C oven and 
sampled after 24 hours (day 21) and then 96 hours (day 24). 
 
2.5 Experimental for Chapter 5 
 
2.5.1 Measuring bag dimensions 
 
100 mL Baxter Viaflo, Fresenius Kabi Freeflex and Maco Pharma Macoflex-N 
infusion bags were emptied, and measurements using a steel rule were made of the 




2.5.2 Bag comparison study samples 
 
Herzuma, Orencia and Mabthera products were prepared under aseptic 
conditions in line with Good Manufacturing Practice, using validated pharmacy 
procedures and in full accordance with instructions outlined within their own Summary 
of manufacturers Product Characteristics. Products were prepared at a clinically low 
concentration by reconstituting the vials with water for injection to give a concentrated 
stock solution.  The stock solution was added to a Fresenius Kabi Freeflex, Baxter Viaflo 
and Macopharma Macoflex-N polyolefin infusion bags of sodium chloride 0.9% and 
stored at 2-8˚C in light-protective bags.  On each day of analysis, samples were removed 
from each test product bag using aseptic technique by withdrawing 3.5 mL into a 
lubricant-free syringe, which was capped and stored at 2-8˚C during the analysis period.  
All test products were prepared in quadruplicate thus a total of 4 bags for each brand of 
polyolefin infusion bag were compounded and used for analysis. 
 
2.5.3 Sampling schedule - Trastuzumab (Herzuma) 
 
Samples were analysed on the day of test product preparation (Day 0) and then 
at days 3, 10, 21, and 30. 
 
2.5.4 Sampling schedule - Rituximab  (Mabthera) 
 
Samples were analysed on the day of test product preparation (Day 0) and then 
at days 3, 10, 18, and 32. 
 
2.5.5 Sampling schedule - Abatacept  (Orencia) 
 
Samples were analysed on the day of test product preparation (Day 0) and then 




2.5.6 SEC HPLC validation for trastuzumab, rituximab and abatacept 
 
The HPLC assays validation were performed according to general method 2.2.24. 
This data has not been presented in the thesis, but is available in Appendices I-III. 
 
 
2.5.7  Scanning electron microscopy  
 
High magnification images were obtained using a JEOL JSM6480-LV scanning 
electron microscope (SEM) with EDX capability using an accelerator voltage of 10kV and 
a spot size of 25nm. The samples were coated with a thin layer of gold using an Edwards 
S150B sputter coater prior to SEM analysis. 
 
2.6 Experimental for Chapter 6 
 
2.6.1 Forced degraded and control sample preparation 
 
250 μL of trastuzumab emtansine vial concentrate (20 mg/mL) was mixed at a 
1:1 ratio with each of the common cleaning agents in a 0.5 mL centrifuge tubes, then 
placed on a heat block at 20 °C for 2 hours. The samples were then removed and 
immediately processed for LC-MS analysis 
 
2.6.2 Brentuximab vedotin 96 well plate set up 
 
Biological activity of brentuximab vedotin was assessed by measuring the 
brentuximab vedotin mediated growth inhibition of two different cell lines. The cell line 
used for on-target toxicity was GCT-27 cells, grown in DMEM supplemented with 10% 
foetal calf serum with 100 U/mL penicillin and 0.1 mg/mL streptomycin. The cell line 
used to assess off-target toxicity was HepG2, grown in DMEM supplemented with 10% 
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foetal calf serum with 100 U/mL penicillin and 0.1 mg/mL streptomycin. Cells were 
harvested from culture and seeded in a Nunclon, cell culture treated, 96 well, flat 
bottomed, clear plastic, plate (ThermoFisher Scientific, Massachusetts, USA) at 2.0 x 104 
cells/well and incubated for 4 hours at 37° C in a Heraeus BBD 6220 incubator 
(ThermoFisher Scientific, Massachusetts, USA). Brentuximab vedotin samples were 
diluted to create a dose response curve from 3000 – 1 μg/mL in NaCl 0.9% for injection. 
10 μL of these brentuximab vedotin solutions were added to wells of mL to both HepG2 
cells, and GCT-27 cells. The final well concentration of brentuximab vedotin was 300, 
100, 30, 10, 3, 1, 0.3 and 0.1 μg/mL for both HepG2 cells, and GCT-27 cells.  
 
2.7 Experimental for Chapter 7 
 
2.7.1 Control and forced degradation samples 
A vial of brentuximab vedotin was reconstituted with water for injection 
according to its summary of product characteristics, to a 20 mg/mL. Two 1 mL aliquots 
were added to 9 mL of 0.9% w/v NaCl for injection, in a 15 mL centrifuge tube were 
made. One was degraded photolytically according method 2.2.20, while the other was 






Chapter 3. Development and implementation of methods for the 
characterisation of a traditional monoclonal antibody 
 
To design an appropriate stability study, it was first required to assess all relevant 
guidance. Then, identify analytical methods able to meet guidance requirements. It 
was considered appropriate to first implement these methods on a traditional mAb, as 
this would provide positive validation data to use as a point of reference when later 
investigating ADCs.  
 
3.1 Critical characteristics and methods to measure them 
 
There are 10 critical quality attributes of a biopharmaceutical product, that must 
be assessed, according to the NHS guidance 102 While they don’t cover ADC’s, they do 
provide a starting point. These attributes, methods for their measurement and a 
rational for choosing a technique are described in detail below.  
 
3.1.1 Colour, clarity and visible particulates 
 
Visible changes, such as colour change, can indicate the formation of a degradant 
species. Loss of clarity, or conversely an increase in turbidity indicates an increase in 
subvisible particulates or precipitation, and visible particulates could indicate 
precipitation. 224 Any of these observations could make a product unsuitable for 
administration, due to potential immunological responses and blockage of blood vessels 
and some visible changes are listed in British pharmacopeia (BP) monographs. 
 
Visible changes can be measured by a visual inspection following a method set 
out in the British pharmacopeia “Method 2.9.20 Appendix XIII B. Particulate 
Contamination. Visible Particulates”. 110 Inspecting products for 5 seconds under normal 
florescent light against a white and then a dark background should allow ample 
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opportunity to spot any changes to clarity, such as increased turbidity, or the 
development of a colour or change in colour. 111 It is also possible if colour is expected 
to compare the samples against colour standards. 112 
 
While it is possible to use a spectrophotometer to measure the total absorbance 
of visible light, delta max and absorbance spectrum, upon reviewing the NHS yellow 
cover documents and stability research papers for therapeutic small molecule studies 
and antibodies, typically only simple visual inspections were performed. 111,113,114 
Consequently, the British pharmacopeia method, was used to assess colour, clarity and 




The BP monograph for a drug states the acceptable pH for that drug at 
therapeutic concentrations. The pH of a drug can change slightly during long term 
storage, especially if the product has weak buffering or even no buffering excipients, 
such as cyclophosphamide 500 mg powder for injection which can have a pH anywhere 
between 3 and 9 as stated in its SPC. 
 
The pH can be measured using indictor solution or paper but most commonly a 
calibrated pH probe. No studies found used indicator paper or solutions, most stability 
studies did not actually assess pH at all. All those that did measure pH, used a pH meter. 
115, 116 Therefore, a pH meter calibrated with three pH standards will be used to assess 
the pH of samples on every timepoint. 
 
3.1.3 Chemical degradation  
 
Drugs may degrade in a variety of ways, resulting in degradants due to glycation, 
hydrolysis, oxidation, deamidation and fragmentation, with each chemical modification 
potentially affecting the rate of aggregation, and functional activity. It is important to 




There are many ways of measuring the chemical degradation of an antibody, 
although over half of the published stability studies investigated did not assess it. Ion 
exchange chromatography (IEX), RP-HPLC following enzyme digestion and LC-MS are the 
most common methods of assessing antibody chemical stability found during literature 
research.  111,117-120 
 
IEX is able to separate charge-based variants of the monomer, often caused by 
oxidation, deamidation and hydrolysis. It has been demonstrated that charge 
heterogeneity impacts drug stability. 121 The method requires an HPLC system, an ion 
exchange column and associated mobile phase. It is one of the most common 
techniques used to assess chemical degradation. 
 
RP-HPLC following enzyme digestion, also known as antibody digest analysis, 
requires an HPLC, a reverse phase column and associated mobile phase. It can separate 
antibody fragments, typically papain and pepsin, or trypsin are used to fragment the 
antibody. This method requires enzymes and creates highly complex spectra which can 
be hard to interpret as well as determining if changes have occurred. It is the least often 
used method found used to assess chemical degradation. 
 
LC-MS is able to measure the exact mass of each species of antibody, to 
approximately 1 kDa. This allows new chemical forms of the antibody to be identified 
and the route of degradation can often be determined by calculating the change in mass. 
For example, glycosylation can be identified by the addition of a mass equal to a known 
sugar. LC-MS can also detect hydrolysis, glycosylation, deamination commonly of 
asparagine, oxidation commonly of methionine and even fragmentation, depending in 
the mass range that is observed. Use of reducing agents to cleave the inter-chain 
disulphide bonds can also be used to decrease the complexity of the samples and 
improve the resolution of species, although it does prevent fragmentation and 
oligermization being assessed. Typically, tris(2-carboxyethyl)phosphine (TCEP) or 
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tris(hydroxypropyl)phosphine (THPP) are used to reduce the disulphide bonds as they 
are known to reduce inter-chain disulphides but not intra-chain disulphide bonds. 122 
 
As stated in 3.2.4, size exclusion chromatography (SEC) was used and it was 
impractical to use a second chromatography-based method as that apparatus would not 
be available, the same is true for RP-HPLC following an enzyme digest. Furthermore, 
enzyme digests are complex and require more time than IEX. IEX does yield useful 
information without too much effort, however the additional information obtainable 
with LC-MS out-weighs the additional sample handling concerns and increased cost. 
Therefore LC-MS will be used to assess chemical degradation, this will be supported by 
pH readings and gel electrophoresis. 
 
3.1.4 Active pharmaceutical ingredient (API) concentration 
 
The API is the drug and most BP monographs state the acceptable loss of 
concentration which can range from 10% to only 2%. Some drugs do not have a drug or 
presentation specific monograph. For example, the British pharmacopeia’s “General 
Monoclonal Antibodies Monograph” covers all mAbs for human use. In this instance 5% 
concentration loss is generally considered an acceptable limit. 
 
The API is the antibody or antibody drug conjugate monomer. It is well known 
that antibodies aggregate into oligomers such as dimer and trimers, therefore it is 
important the method of characterisation can separate the monomer form oligomers. 
Size exclusion chromatography (SEC) is a common technique used that separates and 
sorts molecules by size, buffers are used to ensure the proteins are stabilised in their 
native form. All stability studies found determined the antibody concentration via SEC 
or UV absorbance. 111,123-125 SEC was the most common choice and is mentioned in the 
NHS yellow cover documents. SEC is a well-documented method able to separate the 
monomer from its oligomers, while total UV assays do not accomplish this. 
Consequently, SEC will be used to measure the API concentration, as well as assess levels 
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of dimer and trimer aggregates, this will be using analysis of the area under the curve of 
each species (monomer, dimer trimer) compared to a linearity curve. 
 
 
3.1.5 Sub-visible particulates and aggregation 
 
While visual checks can determine the level of visible particulates and 
aggregation, the majority of aggregates and particulates are sub-visible, or invisible to 
the naked eye. Sub-visible particles and aggregates can be of any size from 10 nm to 
about 100 μm. Aggregated drug is a problem as it can raise an immune response in 
patients, leading to: anti-drug antibodies, faster rates of drug clearance, impaired 
pharmacokinetics and reduced binding strength, ultimately resulting in a lower level of 
care being delivered to the patient. 225 Sub-visible particles are a cause of concern due 
to their ability to cause vein irritation, anaphylactic shock, phlebitis, pulmonary emboli, 
pulmonary granulomas, immune system dysfunction, pulmonary dysfunction, 
infarction, and death. 109  
 
Particles can be related to the packaging, such as rubber from a septum or plastic 
from an injection port. Alternatively, the particles could be undissolved, aggregated or 
precipitated drug/excipient material. Protein-based drugs aggregate, though excipients 
to prevent aggregation are included in many mAb formulations.  
 
Sub-visible particles, whether aggregated drug or not, are of concern and the 
NHS specifically states a maximum number of particles per container at two size ranges, 
greater than 10 μm and greater than 25 μm, which are used when determining the shelf 
lives of small molecule drugs. However, those particles limits are not imposed upon 
biopharmaceuticals as the protein aggregates typically exceed those limits during the 
SPC shelf life (24 h from reconstitution). Consequently, no statistical difference to 




Oligermization was assessed by SEC, which covers the range of ~5 nm to about 
50 nm. This covers antibody monomers and oligomers as antibody monomers have a 
length and width of about 8 by 14 nm. 228 Another technique must be used to assess 50 
nm to 0.1 mm, which is about the limit of visible particulates. There are many methods 
of measuring sub-visible particles, the most common found in antibody stability 
research are summarised below. 
 
Firstly, light obscuration is widely used in small molecules and there are limits 
established in the BP ‘Appendix XIIIA. Particulate Contamination: Sub-visible Particles 
Ph. Eur. method 2.9.19’. Light obscuration methods are mentioned in the NHS yellow 
cover guidance, but it is also recognised that these methods require large volumes of 
sample as well as lacking sensitivity to the translucent protein aggregates.  
 
Another test in the BP, known as microscopic particle count test, requires the 
use of an ocular micrometre and binocular microscope. The test involves counting 
particles in a known volume of solution against a known area and comparing these 
values to BP defined limits of 10 per mL for particles larger than 10 μm and 3 per mL of 
particles larger than 25 μm. 
 
Microflow imaging (MFI) uses a camera, microscope, flow cell and pump to 
capture images of the sample while drawn through the flow cell. The images are used 
to detect particles via a comparison to a blank. MFI is one of the more common method 
of measuring particles in antibody stability studies. 126-130 This technique is widely used 
to measure particulates between 1 and 100 μm. 
 
Resonant mass measurement (RMM) is a less common technique, though it is 
powerful, with the ability to detect particles from 50 nm to 5 μm. 129 RMM utilizes the 
inherent resonating frequency of the sample fluid as a background and detects changes 
as the sample flows past a cantilever, as particles have a different buoyancy depending 
on size, shape and material, which affects the frequency of resonance. Although this 
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technique is interesting and powerful, we do not have access to an RMM such as the 
Archimedes (Malvern Panalytical, Royston, UK). 
 
Dynamic light scattering (DLS) is likely the most common technique used to 
assess protein particulates, greater than 50 nm. DLS measures the rate of change in laser 
light scattering, due particles present in a stationary sample, to determine the speed of 
particles due to Brownian motion. The particle speed can be used to calculate the 
estimate spherical size of said particles using the Stokes-Einstein equation. Thus, particle 
sizes can be calculated from 10 nm to 1000 nm. This technique does have poor 
resolution, grouping particles into peaks and presenting the average particle size of each 
peak and the polydispersity index, a measure of the peaks heterogeneity. However, the 
peaks need to be over three times the size of each other to be distinguished, meaning 
monomer, dimer and trimer are observed as a single peak, as well as any other particle 
peaks. Furthermore, DLS is hypersensitive to larger particles, a 10-fold increase in size 
results in a 1,000,000-fold increase in signal intensity. This makes DLS not very good at 
detecting smaller aggregates and if two peaks are near each other they can be grouped 
into one peak with an average particle size being produced. While DLS is widely used, a 
newer technique has been developed which appears superior in multiple ways. 117,123,129 
 
Nanosight Tracking Analysis (NTA) is a laser-based technique that tracks the 
motion of diffraction patterns due to particles and uses the Stokes-Einstein equation to 
calculate an estimated spherical volume. NTA differs from DLS for two reasons. Firstly, 
it can differentiate particles with a size difference of 0.5 nm and secondly its sensitivity, 
especially at the lower particle sizes is greater than DLS. 111, 126, 129 Meaning data 
produced is more detailed and accurate, however also more sensitive to sample 
heterogeneity. 131-134 
 
It is clear that, no single technique covers the complete range of subvisible 
particulates, although RMM comes the closest. Furthermore, the insensitivity of light 
obscuration and heavy workload required by the BP microscopic particle count test 
demonstrate neither BP methods are ideal techniques. MFI is the best technique to 
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replace these two BP methods, as it can count particles in the 1-100 micrometre range, 
which we could refer to as micro-particles. 
 
NTA appears to be a step forward from DLS, although both are functional 
techniques that produce acceptable data, NTA is the preferred choice. And while RMM 
has very good range and sensitivity it is also unavailable to at Bath University and Bath 
ASU and expensive to buy (£100,000+). While NTA was the preferred technique, 
equipment was unavailable until Bath ASU funded the acquisition of a Nanosight LM10 
(Malvern Panalytical, Royston, UK) in 2016. As such, DLS was used from 2014 – 2016 
using a Zetasizer ZS (Malvern Panalytical, Royston, UK) which was available in the Bath 
University department of Biology. 
 
3.1.6 Higher order structure  
 
Protein function is inherently defined and controlled by its structure, from 
primary sequence of amino acids to its tertiary structure. The sequences of specific 
amino acids will generate secondary structures that interact with each other, for 
example due to hydrophobicity to form an entropically favourable tertiary protein 
structure.  The tertiary shape of an antibody allows the CDR regions to bind to 
complementary antigens with specificity. If the shape of the Fab region changes, the 
CDRs may no longer align with the complementary regions of its target epitope, leading 
to loss of binding efficiency, potential loss of selectivity, or even new target selectivity, 
a facet of antibodies that is explored more using site directed mutagenesis to create 
structure function maps of an antibody and determine key amino acids. 226, 227 The shape 
of the Fc region affects the ADCC and CDC function as well as pharmacokinetic 
properties such as the half-life. The higher order structure refers to the secondary, 
tertiary and quaternary protein structure. The secondary structure consists mainly of 
alpha-helices and beta sheets (parallel and anti-parallel) and random coils, although 
random coils is a term used to describe irregular structure. There are other known 
secondary structures such as 310 helices and π helices, but these are only observed in 
minute amounts. Tertiary structure is less definable but is the three-dimensional shape 
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generated by the secondary structure. Tertiary structure is not always fixed, many 
proteins have flexible regions, such as the hinge region of an antibody. These makes 
measuring tertiary structure more difficult though not impossible. 
 
Protein higher order structure refers to either secondary, tertiary or quaternary 
structure. Techniques that can assess these include, circular dichroism spectroscopy 
(CDS), infra-red spectroscopy (IRS), X-ray crystallography (XRC), NMR spectroscopy 
(NMRS), Cryo 3D electron microscopy (C3DEM) and lastly primary sequence prediction 
algorithms (PSPA) such as PredictProtein (EMBL, München, Germany). 
 
Firstly, sequencing a large protein such as an antibody is laborious, expensive 
and takes more time than is practical, therefore PSPA’s are not useful in this instance. 
Furthermore, the primary sequence is unlikely to change during a stability study, while 
the conformation may change, so even if it was practical to measure the entire primary 
sequence it would not help us assess changes to the higher order structure. 
 
XRC requires the growth of crystals which is difficult and time consuming 
furthermore analysis is incredibly complicated with large proteins, such as antibodies. 
XRC does produce very good information on proteins and is one of the best techniques 
for measuring a proteins structure 135-138 but in this instance, it is not practical to use, 
and the level of detail is unnecessary. 
 
NMRS can assess proteins suspended in liquid which is good as it means our 
antibodies can be assessed in their diluted state. 139-141 NMRS generates a detailed 
structural breakdown of a protein, although it becomes more complicated and difficult 
the larger the protein is. In fact, NMRS using typical NMR equipment is not used to assess 
proteins over 100 kDa. 142 A review of the use of NMR to assess large proteins in 2013 
showed only 5 proteins over 100 kDa had ever been measured. 142 NMRS is best used 
on proteins with a mass of 50 kDa or less. Unlike LC-MS where reducing the disulphide 
bonds and assessing only the light or heavy chains in isolation is feasible, that process 
would have dire implication on the structure and would render the data collected 
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effectively useless in determining if the structure or conformation of the intact antibody 
had changed. 
 
C3DEM is a technique that uses electrons to image proteins, frozen in non-
crystalline ice. Multiple 2D images taken at different angles are combined to create a 3D 
image. The more images taken at each angle and the more angles that pictures are taken 
at increases the level of detail or resolution of the 3D image. 143-146 C3DEM can be used 
to create images of proteins to an atomic level. 147  C3DEM is now being used more than 
XRC to measure the structure of proteins, according to the number of new structures 
added to the international protein data bank. However, the technique is impractical to 
perform on a study day due to the amount of time it takes to prepare samples and image 
them. Furthermore, the equipment is expensive, and access was not readily available. 
Consequently, this method was not employed. 
 
The most commonly used technique for stability studies is CDS, coupled with a 
CD spectrum to structure software such as CDNN (Gerald Bohm, Magderburg, 
Germany). CD spectroscopy is mentioned in the yellow cover documents and has 
successfully been used in many antibody stability studies. 139,148-151 Secondary structure 
composition is estimated based on the CD spectrum which can be tracked over time to 
assess degradation, as well as measuring the change in conformation associated with a 
temperature ramp. This gives structure at room temperature and conformational 
stability in one experiment. While the technique typically requires an hour to perform a 
temperature ramp there is minimal sample preparation involved, elucidating why this 
technique is used in so many stability studies and is mentioned in the NHS yellow cover 
document. 
 
IRS has been used to assess chemical identity due to the unique “fingerprint” 
small molecules have in the 1500 to 500 cm-1 region.  More recently fourier-transform 
infrared spectroscopy (FTIR) has been used with attenuated total resistance (ATR) 
sample cells to investigate the structure of proteins in liquid suspensions 139,148-151. ATR 
increases the surface area of sample that can affect the IR laser. Furthermore, 
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supercooled mercury-cadmium-telluride alloy detectors are used which can detect 
single photons, drastically increasing the sensitivity of the technique. It has been 
demonstrated that two characteristic peaks on an IR spectrum the Amide 1 and Amide 
2 bands are conformationally sensitive, that meaning as the structure changes the bands 
also change. Some sample holders can be used to perform temperature ramps like CDS 
experiments. Initially we did not have access to equipment suitable for performing IRS 
though later during the PhD we able to gain access to one. 
 
Differential scanning calorimetry provides an insight into the thermal stability of 
a compound, 148,150,151 specifically heat enthalpies during state changes and the 
temperatures required to cause state changes. However, while these would correlate 
with structure and structural stability, these measurements are not a directly 
translatable to higher order structure and so this technique is unsuitable for assessing 
antibody higher order structure in isolation. 152 
 
Multiple papers acknowledge all these techniques produce an estimation of the 
proteins higher order structure. 153,154 These estimations will not necessarily be the same 
although they should be similar and certain proteins will have high levels of 
comparability while others will have lower levels of comparability. 155,156 This is thought 
to be due to protein flexibility as well as inherent flaws in each technique, such as the 
suitability of original library of proteins that sample data is compared to. Some structural 
prediction algorithms are known to over predict certain secondary structural features 
and under predict on others. 157 However, as the purpose of the stability study is to 
monitor for change over time ensuring the predicted value is 100% accurate is not 
necessary if the readings are precise and stability indicating. 
 
The first-choice technique is CDS, as it meets all criteria set out in the yellow 
cover document and the required equipment is available at the University of Bath. 
Furthermore, it is the most widely used technique in antibody stability studies, with 
regards to higher order structure characterisation. As covered in chapter 4, CDS proves 
problematic with ADCs, and IRS is investigated as the best alternative. 
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3.1.7 Degradation product concentration 
 
British pharmacopeia drug monographs state an acceptable amount of API 
concentration loss, typically up to 10%, however there are rarely limits on the presence 
of specific degradants listed in a drugs BP monograph. Some monographs do list limits 
on impurities formed during API manufacture, which may also be formed as degradation 
products, but this is unlikely to be an exhaustive list of potential degradation products. 
Furthermore, the BP doesn’t have antibody specific monographs and instead has a 
general monograph. Defining 5% total degradation products and no more than 2% of 
any individual degradation product, even when the concentration loss of API can be 
10%. The main degradants observed in antibodies are oligomers, most commonly 
dimers and trimers, although some fragmentation has been observed. 125-129 
 
Degradants in biopharmaceutical formulations including dimers, trimers and 
other oligomers would be appropriately measured by SEC. Chemical degradation, 
leading to new glycol-forms or oxidised / reduced forms can be detected by LC-MS. 
Nanoscale aggregates and microscale aggregates can be assess using NTA and MFI 
respectively. Reduced DAR ADCs could be tracked using LC-MS. And free payloads may 
show up in LC-MS or SEC, and their toxicity or lack thereof can be monitored in the bio-
assays. It was felt all possible degradants would be assessed using the chosen methods. 
 
3.1.8 Biological activity 
 
The NHS biopharmaceutical stability guidance 102 requires a measure of 
biological activity, stating biochemical assays, cell culture-based assays and animal 
models as methods that can indicate biological activity. Animal based models are not 
useful for chimeric or humanised antibodies due to the immunogenic response likely to 
be raised, not to mention the ethical and financial burdens they come with. Biochemical 
based assays such as binding assays are acknowledged as useful but not giving the whole 
picture, for example an Enzyme Linked Immuno-Sorbent Assay (ELISA) may reveal the 
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binding efficacy but not the receptor activity. Therefore, biochemical assays are not 
recommended in isolation. 
 
Cell Culture Based Assays measure physiological response at the cellular level. A 
cell-based assay needs to show that the molecule will have the defined biological activity 
for its function. The cellular response to be measured also must be determined and may 
include cell signalling, cell death or cell proliferation. It is usual to use a high number of 
replicates for cell-based assays to allow for inherent variation in the assay performance 
and to improve the robustness of the results obtained. Other considerations include a 
good understanding of the methodology including validation to demonstrate that the 
cell-based assays will correlate with in vivo activity. Appropriate controls should be 
incorporated to validate the assay and should include positive reference standards in 
addition to negative controls. 
 
The biological activity of antibodies and ADC used to treat cancer is typically to 
kill the aberrant cells. As explained in the introduction it is deemed inadequate by ICH 
and the NHS to perform simple biochemical tests as the only method of quantifying 
biological or functional activity. In vivo cellular assays provide a much more concrete 
demonstration that the drugs are still able to perform their intended function, while also 
providing a quantitative measure of their activity. 
 
The cell assays we intend to use require incubation of target cell lines with 
defined concentrations of the ADC or antibody. The growth inhibition can be calculated 
by comparing either cell number, metabolic activity or DNA content for control cells not 
exposed to the drug against cells incubated with the drug. The concentration of drug the 
cells would be incubated with and the duration of incubation was determined during 
validation tests. 
 
The three main types of cellular viability assays are cell number, metabolic 
activity or DNA content. Cell number can be determined with reagent such as trypan 
blue which is excluded from viable cells and a haemocytometer, however this is 
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incredibly labour intensive and has a high risk of operator error due to the physical strain 
associated. To overcome this cell counters are now commonly used in laboratories such 
as the Invitrogen Countess Automated Cell Counter (Invitrogen, California, USA). 
However, the cost of consumables required to perform this test and the labour required 
is still very high. 
 
Rather than direct cell measurements via counting cells that exclude a reagent 
such as trypan blue, metabolic activity assays measure absorbance at a defined 
wavelength. This is because a reagent that is metabolized by active cells changes colour. 
The most ubiquitous metabolic activity reagent is MTT, which is metabolized from a 
yellow tetrazolium to a purple formazan. This colour change is easily measurable on a 
plate reader and allows 96 well plate assays to be performed. MTT is very cheap 
although the assay does require a few steps. 
 
First the cells are seeded into each well and left to grow in the presence of a 
defined concentration of the antibody or ADC. After about 5 days the cell growth media 
is aspirated from each well and 1.2 mM MTT diluted in complete colourless growth 
media is added. After about 4 hours of incubation the growth media is aspirated and 
DMSO is added to solubilise the tetrazolium and formazan crystals. The plates can then 
be read using an absorbance plate reader. The MTT assay has been used by thousands 
of scientists and is quite an old assay. 
 
Some other tetrazolium metabolic assay reagents have been developed such as 
XTT, MTS and WST 1-8 which do not require the addition of DMSO to solubilise the 
crystals as they are water soluble. 
 
Resazurin is a blue reagent that can be used similarly to the water-soluble 
tetrazolium reagents, in that it is metabolized by active cells to the pink resorufin. It has 
been demonstrated as more sensitive than the tetrazolium assay reagents, requiring 
fewer cells per well. Resazurin was commonly used as the branded product Alamar Blue 
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which was a combination of Resazurin and additional reagent designed to prevent over 
metabolism of resazurin. 
 
Alternatively, DNA content assays can be used to measure the total DNA content, 
assumed to be directly proportional to the cell number, like metabolic activity assays. 
SYBR green is a dye that binds to DNA allowing it to be measured using fluorescence, for 
example in a fluorescence plate reader. SYBR green is useful as it can be combined with 
other reagents that fluorescence such as resazurin or caspase activity reagents. 
Multiplex imaging of cells can be very useful in investigating cellular activity, however it 
is far beyond what is required for a measurement of the biological activity of drugs that 
cause apoptosis. Furthermore, MTT assays use a very cheap reagent and use of an 
automatic electronic pipette reduces the required effort, thus MTT assays will be used. 
 
To assess off target activity in an ADC all that is required is to change the cell type 
to a non-target cell type and adjust the required concentration of drug added to the cells 
as theoretically they would be far less sensitive to the drugs than the target cells, thus 
requiring far greater concentrations of drug to initiate apoptosis. 
 
3.1.9  Active excipient concentrations 
 
Excipients, while not APIs can have active effects in the body, for example 
hyaluronidase, an enzyme that breaks down hyaluronic acid in the extracellular matrix 
to improve the permeability of a drug in subcutaneous forms can degrade reducing the 
effectiveness of the product without affecting the API concentration. Most formulations 
do not contain active excipients and only use excipients for controlling of pH, solubility 
and preventing aggregation. 
 
No commercially available ADC’s currently include active excipients in their 




3.1.10 Moisture loss 
 
Infusion bags are one of the most common containers for aseptically prepared 
products. Long term storage of infusion bags can lead to minor levels of moisture loss, 
generally accepted to be clinically insignificant during typically 24 – 48-hour storage time 
but worth monitoring upon extended storage. 
 
Moisture loss can be measured by comparison of bag weights taken after the 
sample volume has been withdrawn from the bag on a study timepoint to bag weight 
taken immediately prior to the next sample withdrawal. From personal experience, 
moisture loss from infusion bags stored at 5 °C is less than 0.1% mass during a month, 
while storage at 25 °C is over 0.1% mass during a month. 
 
3.1.11 Container extractables and leachables 
 
Infusion bags contain additives, such as plasticisers, which may leach into drug 
products upon extended storage. This is more likely to occur in drug products that 
contain solubilising excipients, extractables are typically only important if the drug 
contains excipients that could cause extraction of into the drug solution, most drugs do 
not contain excipients able to extract chemicals from the container material. The UV 
absorbance of stored drug solutions can be measured to detect plastic additives, such 
di(2-ethylhexyl)phthalate, leaching into the stored product at  
 
3.2 NHS yellow cover document compliant study design 
 
Having identified the necessary quality characteristics that require evaluation, as 
well as appropriate analytical techniques for their evaluation, it was then decided to 





3.2.1 Following the guidance 
 
As mention in the introduction, the NHS yellow cover document outlines a series 
of study design choices that must be as specified in either the SPC of the drug under 
investigation or as specified in the yellow cover document itself. Some design 
parameters are more flexible as will be discussed. Where possible all guidelines must be 
followed and where not, it must be explained and justified. 
 
3.2.2 Analytical methods 
 
The development and validation of all analytical methods used must be 
described. Methods must be stability indicating, robust and fully validated in accordance 
with the International Conference on Harmonisation (ICH) Q2(R1) document. 105  The 
specificity of the method together with its ability to detect degradants must be 
described. The characterisation techniques we will be using are as defined in section 
3.4.1 to 3.4.12, with general methodologies described in chapter 2, some experimental 




The diluents used and the rationale for their choice must be described. Typically, 
this is 0.9% w/v NaCl for injection, but will be specified in the API’s SPC. The SPC for 
Kadcyla branded trastuzumab emtansine and Remsima branded infliximab states the 
powder must be reconstituted with sterile water, then the reconstituted drug 
concentrate must be diluted into 0.9% NaCl for injection. Therefore, only sterile water 
for injection will be used to reconstitute the lyophilized powders, and subsequently only 








Containers used and the rationale for their choice must be stated. Studies should 
be carried out in the specific containers to be used in clinical practice. It is recommended 
that non-PVC infusion bags be used instead of PVC infusion bags. This means polyolefin 
(PO) infusion bags are the most appropriate container. There are many types of 




The concentrations used and the rationale for their choice must be stated. Ideally 
a clinically high and low concentration can be used with interpolation between the two 
allowed but not extrapolation. According to each drug’s SPC, there is a defined mass of 
drug to be administered as a multiple of the patient’s weight. This means there is not an 
easily definable maximum or minimum concentration, as patient weight can vary. To 
overcome this, Bath ASU’s extensive order history was utilized to identify which 
concentrations of each drug are ordered and made the judgement that if we could cover 
over 100% of the concentrations they had been requested to manufacture, we would 
be producing stability data applicable to almost all possible products. Furthermore, 
where a patient may be outside this range, it is possible to overfill or underfill an infusion 
bag to adjust the final dose while keeping the concentration of the product within the 
range. It is suggested in the NHS stability guidance that biopharmaceuticals demonstrate 
reduced stability at lower concentrations. It is suggested that this may be due to over 
dilution of stabilising excipients, resulting in a faster rate of degradation. To minimise 
the risk posed by studying only a high and low concentrations where the low 
concentration may degrades quickly while the high remains stable, a clinically common 
concentration in addition to the extremely low concentration was investigated too. 
For the infliximab and trastuzumab emtansine study a clinically low, common and high 




3.2.6 Storage conditions 
 
The storage conditions used and the rationale for their choice must be defined, 
although the storage conditions are suggested to be 25 °C ± 2 °C or in the absence of 
light at 5 °C ± 3 °C. If the product is kept at 5 °C ± 3 °C, there must be a 24-48-hour period 
at 25 °C ± 2 °C at the end of the study to demonstrate in-use stability. As light and 
temperature can increase the rate of degradation of drugs, the optimal storage 
condition is refrigerated in the absence of light at 5 °C ± 3 °C, for the duration of the 
study, followed by a room temperature (25 °C ± 2 °C) exposure for at least 24 hours. 
 
3.2.7 Storage duration 
 
The NHS guidance states that studies should be between 48 hours and three 
months. It also recommends that the applied shelf life is no more than 80% of the 
maximum demonstrable shelf life, and if the shelf life of a product exceeds three 
months, the products will require an on-going sterility testing regimen, due to 
microbiological concerns. Therefore, the absolute maximum trastuzumab emtansine 
study duration would be 113 days so that 90 days is no more than 80% of the study 
duration. However, once trastuzumab emtansine has demonstrated instability the study 
can be stopped as the purpose of the study has been achieved. The infliximab study is 
designed to be published to allow UK hospitals to apply a 7 days shelf life to their 
Remsima branded infliximab. 
 
3.2.8 Sample numbers 
 
The number of samples and batches tested and the rationale for their choice 
must be stated. Ideally there will be at least three independently prepared batches for 
each concentration, although this can be one batch stored in three separate containers 
for the duration of the study. Each of these batches ought to be tested in triplicate. This 
meant a minimum of one vial of drug must be reconstituted and the required volume of 
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drug concentrate added to a minimum of three separate infusion bags (the storage 
containers). If one infusion bag were to be compromised, the study would not meet the 
criteria, therefore as long as the cost is not prohibitive, four individual containers will be 
used at each concentration. 
 
3.2.9 Testing protocols 
 
The minimum number of sampling timepoints is T = 0 (or day zero) followed by 
four other timepoints. A timepoint must occur at least every thirty days since the 
previous timepoint. 
 
The infliximab study is designed to prove stability over seven days. Therefore, 
the timepoints chosen for analysis were T = 0, 1, 2, (3/4) and 7. The fourth timepoint 




3.3 ICH Q2 (R1) compliant method validation 
 
3.3.1 Types of analytical test 
 
The Q2 document defines four different types of analytical tests: an 
identification test, a quantitative test for impurities, a limit test for impurities, and a 
quantitative test of the API. Identification tests are tests that ensure the identity of an 
analyte. For example, checking the intact mass of an antibody via LC-MS. Limit tests for 
impurities are intended to accurately reflect the purity characteristics of the sample 
without quantifying the degradant. For example, gel electrophoresis which can detect 
the presence of antibody fragments but not quantify their amount. Quantitative tests 
for impurities are intended to accurately reflect the purity characteristics. For example, 
RP-HPLC analysis of a small molecule with known impurities, which can quantify the 
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concentration of said impurities during a stability study. Quantitative API tests measure 
the analyte present in a given sample for example SEC analysis of the monomer 
concentration. Each type of test requires a different level of validation as set out in 
(Table 3.1). 
 
Impurity limits and quantification tests are not applicable to stability studies as 
the level of impurities are not going to change unless they are also degradants, which 
are characterised by the array of characterisation methods used. 
 
Only the SEC assay could be classed as API quantification methods. This 
technique will require the most rigorous validation, assessing each characteristic as 
stated in Table 3.1. 
 
LC-MS, gel electrophoresis and the total protein UV assay could be defined as 
identification tests, however in all cases this is not the primary purpose of the test. For 
example, the total UV assay could be used to identify the drug via its UV fingerprint over 
the 220 nm to 400 nm wavelength region, however its main purpose is to demonstrate 
no change to the UV absorption indicating no extractables are present. LC-MS could be 
used to identify which antibody we are looking at based on its unique molecular weight, 
but it is being used to detect the emergence of new molecular masses, which would 
indicate degradation. Gel electrophoresis could be used to identify the antibody, by 
comparison of the MW and the band pattern of the reduced antibody, however its 
primary purpose is to demonstrate no change in molecular weight, and no emergence 


















Accuracy - - + + 
Precision - - + + 
Specificity + + + + 
Detection Limit - + - - 
Quantitation 
Limit 
- - + - 
Linearity - - + + 
Range - - + + 
 












SEC API Quantification 
LC-MS Identification 
Gel electrophoresis Identification 
MTT Assay N/A 
Total Protein UV Assay  Identification 
In vitro MTT assay Identification 
 





MFI, NTA and DLS are used to characterise the size and concentration of 
particles, typically aggregated drug. The Q2 (R1) specifically states it does not address 
these techniques, and although it states the ICH may address these in a subsequent 
document, they have not.  
 
The NHS yellow cover documents specify the use of forced degradation to induce 
the formation of typical degradation products. Forced degradation can be used to 
generate degraded samples which can be tested via the different methods required for 
the stability study. According to the NHS yellow cover documents, the ability to detect 
differences between control samples and degraded samples demonstrates the stability 
indicating nature of a technique. Furthermore, the ICH Q5C document 158  “Stability 
testing of Biotechnological/Biological products “, which is a document that informed the 
NHS yellow over documents mentions the use of methods for “the accurate detection 
of degradation changes that may result from deamidation, oxidation, sulfoxidation, 
aggregation or fragmentation during storage”. 
 
Therefore, forced degradation was used on infliximab and trastuzumab 
emtansine to validate the stability indicating nature of all methods, while also 
performing a full API quantification assay validation on the SEC method. It is noted in 
the NHS yellow cover document that bioassays suffer from inherent variability, so the 
acceptance criteria for the MTT assay may be more relaxed than the other assays. 
 
Additionally, according the ICH guidance, measurement of pH is deemed a 
general measurement, and not drug specific, thus it requires no validation beyond a 
suitable and regular calibration. 
 
3.3.2 Forced degradation 
 
Compliant forced degradation required the use of heat, acid, base, light and 
oxidizers. Thermal degradation was used in multiple studies investigating antibody 
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degradation. 159,160 Subjecting antibodies to temperatures above 65 °C can initiate 
aggregation, likely due to protein unfolding and the exposure of typically inaccessible 
motifs. Altering the pH of the drug solution can cause hydrolysis of vulnerable residues 
and also cause aggregation and degradation of the monomer 161, typically it is best to 
neutralise the sample after a defined duration of adjusted pH. Light can degrade many 
drugs, the photostability is typically due to bonds than can be cleaved by UV radiation 
found in natural light. ICH guidelines states, “cool white fluorescent lamps with a lux 
over 20,000” can be used to expose samples to appropriate levels of light. 
Photodegradation can cause antibodies to aggregate, causing a loss of monomer and an 
increase in oligomers, as well as minor structural changes, however it can cause loss of 
biological function. 162,163 Light exposure has also been reported to cause the oxidation 
of amino acid residues in the Fc region. 162,164 Use of oxidising reagents such as hydrogen 
peroxide to degrade antibodies has been demonstrated and measured using LC-MS. 165 
Furthermore it has been demonstrated that the propensity for degradation via adjusted 
pH, photodegradation and oxidative degradation is increased with temperature. 166 As 
stability studies will be based on therapeutic formulations of biopharmaceutics that also 
contain stabilising excipients, we could not use the same conditions used in the 
literature, however they did provide a good starting place. 
 
3.3.3 Linearity validation 
 
The linearity of the response must be determined. A linearity value determined 
via R2 regression analysis must be at least 0.999. This is especially important for RP-HPLC 
and SEC where determining API concentration is crucial to the integrity of the study. 
Even if a study is performed on a single concentration of drug, the chromatography 
method must be linear on a range of concentration at least 20% above and below the 
test concentration. For a range of concentrations, the method must be proven to be 
linear over a range at least 20% below the lowest test concentration and 20% above the 
highest concentration. For the MTT assay, linearity is assessed via dose response curves. 
These curves are used for selecting the optimal concentration of drug to incubate the 
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cells with. Ideally the EC50 can be determined and used as it is the most sensitive to a 
change in the activity of the drug. 
 
Linearity should be established across at least 5 different concentrations. Ideally, 
this should be performed independently three times, with the mean R2 value being used 




Precision can mean three different things under ICH Q2 (R2), it can mean intra-
lab reproducibility, which is only relevant if the assay will be performed in multiple 
locations. It can mean intermediate precision, comparing precision after changes to the 
operator, day or equipment used. Or more commonly it can mean repeatability which is 
measured as a minimum of 6 determination of the single test concentration or at least 
9 determinations covering the range of concentrations. It is the more common definition 
that we must meet. As each of our studies will have three concentrations we tested the 




Ideally test a pure sample, then test the sample spiked with its known degradants 
and closely related compounds if applicable. If the API is discriminated from the 
degradants and/or closely related compounds the test can be considered specific. 
However as already stated there are no known degradants we could order and so forced 




Accuracy can only be determined by testing a standard that has not formed part 
of your linearity and test it or test a sample on a previously validated method and the 
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un-validated method. Furthermore, if linearity, accuracy and specificity have been 
established accuracy may be inferred. As no pure standards are available and each batch 
of infliximab and trastuzumab emtansine can vary due to variable filling overage, the 




This is a measurement of the ability of the method to handle small variations in 
the method, such as variations of the pH, flow rate, sample volume, temperature and 
buffer concentration. This is important if multiple operators or laboratories will be using 
the same method and comparing results, but as the methods are not designed to be 
transferred to other laboratories this was deemed unnecessary. To reduce any potential 
causes of variability, the operators for each technique were assigned and kept the same 
during each study. Flow rate, sample volume, and column temperature are controlled 
via Chromeleon and the inherent variability of the Dionex chromatography system. Each 
system is serviced annually and passes the required annual tests of conformity, linearity, 
precision and accuracy. Mobile phase pH is checked and adjusted to within 0.05 pH units 
of 6.8 and buffer concentration variability is controlled by following a buffer recipe and 
using a calibrated and serviced balance. 
 
3.3.8 Limits of detection (LOD) and quantitation (LOQ) 
 
There are five ways to determine these values, one using visual evaluation, one using 
signal to noise ratios and three ways using the standard deviation of the response and 
slope of the calibration curves created for the linearity determination. The LOD can be 
calculated as three times the standard deviation of the response divided by the slope of 
the calibration curve. The standard deviation of the response can be determined in two 
ways, the easiest is to determine the standard deviation of the y-intercepts. The LOQ 
can be calculated as ten times the standard deviation of the response divided by the 








To evaluate whether the chosen methods were stability indicating and that they 
were validated if necessary, samples produced according to general method 2.3.1 were 
tested using each method chosen in section 3.1. The ability to distinguish control 
samples from degraded samples is the minimum requirement for a method to be 
considered stability indicating as per ICH guidance, with the exception of size exclusion 
chromatography, which requires a full validation.105 The stability indicating nature of 
each method was demonstrated through forced degradation studies. A range of 
degradation pathways were assessed by subjecting freshly prepared samples of diluted 
Remsima (1.5 mg/mL in 0.9 % NaCl solution) to several stress conditions which included 
low pH (according to method 2.2.18), high pH (according to method 2.2.19), oxidation 
(according to method 2.2.21) and exposure to 20,000 lux light (according to 2.2.22). All 
samples were analysed immediately following stress. 
 
Remsima is an infliximab biosimilar. It is one of the first biosimilars to be licensed 
in the UK, along with biosimilars of rituximab and trastuzumab. Remsima is dosed at 5 
mg/kg for most indications but may be 3 or 7.5 mg/kg in some circumstances. When 
diluted into infusion bags, the concentration of Remsima ranges between 0.6 mg/mL 
and 2.5 mg/mL. 236 
 
3.4.2 Visual inspection 
 
Following method 2.2.2, no visual differences compared to the control samples 
were observed for any degraded samples. All samples remained clear and free of visible 
particulates. While this method has not been demonstrated as stability indicating, this 
method is used by healthcare professionals to detect visible changes such as 
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precipitation and colour change. Therefore, it is an acceptable method to use for visual 




pH readings cannot be made for oxidisation, acid or base hydrolysis samples. This 
is because the pH can be altered by the reagents used to degrade the sample. Following 
method 2.2.3 the control samples, photolytically degraded and thermally degraded 
samples could be measured. The control was 6.62 ± 0.02, photolytically degraded 
samples were 6.19 ± 0.22 and the thermally degraded samples were 6.71 ± 0.10. This 
data demonstrates the pH measurement is stability indicating for at least photolytic 
degradation and the pH method is compatible with infliximab. 
 
3.4.4 Microflow imaging analysis of microparticles 
 
To evaluate whether microflow imaging analysis of microparticles (10-100 μm) 
was stability indicating, a control sample was compared to acid, base, oxidation and 
photolytically degraded samples following method 2.2.6 (Figure 3.1). All degradation 
samples had an increase in microparticle concentration for both size categories 
compared to the control. Base degradation had the least effect, about a one magnitude 
increase in microparticle concentration while acidic degradation had the most effect 
with a nearly three magnitudes increase in microparticles. This data demonstrates that 





Figure 3.1.  Microflow imaging comparison of microparticle concentrations (10 -100 μm) in infliximab 
control samples and forced degraded samples. Results are means (n=3) ± one standard deviation.  All 
stressed conditions caused an increase in particles in both size categories, with the acid treated samples 
showing the most significant differences. Data was assessed using a one-way ANOVA, *, **, *** & **** 
indicate p values below 0.05, 0.01, 0.001 & 0.0001 respectively. 
 
3.4.5 Dynamic light scattering analysis of sub-visible particles 
 
To evaluate whether dynamic light scattering analysis of nanoparticles (1-10,000 
nm) was stability indicating, following method 2.2.4, control samples were compared to 
acid, base, oxidation and photolytically degraded samples (Figures 3.2 & 3.3).  
 
Photolytic degradation caused a decrease in the diameter, suggesting a loss of 
the dimer species (Figure 3.2). Oxidation and acid hydrolysis show a clear increase in the 
mean diameter, suggesting an increase in oligomers, such as dimers and trimers (Figure 
3.2). The standard deviation for the base hydrolysis results are too wide to determine 
any real change (Figure 3.2). 
 
While a decrease was noted for the % monomer particles by volume, the 
standard deviations do not indicate that is a real change (Figure 3.3). The base 
hydrolysed samples had a decrease in the percentage volume of monomer/dimer 
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particles, suggesting particles between 50nm and 10,000 nanometres are forming in a 
significant volume, ~5% (Figure 3.2). 
 
This data indicates dynamic light scattering analysis of nanoparticles (1-10,000 
nm) was stability indicating, with evidence of degradation for all types of degradation, 
however it was most sensitive for base hydrolysis (Figure 3.3) and oxidation (Figure 3.2). 
 
 
Figure 3.2. Dynamic light scattering analysis of the monomer/dimer peak mean diameter (nm). Results 
are means (n=3) ± 1 standard deviation. A statistically significant (p < 0.05) increase in particle diameter 
was observed for the oxidization samples, other differences observed where not statistically significant. 
 
 
Figure 3.3. Dynamic light scattering analysis of monomer/dimer particles % volume of particles 1-10,000 
nanometres. Results are means (n=3) ± 1 standard deviation. Only the base degraded sample had a 
statistically significant change from the control (p < 0.05), showing a decrease in % monomer particles by 
volume. This shows that under basic conditions a significant volume of non-monomer particles 
(aggregates and fragment) must be forming, and/or that the volume of monomer particles has decreased 




3.4.6 Circular dichroism analysis of higher order structure 
 
To evaluate whether circular dichroism analysis of higher order structure is 
stability indicating for infliximab, a control sample was compared to acid, base, oxidation 
and photolytically degraded samples (Tables 3.3 & 3.4). This was performed in 
accordance to method 2.2.8. The higher order structure of the photolytically degraded 
sample did not appear different to the control (Table 3.4). Base hydrolysis and oxidation 
appeared to have the most effect, especially on Alpha helix and Antiparallel sheets. 
(Table 3.4). This data demonstrates that circular dichroism analysis of higher order 
structure is compatible with infliximab and stability indicating. Acid and base 
degradation appear to have a similar effect on structure to each other, presumably by 
changing the charge states of the exposed amino acid residues. Oxidation of methionine 
residues on antibodies creates negative charge variants which are known to aggregate 
more readily, which may explain why the oxidised samples have such a distinctly 
different structure. 
 





Alpha Helix 5.80% 5.80% 9.00% 4.60% 4.10% 
Antiparallel Sheet 39.60% 39.50% 32.00% 42.10% 43.30% 
Parallel Sheet 5.50% 5.50% 5.50% 5.40% 5.30% 
Beta-Turn 17.00% 17.00% 17.90% 17.80% 18.40% 
Random Coil 34.80% 34.80% 34.90% 34.90% 34.90% 
Total Sum 102.70% 102.60% 99.30% 104.80% 106.10% 
Table 3.3. Infliximab secondary structure analysis via CDNN deconvolution of circular dichroism spectra 
at 25 °C. compared to the control the photolytic condition had no observable effect. Acid and base 
degradation appear to have a similar effect on structure to each other. 
 





Alpha Helix 0.00% 3.20% -1.20% -1.70% 
Antiparallel Sheet -0.10% -7.60% 2.50% 3.70% 
Parallel Sheet 0.00% 0.00% -0.10% -0.20% 
Beta-Turn 0.00% 0.90% 0.80% 1.40% 
Random Coil 0.00% 0.10% 0.10% 0.10% 
Total Sum -0.10% -3.40% 2.10% 3.40% 
Table 3.4. Absolute change from control in CDNN deconvolution of infliximab circular dichroism spectra 
at 25 °C. Acid and base degradation appear to have a similar effect on structure to each other. 
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3.4.7 Gel electrophoresis analysis of fragmentation and aggregation 
 
To evaluate whether gel electrophoresis analysis of fragmentation and 
aggregation was stability indicating for infliximab, a control sample was compared to 
acid, base, oxidation and photolytically degraded samples (Figure 3.4). This was 
performed in accordance with method 2.2.7 The reduced control sample has clearly 
been reduced into its heavy (~50 kDa) and light (~25 kDa) chains while the intact sample 
has a strong band indicating the intact antibody (~150 kDa). The acid degraded samples 
had a new band at about 100 kDa when reduced and two very feint bands when reduced 
at about 50kDa and 100 kDa, as well as evidence of aggregation at 200 kDa. The base 
degraded sample has two new bands when reduced, one at about 100 kDa and one at 
about 125 kDa. When run intact the base degraded sample appears highly fragmented 
with multiple new bands at 25, 50, 75, 100 and 125 kDa as well as evidence of 
aggregation at 200 kDa. The oxidised sample did not appear to run. It is possible that the 
hydrogen peroxide interfered with the staining reagents used in the method. The 
photolytically degraded sample has numerous additional bands when reduced around 
75, 100, and 125 kDa. The intact photolytic sample has a stronger band at 25 kDa 
compared to the control and an additional band around 50 kDa. This data demonstrates 












Figure 3.4. Gel electrophoresis analysis of fragmentation and aggregation of infliximab control and 
degraded samples. The reduced sample for the acid condition shows a new band with a mass around 100 
kDa, this new band is most likely two heavy chains that still have a disulphide bond between them. This 
band is also present in the base degraded reduced samples. The acid degraded intact sample has feint 
bands that correlate with heavy and light, while the base degraded intact sample have feint bands that 
correlate with LC, HC, HC-LC, and HC-HC-LC, while also showing a marked loss of antibody monomer band 
intensity and an increase in aggregate intensity at the top of the gel. Oxidation may be interfering with 
the experiment as in both reduced and intact conditions the sample does not show up very well. Photolytic 
degradation shows HC-LC, and HC-HC-LC present in the reduced samples and heavy and light chain in the 
intact sample. 
 
3.4.8 Size exclusion chromatography analysis of monomer concentration 
 
Size exclusion chromatography analysis of monomer concentration was 
performed according to method 2.2.16, to determine the concentration of the active 
pharmaceutical ingredient, infliximab monomers. As such, it is outlined in the ICH  
guidance document Q2(R1) 105 that the linearity, precision, specificity and accuracy must 
be validated according to the limits stated in the ICH Q2(R1) document. This was 
performed in accordance to method 2.2.25. 
 
The method must be demonstrated as having a linearity with an R2 value of at 
least 0.999 for a range covering at least 20% higher and lower than the test 
concentrations. (Figure 3.5), plots the mean absorbance (n=3) of samples from 0.3 
mg/mL to 3.0 mg/mL. The R2 value is greater than 0.9999 and is rounded up to 1 by 
Excel. This linearity result exceeds the required minimum linearity for a concentration 





Figure 3.5. Size exclusion chromatography analysis of monomer concentration. Results are a mean (n=3). 
 
The method must be demonstrated as having a precision with a relative standard  
deviation of no more than 2% at each test concentration. Tables 3.5 - 3.7 below, show 
the measured precision from six repeat injections at the clinically low, common and high 
concentration respectively. The determined relative standard deviations are all below 
2%, indicating the method has suitable precision. 
 











Table 3.5. Size exclusion chromatography precision determination at the clinically low concentration.  The 
relative standard deviation is acceptable as the limit is 2.00 %, although this is still a high result, this is 























Table 3.6. Size exclusion chromatography precision determination at the clinically common 
concentration. The result of 0.23% is very good, as the limit is 2.00 %. 
 











Table 3.7. Size exclusion chromatography precision determination at the clinically high concentration. 
The result of 0.32% is very good, as the limit is 2.00 %. 
 
The size exclusion chromatography method must also be demonstrated to be 
specific. Meaning able to differentiate degradants, such as dimers and trimers from the 
monomer. This is demonstrated by analysis and comparison of control samples of 
infliximab to force degradation samples. When photolytically degraded, a loss of 
monomer and increase in dimer is detectable (Figure 3.6). When degraded via acid 
hydrolysis, a detectable loss of monomer and a probable increase in oligomer is 
observed (Figure 3.7). When degraded via oxidation a detectable loss of monomer is 
apparent but no increase in dimer, trimer or higher order oligomers (Figure 3.8). When 
degraded via base hydrolysis a loss of monomer is detected and a large peak due to 
higher order oligomers can be noted (Figure 3.9). This data indicates this method is 




Figure 3.6. Size exclusion chromatogram of infliximab control (Black) vs infliximab photolytically degraded 
(Blue). The X-axis is time (minutes). The photolytically degraded main peak at 21.6 minutes is markedly 
decreased in area compared to the control. The peak at 24.5 minutes is due to a lower molecular weight 
fragment and is only present in the photolytically degraded sample. The broad peak at 20 minutes is due 





Figure 3.7. Size exclusion chromatogram of infliximab control (Black) vs infliximab acidically degraded 
(Blue). The X-axis is time (minutes). The main peak at 22.2 minutes is markedly decreased in peak area in 
the acidically degraded sample, and there is a new very broad band at 17.5 minutes, this is most likely due 





Figure 3.8. Size exclusion chromatogram of infliximab control (Black) vs infliximab degraded via oxidation 
(Blue). The X-axis is time (minutes). The main peak at 22.4 minutes is markedly decreased in peak area in 




Figure 3.9. Size exclusion chromatogram of infliximab control (Black) vs infliximab degraded via base 
hydrolysis (Blue). The X-axis is time (minutes). There is a dramatic loss of monomer peak area coupled 
with an equally dramatic formation of a new peak at 16.3 minutes. 
 
 If the size exclusion chromatography method is demonstrated as linear, precise 
and specific the accuracy can be inferred, following ICH Q2 (R1). 105 This is useful, as no 
standards exist for testing accuracy of infliximab. 
 
The limit of quantification (LOQ) must be less than 80% of the lowest test 
concentration. The LOQ can be calculated as the standard deviation of the y-intercept 
of the linearity graph, divided by the slope then multiplied by 10, as outlined in the ICH 
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Q2 (R1) document 105. The calculated LOQ is 0.04 mg/mL, less than 80% of the clinically 
low test concentration. 
 
This size exclusion method (method 2.2.16) has been demonstrated as linear, 
precise, specific, stability indicating, which allows the inference of suitable accuracy. This 
method is compatible with infliximab and validated to ICH Q2 (R1) standards. 
 
3.4.9 LC-MS analysis of chemical degradation 
 
To evaluate if LC-MS analysis of chemical degradation is stability indicating, 
control samples of infliximab were compared to degraded samples. Following method 
2.2.12-2.2.14 produced acceptable spectra for heavy and light chains (Figures 3.10 & 
3.11). 
 
Figure 3.10. LC-MS spectra for infliximab control sample light chain. Y-axis = TICs, X-axis = Mass (Daltons) 
This figure shows molecular weight for single Remsima light chain is 23434.96 daltons. There is also the 





Figure 3.11. LC-MS spectra for infliximab control sample heavy chain. Y-axis = TICs, X-axis = Mass (Daltons) 
This figure shows molecular weight for Remsima heavy chain is 50826 daltons. There is also the presence 
of a few glycovariants with masses such as 50988 and 51117 daltons. 
 
Acid hydrolysis, base hydrolysis and photolytic degradation did not produce any 
observable changes to the light chain. But oxidation degradation caused two new peaks 
to appear at 23451 daltons and 23499 daltons, these masses correlate with a single 
oxygen addition and a quadruple oxygen addition (Figure 3.12). There are peaks that 









Figure 3.12. LC-MS spectra for infliximab oxidation sample light chain. Y-axis = TIC, X-axis = Mass (Daltons). 
The peak at 23451 is 17 daltons greater than the mass of light chain in figure 3.10. Furthermore, there are 
another four peaks with masses with 16 daltons differences, indicating oxygen addition, most likely at 
methionine residues. 
 
Acid hydrolysis, base hydrolysis and photolytic degradation all cause slight shifts 
in heavy peak masses, but no more than 5 daltons for any peak (Figure 3.13 A, C & D). 
Oxidative degradation of the heavy chains (Figure 3.13 B) caused a drastic change in the 
spectra, with multiple new peaks corresponding to oxidised heavy chains. 
 
This data indicates that this LC-MS based method of chemical degradation 

















Figure 3.13. LC-MS spectra for infliximab heavy chain degraded via (A) photolysis, (B) oxidation, (C) acid 












3.4.10 Cellular assay (MTT) of functional activity 
 
This cellular assay measures the difference in the growth of WEHI-164 cells 
grown in the presence of actinomycin D and tumour necrosis factor alpha (TNF-α). 
Together, TNF-α and actinomycin D, induce apoptosis in the WEHI-164 cells. However, 
infliximab binds to the TNF-α, preventing TNF-α from binding to and activating CD30 
signalling in the WEHI-164 cells. Infliximab can ‘rescue’ the cells, and allow them to grow, 
with more growth theoretically possible at higher concentrations of infliximab. This was 
demonstrated by creating a dose response curve of infliximab mediated ‘rescue’ of 
WEHI-164 cells incubated in the presence of TNF-α and actinomycin D (Figure 3.14), this 
method has previously been used by Augustin et al 107, Kabhar et al 106 and more recently 
Song et al 108. Plate set up was performed according to method 2.3.2, and plate reading 
was performed according to 2.2.11. The dose response curve shows concentrations of 
infliximab below 1000 ng/mL don’t completely ‘rescue’ the cells. Below 10 ng/mL no 
‘rescue’ of cell growth is observed. 100 ng/mL appears to be the EC50 for cell growth 
rescue. Another IgG1 antibody, cetuximab, was used as a negative control, as it has no 
affinity for TNF-α. Cetuximab had no effect on cell growth. This work validates the assay 









Figure 3.14. A dose response curve for infliximab (red) and cetuximab (blue) in a WEHI-164 cell growth 
assay using TNF-α and actinomycin D. The dose response produced a sigmoidal curve for infliximab with 
an EC50 of 94 ng/μL. (n=3) with five repeats of each sample. The data was plotted using GraphPad Prism 
5, and the curve was fitted using non-linear regression with variable slope and four parameter modelling. 
 
3.5 Remsima stability study 
 
3.5.1 Study purpose 
 
First, this study was performed to demonstrate that the methods and study 
design chosen are all appropriate, and provided experience running a stability study, 
highlighting problems that could occur and be better planned for in the trastuzumab 
emtansine study. Secondly, it was hoped the data collected would enable justification 
for a shelf-life extension to Remsima branded infliximab for Bath ASU and all UK 
compounders with a specials license or section 10 exemption. This study was published 
in the International Journal of Pharmaceutics in 2015. 167 All results in this section are 
taken from that paper. 
 
Remsima is a biosimilar of Remicade and the excipients for both are identical 
according to their SPCs. It was expected that Remsima have near identical stability to 
Remicade and as papers existed evidencing stability beyond 7 days for Remicade diluted 
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to clinical concentrations it was expected to generate similar data for Remsima, but this 
time in full compliance with NHS guidance. 229, 102 
 
3.5.2 Study design 
 
The analytical techniques used, and study design is as described in chapter 3 and 
methods used as stated in section 2. To briefly recap, a clinically low, common and high 
concentration of Remsima brand infliximab were diluted in 0.9% NaCl solution for 
infusion, stored in four polyolefin infusion bags each at 5 °C ± 2 °C in the absence of light. 
Samples were withdrawn and tested from each bag on five separate days during a seven-
day period. Furthermore, to reduce cost burden, the total volume was scaled down from 
250 mL to 25 mL and the bag size was reduced from a 250 mL bag to a 50 mL bag. This 
reduced the cost of required Remsima from £28,000 to only £3000. 
 
3.5.3 Visual inspection 
 
Performed according to method 2.2.2. All samples remained clear for the 
duration of the study with no precipitates or particulate matter detected with the naked 
eye. No change in colour or turbidity was observed over the study period. 




Performed according to method 2.2.3. No significant change was observed for 
the pH of samples at any of the concentrations tested throughout the study period 
(Figure 3.15). The pH of samples at the high and common concentration were very 
similar at around pH=6.9, while the pH of the most dilute samples at the low 
concentration was noticeably lower at pH=6.6, possibly reflecting the buffering capacity 
of excipients. Slight variability in pH readings (±0.1 pH units) was observed for all 
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concentrations, however this variability was not significant as the observed pH’s at day 
7 showed almost no change from their respective pH’s at day 0, for all concentrations. 
 
 
Figure 3.15. pH profile of infliximab for clinically low, common and high concentration solutions over the 
study period (n = 4). Error bars represent ±1 SD. There is no statistically significant difference when 
comparing each data point to both the day 0 and day 1 measurements of each concentration. There was 
no clear trend across all concentrations although the common concentration does show a downward 
trend. 
 
3.5.5 Microflow imaging analysis of microparticles 
 
Performed according to method 2.2.6. Quantification of particle numbers was 
carried for particles >10 m and > 25 m in size (Figure 3.16).  At all concentrations 
tested, the number of particles >10 m was significantly higher than the number of 
particles > 25 m for all time points. Also, as is common with flow imaging techniques, 
the standard deviations for replicate samples was found to be quite large, making a 
detailed statistical analysis of results difficult. However, for all concentrations tested the 
largest variations in particle numbers appeared to be between the early time points (day 
0, 1 and 2), with particle numbers appearing to remain relatively constant past day 2.  
Importantly, there appeared to be no appreciable change in average particle numbers 









Figure 3.16. Mean particle number results from FlowCam imaging of Remsima at clinically (A) Low, (B) 
Common and (C) High concentrations (n=4), over the period of the study. Particles >10 μm are shown in 
blue and particles > 25 μm are shown in orange. Error bars represent ±1 SD. There was no statistically 
significant difference observed. There was also no clear trend across all concentrations. 
 
 
3.5.6 Dynamic light scattering analysis of nano-particles 
Performed according to method 2.2.4. Dynamic light scattering results are 
expressed as the mean radius and percentage abundance of detected drug particles 
within the test solution (Figure 3.17). A significantly larger mean radius could suggest 
the formation of aggregates which have a greater spherical volume, while a decrease in 
percentage abundance of drug could be attributed to larger aggregate formation.  The 
measured drug radii were found to be similar for all concentrations throughout the 
study, ranging from 14.3 - 15.1 nm immediately after preparation on day 0, to 12.9 – 





Figure 3.17. Averaged particle radius of clinically low, common and high Remsima samples over the course 
of 7 days as determined by dynamic light scattering.  Each time point consisted of 4 different samples at 
each concentration, which in turn were run in triplicate to provide an average measurement for each bag 
(n = 4). There was no statistically significant difference observed. The only trend was a slight decrease in 
average particle radius for the high concentration, while not statistically significant this could suggest loss 
of trimer and/or dimer relative to the monomer, either through further aggregation into higher order 
aggregates or through separation of the trimer and dimer into monomer. 
 
Additionally, the percentage abundance of drug particles remained constant 
over the study period, demonstrating that there was no significant increase in the 
number of larger particles (<6 μm) at any of the concentrations (Table 3.8). 
 
 
Table 3.8. Averaged drug abundance (percentage) of clinically high, common and low concentrations of 
Remsima samples over 7 days, as determined by DLS. No statistically significant changes are observed. 
This indicates very few, if any, new aggregates are being formed. While the volume remains the same it 
is still possible for pre-existing aggerates to combine, changing the size and number distribution of sub-




  D0 D1 D2 D4 D7 
High 99.82 (±0.12) 99.85 (±0.03) 99.98 (±0.02) 99.92 (±0.04) 99.92 (±0.02) 
Common 99.52 (±0.24) 99.28 (±0.12) 99.59 (±0.05) 99.65 (±0.29) 99.77 (±0.05) 






3.5.7 Size exclusion chromatography 
 
Performed according to method 2.2.16. All HPLC chromatograms of Remsima 
were characterised by a single major peak with an elution time of 21.6 minutes (Figure 
3.18).  For the clinically high concentration batch this comprised, on average, 99.28% (± 
0.15%) of all detected signals over the course of the study.  A minor signal with a 
retention time around 20.0 min was also observed at this concentration, which 
comprised the remaining 0.73% of observed signals. This minor peak was assigned as 
Remsima dimer on the basis of the retention time equating to a molecular weight of 300 
kDa. Chromatograms obtained from samples at common and low concentrations were 
comprised of only a single peak corresponding to the Remsima monomer. Importantly, 
no change in the intensity of signals was observed for any of the batches over the period 
of the study, indicating that the concentration of Remsima remained constant 
throughout (Table 3.9).   
 
 
Figure 3.18. Representative overlay of SE-HPLC chromatograms of clinically high concentrations of 
Remsima at Days 0, 1, 2, 4, and 7. Samples at each time point were run in triplicate and an average peak-
signal calculated. No loss of peak area was observed, thus the concentration of the monomer remained 
















100.20 100.07 99.39 100.06 100.08 
97.05 96.82 96.59 96.91 96.58 
100.26 99.72 99.26 98.96 99.69 
102.48 102.44 101.79 101.72 101.92 
% Mean Day 0 
Concentration 
100.00 99.76 99.26 99.41 99.57 











 101.20 101.35 101.09 101.11 101.20 
98.78 98.69 98.32 99.00 98.54 
100.28 99.74 99.85 99.93 99.65 
99.72 99.04 99.39 99.63 98.76 
% Mean Day 0 
Concentration 
100.00 99.71 99.66 99.92 99.54 
S.D. 1.01 1.18 1.15 0.89 1.21 
  
 Day 




97.75 96.89 96.12 96.60 97.10 
102.96 101.98 102.60 101.75 102.04 
96.66 97.01 96.24 95.71 96.63 
102.60 102.10 101.98 101.57 101.95 
% Mean Day 0 
Concentration 
100.00 99.50 99.24 98.91 99.43 
S.D. 3.25 2.94 3.54 3.20 2.97 
      
 
Table 3.9. SEC of Remsima monomer concentration given as mean % of the mean average D0 
concentration over the period of the study for clinically high, clinically common and clinically low 
concentration batches. Each batch contains 4 replicate devices, with each device tested in triplicate. No 
statistically significant change in monomer concentration relative to day 0 was observed. 
 
3.5.8 Variable temperature circular dichroism 
 
Analysis of variable temperature circular dichroism spectra indicates the protein 
undergoes its most significant changes to secondary structure induced by thermal 
degradation over the temperature range 74-78 °C (Figure 3.19). This temperature range 
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remained largely constant throughout the study period for all concentrations tested. 
Testing was performed according to method 2.2.8. 
 
 
Figure 3.19. Variable temperature circular dichroism data for Remsima samples at a clinically high 
concentration showing structural abundance of (A) α-helix, and (B) β-sheet as a percentage of the total 
protein. Measured over a temperature range of 25 to 90 °C. While the heat ramp profiles of D1 and D7 
are different from D0, 2 and 4, as D1 forms the SPC limit, no clinically relevant changes are presumed to 
have occurred between D0 and D7 
 
The percentage composition of secondary structures α-helix, and β-sheet 
measured at 76 °C was found to vary slightly over the course of the study, though no 
appreciable changes were observed. For the high concentration samples, α-helix 
content varied between 7.2 % and 10 % during the study, while β-sheet varied between 
29.9 % and 35.1 %. At this concentration, the samples at day 1 showed the greatest 
deviation from results at other time points whilst, importantly, day 7 data fell between 
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For the low concentration samples, slightly less variation in secondary structure 
was observed, with α-helix content varying between 8.3 % and 9.7 % during the study, 
while β-sheet varied between 30.7 % and 33.2 %. At this concentration it was the day 2 
samples that showed the greatest deviation from results at other time points, indicating 
that changes to secondary structure may be occurring slower than for the higher 
concentration samples. Additionally, for both the high and low concentrations, it is the 
early time points in the study that exhibit the greatest degree of variations in secondary 
structure (Table 3.10). 
 
 Day 0 Day 1 Day 2 Day 3 Day 4 Day 7 
Conc’ α β α β α β α β α β α β 
Low 8.3 33.2 8.6 32.7 9.7 30.7   9.3 31.7 9.0 31.7 
Common 8.2 33.1 8.4 32.9 7.9 33.6 7.9 33.7   8.0 33.8 
High 8.2 33.6 10 29.9 7.7 34.3   7.2 35.1 9.1 31.9 
 
Table 3.10. Deconvoluted CD data for Remsima samples at low, common and high concentrations 
(acquired at 76 °C) over the period of the study.  All values stated are given as the percentage of total 
structural abundance in a-helix or b-sheets. No clear trend is observed across all concentrations, with 
only small and reversible changes being noted during the study period. 
 
3.5.9 Gel electrophoresis 
 
Performed according to method 2.2.7. Protein separation of day 0 samples for 
all concentrations was characterised by a single band of approximately 150 kDa for the 
native (non-reduced) samples and two bands of approximately 50 kDa and 25 kDa for 
the reduced samples (Figures 3.20 A & C). No change to either the molecular weight or 
intensity of the bands was observed for any samples throughout the study period for all 
concentrations, as is demonstrated by the day 7 samples shown (Figures 3.20 B & D). 





Figure 3.20. Protein separation analysis of Remsima samples (5 µg per well) showing (A) Day 0 for the 
clinically high and low concentrations, (B) Day 7 for clinically high and low concentrations, (C) Day 0 for 
the clinically common concentration and (D) Day 7 for the clinically common concentration. Lane 1 in all 
gels is a protein ladder standard. No changes are observed between D0 and D7, no new peaks or changes 
in band intensity were seen, suggesting Remsima’s disulphide bonds remain intact and the level of 
aggregation does not increase. 
 
3.5.10    LC-MS analysis 
 
Performed according to methods 2.2.12-2.2.14. Mass spectral analysis of the 
light chain of Remsima on day 0 across all concentrations is characterised by a single 
major species of mass 23.4 kDa (Figure 3.21 A). The mass of this species remained 
constant over the study period, with no additional peaks appearing, indicating that the 
chemical identity of the light chain did not change. 
 
The mass spectrum of the heavy chain of Remsima is characterised by a series of 
molecular ion peaks of around 51 kDa in mass (Figure 3.21 B). The complexity of this 
spectrum is characteristic of antibody heavy chains owing to the heterogeneity of N-
linked glycan profiles. Comparison of the heavy chain mass spectra at day 0 and day 7, 
for all concentrations, revealed no obvious change in chemical composition at any point 
A   High         Low High   Low 
B   High         Low High   Low 
C  Common 
D  Common 
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during the study period. Importantly, this technique demonstrates the stability of the 
primary peptide chain, as well as the glycan profile of the antibody which can influence 
functional activity and pharmacokinetics of the protein. 
 
 
Figure 3.21. Comparison of LC-MS spectra for samples of Remsima stored at 0.60 mg/mL.  Day 0 (top) 
versus Day 7 (bottom) spectra are compared for (A) light chain and (B) heavy chain. Y-axis = TICs, X-axis = 
Mass (Daltons). No changes are observed between the D0 and D7 samples, the glycosylation pattern 
appears to remain identical. 
 
3.5.11  Biological activity 
 
Plate set up was according to method 2.3.2 and plate reading was performed 
according to method 2.2.11. Samples of diluted Remsima typically prevented around 
80% of the TNF-α induced death of WEHI cells when tested at 1 μg/mL in this assay. This 
level of biological activity was equivalent to that observed for freshly prepared samples 
of Remicade (1 μg/mL), the bio-originator that Remsima is based on. Samples of 
Remsima tested at Day 0 showed the most dramatic variability in biological activity, both 
across the three concentrations and within each batch (Figure 3.22). This variability in 
activity appeared to diminish over the period of the study, such that Day 7 data 
demonstrated the least amount of inter- and intra- batch variability. Owing to the 
variability in the data, statistical analysis (t-test) was performed to identify changes of 
significance in the biological activity of the drug, Day 1 (SPC limit) data was compared to 
both Day 0 and Day 7 data (Table 3.11). Analysis demonstrated a statistically significance 
in biological activity between Day 0 and Day 1 samples (within the SPC assigned shelf-
life) at all concentrations tested. However, no significance was assigned to differences 
between activities at Day 1 and Day 7, across all concentrations. This is most likely due 
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to the smaller error bars on day 0 than day 7, as well as the mean day 0 data point for 
the common concentration appearing erroneous, compared to the activity of the low 
and high concentrations. 
 
Figure 3.22. Functional activity of Infliximab was tested by its ability to neutralise TNF-alpha in a WEHI cell 
death assay. Infliximab was tested at 1 μg/ml and results indexed against results for Remicade to control 
for inter assay variation. Data shown are mean (n=3) with SD of pooled results for each concentration. No 







Data tested D1 vs D0 D1 vs D7 
p-value 0.011 0.2877 
Are means sig diff? yes no 
Summary * ns 







 Data tested D1 vs D0 D1 vs D7 
p-value <0.0001 0.3053 
Are means sig diff? yes no 
Summary **** ns 




Data tested D1 vs D0 D1 vs D7 
p-value 0.0016 0.2777 
Are means sig diff? yes no 
Summary ** ns 
 
Table 3.11. Statistical analysis of functional activity. Data shown in (Figure 3.22) were subjected to an 
unpaired t-test using Prism 5 software, comparing Day 7 with Day 1 (the SPC limit) and subsequently, Day 
7 with Day 1.  
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3.5.12   Remsima study discussion 
 
This study has employed study design and testing methodology which are 
compliant with NHS guidance requirements for performing a robust evaluation of 
antibody stability over a period of extended storage. We have used a number of 
analytical and biological techniques to evaluate the stability of diluted solutions of 
Remsima stored at 4 °C for a period of 7 days. Overall, no chemical or physical instability 
was observed, while the drug was also found to retain full biological activity. 
 
The techniques of LC-MS, SE-HPLC and gel electrophoresis showed no change for 
any sample examined throughout the study, indicating that full integrity of the chemical 
structure (protein and carbohydrate) of the drug is retained.  
 
However, variable temperature circular dichroism does indicate minor changes 
in the secondary structure of the drug immediately following dilution, which appears to 
be accompanied by greater variability in numbers of particles >10 μm in size. Initial 
dilution of infliximab results in dilution of excipients, such as polysorbate 80, as well the 
polyolefin bag surface to interact with resulting in reorganisation of protein surface 
interactions. This fact is further supported by results from DLS spectra which 
demonstrates a measurable drop in hydrodynamic volume of the antibody immediately 
following dilution. In all cases however, the observed variability is reduced over time as 
the drug gradually reaches equilibrium under new conditions.  
 
It is also of interest to note that, although minor, the initial changes to secondary 
structure and variability in particle number do appear to show a measurable impact 
upon the biological activity of the drug. A statistically significant difference can be 
attributed to the mean activities of day 0 and day 1 samples, whilst no such difference 
is present between day 1 and day 7 samples. In totality, these results suggest that the 
process of drug dilution contributes a more dramatic impact on drug quality than does 




3.5.13   Remsima study conclusions 
 
Here we have demonstrated the stability of Remsima brand infliximab over a 7-
day period when diluted in sodium chloride solution and stored in polyolefin bags at 2 - 
8 °C. A range of analytical techniques were used to assess the physico-chemical and 
functional integrity of the drug over time.  Furthermore, the methods and techniques 
used here are fully compliant with NHS guidance for evaluating the stability of 
biologicals, enabling this data to be used for the application of 7-day shelf-life to 
Remsima products, when prepared under a Section 10 exemption or a Specials License. 
This work demonstrates the validity of the study design and characterization methods 




Chapter 4. Evaluation and development of methods for 
characterisation of trastuzumab emtansine 
4  




Compared to antibodies, ADCs have unique critical stability characteristics due 
to the conjugation of warheads via linkers. Off-target toxicity is also an important issue 
if the warheads become detached via hydrolysis of an ester or amide, as the warheads 
rely solely on the targeting provided by the antibody. Section 4.1 details the additional 




The DAR is one of the most distinguishing characteristics an ADC has compared 
to a regular antibody. We know that an individual trastuzumab emtansine molecules 
DAR will not be the same as all the other molecules. We know there are ADCs in a 
trastuzumab emtansine vial with DARs ranging between 1 and 8 as well as naked 
antibody in the mixture too. 87 - 89 We also know that high (7-8) DAR ADCs have reduced 
biological half-lives, and low (1-2) DAR ADCs have reduced potency. 90 That is why ADCs 
are typically designed to have a mean DAR of about 4, and the majority of DAR species 
to be between 3 and 6. 87-89 Monitoring the mean DAR or payload binding would indicate 
if payloads are detaching. Increased off target activity, or loss off on target activity could 
also indicate change in DAR. Lastly the concentration of free payloads and warheads 






4.1.3 Positional isomers 
 
Positional isomers refer to variations in binding sites of ADCs with the same DAR. 
For example, a DAR of 1 trastuzumab emtansine ADC could be one of about 30 possible 
positional-isomers. The level of complexity increases, and it is quite possible that it is 
unpractical to attempt to assess positional-isomers. However, enzymatic fragmentation 
of an antibody coupled with a method of separation and detection with enough 
resolution may be able to provide some measure of the positional-isomers. However, 
this will only change from batch to batch of the trastuzumab emtansine. Once linkers 
and warheads have been attached to the antibody, the payloads should not rearrange 
during storage. It is possible we could observe functional activity and/or physico-
chemical stability differences between positional-isomers, but this information will 
unlikely be useful in determining the overall stability of trastuzumab emtansine as we 
have no control over the positional-isomers present. As such, while positional-isomers 
are important regarding stability and even potency of ADCs, as specific binding locations 
may affect the binding of the ADC to the receptor or affect CDC and ADCC, they are not 
under our control or going to change during storage, therefore will not be investigate 
further. 197 
 
4.1.4 Free payloads / warheads 
 
As the payloads can become detached, and the warheads are extremely 
cytotoxic, they have the potential to be hazardous degradation products. Trastuzumab 
emtansine’s payloads contain amide bonds and ester bonds. These are bonds which may 
be hydrolysed, liberating a portion of the payload. Amide and ester bonds are most to 
acid and base hydrolysis. As the linker is stable in human lysosomes, which have a pH of 
about 4.5, the ester and amides must require more acidic conditions to be degraded. 
The payload can also be liberated at the ester via a retro-Michael reaction involving any 





4.1.5 Off target toxicity 
 
The trastuzumab antibody is very specific for HER2, however off target toxicity 
could arise if fragments of the payloads, detach and diffuse into non-target cells. 
Payloads could detach due to ester or amide hydrolysis, trastuzumab emtansine is most 
likely to detach from its payloads under more basic conditions than it is stored and 
formulated at. While it could be possible to detect free payloads, determining if there is 
an increase in off target activity would require a cell-based assay. The activity of 
trastuzumab emtansine to kill target cells that express high levels of HER2 compared to 
the activity of trastuzumab emtansine to kills non-target cells, ideally that express 
normal low levels of HER2. 
 




To evaluate whether the methods used in the infliximab study are compatible 
with the ADC trastuzumab emtansine, control samples and force degraded samples of 
trastuzumab emtansine, made following method 2.4.1, were tested using each method 
successfully used on infliximab in chapter 3. The ability to distinguish the control from 
at least one type of degradation is the minimum requirement for a method to be 
considered stability indicating as per ICH guidance. 105 Samples of trastuzumab 
emtansine were degraded using acid hydrolysis, base hydrolysis, oxidation, photolysis, 
and thermal degradation according to methods 2.2.17 - 2.2.21 respectively. 
 
Trastuzumab emtansine is dosed at 3.4 mg/kg or 2.4 mg/kg. When prepared into 
an infusion bag, according to its SPC, the concentration ranges between 0.5 and 1.5 





4.2.2 Visual inspection 
 
Following the procedures set out in method 2.2.2, no visual differences 
compared to the control samples were observed for any degraded samples. All samples 
remained clear and free of visible particulates. This technique appears entirely 
unaffected by the change to testing the ADC trastuzumab emtansine. The structure of 
trastuzumab emtansine was not expected to have an effect on the compatibility of the 




Because pH is altered by oxidative, acidic and basic reagents, only control 
samples, photolytically degraded and thermally degraded samples were measured 
following method 2.2.3. The control was 5.67 ±0.03, photolytically degraded samples 
were 6.61 ± 0.09 and the thermally degraded samples were 6.04 ± 0.61. This 
demonstrates pH can be stability indicating and the pH method is compatible with 
trastuzumab emtansine. 
 
4.2.4 Microflow Imaging analysis of microparticles 
 
When measured following method 2.2.6, all investigated paths of degradation 
were observed to cause an increase in microparticles (10-100 μm) of both size 
categories, except those >25 μm for the ‘Acid Degraded’ condition (Figure 4.1). These 
results clearly demonstrate the stability indicating nature of the MFI method. This 
technique is entirely unaffected by the change to testing the ADC trastuzumab 
emtansine. Note the photolytic control is only for comparison to the photolytic 





Figure 4.1. Microparticles / mL for trastuzumab emtansine controls and degraded samples, as measured 
by MFI. Effect of various methods of degradation on microscale particles per mL. For both size categories 
of microparticle, only the photolytically degraded sample was significantly different from the photolytic 
control. results are a mean (n=3) with error bars reporting 1 standard deviation. The effect of photolytic 
degradation was statistically more significant on the number of particles greater than 25 μm than the 
number of particles greater than 10 μm. *** = p <0.001, **** = p <0.0001 
 
4.2.5 UV assay for extractables and leachables 
 
The purpose of this techniques is to detect plasticisers that have leached into the 
drug solution. Figure 4.2 below, shows UV scans of the three concentrations used in the 
stability study, obtained following method 2.2.10. UV absorption at 280 nm is caused 
primarily by amino acids with aromatic rings, such as tyrosine, tryptophan and 
phenylalanine. Trastuzumab emtansine’s warhead, DM-1, contains only affects lysine 
residues for trastuzumab emtansine, which an aromatic ring which slightly increases the 
molar absorption co-efficient at 280 nm. Leachables, such as DEHP, would cause an 
increase in the absorbance at 226 nm and above 300 nm. 231, 232 This technique is 




Figure 4.2.  UV absorbance from 220 nm to 400 nm of a clinically High (Green), Common (Blue) and Low 
(Red) concentration of trastuzumab emtansine. No absorbance from 300 nm to 400 nm means common 
plasticisers such as DEHP should be detectable even in small amounts. 
 
4.2.6 Gel electrophoresis 
 
Following method 2.2.7, The photolytic and thermal samples had discernible 
differences compared to the control (Figure 4.3). No difference was noted with the 
acidic and basic hydrolysis methods, while the oxidized sample failed to either stain or 
run properly, the hydrogen peroxide is likely interfering with the staining reagents.  
 
The thermally degraded samples each had a new band below 10 kDa, 
suggesting fragmentation in addition to greater intensity of the wide band above 200 
kDa, indicative of aggregation. The photolytically degraded samples each had an 
additional band around 120 kDa, suggesting incomplete reduction as well as an 
increase in intensity of the wide band above 200 kDa, indicative of aggregation. This 
data indicates the gel electrophoresis method is compatible with trastuzumab 
emtansine and is stability indicate, however these findings also suggest thermal stress 
is driving aggregation, perhaps through partial unfolding of the antibody exposing 
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hydrophobic regions that would normally be inaccessible, as well as causing 
fragmentation of sub 10kDa species, this could be payloads. While photolytic stress 
also drives aggregation, the fragmentation of species with a molecular weight between 
10 and 20 kDa is very curious, as no fragment of an ADC is that size, suggesting intra-




Figure 4.3. Gel electrophoresis images of reduced trastuzumab emtansine: sample controls [A1, C1, E1], 
thermally degraded samples [G1, A2 & C2] and photolytically degraded samples [E2, G2 & B1]. Compared 
to the control samples, the thermally degraded samples show a marked increase in aggregate band 
intensity, (bands above the 200 kDa marker), as well as new bands below the 10 kDa marker. Compared 
to the control samples, the photolytically degraded samples show a slight increase in aggregate band 







4.2.7 Dynamic light scattering analysis of nano-particles 
 
This technique was not used as a better technique, Nano-tracking analysis, 
became available after the Infliximab study had been performed. However, work by 
Cockrell et al  168 used DLS analysis, to assess aggregation of a model antibody drug 
conjugate after photodegradation. Their model ADC was trastuzumab linked to eosin via 
its lysine residues. Cockrell et al found they were able to detect aggregation following 
photolytic degradation of their model ADC, but not for trastuzumab. That work indicates 
DLS would likely have been compatible and stability indicating. 
 
4.2.8 Nano-tracking analysis of nano-particles 
 
Following method 2.2.5, NTA was able to measure the concentration (per mL) of 
nano-particles (1-1000 nm) in trastuzumab emtansine control and degraded samples 
(Figure 4.4). The stability indicating nature of the technique was demonstrated by the 
ability to detect differences in the degraded samples compared to the controls. All 
conditions increased the concentration of nano-particles. With acidic and thermal 
degradation having the most significant effect. NTA appears compatible and stability 
indicating. Acidic degradation caused the most statistically significant amount of change, 
suggesting that acid hydrolysis affects the structure of trastuzumab emtansine the most 
while basic degradation appears to have had the least statistically significant effect on 
particle concentration. This is interesting as acid and base stress will cause hydrolysis of 
the linker however that is not likely to drive aggregation. It appears that acidic 
environments cause the conformation of the antibody to expose hydrophobic residues 
that would typically be inaccessible to a greater extent than basic environments. 
Oxidation of methionine residues is known to cause aggregation in antibodies and it is 
reasonable to assume the same is true for ADCs. Thermal degradation can also cause 






Figure 4.4. Nano-particles per mL for control and degraded trastuzumab emtansine.  Plots are a mean 
average (n=3) ± 1 standard deviation. All stress conditions increased the concentration of nanoparticles. 
*, ** & **** indicate p < 0.05, 0.01 & 0.0001 respectively. 
 
4.2.9 LC-MS analysis 
 
Trastuzumab emtansine was reduced into its heavy and light chains and 
analysed using method 2.2.12. (Figures 4.5 & 4.6). Heavy and light chains with up to 
two payloads are detectable with mass differences matching molecular weight of a 
single payload. The samples were run according to method 2.2.13 and the data was 
processed according to method 2.2.14 
 
Degradation using heat and photolysis could be detected as a loss in peak 
intensity compared to the controls, as well as an increase in peak intensity at about 
50650 kDa, (Figures 4.5 & 4.6). Peak intensity loss appears more prevalent on chains 
with more payloads Furthermore, an increase in peak intensity is observed at 50650 
daltons, indicating successful detection of a chemically different heavy chain species 
formed during photolytic degradation (Figure 4.6). Therefore, this method appears to 
be compatible with trastuzumab emtansine and is stability indicating for at least 




Figure 4.5. Mass spectra between 23300 and 25400 daltons of trastuzumab emtansine light chains, 
following TCEP reduction. Control sample spectra are (Black), thermally degraded sample spectra are 
(Red) and photolytically degraded samples are (Green). First, there are three distinct peak clusters, each 
pertaining to light chain with either 0, 1 or 2 bound payloads. Second, it is notable that the peak cluster 
patterns, which are due to variable glycosylation, are not identical between the peak clusters. It could be 
possible that specific glycosylation profiles influence linker conjugation for trastuzumab emtansine, 
however this has not been investigated further. Third, in the thermally and photolytically degraded 
samples the signal intensity of the peaks is reduced compared to the control. Finally, in the thermally and 
photolytically degraded samples some peaks are greater in magnitude while the main peaks of the clusters 
have decreased, indicating that this technique is able to detect changes in the glycosylation peak profiles 






Figure 4.6. Mass spectra between 50300 and 53100 daltons of trastuzumab emtansine heavy chains, 
following TCEP reduction. Control sample spectra are (Black), thermally degraded sample spectra are 
(Red) and photolytically degraded samples are (Green). First, there are three distinct peak clusters, each 
pertaining to heavy chain with either 0, 1 or 2 bound payloads. Second, it is notable that the peak cluster 
patterns, which are due to variable glycosylation, are not identical between the peak clusters. It could be 
possible that specific glycosylation profiles influence linker conjugation for trastuzumab emtansine, this 
was also noted for the light chains. Third, in the thermally and photolytically degraded samples the signal 
intensity of the peaks is reduced compared to the control. Finally, in the thermally and photolytically 
degraded samples some peaks are greater in magnitude while the main peaks of the clusters have 
decreased, indicating that this technique is able to detect changes in the glycosylation peak profiles for 





















4.2.10 MTT cellular assay 
 
The plate was set up according to 2.4.2, the plates were read according to 
method 2.2.11. Theoretically, trastuzumab emtansine should only bind, become 
internalised and then initiate apoptosis in cells with a high HER2 expression. Therefore, 
on-target activity and can be well modelled with the cell line BT-474. BT-474 is a breast 
cancer cell line with a highly upregulated HER2 expression, that has been used by 
numerous studies to investigate trastuzumab activity and model breast cancer since 
1979. 169-172 A log10 dose response curve of percentage cell death of a control sample vs 
a photolytically degraded sample of trastuzumab emtansine demonstrates a loss of 
activity via a shift of the dose response curve to the right (Figure 4.7 A). Off target 
activity is a concern for ADCs as their payloads can become detached and cause 
apoptosis in any cells the payloads are able to diffuse or get transported into. To assess 
off target activity a human epidermal skin cell line known as HaCaT’s was used to 
measure off target activity on the skin (Figures 4.7 B), while hepatic cell line HepG2, was 
used to assess off target activity at the liver (Figures 4.7 C). Note the loss of activity at 
the lower concentrations for the photolytically degraded trastuzumab emtansine is 
significant for the on-target cell line but insignificant for the off target cell line. 
 
MTT analysis of biological activity appears to be unaffected when measuring the 
ADC trastuzumab emtansine, however the cell lines used are completely different to 
those used in the infliximab study. This data suggests this method is valid and stability 













Figure 4.7. Log10 dose response curves of (A) BT-474 cells, (B) HaCaT cells and (C) HepG2 cells to control 
samples and photolytically degraded trastuzumab emtansine. Samples were tested in quintuplicate. 
Results are means (n=5) ± 1 standard deviation. All dose response curves exhibit the classic sigmoidal 
curve associate with a dose response that crosses the EC50. The control and degraded dose response 
curves for BT-474 cells do not overlay, with a shift towards the right on the X-axis, seen when 
photolytically degraded. The EC50 for the control trastuzumab emtansine against the BT-474 cells was 77.3 
ng/mL which dramatically increased to 239.7 ng/mL for the degraded drug. The control and degraded 
dose response curves for HaCaT and HepG2 cells overlay, with minimal change in the EC50. The EC50 for 
the control trastuzumab emtansine against the HaCat cells was 4.4 μg/mL which slightly decreased to 3.6 
μg/mL. The EC50 for the control trastuzumab emtansine against the HepG2 cells was 1.7 μg/mL which 



































































4.2.11 Size exclusion chromatography analysis of monomer and oligomers 
 
To investigate compatibility of size exclusion chromatography analysis, 
trastuzumab emtansine and its parent antibody, trastuzumab were analysed using 
method 2.2.16, previously used for infliximab (Figure 4.8). The monomer peak has 
clearly been affected, with the plate number dropping from 5394 to 596 and the 
asymmetry increasing from 1.2 to 1.7. An asymmetry of 1 is a perfectly symmetrical 
peak, while an asymmetry above 1.5 is bad for analytical chromatography and an 
asymmetry above 2.0 is unacceptable. Any secondary interaction to the stationary phase 
(column material) will cause peak tailing, leading to an unacceptable degree of peak 
asymmetry as well as a loss of resolution and theoretical plate number. Trastuzumab 
emtansine’s payloads appear to be interacting with the stationary phase, resulting in a 
drastically impaired peak unsuitable for a full validation. This finding agrees with work 
by Wakankar et al, 173 who found impaired peak shape for ADCs analysed using 
traditional methods. This method is not compatible with trastuzumab emtansine and 
cannot be validated to determine its stability indicating nature. 
 
Figure 4.8. A chromatographic overlay of the mAb trastuzumab in (Blue), and the ADC trastuzumab 
emtansine in (Black) both at 2 mg/mL using the same method. The X-axis is time (minutes). The peak for 
trastuzumab is resolved from the dimer peak and fragment peak, and has acceptable peak shape, while 
the peak for trastuzumab emtansine has a much broader peak that has unacceptable levels of fronting 







4.2.12 Circular dichroism analysis of higher order structure 
 
To investigate the compatibility of circular dichroism analysis of higher order 
structure, trastuzumab emtansine, its parent antibody trastuzumab and denosomab, an 
IgG2 antibody with a different target antigen, were analysed using method 2.2.8, 
previously used for infliximab (Figure 4.9 & Table 4.1). 
 
It was found that the CD spectra of trastuzumab and trastuzumab emtansine 
were similar which made sense but when processed using CDNN into a prediction of 
secondary structure, the prediction did not appear correct (Table 4.1). Although 
trastuzumab emtansine has payloads bound to the lysine residues, the secondary 
structure of the antibody should not be affected significantly. It is likely that High DAR 
forms of trastuzumab emtansine would exhibit the most altered structure, or 
trastuzumab emtansine with payloads bound to lysine residues around the hinge region 
may have reduced flexibility, affecting the most favourable resting conformation. 
However, these effects should be minimal, and there are no reports of trastuzumab 
emtansine having a significantly different secondary structure to trastuzumab. When 
measuring trastuzumab and trastuzumab emtansine CD they appear similar (Figure 4.9).  
 
Figure 4.9. The CD spectra for 0.3 mg/mL trastuzumab in (Green), trastuzumab emtansine in (Blue) and 
denosumab in (Pink). The spectra for trastuzumab and trastuzumab emtansine are very similar in shape, 
though the signal intensity appears to be stronger for trastuzumab emtansine, even though they are at 




However, when deconvoluted via CDNN, the predicted structure does not correlate 
with a realistic estimation of secondary structure, see (Table 4.1). Note that 
denosumab which is an IgG2 antibody that binds to a completely different receptor 
and has a different primary sequence has a more similar structure to trastuzumab than 
trastuzumab emtansine, according to CDNN estimation. 
 
Secondary Structural Motif Trastuzumab Denosumab 
Trastuzumab 
Emtansine 
Helix 5.3% 5.8% 14.3% 
Antiparallel 41.0% 40.7% 35.4% 
Parallel 5.6% 5.5% 5.5% 
Beta-Turn 14.8% 14.0% 20.8% 
Random Coil 33.4% 34.7% 36.7% 
    
Total Sum 100.1% 100.7% 112.7% 
 
Table 4.1. CDNN structural estimation from the CD spectra for 0.3 mg/mL trastuzumab, trastuzumab 
emtansine and denosumab. Trastuzumab and denosumab have well predicted structures with the total % 
of secondary structure summing to approximately 100%. Trastuzumab emtansine has a secondary 
structure that adds up to over 112%, which highlights something must be wrong. The most notable 
differences between trastuzumab and trastuzumab emtansine occur at the alpha helix, which increase 
9%, beta turns, which increase 6%, random coil which increases 3%, and antiparallel sheet, which 
decreases 5.6%. 
 
The secondary structure composition does not look right for trastuzumab 
emtansine. As well as the specific structural estimations not matching up, the structural 
sum adds up to 112.7%, while trastuzumab and denosomab only add up to 100.3 and 
100.6 respectively. 
 
There are two ideas that may partially explain why this is observed. Proteins have 
chiral centres that contribute to their inherent circular dichroism (the degree to which 
they preferentially absorb left or right handed polarised light). This is conformationally 
sensitive and using CDNN to deconvolute the spectra based on a comparison to a known 
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library of proteins, along with the specific concentration, exact number of amino acids 
and molecular weight with an accuracy of 0.1 daltons. 
 
The first idea was, the mass being used in the deconvolution calculations was 
wrong, as CDNN is based only on proteins and not ADCs, which have additional mass not 
due to protein but due to payloads. The second idea was, the payloads themselves were 
affecting the circular dichroism of the ADC, as the payloads contain a chiral centre that 
is unrelated to the antibody’s circular dichroism. 
 
Attempts to spoof CDNN by using the mass of trastuzumab instead of 
trastuzumab emtansine were made, but the results still had Total structural sums over 
110%. This leads me to believe that the chiral centres in the payloads are interfering 
with the CDNN structural deconvolution. 
 
This method of determining secondary structure was not feasible to use with the 
ADC trastuzumab emtansine and is predicted to be incompatible to any ADCs with 
payloads containing chiral centres, which includes all four currently licensed ADCs. Thus, 
a new method of determining secondary structure is required. 
 
In summary, analysis of higher order structure using the circular dichroism based 
method previously applied to infliximab is unsuitable for trastuzumab emtansine and 
therefore cannot be determine to be stability indicating. 
 
The issues with deconvolution of CD spectra to secondary structure predictions 
is not reported in literature, although the only published papers that used CD to 
investigate ADC structure did not attempt to deconvolute the data to estimate 
secondary structure, as is typically done for normal antibodies, and instead reported the 
mean residue ellipticy. 233, 234 In 2016, Arakawa et al identified differences between a 
model ADC and its parent antibody in the near-UV region as well as claiming that many 
cytotoxic drugs have many cytotoxic drugs have UV absorbance that can interfere with 
optical properties of ADCs. 234 
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4.3 Optimisation of a SEC method for API quantification 
 
4.3.1 Literature research 
 
SEC is an essential method, required for characterising a mAb or ADC. A stability 
indicating method can quantify the concentration of the monomer, dimer and trimer. 
Oligermization of antibodies is known to affect their activity, immunogenicity and 
pharmacokinetics. 174 Thus, monomer, dimer and trimer concentrations are critical 
characteristic, as stated in the NHS biopharmaceutical stability guidance. 102 
 
Standard SEC methods for mAbs, have been demonstrated as unsuitable to 
characterise the ADC trastuzumab emtansine, it is believed this is due to secondary 
interactions of the ADCs payloads with the stationary phase. To reduce the effect of 
payload secondary interactions Wakanker et al added varying amounts of different 
organic modifiers, such as acetonitrile and propan-2-ol. 173 They found 15% propan-2-ol 
to 85% 200mM potassium phosphate / 250mM potassium chloride adjusted to pH 6.95 
minimised the secondary interactions and produced suitable chromatograms. An issue 
regarding the addition of organic solvents to a mobile phase is salt precipitation. This 
can affect HPLC modules as well as cause irreparable damage to a size exclusion 
chromatography column. The column manufacturer Phenomenex claim their SEC 
columns could quantify ADCs without the need to add organic modifiers at all, with 
published data showing addition of organic modifier did not change the chromatograms. 
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4.3.2 Experimentation with Phenomenex’s Yarra and BioSEP columns 
 
Phenomenex have a public technical note demonstrating the use of their Yarra 
SEC-s3000 column to separate monomer and dimer of a model ADC without using 
organic additives to prevent secondary interaction of the payloads with the column. 175 
Using trastuzumab emtansine and following method 2.4.3, the results could not be 
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replicated (Figure 4.10). When organic phase was added the peak shape improved, 
showing the column was affected by the non-specific interactions caused by the 
payloads. Phenomenex make a BioSep-SEC-s4000 column marketed as an equivalent or 
superior to the Tosoh G3000 SWxl, which had been used for the infliximab analysis in 
chapter 3. As we had a negative experience with the Yarra, we were given a BioSep-SEC-
s4000 as compensation. Preliminary testing confirmed the BioSep was equivalent to the 
Tosoh G3000 SWxl. Due to the significant difference in price, (£800 cheaper), the BioSEP-




Figure 4.10. A SEC chromatogram of trastuzumab emtansine, tested on the Yarra SEC-3000 with the 
manufacturers recommended method. The X-axis is time (minutes). The monomer elutes at about 10 
minutes, with a poor peak shape due to tailing. An aggregate peak elutes around 6 minutes, which also 
exhibits poor peak shape, with both fronting and tailing. 
 
4.3.3 Adjusting the mobile phase 
 
The effects of different organic modifiers, such as acetonitrile and propan-2-ol 
(IPA) were investigated, as well as the effect of altering the: buffer salts, final pH, buffer 
strength, SEC column type and flow rate. 
 
Trastuzumab emtansine’s payloads are hydrophobic, causing hydrophobic 
interaction with the SEC column stationary phase. 173 Addition of organic modifiers 
reduces the tailing observed due to hydrophobic interaction. 173 Method 2.4.4 was used 
to compare 0, 5, 10 15 and 20% acetonitrile, IPA and ethanol (Figure 4.11). Ethanol least 
improved the peak shape, while acetonitrile and propan-2-ol had more similar effects. 
Addition of 10% propan-2-ol produced the best results, according to retention time, 
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peak resolution and asymmetry, thus propan-2-ol was selected as the most suitable 
organic modifier.  These findings reflect Wakankar’s original work. 173 IPA is notably 
more viscous than acetonitrile or ethanol and is also cheaper than ethanol or 
acetonitrile. As the modifier is being used in sub 25% amounts the potential increase on 
backpressure is negligible, but the difference in price of IPA over acetonitrile makes the 
decision to use IPA much easier. 
 
 
Figure 4.11. Chromatograms of trastuzumab emtansine with 0 % organic modifier in (Blue) which has 
clear peak tailing and the worst peak shape, 10 % ethanol in (Pink) which had the second worst peak 
shape due to tailing, 10 % acetonitrile in (Black) with the second-best peak shape and 10 % propan-2-ol 
in (Brown) which had the best peak shape according to asymmetry calculated by Chromeleon. The X-axis 
is time (minutes). 
 
One of the biggest risks of adding organic modifiers is precipitation. There were 
three approaches to minimising this risk: reduce the concentration of salt in the mobile 
phase, reduce the amount of organic solvent in the mobile phase, use more soluble and 
miscible reagents. The American USP standard method for antibodies uses potassium-
based buffers, while most other countries use sodium-based buffers. Previous work had 
used sodium phosphate as the buffer but it has been shown that sodium is less soluble 
in organic solvents than potassium. 176 When comparing potassium-based buffers to 
sodium-based buffers following method 2.4.5, no discernible difference could be noted 
with no change in peak asymmetry, plate number, retention time or absorbance (Figure 





Figure 4.12. Chromatograms of a mAb using a sodium-based buffer in (Blue) and a potassium-based buffer 
in (Black). The X-axis is time (minutes). Both peaks exhibit good peak shape, with low asymmetry, excellent 
signal to noise, however both do also have small amounts of fronting and tailing. 
 
An alkali chloride such as sodium or potassium chloride is typically added to 
antibody mobile phases. The alkali chloride inhibits non-specific interactions of the 
proteins with the stationary phase. 235 However more modern columns are designed to 
minimise these interactions and with the addition of an organic modifier it was decided 
to investigate the effect of the alkali chloride concentration. Following method 2.4.6, we 
found that mobile phases with organic modifier use in conjunction with a more modern 
BioSep-SEC-s4000 column there was no effect on the peak quality (Figure 4.13) and 
noted a slight decrease on HPLC backpressure as well. There was no change in peak 
asymmetry, and a 1.6% loss of peak area and a 0.3% loss of theoretical plates, but these 




Figure 4.13. Chromatograms of trastuzumab emtansine with 300mM sodium chloride in the buffer in 
(Blue), and with 0mM sodium chloride in the buffer in (Black). The X-axis is time (minutes). Both 
chromatograms overlay with the 300 mM NaCl condition having a slightly higher peak height and 




The buffer salt concentration is different in many published HPLC methods but 
is most often 100 mM. 111, 123-125, 173, 175, 235 Ideally, the lowest concentration as possible 
would be used, as this is the least likely to cause a precipitation event and is a more 
economical use of reagents. Following method 2.4.7, we investigated the use lower 
concentrations (Figure 4.14). 25 mM buffer drastically impairs peak shape and peak 
metrics, the 50 mM buffer has visually impaired peak shape and peak metrics, while the 
75 and 85 mM buffers appear visually almost identical. The 85mM buffer produced 
better plate numbers and resolution, as well as a larger absorbance for the dimer peak 
(Peak 1, 6.027 mins). 85 mM was the best concentration based on asymmetry and peak 
area, therefore, 85mM potassium phosphate was chosen as the optimum pH buffer. 
 
 
Figure 4.14. Chromatograms of an ADC using a phosphate buffer that is 25 mM (Blue), 50 mM (Pink), 75 
mM (Brown) and 85 mM (Green). The X-axis is time (minutes). The stronger the concentration of 
phosphate buffer, the greater the peak height, peak area and lower the asymmetry. 
 
The last way to reduce the risk of a precipitation event is to reduce the % of 
organic modifier in the mobile phase. Following method 2.4.8 we investigated the effect 
of different ratios of potassium phosphate buffer to IPA, (Figures 4.15 and 4.16). 
Increasing the concentration of IPA up to 20% was found to improved the peak shape 
and absorbance, but above 20% was found it increase asymmetry and reduce 
absorbance (Figure 4.15).  
 
To find the optimal % of IPA we needed to identify the best balance of all peak 
metrics, including total absorbance, peak shape, plate number and column 
backpressure. While column backpressure is a limiting factor, the most important factor 
for us was the peak shape or the asymmetry, followed by absorbance or peak area and 
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then plate number. While following method 2.4.9, we found the column backpressure 
was inversely proportional to the IPA% and was unacceptable above 20%. 
Chromatograms at 14-17% IPA were compared and it was found above 16% plate 
number and asymmetry worsened, and below 16% asymmetry and total absorbance 




Figure 4.15. Chromatograms of trastuzumab emtansine with different total % of IPA in the mobile phase. 
0% (Black), 5% (Dark Blue), 10% (Pink), 15 % (Grey), 20% (Brown), 25% (Light Blue), 30% (Green). The X-
axis is time (minutes). 20% acetonitrile (Brown) gives the best result, with the greatest peak height, largest 
peak area and lowest asymmetry. It is a dramatic difference between 20% and 0%, demonstrating how 
much tailing occurs with no acetonitrile present. 
 
 
Figure 4.16. Chromatograms of trastuzumab emtansine with different total % of IPA in the mobile phase. 
14% (Green), 15% (Light Blue), 16% (Pink), 16.5 % (Brown), 17% (Dark Blue). The X-axis is time (minutes). 
When the acetonitrile contact was 17 % (Dark Blue) has the greatest peak height and peak area but at 16 
% (Pink) it had the best peak shape, with the lowest asymmetry and highest number of thermotical plates, 





4.3.4 Adjusting HPLC running parameters 
 
Column temperature for antibody SEC methods is typically set at room 
temperature, or 20/25 °C. Increasing the temperature of SEC analysis of proteins has 
been shown to improve the efficiency of separation but only at extremely elevated 
temperatures (150 °C). 177 This was not due to affecting the relative separation but by 
improving the fluid dynamics inside the column. 177,178 At more normal temperatures 
(<40 °C), the effects are very minimal, although it has been demonstrated that peak 
absorbances can be affected, as well as reducing column backpressure. The Bio-SEP 
4000 column has a maximum operational backpressure of 1500 psi, and the method was 
running between 1000 and 1400 (depending on flow rate). Therefore, the effects of 
adjusting the temperature of the column oven were investigated, following method 
2.4.10 (Figure 4.17). Pressure was inversely proportional to temperature, but total 
absorbance was greatest at 30 °C. Furthermore, peak shape at 40 °C was significantly 
affected with poor tailing. 30 °C was the optimum column oven temperature. 
 
 
Figure 4.17. Chromatograms of an ADC method at 25 °C (Black), 30 °C (Blue), 35 °C (Pink) and 40 °C 
(Brown). The X-axis is time (minutes). At 40 °C (Brown) there is a very large increase in tailing, or possibly 
even a new peak emerging in the tail of the monomer peak. At 30 °C (Blue) the peak has the greatest 
height, area and lowest asymmetry. 
 
Flow rate is directly proportional to backpressure, and it is known to affect, 
retention time, peak shape and even separation. 178 Ideally an HPLC method will be as 
short as possible, therefore the method ought to be as high a flow rate as possible, 
without compromising the separation or peak quality. The effect of varying the flow rate 
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between 0.5 and 1.5 mL/min was investigated, following method 2.4.11 (Figure 4.18). It 
was found increasing the flow rate improved the retention time and column asymmetry, 
but also decreased the total peak area and plate number. Retention time, plate number, 
peak area, resolution and asymmetry are inversely proportional to flow rate while 
backpressure is directly proportional to flow rate. As a high flow rate caused: higher 
pressure, reduced sensitivity of the method for dimers and trimers, and reduced peak 




Figure 4.18. Chromatograms of an ADC run with different flow rates. 1.5 mL/min (Green), 1.25 mL/min 
(Pink), 1.0 mL/min (Brown), 0.75 mL/min (Blue) and 0.5 mL/min (Grey). The X-axis is time (minutes). 
Retention time is inversly proportional to the flow rate. With the shortest retention time of 6.8 minutes 
for 1.5 mL/min and the longest retention time of 10.5 minutes at 0.5 mL/min. Peak height and are was 
inversely proportional to flow rate too, with 0.5 mL/min producing the largest peaks. 
 
4.3.5 The fully optimise’ SEC method 
 
The final method is as follows. Column of choice is a Phenomenex BioSep SEC-
s4000 with dimensions 300 mm × 7.8 mm, particle size 5 μm and pore size 500 Å fitted 
with a guard column. Isocratic elution was performed with the mobile phase being a 15 
: 85 mix of propan-2-ol / 100 mM potassium phosphate buffer (pH 6.80) containing 
15mM NaN3 as an anti-microbial agent.  The column temperature was 30 °C, the 
injection volume was 20 μL and UV detection was set at 280 nm.  The flow rate was 0.75 
mL/min and the run time was 25 min, with the monomer peak eluting at 12.5 minutes 
(Figure 4.19). Compared to using the infliximab method, the asymmetry was 1.1, down 




Figure 4.19. A chromatogram of a clinically high concentration of trastuzumab emtansine run using the 
final study method. The X-axis is time (minutes). Retention time of 12.5 minutes for the monomer and 6.5 
minutes for the dimer. 
 
4.3.6 Validation of the optimized size exclusion chromatography method 
 
Size exclusion chromatography analysis of monomer concentration is a method 
used to determine the concentration of the active pharmaceutical ingredient, 
trastuzumab emtansine monomers. As such, it is outlined in the ICH  guidance document 
Q2(R1) 105 that the linearity, precision, specificity and accuracy must be validated 
according to the limits stated in the ICH Q2(R1) document. Validation samples were 
prepared according to method 2.4.1 and degraded using methods 2.2.18 to 2.2.22. 
 
The method must be demonstrated as having a linearity with an R2 value of at 
least 0.999 for a range covering at least 20% higher and lower than the test 
concentrations. (Figure 4.20), plots the mean absorbance (n=3) of samples from 0.2 
mg/mL to 2.0 mg/mL. The R2 value is greater than 0.9999 and is rounded up to 1 by 
Excel. The linearity exceeds the required minimum linearity for a concentration range 




Figure 4.20. Size exclusion chromatography analysis of trastuzumab emtansine monomer concentration. 
Results are a mean (n=3). The R2 = 0.9999 across the entire range 
 
The method must be demonstrated as having a precision with a relative standard 
deviation of no more than 2% at each test concentration. (Tables 4.2 - 4.4) below, show 
the measured precision from six repeat injections at the clinically low, common and high 
concentration respectively. The determined relative standard deviations are all below 
2%, indicating the method has suitable precision. 
 











Table 4.2. Size exclusion chromatography precision determination at the clinically low concentration. The 
RSD of 0.6 % is well below the limit of 2.0 %, indicating the method is precise enough at the lowest 


















Table 4.3. Size exclusion chromatography precision determination at the common concentration. This 
RSD will pass the limit of 2%, but it’s the closest to failing of all the concentrations tested.  
 











Table 4.4. Size exclusion chromatography precision determination at the clinically high concentration. The 
RSD of 0.47 % is the best obtained for all concentrations of trastuzumab emtansine tested. 
 
The size exclusion chromatography method must also be demonstrated to be 
specific, meaning it is able to detect degradants such as dimers and trimers. This is 
demonstrated by analysis and comparison of control samples of trastuzumab emtansine 
to force degradation samples. When photolytically degraded, a loss of monomer is 
detectable (Figure 4.21). When degraded via acid hydrolysis, a loss of monomer is 
detected (Figure 4.22). When degraded via base hydrolysis a large loss of monomer is 
observed along with the emergence of multiple fragments of trastuzumab emtansine 
with lower molecular weights than the monomer (Figure 4.23). When degraded via 
oxidation a loss of monomer is detected (Figure 4.24) and a large peak eluting at 16 
minutes is due to a preservative in the hydrogen peroxide, it is not a degradation 
product. This data indicates this method is specific and stability indicating. Furthermore, 




Figure 4.21. Size exclusion chromatogram of trastuzumab emtansine control (Blue) vs trastuzumab 
emtansine photolytically degraded (Brown). The X-axis is time (minutes). Peak height and peak area is 
reduced when comparing the control to degraded sample.  
 
 
Figure 4.22. Size exclusion chromatogram of trastuzumab emtansine control (Black) vs trastuzumab 
emtansine acidically degraded (Blue). The X-axis is time (minutes). Peak height and peak area is reduced 
when comparing the control to degraded sample. 
 
 
Figure 4.23. Size exclusion chromatogram of trastuzumab emtansine control (Black) vs trastuzumab 
emtansine degraded via base hydrolysis (Blue). The X-axis is time (minutes). Base degradation has caused 
a large loss of monomer peak area, as well induce the formation of more aggregates, show as larger peak 
areas to the left of the monomer peak, and more notably, the formation of fragments, seen at new peaks 






Figure 4.24. Size exclusion chromatogram of trastuzumab emtansine control (Black) vs trastuzumab 
emtansine degraded via oxidation (Blue). The X-axis is time (minutes). Degradation has presented itself 
as a loss of monomer peak height. No aggregates or fragments were detected. 
 
 If the size exclusion chromatography method is shown to be linear, precise and 
specific the accuracy can be inferred. This is useful, as no standards exist for testing 
accuracy of trastuzumab emtansine. 
 
The limit of quantification (LOQ) must be less than 80% of the lowest test 
concentration. The LOQ can be calculated as the standard deviation of the y-intercept 
of the linearity graph, divided by the slope then multiplied by 10, as outlined in the ICH 
Q2 (R1) document. 105 The calculated LOQ is 0.09 mg/mL, less than 80% of the clinically 
low test concentration. 
 
This size exclusion method has been demonstrated as linear, precise, specific, 
stability indicating, which allows the inference of suitable accuracy. This method is 
compatible with trastuzumab emtansine and validated to ICH Q2 (R1) standards. 
 
4.4 Developing new methods for characterising secondary structure 
 
4.4.1 Reviewing initial literature research 
 
The next best alternative to CD was IR, as IR spectra can be compared to 
quantitative data sets (QDS) to estimate the amount of beta sheet and alpha helix 
present. This is due to the conformational sensitivity of the Amide 1 and 2 bands, 
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detected via IR spectroscopy. However, we did not have access to an appropriate 
instrument. 
 
4.4.2 IR in practice – Visiting Bruker 
 
Bruker has a UK based purpose-built facility for the demonstration and testing of 
their equipment. We travelled to Coventry multiple times with a selection of diluents, 
antibodies, infusion proteins and ADCs to test on their infra-red spectrometers. The 
samples needed to be tested were all liquids and even clinically high concentrations are 
low concentrations for most IR spectrometers. Initially a spectrophotometer fitted with 
a Bruker AquaSpec transmission cell module was tested. Mason et al have previously 
used a Bruker AquaSpec to analyse antibody structure. 148 The AquaSpec could be 
purchased with a prebuilt quantitative data set created and validated by Bruker. At 
clinically high concentrations (2 mg/mL) it was able to detect trastuzumab and a few 
other antibodies, but not trastuzumab emtansine. At supra clinical concentrations (10 
mg/mL), it could detect trastuzumab emtansine, and could use the integrated QDS to 
estimate the structure of both trastuzumab emtansine and trastuzumab. The 
predictions were close to each other and similar to what would have expected for an 
antibody. 
 
However, this set up was unsuitable as we would certainly need to assess 
structure at much lower concentrations than the AquaSpec was able to. It was found 
that at clinically low concentrations (<1 mg/mL) most of their spectrometers could not 
detect the protein, and many that could, had abysmal signal to noise ratios, most likely 
due to too short an absorbance pathlength.  
 
The best equipment configuration was the Bruker Tensor 2 infra-red 
spectrophotometer (Bruker, Coventry, UK) fitted with a Harrick BioATR Cell 2 sample 
holder (Harrick Scientific Products, New York, USA) connected to a Huber Ministat 125 
Peltier (Huber, Offenburg, Germany). The Harrick BioATR Cell 2 uses attenuated total 
reflectance to increase the contact area of the sample with the IR beam, therefore 
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increasing sensitivity.  With this set up trastuzumab below clinically relevant 
concentrations was detectable, as well as above clinically relevant concentrations. 
However, there was no prebuilt QDS for the BioATR module. 
 
Following discussions with my supervisor Dr Andrew Watts and Bruker UK’s lead 
infra-red applications scientist Dr Christopher Stapleton, Bath ASU purchased the Tensor 
2, with a BioATR module and Ministat peltier. The task of using these to construct and 
validate a new quantitative data set became a crucial part of the PhD project. 
 
4.4.3 QDS – Design 
 
A quantitative data set (QDS) is a library of spectra with known values. A QDS can be 
used to perform many functions depending on which samples are used to create the 
library and which characteristics or dimensions are known to affect FT-IR spectra. FT-IR 
spectra are conformationally sensitive, specifically to alpha helices and beta sheets. 
Furthermore, 1000s of published protein structures are freely available on the 
“Research Collaboratory for Structural Bioinformatics” (RCSB) “Protein Data Bank” 
(PDB). The PDB website contains published structural conformation data based on NMR, 
XRC & 3DCEM methods as well as primary sequences and prediction algorithms.  A list 
of proteins with known structures on the PDB was constructed. Structures with at least 
two or three independent and close if not identical predicted structures were used. It 
was important to note the type of technique used to make these measurements, and 
the resolution of the technique, as these can be causes for dissimilar structure 
estimations. Thus, only XRC based atomic structure predictions were used. The atomic 
structure, as defined by XRC, is then processed by an algorithm such as DSSP 179 which 
generates a percentage of secondary structural features, such as alpha-helix and beta-
sheet. To ensure consistency only the DSSP based estimations from PDB was used. 
STRIDE 180  and DSPP are the two main secondary structure prediction methods and have 
been demonstrated to have a 95% agreement on secondary structure181, though DSSP 
tends to overpredict alpha-helices, while STRIDE overpredicts beta-sheet. DSSP data was 
used as it is the default algorithm on PDB.  Furthermore, these exact proteins had to be 
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available to purchase at a reasonable price from Sigma Aldrich, many proteins can be 
produced by different organisms, and these proteins can have different structural 
conformations, even though they have the same name. While Brukers AquaSpec QDS is 
based on 43 proteins, only 14 proteins were selected, see (Table 4.5), which covered 
alpha-helix structures from 1% to 76%, and beta-sheet from 0% to 46%. CD structure 
predictions for antibodies and the AquaSpec’s structure prediction for trastuzumab and 
trastuzumab emtansine informed us a range from about 4% alpha helix to 15% and from 
30% beta sheet to 40% beta sheet was required. Furthermore, this QDS would be usable 
on more than just antibodies and ADCs. The QDS can work on any protein, therefore we 
expanded the range beyond what would have been required for just ADCs and mAbs to 
cover to improve future applicability of the QDS. 











Hemoglobin Homo sapiens (Human) 65.0 76 0 2DN1 
Park et al 2006 
182 
Myoglobin Equus ferus (Horse) 16.7 74 0 5CN5 
Barends et al 
2015 183 
Albumin Bos taurus (Cattle) 66.5 73 0 3V03 





44.0 49 4 1HCH 





14.3 41 10 5WRB 
Sugahara et al 
2017 186 
Aldolase Leporidae (Rabbit) 161.0 44 14 3B8D 
Maurady et al 
2002 187 
Lipoxidase Glycine max (Soybean) 6.5 40 14 3PZW 
Chruszcz et al 
2008 188 
Catalase Bos taurus (Cattle) 0.3 31 17 3RGS 
Purwar et al 
2011 189 
Alcohol Oxidase Pichia pastoris (Yeast) 0.7 30 20 5HSA 





0.2 34 23 1CF3 
Wohlfahrt et 





146.0 28 29 4W6Z 
Raj et al 2014 
192 
RNase A Bos taurus (Cattle) 13.7 20 35 6ETK 
Vergara et al 
2018 193 
Trypsin Sus (Pig) 23.8 5 41 1S81 





52.0 3 46 1JBC 
Parkin et al 
1996 195 
 
Table 4.5. The 14 proteins in the QDS, with their DSSP derived % alpha-helix and beta-sheet, molecular 
weight, species of origin, protein data bank code and the primary data source. 
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4.4.4 QDS – Construction 
 
10 mg ± 0.1 mg of each of the 15 proteins was weighed out into a 10 mL 
volumetric flask. This was then reconstituted in 0.9% NaCl for injection to make a final 
concentration of 1 mg/mL. The Tensor 2, with the BioATR fitted, was purged for 30 
minutes before the sample well was cleaned using 5% v/v Hellmannex III solution. The 
well was rinsed out with ultrapure water and dried with soft cotton buds (Lidl, London, 
UK). 20 μL of 0.9% NaCl for injection was pipetted into the sample well, then a 
background reading was taken. The settings for each sample measurement are 
described in (Table 4.6). Once the background had been fully acquired, the NaCl was 
completely drawn up and discarded using a 100 μL pipette (Gilson, Bedforshire, UK). 
Then 20 μL of a protein solution would be pipetted into the well. A measurement would 
be recorded, then the sample drawn up and discarded, the cell rinsed with ultrapure 
water, dried with a cotton bud then 20 μL of 0.9% NaCl for injection was pipetted into 
the sample well, then a background reading was taken. This was repeated until three 
spectra had been recorded for each protein solution. These 42 spectra were used to 
create the QDS. Once all the protein spectra had been captured, they were collated 
inside a QDS file using the OPUS “Setup Quant 2 Method” feature. Each protein’s 
triplicate spectra were grouped together and assigned their alpha-helix and beta-sheet 
content inside the QDS builder. Then the ‘Interactive Region Selection’ tool was used to 
specify which regions of the spectra were to be calibrated and used for the 
conformational identification. The amide 1 and amide 2 bands were selected, (Figure 






Figure 4.25. QDS spectra integration region selection for all 14 proteins that constitute the QDS. Amide 1 
is detected between 1705 cm-1 and 1600 cm-1, amide 2 is detected between 1590 cm-1 and 1485 cm-1. X-
axis is wavenumber (cm-1). Y-axis is absorbance (AU). All 14 proteins have slightly different amide 1 and 2 
bands. 
 
Once the Amide 1 and 2 bands had been selected, investigations into the effect 
of the different pre-processing methods on the QDS were possible. OPUS offers 11 types 
of spectral pre-processing, with some options having further levels of optimisation. 
 
The following quote is taken directly form the OPUS Quant User manual 196 “In 
quantitative analysis, the effective pathlength of the infrared light in the sample (sample 
thickness) is assumed to identical in all measurements. A lack of reproducibility in 
sample preparation can easily cause variations in sample thickness. If the thicknesses 
are different or unknown, this effect can be eliminated by a normalization of the spectra. 
The purpose of data pre-processing is to ensure a good correlation between the spectral 
data and the concentration values.” Normalisation stretches a spectra along its y-axis to 
reduce visible differences based on magnitude, which is a factor dependent on 










Resolution 4 cm-1 
Scans / sample 120 
Scans / background 120 
Scan Range 4000 cm-1 to 900 cm-1 
Result spectrum Absorbance 
Additional data treatment H2Ocomp ([<FILE>:ScSm], [<FILE>:ScRf], [H2O=7]); 
Data blocks to be saved Absorbance / Single Channel / Background 
External Synchronisation Off 
Source Setting MIR 
Beamsplitter KBR 
Optical Filter Open 
Aperture Setting 6 mm 
Measurement Channel Sample Compartment 
Detector Setting LN-MCT Photlovlotaic [Internal] 
Scanner velocity 15 KHz 
Measurement Signal Gain Automatic 
Measurement preamp Gain Reference 
Delay before measurement 0 seconds 
High pass filter ON 
Low pass filter Automatic 
Acquisition mode Double Sided, Forward-Backward 
Correlation Mode OFF 
Phase resolution 32 
Phase correction mode Power Spectrum 
Apodization Function Blackman-Harris 3-Term 
Zerofilling Factor 4 
 







The following methods can be applied within the OPUS quant builder: 
• Linear Offset Subtraction shifts the spectra to set the y-minimum to zero. 
• Straight Line Subtraction fits a straight line to the spectrum and subtracts it. This 
accounts for a tilt in the recorded spectrum. 
• Vector Normalization normalizes a spectrum by first calculating the average intensity 
value and subsequent subtraction of this value from the spectrum. Then the sum of 
the squared intensities is calculated, and the spectrum is divided by the square root 
of this sum. This method is used to account for different samples thickness, for 
example. 
• Min-Max Normalization first subtracts a linear offset and then sets the y-maximum 
to a value of 2 by multiplication with a constant. Used like the vector normalization. 
• Multiplicative Scatter Correction performs a linear transformation of each spectrum 
for it to best match the mean spectrum of the whole set. This method is often used 
for spectra measured in diffuse reflection. 
• First Derivative calculates the rate of change of the spectrum. This method 
emphasizes steep edges of a peak. It is used to enhance small features over a broad 
background. Spectral noise is also enhanced.  (To exemplify, the first derivative of a 
distance time graph is speed) 
• Second Derivative calculates the rate of change of the first derivative graph. It is used 
to greatly enhance small features over a broad background. Spectral noise is also 
greatly enhanced. (To exemplify, the second derivative of a distance time graph is 
acceleration) 
 
Furthermore, first derivative method can be used in combination with Min-max, 
straight line subtraction or vector normalisation. No general recommendation can be 
given whether a given data set should be pre-processed or which method is suited best 
for it. Therefore, the optimal data pre-processing method can only be found empirically 
by applying several methods to your spectral data and comparing the results. 
 
There are four metrics that can be used to evaluate the QDS method. The R2 value, 
the root mean square error of the coefficient of variation (RMSECV), the residual 
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predictive deviation (RPD) and bias. According to the Bruker Quant manual, the most 
capable QDS method will be the one with the lowest RMSECV and highest RPD. Although 
R2 and bias can also be useful indicators when methods have similar RPDs and RMSECVs. 
A cross validation within OPUS to measure these values for each type of pre-processing 
possible was performed (Table 4.7). First derivative + Vector normalization and First 
derivative + Multiplicative scattering appeared to be the best. The five best methods 
were taken and the mean cross validation metrics of alpha and beta compared to select 
the best pre-processing method available (Table 4.8). The best method was ‘First 
derivative + Vector Normalisation’. This method has an adjustable smoothing at 5, 9, 13, 
17, 21 and 25. Effect of this smoothing were investigated (Table 4.9) and found that 
higher levels of smoothing improved the Alpha helix prediction but worsened the beta 
sheet prediction. An average of the alpha and beta sheet metrics was calculated (Table 
4.10), finding 25 levels of smoothing was better overall as alpha helix prediction 
improvement is greater than loss in beta sheet. 
Pre-processing method Structure R2 RMSECV RPD Bias 
None 
Alpha 73.46 11.3 1.95 0.987 
Beta 68.32 7.88 1.79 -0.899 
Linear Offset 
Elimination 
Alpha 57.7 14.2 1.55 1.53 
Beta 45.54 10.3 1.37 -1.42 
Straight line subtraction 
Alpha 60.31 13.8 1.6 1.6 
Beta 53.67 9.52 1.48 -1.34 
Vector Normalization 
Alpha 84.91 8.48 2.59 -0.929 
Beta 84.14 5.57 2.51 0.008 
Min-Max Normalization 
Alpha 88.78 7.31 2.99 -0.272 
Beta 84.58 5.5 2.55 0.336 
Multiplicative scattering 
correction 
Alpha 87.78 7.63 2.86 -0.299 
Beta 86.67 5.11 2.74 0.233 
First Derivative 
Alpha 67.75 12.4 1.76 0.136 
Beta 76.78 6.74 2.08 -0.336 
Second Derivative 
Alpha 73.72 11.2 1.95 -0.333 
Beta 74.84 7.02 2 0.567 
First Derivative + 
Straight line subtraction 
Alpha 67 12.5 1.74 -0.17 
Beta 72.5 7.34 1.91 0.219 
First Derivative + Vector 
Normalization 
Alpha 88.26 7.48 2.92 -0.445 
Beta 89.43 4.55 3.08 0.066 
First Derivative + 
Multiplicative Scattering 
Alpha 87.29 7.78 2.81 -0.028 
Beta 88.15 4.82 2.91 -0.027 
Table 4.7. QDS cross validation evaluation metrics. First derivative + vector normalisation produced the 





Pre-processing method Structure R2 RMSECV RPD Bias 
Vector Normalization Total 84.53 7.03 2.55 -0.46 
Min-Max Normalization Total 86.68 6.41 2.77 0.03 
Multiplicative scattering 
correction 
Total 87.23 6.37 2.8 -0.03 
First Derivative + Vector 
Normalization 
Total 88.85 6.02 3 -0.19 
First Derivative + 
Multiplicative Scattering 
Total 87.72 6.3 2.86 -0.03 
 
Table 4.8. QDS cross validation evaluation metrics averaged between alpha helix and beta sheet. First 
derivative + vector normalisation produced the best measurements, while linear offset produced the 
least linear estimations. 
 
 
Table 4.9. QDS cross validation evaluation metrics for alpha helix and beta sheet individually. Alpha helix 
is best estimated with a larger degree of smoothing, produced the best R2, RMSECV and RPD, however 












5 87.26 7.79 2.81 -0.43 
9 87.38 7.76 2.82 -0.44 
13 87.55 7.70 2.84 -0.44 
17 87.77 7.64 2.86 -0.44 
21 88.01 7.56 2.89 -0.44 
25 88.26 7.48 2.92 -0.45 
Beta Sheet 
5 89.67 4.50 3.11 0.16 
9 89.67 4.50 3.11 0.15 
13 89.65 4.50 3.11 0.13 
17 89.62 4.51 3.10 0.11 
21 89.55 4.52 3.09 0.09 
25 89.43 4.55 3.08 0.07 
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5 88.47 6.15 2.96 -0.14 
9 88.53 6.13 2.97 -0.15 
13 88.60 6.10 2.98 -0.16 
17 88.70 6.08 2.98 -0.17 
21 88.78 6.04 2.99 -0.18 
25 88.85 6.02 3.00 -0.19 
 
Table 4.10. The mean QDS cross validation evaluation metrics of alpha helix and beta sheet. Comparing 
the effect of different smoothing values on prediction capability. It is clear now that the improvement to 
alpha helix prediction at higher levels of smoothing outweigh the detriment to beta-sheet prediction. 
 
Overall, structure prediction is better with more smoothing, being best at level 
25 for all evaluation metrics except bias, which favours a smoothing value of 17, and 
gets worse with more or less smoothing applied. 
 
The last variable is the partial least squares (PLS) rank fit, which can vary from 1-
10, but is automatically chosen for alpha helix and beta sheet, though they can be 
manually adjusted if necessary, see (Figure 4.26 A & B). Quant builder automatically 
identifies the optimal rank as 2 for alpha helix and 1 for beta sheet. The final pre-
processing method was First Derivative + Vector Normalization, with a smoothing level 
of 25, see (Figure 4.27 & Table 4.11). 
 





Table 4.11. The R2, RMSECV, RPD and Bias for alpha helix and beta sheet are listed in (Figure 4.27). The 
prediction for beta sheet is better than the prediction for alpha helix but both have excellent levels of 







Figure 4.26. The RMSECV (Y-Axis) vs Rank (X-Axis) for alpha helix (A) and beta sheet (B). The lowest 




















Figure 4.27. Plots of the predicted (Y-axis) vs PDB (X-Axis) values of % alpha helix (A) and beta sheet (B). 






































PDB % Alpha helix 
PDB % Beta sheet 
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4.4.5 QDS – Validation 
 
While the QDS method had already been through an extensive cross validation 
it is important to compare results to validated method, such as circular dichroism 
spectroscopy, to ensure the predictions for antibodies are not too dissimilar, as that may 
suggest the pre-processing method is over-fitting the data causing false structures to be 
predicted. To do this, 12 different therapeutic antibodies were measured in triplicate via 
IRS and then tested via CDS, following method 2.4.13. The results showed mostly similar 
structures (Figure 4.28) with pertuzumab and infliximab having the greatest and 
smallest difference in % alpha helix respectively (Table 4.12) and bevacizumab and 
cetuximab having the greatest and smallest difference in beta sheet respectively (Table 
4.12). It is not required for these methods to be statistically equivalent, as it is well 
documented no secondary structure predictive test is 100% accurate, and even the most 
commonly used do not have 100% agreement. However, it is promising to see that 
almost two thirds of the antibodies had statistically insignificant differences for either 
alpha helix or beta sheet and a third had no statistically significant difference at all. 
 
Figure 4.28. A comparison of CD secondary structure predictions vs IR secondary structure predictions. 
Note the difference in alpha helix prediction for trastuzumab emtansine. Statistics are presented in 
(Table 4.12). Both techniques predict similar secondary structure values for most of antibodies for 
example cetuximab or natalizumab, but in some circumstances are notably different for example 




IR prediction difference from CD prediction 
Sample Alpha Helix SD Beta Sheet SD 
Bevacizumab +1.1 *** 0.5 -3.9 **** 0.9 
Cetuximab -0.3 0.7 -0.8 0.6 
Denosomab +1.6 **** 0.8 -4.0 **** 1.6 
Infliximab +0.0 0.8 -4.1 **** 2.0 
Natalizumab -0.1 0.3 -1.2 0.7 
Nivolumab -0.9 * 0.5 -1.4 0.4 
Obinituzumab +1.9 **** 0.6 -2.0 ** 0.7 
Ofatumumab -1.5 **** 0.4 -2.6 **** 0.2 
Pertuzumab +2.2 **** 0.4 -2.1 ** 0.2 
Rituximab +0.5 0.2 -1.2 0.3 
Trastuzumab +0.5 0.5 -3.3 **** 1.4 
Vedolizumab -0.4 0.7 -3.8 **** 0.7 
Average mAb +0.4 0.5 -2.5 0.8 
 
Table 4.12. Absolute difference between the IR prediction and the CD prediction of alpha helix and beta 
sheet including standard deviation and results of statistical analysis. The alpha helix and beta sheet 
content are significantly different for 4 of the antibodies tested, either a alpha or beta was different for 5 
of the antibodies tested and there were no significant differences for 3 of the antibodies tested. *, **, *** 
& **** indicate a p value < 0.05, 0.01, 0.001 & 0.0001 respectively. 
 
 
Comparing trastuzumab to trastuzumab emtansine via IR shows results that 
agree with the literature (Figure 4.29). A two-way ANOVA showed a statistically 
significant difference between the alpha-helix prediction between trastuzumab and 













Figure 4.29. IR and CD prediction of alpha helix and beta sheet for trastuzumab and trastuzumab 
emtansine. IR analysis of trastuzumab emtansine’s alpha helix and betas sheet content shows no 
significant differences compared to the trastuzumab structure. CD analysis shows significant levels of 
difference for both alpha helix and beta sheet. ** & *** indicate a p value < 0.01 & 0.001 respectively. 
 
IR secondary structure determination using the QDS has been shown to predict 
very similar values to CD based methods when testing antibodies (Figure 4.28 & Table 
4.12). However, unlike CD methods, the IR method detects no significant difference 
between the secondary structure of trastuzumab vs trastuzumab emtansine.  
 
The IR method has been demonstrated as stability indicating, following method 
2.4.14 (Figures 4.30 & 4.31), and a good predictor of both alpha helix and beta sheet 
secondary structure composition. By designing, building and validating this quantitative 
data set for infrared spectroscopy analysis, the problems encountered with the original 
circular dichroism analysis method had been overcome. Now characterisation of an 
ADCs higher order structure is possible using a rapid IRS test, a big step towards enabling 
an NHS compliant stability study to be performed. While secondary structure 
characterisation won’t detect tertiary structure events such as misfolding, it still meets 
the required guidance requirements, and IR is a viable alternative to the traditional CD 






Figure 4.30. IR analysis of forced degradation of obinituzumab higher order structure presented as total 
% alpha helix and beta sheet (A) and (B) absolute change in % alpha helix and beta sheet from control. 
Acid and base hydrolysis had the most significant effect on alpha helix content while oxidation had the 
most significant impact of beta sheet. Only thermal degradation caused a significant decrease in alpha 







Figure 4.31 IR analysis of forced degradation of trastuzumab emtansine’s higher order structure 
presented as (A) total % alpha helix and beta sheet and (B) absolute change in % alpha helix and beta 
sheet from control. Acid degradation caused the most significant change, with differences noted in the 
alpha helix and beta sheet, while oxidation and thermal only caused significant changes to either alpha 
helix or beta sheet. Base degradation did not cause any significant changes, however slight increases to 














4.5 Methods to measure DAR 
 
4.5.1 Reviewing initial literature research 
 
No standard method is used for measuring an ADCs DAR is listed in the NHS or 
ICH guidance. That is because ADCs are not covered by these documents. Furthermore, 
literature research has shown that the site of payload attachment, currently either a 
lysine or cysteine residue, has a significant effect on drug heterogeneity. More 
specifically, ADCs that utilize attachment via lysine are dramatically more variable due 
the number and location of accessible lysine residues. 
 
For ADCs with cysteine linked residues either high resolution mass spectrometry 
or hydrophobic interaction chromatography (HIC) can be used to measure the DAR. HIC 
is favoured due to its much lower entry cost, running costs and level of required 
expertise. For lysine linked ADCs HIC struggles to work due to the vast heterogeneity 
causing a near infinite spread of hydrophobicity. Therefore, no resolution of peaks is 
possible. Hence, high resolution mass spectrometry, more specifically MALDI-TOF MS is 
the only technique that appears to be used to assess DAR in lysine linked ADCs. 89,197,198 
 
4.5.2 HIC trials 
 
In 2005 and 2011 Hamblett et al 199 and Wakanker et al  173 used HIC methods to 
quantify the DAR of a cysteine linked ADC. It was decided to replicate that work and to 
investigate if using more modern column technologies could separate the different DARs 
of trastuzumab emtansine using HIC. 
 
Wakanker used a Tosoh Butyl-NPR column and was able to separate the DAR 0, 
2, 4, 6 and 8 peaks, of a cysteine linked ADC, from each other at 280nm. This work was 
repeatable, following method 2.4.15 (Figure 4.32). We were also able to identify the 
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DAR 1, 3, 5, and 7 peaks, although these are so small they are hard to identify, especially 
DAR 5 and 7.  
 
Figure 4.32. HIC analysis of a cysteine linked ADC (brentuximab vedotin), showing full separation of DARs 
0, 2, 4, 6 and 8. Peaks for DARs 1, 3, 5 and 7 have been labelled. The X-axis is time (minutes). 
 
The method was repeated on trastuzumab emtansine, but it only produced a 
single large band with no separation of any DARs (Figure 4.33). This agrees with the 
literature as HIC has not been successfully used to assess a lysine linked ADCs DAR 173. 
 
 
Figure 4.33. HIC analysis of a lysine linked ADC (trastuzumab emtansine) on a TOSOH Butyl-NPR, showing 
no separation of DARs 0, 1, 2, 3, 4, 5, 6, 7 and 8. The X-axis is time (minutes). 
 
To investigate if more modern chromatography technology could improve the 
separation of trastuzumab emtansine, a ThermoFisher Scientific MAbPac HIC-10 column 
with pore size of 5 μm, internal diameter of 4.6 mm and length of 100 mm, was 
purchased. This column had been advertised in the literature as able to separate and 
produce peaks of a cysteine linked antibody with all DAR forms resolved and producing 
distinguishable peaks, a clear improvement over the methods that Wakankar and 
Hamblett had been using and compared to the Tosoh-Butyl-NPR column. Following the 
method used in the ThermoFisher application note (method 2.2.15) , it was not possible 
to generate acceptable spectra for trastuzumab emtansine, though there were hints of 
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peaks.  To improve the separation, the concentration of ammonium sulphate in mobile 
phase A, was increased from 1.5 M to 3 M, the concentration of sodium phosphate was 
reduced from 100 mM to 50 mM in mobile phase B. The flow rate was reduced to 0.5 
mL/min and the gradient increased from 28 minutes to 3 hours. This was a highly 
impractical method but did enable the detection of some peaks for trastuzumab 
emtansine’s different DAR forms. However, the peaks were only visible after a blank 
subtraction and the quality of the peaks was poor, with little to no resolution and a 
drifting baseline (Figure 4.34). 
 
 
Figure 4.34. HIC analysis of a lysine linked ADC (trastuzumab emtansine) on a MAbPac HIC-10 column, 
showing 7 peaks with poor peak quality and resolution. The X-axis is time (minutes). 
 
BIA separations monolith disk technology was also investigated. Monolith disks 
are hard sponge-like materials with interactive chemistry all over the monolith surface. 
This gives monoliths a huge increase in effective interaction area compared to normal 
columns. This means the “columns” don’t need to be as long as a typical HPLC column 
50mm-300mm, and are about 5mm long, explaining why they are called monolith disks. 
These ‘disks are so short that multiple discs (up to 4) can be inserted into a disc holder. 
Following method 2.4.16, investigations using C4, protein G and protein A disks found 
them to be worse than normal columns for HIC DAR analysis. 
 
All of the work with HIC only demonstrated that HIC still cannot be used to asses 
DAR for lysine linked ADCs. The ‘best’ modern HIC column was only able to separate 
trastuzumab emtansine DARs with an entirely impractical method. Therefore, LC-MS 




4.5.3 Intact ADC LC-MS 
 
LC-MS can be used to detect the accurate mass of compounds, this theoretically 
allows detection of different DAR forms, as each form will be at least 957 daltons 
different, the mass of a complete trastuzumab emtansine payload. LC-MS analysis of 
mAbs is often performed under reducing conditions to separate the heavy and light 
chains, increasing the signal to noise ratio. However, ADCs are analysed intact as the 
DAR is a ratio of drug to antibody and reducing the antibody into heavy and light chains 
would prevent that being measured. 
 
To establish a baseline for trastuzumab emtansine with no payloads attached 
(naked trastuzumab), trastuzumab was run intact on the same LC-QTOF mass 
spectrometer following method 2.4.17 (Figure 4.35). Mass differences noted here are 
likely due to heterogeneous binding of sugars, as the masses of mannose, glucose and 
galactose residues are 162 daltons. The same sample of trastuzumab was also run 
reduced to help with structural identification (Figures 4.36 & 4.37). The mass of 
trastuzumab, which is equivalent to a DAR 0 trastuzumab emtansine, was established as 
ranging between 147.8 kDa and 148.7 kDa depending on the level of glycosylation at the 
heavy chains. Mass differences are likely due to heterogenic binding of sugars, as the 
masses of mannose, glucose and galactose residues are 162 daltons. One peak shows a 
difference of 204 daltons, which matches either an N-acetylgalactosamine or an N-
acetylglucosamine. Attempts at running trastuzumab emtansine intact produced 
spectra that did not match this, (Figure 4.38). Mass differences, approximately 
equivalent to a single payload, are observed between peaks in clusters of variable 
glycosylation. The mass spectrometry technician stated the deconvolution algorithm 




Figure 4.35. Intact LC-MS analysis of trastuzumab. Y-axis = TICs, X-axis = Mass (Daltons). Peaks around 148 




Figure 4.36. LC-MS analysis of trastuzumab light chains. Y-axis = TICs, X-axis = Mass (Daltons). Only three 
peaks were detectable with one peak dominating at 23439 daltons, and with mass differences of 21 






Figure 4.37. LC-MS analysis of trastuzumab heavy chains. Y-axis = TICs, X-axis = Mass (Daltons). Multiple 




Figure 4.38. LC-MS analysis of intact trastuzumab emtansine. Y-axis = TIC, X-axis = Mass (Daltons). Multiple 
peak clusters were observed with peak height differences of about 960 daltons, which matches the mass 
of trastuzumab emtansine’s payload. The signal to noise ration was very poor, with signal levels ten times 






4.5.4 PNGase F  
 
To reduce sample complexity, the enzyme ‘Peptide N-Glycosidase (PNGase) F’  
was used to cleave the N-linked oligosaccharides from the heavy chains. PNGase F was 
purchased from New England Biolabs (New England BioLabs, Massachusetts, USA), and 
used according to the non-denaturing enzyme protocol (Method 2.4.18). However, the 
method was only partially successful, not ever fully deglycosylating the antibody, and 
used large amounts of PNGase F, while also taking a full day of incubation, which is 
unpractical for a stability study method intended to be run on the day. 
 
PNGase F Rapid, an improved enzyme designed with activity equivalent to 
PNGase F over 24 hours at 37 °C in only 15 minutes at 75 °C and then 50 °C, was then 
investigated. Following method 2.4.19 the deglycosylation was underwhelming. Both 
PNGase F and PNGase F rapid recommend the addition of denaturing reagents to reduce 
steric hinderance of the enzyme. However, those protocols are designed for analysis of 
the glycan groups and not the protein. Furthermore, PNGase F rapid was even more 
expensive and had not worked better in any observable way, while adding heating steps 
and a buffer exchange step to remove the PNGase F from the sample before LC-MS 
analysis. While other enzymes were available for protein deglycosylation it was decided 
not to pursue deglycosylating enzymes further. 
 
4.5.5 A new way of thinking about LC-MS data and DAR 
 
Following method 2.2.12-2.2.14 had already satisfactorily characterised the 
glycosylation of antibodies such as infliximab and trastuzumab emtansine (Figures 4.5 
& 4.6). Below are spectra for the light and heavy chains of trastuzumab emtansine 
(Figure 4.39 & 4.40). Mass differences of 957, exactly matching a single trastuzumab 
emtansine payload, are observed between peaks. 
The data for light chains confirms that there are no more than two lysine residues 
with payloads bound on the light chain, and that double payload binding is less common. 
The data for heavy chains confirms that there are no more than two lysine residues with 
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payloads bound on the heavy chain, and that double payload binding is less common. 
This makes sense, as it is known that trastuzumab emtansine has a maximum DAR of 8, 
which would be made from two light chains with two payloads and two heavy chains 
with two payloads. If we had found heavy or light chains with bound three payloads it 
would suggest the possibility of DAR 10-12 trastuzumab emtansine could be present but 
that has not been reported in any literature. 85, 86, 89 The reaction to attach the payloads 
results in a heterogeneous mixture of DARs and to create a mixture with a mean DAR 
between 3 and 4, the linker attachment reaction is controlled to prevent under or over 
linking. As we don’t see peak differences equivalent to a single linker, it appears the 
linker to warhead attachment step is designed to ensure maximum yield of conjugated 
antibody.  
 
While looking at this data the reasons why DAR needed to be measured were 
thought about in detail. For an API manufacturer such as Lonza (Lonza, Basel, 
Switzerland) which makes trastuzumab emtansine for Roche, or a drug research 
company such as Genentech (Genentech, California, USA) who designed trastuzumab 
emtansine for Roche, knowing the exact DAR is important. However, a stability study 
does not need to measure the exact DAR. Change in DAR would be matched by a change 
in the peak heights for the heavy and light chains. Once manufactured, an ADC can only 
lose payloads. If the DAR were to decrease, the intensity of light and heavy chain peaks 
corresponding to zero payloads bound, will increase while the intensity of peaks 
corresponding to chains with 1 or 2 payloads bound will decrease. However, the values 
would need to be comparable from sample to sample, timepoint to timepoint. 
Experience with this method had taught me that variability in sample signal intensity 
was common, due to inconsistencies in sample recovery from the centrifugal spin filters. 
Usually, this is not a problem as absolute peak intensity is not important for monitoring 
that glycosylation profile. However, the DAR profile needs to be quantified even if it is 
not the DAR value itself. To normalise samples, the ratio of masses corresponding to 
naked (payload = 0), single (payload = 1), and double (payload = 2) chains could be 
compared. To do this an XY plot of the deconvoluted mass spectrum, with X being mass 
and Y being total ion count (TIC) could be extracted.  Then the TICs for all masses 
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corresponding to naked, single and double chains for heavy and light chains summed 
separately. Then we could express the total naked light chain TICs as a % of the total 
TICs for light chain and express the total naked heavy chain TICs as a % of the total TICs 
for heavy chain. Doing this enables the capturing of count data for all masses 
corresponding to naked, single or double chains. 
 
 
Figure 4.39. LC-MS analysis of trastuzumab emtansine light chains. Y-axis = TIC, X-axis = Mass (Daltons). 
Three main peaks were detected with mass differences of about 960 daltons. One peak matches the mass 






Figure 4.40. LC-MS analysis of trastuzumab emtansine heavy chains. Y-axis = TIC, X-axis = Mass (Daltons). 
Three main peaks were detected with mass differences of about 960 daltons. One peak matches the mass 
of trastuzumab heavy chain, suggesting the heavier two peaks correspond to a light chain with one or two 




4.5.6 Validation of new method using forced degradation 
To test this theory, trastuzumab emtansine was degraded following method 
2.42, specifically to liberate the payloads. The structure of trastuzumab emtansine has 
been identified and drawn, in chapter 1. The bonds most likely to break and liberate the 
payload are the amide and ester bonds (Figure 4.41). This could create three different 
masses of payload fragment. Hydrolysis at the ester would create a fragment with a 
molecular weight of 564 daltons, hydrolysis of the amide in DM-1 would create a 
fragment with a molecular weight of 650 daltons, and hydrolysis of the amide on the 
linker would create a fragment of around 958 daltons. 958 daltons is just an entire 
payload, so peaks with a mass difference of 650 or 564 daltons were of interest. Upon 
reviewing the forced degradation data for trastuzumab emtansine it was found there 
were no exact matches for these mass losses, the closest matches would often be 10-20 
daltons off or well below the signal to noise ratio. As hydrolysis was the main route of 
degradation It was decided to use phosphate buffers to degrade trastuzumab emtansine 
at an elevated temperature before neutralising it. The intention was to cause hydrolysis 
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at the amides and/or ester in DM-1 and the SMCC linker and cause fragmentation. 
Following method 2.4.20, trastuzumab emtansine was exposed to pH 9-11 at 50 °C for 
3 hours, this over degraded trastuzumab emtansine (Figure 4.42) resulting in dramatic 
loss of payload and at visual aggregation at pH 11. Then degradation was the assessed 
at less extreme conditions, using pH 7, 8 and 9 at 40 °C for only 90 minutes, following 
method 2.4.21 (Figure 4.43) but degradation was underwhelming, except at pH 9. 
 
 
Figure 4.41. Chemical structure of trastuzumab emtansine’s payload. Amide bonds are shown in orange, 




Figure 4.42. LC-MS spectra of trastuzumab emtansine heavy chains after 3 hours incubation at 50 °C. (A) 
is the control, (B) was at pH 9, (C) was at pH 10 and (D) was at pH 11. Y-axis = TIC, X-axis = Mass (Daltons). 




Figure 4.43. LC-MS spectra of trastuzumab emtansine heavy chains after 1.5 hours storage at 40 °C. (A) is 
the control, (B) was at pH 7, (C) was at pH 8 and (D) was at pH 9. Y-axis = TIC, X-axis = Mass (Daltons). The 




Finally, following method 2.4.22, trastuzumab emtansine samples were pH 
adjusted to pH 9 and stored for 1-3 hours on a heat block at 45 °C before being removed 
and neutralized. This degraded the heavy and light chains without stripping them 
completely (Figure 4.44 & 4.45). Increased duration of storage at pH 9 and 45 °C caused 
greater amounts of degradation for both heavy and light chains. The intensity of peaks 
corresponding to double payload chains are more affected than peaks corresponding to 
single payload chains. This is accompanied by an increase in signal intensity for naked 
chain peaks. 
 
All of the degradation experiments for this were performed in triplicate and the 
data processed, according to method 2.4.23, to compare the relative ratios of the TICs 
to calculate means for each condition (Figure 4.46 & 4.47). Payloads on the light chains 
appear to be more easily hydrolysed than those on heavy chains, both double and single 
payload chains are easily hydrolysed. 180 min at pH 10 & 50 °C causes over 95% of light 
chains to lose their payloads. Also, it is noticeable that the single payload heavy chains 
do not appear to be affected until much harsher conditions are used. 180 min at pH 10 
& 50 °C causes 100% of double payload chains to be degraded but only ~50% of the 
single payload chains. 180 min at pH 9 & 45 °C and gentler conditions do not appear to 
affect the single payload heavy chains. It is more likely that when a double payload heavy 
chain is hydrolysed, only one payload is liberated while the other payload is unaffected. 
This means if a double and single chain are both hydrolysed, it will appear as though the 
double payload was completely hydrolysed while the single payload chain was not 
hydrolysed. This could explain why the double payload heavy chain appears to degrade 
directly to naked heavy chain. This phenomenon could also explain why the single 
payload chain appears to increase in some instances. 
 
This work demonstrates that the payload binding profile can be monitored using 
this method. And that it is stability indicating and quantitative. While the payload 
binding profile of heavy and light chains is not the exact DAR, it is directly related. And 




Figure 4.44. LC-MS spectra of trastuzumab emtansine heavy chains stored at pH 9 and 45 °C. Samples 
were neutralized after 1 hour (A), 1.5 hours (B), 2 hours (C), and 3 hours (D). Y-axis = TIC, X-axis = Mass 




Figure 4.45. LC-MS spectra of trastuzumab emtansine heavy chains stored at pH 9 and 45 °C. Samples 
were neutralized after 1 hour (A), 1.5 hours (B), 2 hours (C), and 3 hours (D). Y-axis = TIC, X-axis = Mass 







Figure 4.46. Bound payload profiles of trastuzumab emtansine light chains, following base hydrolysis. 










Figure 4.47. Bound payload profiles of trastuzumab emtansine heavy chains, following base hydrolysis. 
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4.6 Trastuzumab emtansine stability study 
 
4.6.1 Reasons for performing this study 
 
Trastuzumab emtansine has been investigated in two clinical trials, ‘EMILIA’ 
103,200 and ‘TH3RESA’. 104 A review of trastuzumab emtansine from the Lancet stated, 
 
“Together with EMILIA, findings from TH3RESA substantiate the potential of antibody–
drug conjugates to achieve a more favourable benefit-to-risk profile than that seen with 
traditional combinations of chemotherapy and targeted agents in epithelial cancers. 
Data from these two, large phase 3 studies suggest that trastuzumab emtansine is 
effective across the natural history of HER2-positive advanced breast cancer, spanning 
from disease with previous exposure only to adjuvant treatment, to progressive heavily 
pre-treated disease after regimens incorporating trastuzumab and lapatinib. 
Trastuzumab emtansine should be considered as a new standard for patients with HER2-
positive advanced breast cancer” 
 
The EMILIA study demonstrated that trastuzumab emtansine provided 6 months 
extra median overall survival, a 50% increase in median progression free survival and a 
50% increase in the duration of response, compared to the gold standard treatment of 
lapatinib + capecitabine. During the EMILIA study 4 patients from the lapatinib + 
capecitabine arm died due to coronary artery disease, multiorgan failure, coma, and 
hydrocephalus, while only one patient died in the trastuzumab emtansine arm, which 
was due to metabolic encephalopathy after CNS progression. The TH3RESA study also 
demonstrated 6 months of additional overall survival using trastuzumab emtansine vs 
the physician’s gold standard choice, furthermore the physician’s choice had a 17.5% 
increase in adverse effects, relative to trastuzumab emtansine. The evidence explains 
why Dr Krop said “Trastuzumab emtansine should be considered as a new standard”. 
However as stated in a 2017 Lancet article 201, the UK’s National Institute of Clinical 





In an unopened vial the product is stable for up to 3 years when stored at 2-8 °C.  
The reconstituted concentrated solution is stable for up to 24 hours when stored at 2-8 
°C, followed by a further 24 hours at 2-8 °C when diluted in sodium chloride 0.45% or 
0.9%.  This stability is acceptable if compounding inside a hospital pharmacy, but it 
impedes the use of external aseptic compounders, as only 24 hrs is not enough to easily 
compound, transport and administer a product. However, with an extended shelf life 
the logistical issues can be overcome, the product can be made days to weeks in advance 
and be waiting at the hospital ready for the patient. An extended shelf life also enables 
wastage savings, estimated to be over £1300 per dose, by combining multiple patient 
orders together to maximise vial usage. There are also logistical benefits and cost 
benefits due to batch manufacture, lower overheads of external units and competition 
between external compounding units, lowering the overall cost per patient. Coupled 
with a ‘special deal’ that Roche is offering the NHS regarding trastuzumab emtansine, a 
shelf life extension should improve patient access and therefore the outcome for NHS 
patients with HER2-positive advanced breast cancer who have previously received 
trastuzumab and lapatinib. 
 
4.6.2 Study design 
 
A clinically low, common and high concentration of Kadcyla brand trastuzumab 
emtansine were stored in four polyolefin infusion bags each. To reduce the cost burden, 
the volume of trastuzumab emtansine solution stored was reduced from 250 mL to 50 
mL, which saved £130,000. The bags were stored at 5 °C ± 2 °C in the absence of light. 
Samples were withdrawn and tested from each bag on days 0, 1, 4, 7, 11, 14, 18, 20, 21 
& 24. After sampling the bags at day 20, the samples were kept at 25 °C and not returned 
to the fridge, thus day 21 samples, had 20 days refrigerated and one day at “room 
temperature”, as per yellow cover specification, and day 24 had 4 days at room 
temperature. This study is designed to be compliant with Part 2 (biopharmaceuticals) of 
the current NHS yellow cover document: A Standard Protocol for Deriving and 
Assessment of Stability. 102 which means the measurement of all stated critical quality 
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attributes as defined by the NHS guidance document, 102 as well as off target toxicity and 
payload binding.  
 
4.6.3 Test methodology 
 
The methods used are as described in chapter 2 and have previously been used 
in the infliximab study other than SEC, IR and the additional data processing of the LC-
MS data and NTA instead of DLS. 
 
4.6.4 Visual inspection 
 
Following method 2.2.2, all samples remained clear and colourless for up to 24 
days with no evidence of precipitates or particulate matter.  No change in colour or 
turbidity was observed over the 24-day study period.  Representative photographs are 
available in appendix V. 
 
4.6.5 Moisture loss 
 
Following method 2.2.1, no cumulative moisture loss was observed throughout the 
course of the study, less than 0.1% relative mass difference was observed between 
each sampling timepoint. (Figure 4.48). 
 
Figure 4.48. Moisture loss from infusion bags containing trastuzumab emtansine over time, no trend 






Following method 2.2.3, the mean pH of trastuzumab emtansine throughout 
the study is shown in (Figure 4.49). No strong trend is observed, though the mean pH 
on day 25 is 0.1 pH units lower for the low and common concentrations and 0.05 pH 
units for the high concentration. The pH is also lower the higher the concentration is, 
this is due to the pH of the trastuzumab emtansine vial concentrate being lower than 
the pH of the 0.9% NaCl diluent.  
 
 
Figure 4.49. pH changes of trastuzumab emtansine over time, no strong trend observed at any 
concentration. Storage at 25 °C is denoted with dashed lines. 
 
 
4.6.7 Gel electrophoresis 
 
The macromolecular structure of trastuzumab emtansine was assessed by gel 
electrophoresis at each timepoint, according to method 2.2.7, as shown by 
representative runs from day 0 and day 24 (Figure 4.50 & 4.51).  The results indicate 
that compared to day 0, no change to the mass of trastuzumab emtansine occurred 
throughout the study period for the Low, common or high concentration samples.  
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Thus, the antibody structure remains structurally intact upon extended storage and 
does not undergo fragmentation to any measurable extent. 
 
 
Figure 4.50. Gel electrophoresis profile of trastuzumab emtansine at a low (A-H), common (I-Q) and high 
(R-Y) concentration for day 0. L is a digital ladder, while Z is a fresh vial sample for comparison. All intact 
samples and control appear the same as each other as do all reduced samples. 
 
 
Figure 4.51.  Gel electrophoresis profile of trastuzumab emtansine at a low (A-H), common (I-Q) and high 
(R-Y) concentration for day 24. L is a digital ladder, while Z is a fresh vial sample for comparison. All intact 
samples and control appear the same as each other as do all reduced samples. 
 
4.6.8 Microflow imaging analysis of microparticles 
 
The abundance of sub-visible particles above 10 µm was measured by microflow 
imaging, according to method 2.2.6, throughout the study period (Figure 4.52, 4.53 & 
4.54) show the mean particle count per unit volume measured for the low, common and 
high trastuzumab emtansine solutions respectively.  A common trend observed across 
all concentrations is that the mean particle count per mL reaches an apex at day 11 or 
14, after which particle counts decrease to a level which is largely maintained to day 25.  
With the exception of a transient increase observed on D14 for the common 
concentration bags (Figure 4.53), at no point is a statistically significant increase in mean 
particle count observed compared to the SPC limit on day 1 (p < 0.05, one-way ANOVA 
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with post hoc Bonferroni).  The data recorded therefore strongly suggests that 
trastuzumab emtansine undergoes reversible aggregation, perhaps as a result of 
adsorption onto the surface of the container material, and subsequent release.  The 
increase in particulates observed around day 11 coincides with the decrease in API 
observed on day 11 with SE-HPLC analysis, when the measured monomer abundance 
drops by 2.0%, 1.1% and 1.7% for the low, common and high concentrations 
respectively.  The decrease in observed concentration could be the result of aggregated 
protein being impeded by the HPLC guard column (5 µm pore size) or could be because 
of adsorption onto the bag surface and subsequent aggregation. Overall the abundance 
of sub-visible particles shows no sustained pattern of increase over the study (24 days). 
 
 
Figure 4.52. Mean particle count observed throughout the study period for the low concentration 
trastuzumab emtansine. Day 21 & 24 have dashed columns to indicate room temperature data points. 
 
 
Figure 4.53. Mean particle count observed throughout the study period for the common concentration 
trastuzumab emtansine. Day 21 & 24 have dashed columns to indicate room temperature data points. 





Figure 4.54. Mean particle count observed throughout the study period for the common concentration 
trastuzumab emtansine. Day 21 & 24 have dashed columns to indicate room temperature data points. 
 
 
4.6.9 Infrared spectroscopy structure determination 
The secondary structure of the trastuzumab emtansine protein was determined 
by analysis of FTIR spectra which were obtained throughout the study period accordein 
to method 2.2.9.  The results are shown in (Figures 4.55 & Table 4.13) with data 
presented as the % of the a-helix or b-sheet abundance measured at each timepoint 
respectively. The results show that no significant change in the secondary structure of 
the trastuzumab protein is occurring upon extended storage at any concentration, and 
the antibody secondary structure remains conformationally stable for up to 20 days 
when stored at 2-8 C, following storage at 25 C for up to 120 hours. The trastuzumab 
emtansine powder for reconstitution contains sucrose and polysorbate 20, both help to 
stabilise the protein even when diluted to clinically relevant concentrations. The sucrose 
limits local mobilisation and the polysorbate 20 is a surfactant that protects the protein 
form liquid-air and liquid-solid interfaces. 237 Together, these two stabilisers ensure 





Figure 4.55. Change in α-helix and β-sheet abundance of trastuzumab emtansine throughout the study 
period. Both alpha helix and beta sheet content remained constant during the study. No significant 






  Alpha Helix  Beta Sheet 
 Day 0 20 24  0  20 24 
Low 
Mean 5.3 5.4 5.5  37.4 37.3 37.3 
SD 0.2 0.7 0.6  0.2 0.6 0.2 
Common 
Mean 5.5 5.5 5.4  37.4 37.4 37.3 
SD 0.3 0.3 0.3  0.2 0.4 0.2 
High 
Mean 5.9 6.0 5.9  37.2 37.1 37.1 
SD 0.2 0.3 0.2  0.2 0.3 0.3 
 
Table 4.13. Measured alpha helix and beta sheet for Day 0, 20 and 24. There was no statistical 





4.6.10  SEC analysis of monomer concentration 
 
SEC was used to measure the concentration of trastuzumab emtansine, and early 
oligomerization over the course of the study, by measuring the area of the peak 
associated with the trastuzumab emtansine monomer and dimer at each time-point, 
according to method 2.217.  The results are summarised in (Figure 4.56), where they are 
expressed as % monomer relative to day 0.  The absolute concentrations of each sample 
have been measured over the course of the study but will not be part of this thesis as 
that would circumvent the anonymisation of the concentrations. 
 
The results indicate that after 20 days storage at 2-8 °C, no net loss in protein 
monomer was observed at low or common concentration samples; however, a small but 
statistically significant change was observed in the low concentration samples on day 11 
compared to day zero and one (p = < 0.05, one-way analysis of variance with a post hoc 
Bonferroni).  These results indicate that no aggregation or fragmentation of the antibody 
protein is occurring to any measurable extent throughout the refrigerated study period.  
After storage for 4 days at 25 °C, a small decrease in protein monomer was noted in all 
concentrations relative to day 0, decreasing by 0.2%, 0.3% and 1.4% in the low, common 
and high concentrations respectively, but this change was statistically insignificant. 
Figure 4.56. SEC analysis of trastuzumab emtansine monomer concentration relative to day 0. No trend 
is overserved, no change noted is statistically significant. However, the common concentration did reach 
102 % relative to day 0 on day 1 and the low concentration reach 98 % relative to day 0 on day 11. 
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4.6.11  Nano-tracking analysis of nano-particles 
 
The mean particle count of sub-visible particles below 1 µm (50-950 nm) was 
measured by nanoparticle tracking analysis throughout the study period following 
method 2.2.5. (Figures 4.57 – 4.59) show the mean particle count per unit volume (in 
millions) measured for the low, common and high concentration of trastuzumab 
emtansine solutions respectively.   
 
Overall the particle count remains steady over the study across all bags, no 
sample is statistically significantly different from day 0 (p < 0.05, one-way ANOVA, post 
hoc Bonferroni).  In all concentrations, the highest mean particle count is observed after 
storage at 25 °C for either 24h (high) or 120h (low and common).  This is in-line with the 
SEC results, where we see a slight decrease in the monomer concentration during 
storage at 25 °C. Overall, there is no significant trend or change in nanoparticle 
concentration detected during the study. 
 
 
Figure 4.57. NTA analysis of nanoparticle concentration for the low concentration of trastuzumab 
emtansine. No statistically significant change is observed and no trend of particle concentration increase 




Figure 4.58. NTA analysis of nanoparticle concentration for the common concentration of trastuzumab 
emtansine. No statistically significant change is observed and a slight trend in particle concentration is 
seen but this is not statistically significant. 
 
Figure 4.59. NTA analysis of nanoparticle concentration for the high concentration of trastuzumab 
emtansine. No statistically significant change is observed and no trend of particle concentration increase 
or decrease is noted. 
 
4.6.12  UV analysis of extractables and leachables 
 
Freeflex infusion bags, used as the containers for this study, are marketed as 
“plasticizer free” by the manufacturer, as the bags do not contain DEHP. 202  Regardless 
to maintain compliance with the NHS stability guidance for biopharmaceuticals, 102 the 
UV absorbance spectra of trastuzumab emtansine was recorded, according to method 
2.2.10, to monitor for the accumulation of any leachable and/or extractable substances 
throughout the study period.  The results are shown in (Figure 4.60) where trastuzumab 
emtansine exhibits a delta max at 280 nm.  No changes to the delta max or absorption 
values are apparent from the spectra, indicating that no chromogenic substances are 
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accumulating in the solutions, to any measurable extent, when stored in Freeflex bags 
for periods of up to 20 days at 2-8 °C followed by 4 days at 25 °C. This seems like an issue 
that should be debated with the NHS, as this was unnecessary research that revealed 
plasticizer free bags don’t leach plasticisers.  
 
The absorbance at 280 nm was also recorded and plotted over time as a quick 
measurement of total protein concentration during the study (Figure 4.61).   No 
decrease in protein concentration is observed compared to the measurement recorded 
on day 1 (SPC limit). This measurement was of interest, as small monomer decreases 
detected via SEC, combined with no increase in detectable oligomers could be due to 
aggregates with a diameter greater than 5 μm being trapped on the SEC column. If the 
detection at 280 nm via the UV assay remained high, while the detection of monomer 
at 280 nm via SEC declined, it could suggest aggregates larger than 5 μm were forming. 
 
 
Figure 4.60. UV profile between 220 nm and 400 nm for trastuzumab emtansine, at day 0 and day 24.  
Delta max was unchanged, no change was noted. 
 
 
Figure 4.61. UV absorbance at 280 nm for each study concentration. Dashed lines represent 25 °C storage. 
The absorbance remains constant throughout the study, no trend of loss is apparent, no changes from 



















4.6.13 LC-MS – Chemical degradation 
 
LC-MS data gathered following methods 2.2.12-2.2.14, shows no evidence of 
chemical degradation occurring to the light or heavy chain fragments of the antibody 
throughout the course of the study, see (Figure 4.62 A, B, C & D), as a demonstration 
that the trastuzumab glycoprotein molecule remains structurally stable for up to 20 days 
when stored at 2-8 °C or following storage at 25 °C for up to 120 hours after this 20 day 
period. 
 
4.6.14 LC-MS – Payload binding 
 
Additional data processing, following method 2.2.23, of LC-MS data was also 
used to confirm that the cytotoxic DM1 and MCC-DM1 payloads remained covalently 
attached to the trastuzumab protein throughout the course of the study.  The results 
are expressed as the payload (P) to light chain (LC) or heavy chain (HC) ratio, as shown 
in (Figures 4.63 – 4.65).    A trend which indicated an increase in P:LC = 0 or P:HC = 0 
throughout the course of the study, accompanied by a decrease in P:LC = 1 or 2 and P:LC 
= 1 or 2 would suggest that cytotoxic payloads are becoming detached from the 
trastuzumab protein upon extended storage; however this is not observed throughout 
the study.   
 
The results indicate that the cytotoxic DM1 containing payloads remain 
conjugated to the antibody throughout the study period, and that no premature release 





Figure 4.62. Reduced LC-MS analysis of the common concentration of trastuzumab emtansine. Light chain 
day 0 (A), Light chain day 24 (B), Heavy chain day 0 (C) & Heavy chain day 24 (D). Y-axis = TIC, X-axis = 




Figure 4.63. LC-MS analysis of low concentration trastuzumab emtansine showing the observed change 
over time in relative total ion count of light chains (A) and heavy chains (B) with zero, one or two payloads 
bound. No trend of loss is observable for any of the light or heavy chain species.  
 
 
Figure 4.64. LC-MS analysis of common concentration trastuzumab emtansine showing the observed 
change over time in relative total ion count of light chains (A) and heavy chains (B) with zero, one or two 
payloads bound. No trend of loss is observable for any of the light or heavy chain species. 
 
 
Figure 4.65. LC-MS analysis of high concentration trastuzumab emtansine showing the observed change 
over time in relative total ion count of light chains (A) and heavy chains (B) with zero, one or two payloads 
bound. No trend of loss is observable for any of the light or heavy chain species. 
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4.6.15  Cellular Assay – On target activity 
 
Plate set up was performed according to method 2.4.2 and the plate was read 
according to method 2.2.11. Trastuzumab emtansine was assessed by measuring its 
ability to inhibit the growth of BT474 cells which express the HER-2 receptor via an MTT 
assay to measure cellular metabolism. This assay models the mechanism of action of the 
drug in the patients. Efficient inhibition of the growth of this cell line is dependent upon 
the integrity of the ADC. To control for intra assay variability the performance of the 
stability samples was indexed against that of a trastuzumab emtansine reference sample 
stored as concentrate in the glass vial. Throughout the study the performance of the 
stability study samples matched that of the reference sample (Figure 4.67). The 
performance of samples B.3 and B.4 was low on Day 20 (Figure 4.67 B), although this 
can be explained by the poor growth of the control samples on the assay plate these 
two samples were tested on. In agreement with this, subsequent tests on these samples 
saw the results return to normal. These data demonstrate that there was no statistically 
significant loss of on target activity over the course of the study (p<0.05, one-way 
analysis of variance with post hoc Bonferroni). 
 
4.6.16  Cellular Assay – Off target activity and hepatocyte toxicity 
 
Plate set up was performed according to method 2.4.2 and the plate was read 
according to method 2.2.11. Trastuzumab emtansine was assessed by measuring its 
ability to inhibit the growth of human keratinocyte cell line ‘HaCaT’ and the hepatic 
carcinoma cell line ‘HepG2’ which do not express the HER-2 receptor. To control for intra 
assay variability the performance of the stability samples was indexed against that of a 
trastuzumab emtansine reference sample stored as concentrate in the glass vial. 
Throughout the study the performance of the stability study samples matched that of 
the reference sample (Figure 4.68). The performance of samples A.3, A.4 and C3 were 
low on Day 7 (Figure 4.68 A), although this could be explained by a dilution error on the 
assay plate these two samples were tested on. In agreement with this, subsequent tests 
on these samples saw the results return to normal. To test more specifically for any 
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changes in liver toxicity of the study samples the HepG2 was used (Figure 4.69). The 
performance of the stored samples matched that of the reference sample in these tests. 
These data sets demonstrate that there was no measurable change in functional activity 
of the stored trastuzumab emtansine samples over the course of the study. 
 
4.6.17  Trastuzumab emtansine stability study conclusion 
 
The results of this stability study described in section 4.6 indicate that 
trastuzumab emtansine remains physico-chemically and functionally stable for up to 20 
days when diluted between a clinically low and high concentration with sodium chloride 
0.9% solution for infusion and stored at 2-8 °C in a Fresenius Kabi Freeflex infusion bag.  
The study also indicates that further storage at 25 °C for up to 96 hours has no 
detrimental effect on the physicochemical or functional stability of trastuzumab 
emtansine. A major outcome for this study is the application of a 21-day extended shelf 
life for Kadcyla brand trastuzumab emtansine. 
 
A 2016 study found that on average, £1312 of Kadcyla is wasted per dose. 278 As 
Kadcyla is administered every three weeks, according to the median overall survival 
found in the EMILIA and THER3SA trials, a patient should receive 40 cycles of treatment. 
103, 104 This amounts to £52,480 of wasted drug per patient. The 21-day shelf life allows 
Bath ASU to minimise this wastage by manufacturing multiple doses for either the same 
or different patients simultaneously, and they can be easily transported to different 
hospitals around the UK ready for the patients up to three weeks in advance. These 
savings can be passed onto UK hospitals, reducing the cost burden of Kadcyla as well as 
providing a unique product, the first ready to use extended stability ADC product in the 








Figure 4.67.  On target functional activity of trastuzumab emtansine samples stored diluted at low (A), 
common (B), and high (C) concentrations. The performance of the stability study samples was indexed 
against that of a trastuzumab emtansine reference sample. Data shown are means with SD of 
quintuplicate replicate measurements for each of four bags per concentration. No statistically significant 











Figure 4.68. HaCaT assessed, off target toxicity of trastuzumab emtansine samples stored diluted at low 
(A), common (B), and high (C) concentrations. The performance of the stability study samples was indexed 
against that of a trastuzumab emtansine reference sample. Data shown are means with SD of 
quintuplicate replicate measurements for each of four bags per concentration.  No statistically significant 
change was observed for any of the concentrations tested. Some data points are off the scale due to 










Figure 4.69.  HepG2 assessed, off target toxicity of trastuzumab emtansine samples stored diluted at low 
(A), common (B), and high (C) concentrations. The performance of the stability study samples was indexed 
against that of a trastuzumab emtansine reference sample. Data shown are means with SD of 
quintuplicate replicate measurements for each of four bags per concentration. No statistically significant 










An outcome of the Remsima infliximab study was hundreds of UK hospitals using 
that data to apply a seven-day shelf life to their Remsima products. However, some 
hospitals phoned and asked if they could compound Remsima using a different brand of 
polyolefin infusion bag and still apply the 7-day shelf life. It is well established that the 
chemical composition of storage devices such as intravenous (IV) infusion bags, can have 
a significant impact on the stability and quality of pharmaceutical products, especially 
when storage in the device is over extended periods of time. 126,203-205 Currently there 
are four main types of plastics used in the manufacture of IV infusion bags, those being 
polyethylene (PE), polypropylene (PP), poly ethylene vinyl acetate (EVA) and polyvinyl 
chloride (PVC). Combined with this, there are also a number of processes used for the 
manufacture of infusion bags, such as co-extrusion and co-polymerisation, while the 
plastic can also be either a high density or low-density polymer. Finally, IV infusion bags 
may be comprised of a single plastic layer, or multiple layers, in which case not all of the 
component plastics will be in contact with the drug. In terms of the specific drug quality 
aspects affected by the chemical composition of infusion bags, the majority of studies 
have evaluated their impact on small molecule drugs. Here, the leaching of plasticisers 
such as di-2-ethylhexyl-phthalate (DEHP) from PVC bags, permeability of oxygen, 
differing degrees of drug adsorption to the plastic, and differences in aggregation, are 
found to be the predominant factors influencing drug quality 126,127,203-205 
 
While primary drug manufacturers must demonstrate the compatibility of drugs 
with both diluents and storage devices during the ‘within-use’ period, the requirements 
for set out in the NHS yellow cover documents for extended stability studies and the 




“Extrapolation of data between different containers and infuser devices may be 
permissible provided the drug degradation pathway and physical properties of the 
container are well understood. Critical physical properties of a container include oxygen 
permeability, water permeability (water loss), light permeability, material constitution 
and possible extractives and adsorbent potential. Any extrapolation must be evaluated 
and justified. Non-PVC containers (polyolefin) should routinely be the first-choice 
container. The choice of flexible versus semi-rigid containers is product and/or study 
specific but it may not always be possible to extrapolate between the two due to 
fundamental differences in certain properties, which include the material and quantity 
of residual air” 101. 
 
This allows stability data collected for a drug in one container type to be applied to 
products made in another container type, often hospitals will request a product in a 
specific brand of container, this can help reduce administration errors, as the overage in 
different brands of infusion bags can vary from 70 mL to 95 mL in a 250mL Fresenius 
Kabi infusion bag compared to a Baxter infusion bag. What this difference in overage 
volume means is that specific doses will need to be made in different bag sizes and at 
different concentrations which can cause confusion when changing bag brand or type 
between hospital inhouse compounding units and external aseptic compounding units. 
Ideally all compounders could use the same infusion bag but even NHS hospitals will use 
different bags depending on which regional contract tender they have to abide by. This 
means that it is not possible to perform a stability study in a single bag type that will suit 
all hospitals, hence hospitals will request that products be made in the bag types they 
prefer and explains why the NHS stability guidance document will allow stability data 
gathered in one bag to be applied to different bag types. 
 
5.2 Study design 
 
This study was designed to investigate what difference infusion containers had on 
biopharmaceutical stability, and if stability data generated in one container can be safely 
applied to a different container. As such, this is not a stability study, but a bag 
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comparison study to investigate the characteristics of biopharmaceutical products most 
likely to be affected by a change in container material. Therefore, this study will assess 
monomer concentration, reversible soluble aggregates (dimers, trimers), nanoparticle 
formation, microparticle formation, visible changes, moisture loss, as well as utilizing 
scanning electron microscopy to evaluate the morphology of the bag surfaces in detail. 
 
The stability of three different types of licensed biopharmaceutical were 
investigated: a chimeric antibody, a humanized antibody and a fusion protein, when 
stored in three different brands of PO infusion containers Viaflo, Freeflex and Macoflex 
(Figure 5.1). All three are described as ‘polyolefin’ infusion bags, however their plastics 
are formed using a variety of chemical monomers and each bag is then manufactured 
using different processes. Viaflo infusion bags are comprised of polyamide, polyethylene 
and polypropylene polymers and manufactured using a co-extrusion process. Freeflex 
bags are manufactured using a multi-layer process, where the inner layer in contact with 
the drug is composed of polypropylene. Macoflex-N bags are manufactured using a co-
polymerisation process where the plastic is formed from a mixture containing both 
ethylene and propylene monomer units. 
 
 To improve data comparability the surface area of each bag was calculated, 
following method 2.5.1, (Table 5.1) and a modified final volume was created by 
withdrawing all saline from the bags before adding a known volume of saline back into 
the bag, followed by a volume of drug. Four replicate bags were made for each 
combination of drug and bag, resulting in 36 samples, which were stored at 25 °C. To 
manage this work, manufacture of the samples was staggered allowing all work on a 
single day to be confined to a single drug.  
 
Table 5.1. The dimensions, calculated surface area, study fill volume and surface area to volume ratio of 










Surface Area : 
Volume 
Baxter 85 123 209 21.3 9.8 
Fresenius Kabi 85 115 196 20.0 9.8 





Figure 5.1. A photograph of the three brands of infusion bags investigated during this comparison study. 





5.3.1 Visual inspection 
 
Following method 2.2.2, all infusion bags remained clear for the duration of the 
study with no visible precipitates or particulate matter detected with the naked eye. No 
change in colour or turbidity was observed over the study period for any drug in any of 
the three bag types. 
 
5.3.2 Size exclusion chromatography analysis of monomer concentration 
 
Following method 2.2.16, all HPLC chromatograms of the drugs were 
characterised by a single major peak. Results from HPLC analysis are presented as the 
percentage change relative to Day 0 samples for each drug across the three types of 
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infusion bag tested (Figure 5.2). Each mean percentage presented for a given drug in a 
particular type of bag is derived from the average abundance of drug (measured in 
triplicate) across four independent storage devices. As such, each mean percentage 
represents an average calculated from twelve independent chromatograms. Both 
Trastuzumab (Figure 5.2 A) and Abatacept (Figure 5.2 C) showed no obvious change in 
drug concentration in any of the devices tested throughout the study period. Rituximab 
abundance increased over the study (Figure 5.2 B), which was considered likely to be 
due to incomplete mixing of the Day 0 sample.  
 
Figure 5.2.  SEC analysis of monomer concentration relative to day 0 for (A) Trastuzumab, (B) Rituximab 
and (C) Abatacept, when stored in three brands of polyolefin infusion bag. Rituximab showed a trend of 
increase, and Mako Pharma bags showed a statistically significant but temporary increase in abatacept 








5.3.3 Dynamic light scattering analysis of sub-visible particles 
 
Dynamic light scattering results collected according to method 2.2.4, are 
expressed both as the mean diameter and percentage abundance of detected drug 
particles within the test solution (Figure 5.3). A significantly larger mean diameter could 
suggest the formation of aggregates which have a greater spherical volume, while a 
decrease in percentage abundance of drug monomer could be attributed to larger 
aggregate formation.  The measured drug diameters were found to be similar for all bags 
throughout the study (Table 5.2), ranging from 9.63 – 13.60 nm immediately after 
preparation on day 0, to 9.88 – 12.92 nm on day 30. The small differences seen in (Figure 
5.3 A) could be due to monomer/dimers further aggregating into microscale particles, 
which appears to occur more readily in Mako Pharma bags, though the differences 
between the bags was statistically insignificant. 
 
 
Table 5.2. Monomer/Dimer mean diameter (nm) for all drug and bag combinations during the bag 
comparison study (n=4). No statistically significant changes were observed. 
Drug Bag Brand  Day 0 Day 3 Day 10 Day 21 Day 30 
Trastuzumab 
Baxter 
Mean 12.0 12.5 14.6 13.5 11.9 
±SD 1.3 1.0 1.8 1.4 1.9 
Fresenius Kabi 
Mean 12.6 11.6 14.1 12.1 11.9 
±SD 1.5 1.3 1.3 0.7 0.9 
Mako Pharma 
Mean 13.6 13.3 14.7 12.7 12.9 
±SD 1.4 2.5 1.4 1.7 1.2 
Rituximab 
Baxter 
Mean 11.9 13.8 13.1 10.9 10.6 
±SD 1.7 1.7 1.7 1.7 1.7 
Fresenius Kabi 
Mean 12.6 11.9 12.5 11.2 11.5 
±SD 2.0 1.7 1.7 1.7 1.7 
Mako Pharma 
Mean 13.6 13.3 14.7 12.7 12.9 
±SD 1.4 2.5 1.4 1.7 1.2 
Abatacept 
Baxter 
Mean 9.7 9.6 9.5 9.6 9.9 
±SD 0.4 0.4 0.2 0.2 0.2 
Fresenius Kabi 
Mean 9.6 9.8 9.6 9.6 9.9 
±SD 0.3 0.4 0.2 0.2 0.2 
Mako Pharma 
Mean 9.6 9.6 9.4 0.4 9.8 




Figure 5.3. Change in % monomer/dimer by volume for (A) Trastuzumab, (B) Rituximab and (C) Abatacept, 
stored in three brands of polyolefin infusion bag. There were no significant differences between bag 
brands for any of the drugs tested, however there was a statistically insignificant difference noted for 
trastuzumab between all bag types on day 21, and on most days between Mako Pharma and other brands. 
 
5.3.4 Microflow imaging analysis of micro-particles 
 
Microflow imaging results, gathered according to method 2.2.6, revealed a 
dramatic difference in the change in concentration of particles greater than 10 μm and 
greater than 25 μm between the different bag types (Figure 5.4 & 5.5). These particle 
sizes, are of particular interest as hard particles over 10 μm can occlude blood vessels. 
206 Furthermore, the United States of America, British and European pharmacopeia all 
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place concentration limits on the number of particles present with mean diameters 
above 10 μm and 25 μm. 110,206 Sub-visible particles are a cause of concern due to their 
ability to cause vein irritation, anaphylactic shock, phlebitis, pulmonary emboli, 
pulmonary granulomas, immune system dysfunction, pulmonary dysfunction, 
infarction, and death. 109 And aggregated drug is a problem as it can raise an immune 
response in patients, leading to inflammation, anti-drug antibodies, as well as faster 
rates of drug clearance. 109 Furthermore, aggregated drugs can have reduced binding 
strength and impaired pharmacokinetics. The aggregation profiles for particles with 
diameters above 10 μm and 25 μm generally follow the same trends, (Figure 5.4 & 5.5). 
 
Regarding particles greater than 10 μm, the chimeric antibody rituximab 
aggregates the least overall and, in the Fresenius Kabi and Maco Pharma bags actually 
demonstrates a decrease from levels of particulates on day 0, while in a Baxter bag 
becomes significantly different by day 32 (Figure 5.4 B) (p<0.05, one-way analysis of 
variance with post hoc Bonferroni). Furthermore, rituximab on day 0 has a significantly 
higher concentration of particles over 10 μm in a Maco Pharma and Fresenius Kabi bag, 
compared to the Baxter bag (Figure 5.4 B).  
 
Trastuzumab in a Fresenius Kabi bag is significantly different by day 10, while in 
a Baxter bag it is not significantly different until day 30 (Figure 5.4 A). At no measured 
point was trastuzumab different in a Maco Pharma bag (Figure 5.4 A).  At each timepoint 
the bag type with the highest and lowest amount of particles over 10 μm remained the 
same. The concentration of particles over 10 μm in a Maco Pharma bag throughout the 
study, never exceeded the concentration of 10 μm in a Fresenius Kabi bag, and the 
concentration of particles over 10 μm in a Baxter bag only exceeded it by Day 30 (Figure 
5.4 A). 
 
Abatacept was the most aggregation prone drug, reaching almost 40 thousand 
particles > 10 μm per mL by day 31 in the Baxter bags (Figure 5.4 C). Abatacept in Maco 
Pharma bags was not significantly different until day 31, while it was deemed 
significantly different by day 10 for FK bags and day 5 for Baxter bags (p<0.05, one-way 
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analysis of variance with post hoc Bonferroni). The trends in the particles greater than 
25 micrometres matches the trends observed in the particles greater than 10 
micrometres. While particles greater than 10 μm in all bags were similar on Day 0, the 
particles concentrations rose much faster for Fresenius Kabi and especially Baxter bags, 
which on Day 0 had the lowest concentration of particles for Abatacept. By Day 20 the 
particle levels in Baxter bags had eclipsed those in Fresenius Kabi bags (Figure 5.4 C). 
 
Regarding particles over 25 μm, the trends are very similar to the trends seen 
with the particles over 10 μm. However, the absolute numbers are almost ten-fold lower 
for all combinations of bag and drug. The Fresenius Kabi bag had the highest level of 
particulates for trastuzumab on Day 0 and demonstrated the greatest increase in 
particle levels by Day 30, while the Maco Pharma bag had the lowest level of aggregates 
on Day o and the smallest increase by day 30 (Figure 5.5 A). 
 
For rituximab, the Baxter bags had the greatest level of increase by day 32, while 
the Maco Pharma bags had the greatest level of particles on Day 0 and the particle 
concentration only decreased over the study. Fresenius Kabi bags had the lowest level 
of particle on day 0 and particle concentrations only decreased over time (Figure 5.5 B). 
 
Abatacept was the most aggregation prone for 25 μm particles as well, reaching 
around 5000 / mL in the Baxter bags. The trends for 10 μm particles were conserved, 
with Baxter bags having the highest rate of aggregation, and Maco Pharma bags having 
the lowest rate of aggregation. Baxter bags also had the lowest level of particulates on 






Figure 5.4. Change in concentration of microparticles > 10 μm for (A) Trastuzumab, (B) Rituximab and (C) 
Abatacept, stored in three brands of polyolefin infusion bag. Particles for trastuzumab and abatacept 
increased upon storage, however the rate of increase was greatest for abatacept in Baxter bags and 
greatest for trastuzumab in Fresenius Kabi bags. The trend of increase was only observed for rituximab 
stored in Baxter brand bags. *, **, *** & **** indicate a p value < 0.05, 0.01, 0.001 & 0.0001 respectively. 




Figure 5.5. Change in concentration of microparticles > 25 μm for (A) Trastuzumab, (B) Rituximab and (C) 
Abatacept, stored in three brands of polyolefin infusion bag. Particles for trastuzumab and abatacept 
increased upon storage, however the rate of increase was greatest for abatacept in Baxter bags and 
greatest for trastuzumab in Fresenius Kabi bags. The trend of increase was only observed for rituximab 
stored in Baxter brand bags. The trends for particles > 25 match the trends for particles >10 μm.  *, **, 
*** & **** indicate a p value < 0.05, 0.01, 0.001 & 0.0001 respectively. The colour of the * indicates to 











5.3.5 Scanning electron microscopy 
 
Scanning electron microscopy was used to image the inner bag surface according 
to method 2.5.7. This was to investigate if the physical surface was different and could 
contribute to adhesion and aggregation. This SEM work was performed by Mrs Ursula 
Potter (University of Bath, Bioimaging Suite). We can see the surface at a x10,000 
magnification where the Baxter Viaflow had a rougher surface than either the Maco 
Pharma or Fresenius Kabi infusion bag (Figure 5.6).  
 
We also imaged a Baxter Viaflow and Maco Pharma MacoFlex-N bag after two 
days storage containing trastuzumab at 25 °C for 48 hours (Figure 5.7). This was to 
measure any differences at the bag surface. It was possible to image a large protein 
aggregate adhered to the bag surface for both bags, however the particle for the Baxter 
bag has a larger diameter and is strafed by two other asymmetrical adhered particles 
(Figure 5.7 A). The Maco Pharma bag had a single, more irregular particle, appear to 
protrude off the bag surface more than the particle on the Baxter bag, this particle has 
a more three-dimensional structure to it (Figure 5.7 A). It is interesting to note the 
difference in the adhered aggregates shapes, perhaps the smoother Macopharma bag 
plastic was lass easy to adhere to than the already bound protein, thus a more 3D 
structure emerges naturally, while in the Baxter bag the protein-surface interaction is as 
if not more viable than a protein-protein interaction, thus leading to wider, flatter 
protein deposits. Alternatively it is possible that similar structures to the 3D structure 
seen on the x10000 magnification may be acting as scaffold to the protein. 
 
The differences in their surface structure must be related to the plastics types 
and the manufacturing processes used. The Baxter bag appears to have the roughest 
surface and is the only bag that is made using a co-extrusion of polyamide, polyethylene 
and polypropylene. Perhaps this process causes the roughness noted. The Maco Pharma 
and Fresenius Kabi bags have inner surfaces comprised of a single material, of either 
polypropylene or a polypropylene/polyethylene copolymer, perhaps this explains why 





Figure 5.6. SEM images of (A) Baxter Viaflo, (B) Fresenius Kabi Freeflex, and (C) Maco Pharma Macoflex-
N polyolefin infusion bags at x10000 magnification. The Baxter Viaflo bag has a rougher surface 








Figure 5.7. SEM images of (A) Baxter Viaflo and (B) Maco Pharma Macoflex-N polyolefin infusion bags at 
x2000 magnification after 2 days storing trastuzumab at 25 °C. Both show aggregates, with the Baxter bag 






5.4 Bag comparison study discussion 
 
No significant or conserved differences in the mean monomer/dimer diameter 
or percentage abundance by volume were found using DLS (Figure 5.3 & Table 5.2).  SEC 
also found no significant or clinically relevant loss of monomer or increase in dimer and 
trimer.  (Figure 5.2), suggesting that nanoscale particles formation, early oligomerisation 
and concentration are not significantly difference for trastuzumab, rituximab or 
abatacept when stored in Baxter Viaflow, Fresenius Kabi Freeflex or Maco Pharma 
Macoflex-N polyolefin infusion bags at 25 °C. 
 
However, results from the MFI (Figure 5.4 & 5.5) clearly indicate a dramatic and 
statistically significant difference occurs during storage with regards to microscale 
particulates above 10 and 25 micrometres, between most bags containing for all drugs 
tested. Protein aggregation differences due to the container brand, are most likely due 
to differences in the inner surface of the infusion bags. Protein interactions at solid 
interfaces are a known issue, which is why non-ionic surfactants such as polysorbate 20 
and 80 are added to biopharmaceutical formulations. 237 Proteins will mainly adhere to 
surfaces via van der Waals forces, electrostatic interaction of the surface charge and 
charge of the protein, also known as the zeta potential and hydrophobic interactions. 
238 The inner surfaces were PP, PP & PP co-polymer and a PP, PE & polyamide copolymer. 
I propose the zeta potential of these surfaces is different, based on research that 
measured the zeta potential of multiple polymeric plastics including PP. 239 The same 
paper also identified that at different pHs the plastic polymers zeta potential also 
changed but at different rates in a non-linear trend. 239 It is possible that as the different 
drug solutions are at different pHs, ranging from pH 6 to pH 7.5, the zeta potential of 
each bag plastics could be different for each drug. This could certainly impact the protein 
surface interaction, which would affect adhesion, which affects conformation, which 
affects aggregation. It is possible that the Fresenius Kabi bags have a stronger Zeta 
potential than the Baxter or Maco Pharma bags when filled with the trastuzumab 
solution. Rituximab also uses polysorbate 80 as its non-ionic surfactant while 
trastuzumab uses polysorbate 20 and abatacept uses poloxamer 188 as stated in their 
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summary of product characteristics, however the SPCs do not state the concentration. 
Studies have shown that at the same concentrations, polysorbate 20 is better at 
preventing protein adsorption to plastic than polysorbate 80. 240 At a high 
concentrations poloxamer 188 outperforms polysorbates as a surfactant. 240 However 
the degree of microparticle aggregation seen between the drugs does not correlate with 
these facts. One explanation could be, due to the dilution of the drugs, the 
concentration of the surfactants is too low to work effectively as surfactants. However, 
as the concentration of the surfactants is not stated in the SPCs of any drugs it is purely 
speculation. 
 
The SEM results (Figure 5.6) demonstrate the surface for polyolefins bags can be 
different at a subvisible level, leading to different types of aggregation forming at the 
bag surface (Figure 5.7). It is possible that the microarchitecture of the bags, including 
differences in surface roughness may have in impact on the protein-surface interactions, 
as a rougher surface as seen in Baxter Viaflo bags increases total internal surface area 
but also can reduce the size of potential binding patches. This may partially explain why 
abatacept, which is a fusion protein and thus requires a smaller surface to bind to 
aggregates so much more in Baxter bags than the Fresenius Kabi and Maco Pharma bags. 
 
It is demonstrable that not all polyolefin infusion bags are equal with regards to 
the aggregation of biopharmaceuticals. Furthermore, no bag type we investigated can 
be considered inferior or superior to another for all drugs we investigated, as results 
(Figure 5.4 & 5.5) show at different times and for different drugs each bag could be 
considered ‘best’. 
 
This work was presented to members of the NHS regional quality assurance 
committee and the NHS yellow cover document was then amended in 2017 with “… care 
should be taken when extrapolating to a different manufacturer’s container, there is 




An important outcome for patient safety, has been the change in stance of Bath 
ASU, the UKs largest supplier of ready to administer aseptically compounded products 
to the NHS on stability data. While the NHS does not want to explicitly forbid all stability 
data extrapolation to different containers, Bath ASU’s quality assurance department 
now does not accept any changes in container material or manufacturing technique 
from drug stability research. 
 
 While this thesis is primarily interested in ADC stability, the cost required 
to investigate the effect of different storage containers on aggregation was too high to 
use Kadcyla or Adcetris, thus, cheaper antibodies and fusion proteins were used as 
model biopharmaceuticals.  
236 
 
6 Chapter 6. Initial safety considerations for trastuzumab 




Within the secondary care setting, drugs for intravenous infusion or injection can 
be can be prepared into ready-to-use forms at a wide variety of locations, by a range of 
staff with varying skill levels.  For example, a ward nurse can reconstitute a lyophilized 
powder in a vial, then transfer a volume of concentrated drug into a device to be 
administered to a patient on the ward. Alternatively, hospital pharmacy technicians can 
aseptically compound medicines and have them sent to wards. Lastly, external aseptic 
compounders, such as Bath ASU, can compound medicinal products according to a 
doctor’s instructions, then the products can be transported to the hospital and then to 
the ward. This means that many people can be involved in the manipulation and 
transport of drugs, including highly cytotoxic and mutagenic cancer therapies. 
While antibody therapies activate the immune system to induce cell death, they 
are not themselves directly cytotoxic. As they are proteins, they are digested when 
swallowed preventing them from functioning. Due to their size mAbs cannot be 
absorbed through unbroken human skin (unless mAbs are aerosolised and inhaled onto 
mucosal membranes). While some antibodies have evidence of teratogenicity (ability to 
affect embryo or foetal development), such as bevacizumab and trastuzumab this is only 
when administered at therapeutic doses and no evidence from human trials, animal 
trials or pharmacovigilance suggest subtherapeutic doses are teratogenic, carcinogenic 
or mutagenic. Because of this, antibodies are handled with less caution than cytotoxic 
drugs such as vincristine. ADCs, however, combine extremely potent cytotoxic drugs, 
often too cytotoxic to be administered unconjugated, for example DM-1 or MMAE. 
When bound to the antibody, the toxic warheads of an ADC cannot exert their cytotoxic 
action. But when the payloads are detached they are active. Furthermore, at high 
concentrations even intact trastuzumab emtansine can cause cell death in cell lines that 
don’t express HER2 (Figure 4.7). While validating LC-MS methods for assessing 
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trastuzumab emtansine payload binding, loss of payload was observed at pHs as low as 
7 at 40 °C with dramatic loss occurring following exposure to pH 10 at 50 °C (Figure 4.44 
& 4.45). This indicates payloads may be cleaved from ADCs, exposed to cleaning agents.   
Procedures for managing ‘spills’ of trastuzumab emtansine will vary from 
hospital to hospital, however a spill could occur at any point during manufacture or 
transport of a trastuzumab emtansine product at a compounding unit to administration 
at the ward. The procedures for spills in hospitals tends to be different depending on 
the area that the spill occurs, and the type of substance spilt. For example, alcohol is the 
biocide of choice for critical surfaces such as laminar air flow cabinets in aseptic 
preparation areas according to a study of UK hospitals in 2000 by Murtough et al 207. The 
NHS Southern Health Trust document ‘Infection Prevention and Control policy: 
Appendix 12 - Version 3’ 208 outlines recommended classes of disinfectants, key points 
about each type and examples of that disinfectant used in Southern Health NHS trust 
hospitals. This information is summarized in Table 6.1. 
 
 
Table 6.1. Table of disinfectants used in NHS Southern Health Trust hospitals. 208 
 
It was noticed the conditions used to de-drug (cause payloads to be removed) 
trastuzumab emtansine, during the validation of LC-MS methods (Figure 4.44 & 4.45), 
Disinfectant Class Key Points Named Example 
Chlorine based 
disinfectants 
Wide range of bactericidal, virucidal, 





Good bactericidal, virucidal, and 
fungicidal activity. 
Superior sporicidal activity. 
Tristel (Chlorine dioxide) 
Clorex (Hydrogen Peroxide) 
Alkylating Agents Not recommended for use Gigasept Rapid (Peracetic Acid) 
70% Ethanol 
Indicated for in-patient setting 
decontamination. 
Klercide Spray 
Blue Clinell Wipes 
Chlorhexidine Gluconate 
Indicated for ports decontamination 
on medical devices 
Green Clinell Wipes 
Quaternary Ammonium 
Compounds 
Good bactericidal, virucidal, and 
fungicidal activity. 
Recommended for cleaning and low-
level disinfection. 




were not as severe as originally imagined, with evidence of de-drugging even at pH 7. 
Due to the potent cytotoxicity of the warheads and relative ease of de-drugging, we 
wanted to investigate the potential for de-drugging while in-use at the workplace and 
evaluate any potential risk to staff and patients. The most likely scenario to cause de-
drugging is during a spill, as any cleaning agents used may be strong enough to degrade 
the ADC, (Table 6.1). Therefore, preliminary work to assess the safety of trastuzumab 
emtansine in the workplace was carried out. 
 
6.2 Common cleaning agents as payload liberators 
 
We first sought to investigate whether the common cleaning/disinfecting agents used 
in NHS hospitals and aseptic compounding units were capable of causing de-drugging of 
Kadcyla under in-use workplace conditions. Following method 2.6.1, trastuzumab 
emtansine concentrate from the vial was mixed at a ratio of 1:1 with the common 
disinfectants listed in Table 6.2 and the effect on the payload binding profiles via the LC-
MS method used in the Kadcyla study was assessed, as an indication of payload 
liberation or de-drugging (Figure 6.1 – 6.4). Samples were left for 120 minutes at 20 °C, 
before being processed for LC-MS analysis via spin filtration (thus removing the 
disinfectants from the sample and preventing further degradation). Here, it was found 
that Bleach, Prochlor and Actichlor treatments drastically reduced signal intensity of 
heavy and light chain peaks, over degrading the ADC (Figure 6.2 & 6.4). Klercide (70% 
ethanol), InSpec N10 detergent and 35% hydrogen peroxide treatments, all cleaved 
payloads from trastuzumab emtansine. The 70% ethanol was the gentlest condition, 
while N10 detergent and 35% hydrogen peroxide formed new detectable peaks (Figure 









Disinfectant Class Name pH 
Chlorine based disinfectants Actichlor (Dichloroisocyanurate) 5.87 
Chlorine based disinfectants Prochlor (Calcium Hypochlorite) 3.15 
Oxidising Agents Hydrogen Peroxide 35% (Aqueous) 2.46 
Oxidising Agents Bleach (Sodium Hypochlorite) 12.78 
70% Ethanol Klercide (70% Ethanol) 5.51 
Quaternary Ammonium Compound N10 detergent 12.67 
 
Table 6.2. Table of disinfectants mixed with trastuzumab emtansine vial concentrate. 
 
 Compared to the control, which was water, de-drugging was apparent after 
exposure to a common cleaning agent (Figure 6.1-6.4). The control spectras for 
comparison are (Figure 6.1 A & 6.2 A). Exposure to the Klercide 70% ethanol spray, had 
the smallest effect, but the peak height for the single chain species diminishes while the 
peak height for the naked chains increase (Figure 6.1 B & 6.3 B). Exposure to the N10 
detergent almost completely de-drugged the light and heavy chains see (Figure 6.1 C & 
6.3 C). A new peak was also formed at around 23888 Daltons (Figure 6.1 C). Exposure to 
35% hydrogen peroxide caused almost complete de-drugging, a loss in overall signal 
intensity and the appearance of multiple new peaks, most likely oxidised variants of the 
original heavy and light chains (Figure 6.1 D & 6.3 D). Exposure to 1000 parts per million 
Actichlor caused complete loss of all original mass signals, as well as a 100- fold loss in 
signal intensity (Figure 6.2 A & 6.4 A). Exposure to Prochlor caused another dramatic 
loss of signal intensity, and complete de-drugging, though as no naked peak chains can 
be identified it might have caused mass fragmentation (Figure 6.2 B & 6.4 B). Exposure 
to Bleach was similar to exposure to Actichlor and Prochlor, with no masses 
corresponding to heavy or light chains detectable and a huge loss of signal intensity 
(Figure 6.2 C & 6.4 C). The de-drugging is most likely occurring due to hydrolysis at the 
amide between the lysine and SMCC linker. This is suggested as there were no species 




































Figure 6.1. LC-MS spectra of trastuzumab emtansine light chain following exposure to (A) Water, (B) 70% 
Ethanol, (C) N10 Detergent and (D) 35% Hydrogen peroxide. Y-axis = TICs, X-axis = Mass (Daltons). The 
peaks at 24397 and 25354 daltons are diminished in height compared to the water treated sample. Three 






















































Figure 6.2. LC-MS spectra of trastuzumab emtansine light chain following exposure to (A) 1000 ppm 
Actichlor, (B) Prochlor and (C) Bleach. Y-axis = TIC, X-axis = Mass (Daltons). None of the peaks observed in 


















































Figure 6.3. LC-MS spectra of trastuzumab emtansine heavy chain following exposure to (A) Water, (B) 70% 
Ethanol, (C) N10 Detergent and (D) 35% Hydrogen peroxide. Y-axis = TICs, X-axis = Mass (Daltons). The 
peaks at 52553 and 52512 are diminished in the degraded samples compared to the water control. H2O2 

























































Figure 6.4. LC-MS spectra of trastuzumab emtansine heavy chain following exposure to (A) 1000 ppm 
Actichlor, (B) Prochlor and (C) Bleach. Y-axis = TICs, X-axis = Mass (Daltons). All peaks are diminished in 










6.3 The effect of payload liberation to on and off target toxicity 
 
The fact photolytic degradation causes payload liberation in trastuzumab 
emtansine samples using LC-MS has already been demonstrated (Figures 4.5 & 4.6). The 
same samples were also used in the original assay validation for the trastuzumab 
emtansine assay using BT-474, HaCaT and HepG2 cells, demonstrating that trastuzumab 
emtansine did not exhibit increased toxicity towards target on or off target cell lines 
(Figure 4.7) with very small changes to the EC50s for both off target cell lines compared 
to the change to the EC50 on the target cell line, which became over 300% less potent 
once photolitically degraded. 
 
As LC-MS data suggests that the entire payload is being cleaved, and not just a 
portion of the DM-1 warhead, it is possible that the liberated payload is unable to enter 
cells and act as a cytotoxic agent. While DM-1 is extremely potent, the linker prevents it 
entering cells. This finding can be supported with the results from a 2006 study by 
Erickson et al that found during normal use, trastuzumab emtansine’s lysine + payload 
metabolite is further reduced to S-methyl-DM-1 which is 105 fold more toxic inside 
cells0. 209 Work by Kovtun et al 2006, demonstrated that thioether linked ADCs did not 
exhibit bystander effect cell killing, while reducible bond containing linker ADCs did. 210 
To test whether brentuximab vedotin could exhibit bystander killing, brentuximab 
vedotin degraded photolytically was assessed via an MTT assay following methods 2.6.2 
and 2.2.11. The on-target cell line was changed to GCT-27 cells, which express CD30. The 
results demonstrate that photolytic cleavage of the bond between the ADC and warhead 






Figure 6.5. Dose response curves of brentuximab vedotin control sample vs photolytically degraded 
sample with GCT-27 cells. EC50 for the control was 5.5 μg /mL and 2.6 μg /mL for the degraded drug. A 








Figure 6.6. Dose response curves of brentuximab vedotin control sample vs photolytically degraded 
sample with HepG2 cells. EC50 for the control was 23.0 μg/mL and 10.4 μg/mL for the degraded drug. A 
shift to the left on the X-axis is noted, as well as the EC50 more than halving following photo-degradation. 
 
 




















Photolytic Degradation of Adcetris





















6.4 Conclusion regarding ADC in use safety 
 
Trastuzumab emtansine payloads can clearly be cleaved by exposure to common 
hospital cleaning agents, as demonstrated by the LC-MS spectra (Figure 6.1 – 6.4), this 
is most likely due to hydrolysis of the amide connected to the lysine. However cellular 
activity assays of trastuzumab emtansine, comparing photodegraded to control samples 
(Figure 4.7), demonstrate that the off-target toxicity is not affected and on target 
toxicity is reduced when trastuzumab emtansine is de-drugged. Literature supports the 
idea that catabolites of ADCs with non-reducible thioether linkers such as trastuzumab 
emtansine are not capable of entering cells and causing apoptosis. However, reducible 
bond containing ADCs such as brentuximab vedotin, can also be degraded leading to 
payload release, and these have been demonstrated as increasing off target toxicity and 
on target toxicity (Figure 6.5 & 6.6) where the EC50 dropped from 5.5 to 2.6 μg/mL 
following photolytic degradation against the on-target cell line and against the off-target 
cell line the EC50 dropped from 23.0 to 10.4 μg/mL following photolytic degradation. 
Treating ADCs with cell permeable degradants, such as brentuximab vedotin, as 
cytotoxic is appropriate behaviour, considering the potential harm they could cause, 
where they to become de-drugged. But is unnecessary for ADCs such as trastuzumab 
emtansine, that have non-cell permeable degradants. 
 
Therefore, although trastuzumab emtansine can be de-drugged by many 
common cleaning agents used in NHS hospitals and aseptic compounding units, it is not 
likely to become more dangerous during a clean-up of a ‘spill’ incident. However, this 
may not be the case for brentuximab vedotin, though not enough work has been 
conducted to draw conclusion about brentuximab vedotin’s safety in the workplace. To 
roughly gauge how dangerous completely de-drugged brentuximab vedotin solution 
would first look at the LD50 of MMAE which has been stated as 1 mg/kg in humans. 241 
The mass of MMAE is 718 daltons, the mass of brentuximab vedotin is 153 kDa. The 
mean DAR of brentuximab vedotin is 4, therefore approximately 2 % of brentuximab 
vedotin is MMAE. As all vials of brentuximab vedotin are 50 mg, this means an entire 
vial contains 1 mg of MMAE. Therefore, one vial per kilogram of person is around the 
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LD50. While this may suggest brentuximab vedotin de-drugging is not a big risk to 
human life, it is worth noting that doses of cytotoxic drugs below their LD50 can still 
have harmful impact. For example, vincristine has an LD50 of 1 mg/kg in rats, but at 
0.05 mg/kg it causes reproductive and developmental toxicity. 242 Furthermore, 6 
doses of 0.02 mg/kg/week caused central nervous system toxicity in dogs. 242 While a 
single vial may not contain enough MMAE to kill a human it certainly could have 
enough MMAE to cause harm to humans,  especially upon repeated exposure.  
248 
 





Brentuximab vedotin, marketed as Adcetris by Seattle genetic (Seattle Genetics, 
Seattle, USA), was the second ADC licensed for use in humans. As described in the 
introduction it has significant differences in its design compared to trastuzumab 
emtansine, specifically the attachment of payloads via cysteine instead of lysine residues 
and the cleavable nature of the linkers, including its self-immolating structure. This 
means that brentuximab vedotin is far less heterogeneous with regards to DAR and 
distribution of payload87 and the degradants include free warhead, which has been 
demonstrated to have a strong, non-selective cytotoxic activity against human cell lines 
(Figure 6.5 & 6.6). 
 
 




As a preliminarily investigation of method compatibility and to identify any 
immediate issues arising due to the differences from the structure of brentuximab 
vedotin compared to trastuzumab emtansine, control samples and a photolytically 
degraded sample were compared, the samples were prepared according to method 
2.7.1. One sample was stored refrigerated for 12 hours, while the other was stored at 
25 °C under 20,000 Lux. The intention was to evaluate a control sample (12 hours at 4 
°C) to determine if any problems were apparent with a particular study method, and 
also to evaluate a degraded sample (20,000 Lux at 25 °C) to determine whether each of 





7.2.2 Visual inspection 
 
To evaluate the visual inspection technique, a control sample of brentuximab 
vedotin and photolytically degraded sample brentuximab vedotin were compared. The 
control was clear with no visible colour, particles or turbidity. The photolytically 
degraded sample had turned cloudy and turbid (Figure 7.1). As visual inspection can 
distinguish a control sample and photolytically degraded sample, this technique appears 
to be stability indicating. Visual inspection is unaffected by testing brentuximab vedotin 
as opposed to trastuzumab emtansine or infliximab. 
 
Figure 7.1. Photographs of control (A & C) and photolytically degraded (B & D) samples. The samples were 




To evaluate the pH technique (method 2.2.2), a control sample of brentuximab 
vedotin and photolytically degraded sample brentuximab vedotin were compared. The 
pH was 6.42 for the control and photolytically degraded sample. While this technique is 
unaffected by testing brentuximab vedotin as opposed to trastuzumab emtansine or 
infliximab, it does not appear stability indicating. However according to the ICH Q2 (R1) 
guidance 105 “pH measurement is a general method and does not require a validation”. 
Therefore, it does not matter that it is not stability indicating for photolytic degradation 






7.2.4 Nano-tracking analysis of nano-particles 
 
To evaluate nano-tracking analysis of nanoparticles (method 2.2.5), a control 
sample of brentuximab vedotin and photolytically degraded sample of brentuximab 
vedotin were compared. The particle count was dramatically different between the 
control sample and photolytically degraded sample (Figure 7.2). The photolytically 
degraded sample had a concentration of nanoparticles almost two orders of magnitude 
higher than the control sample. This indicates the method is compatible and likely to be 
stability indicating. Nano-tracking analysis appears unaffected when testing 




Figure 7.2. Nano-tracking analysis of a control sample and photolytically degraded sample of 
brentuximab vedotin. Photolytic degradation has caused a statistically significant increase in the number 
of nanoparticles. **** indicates a p value less than 0.0001. 
 
7.2.5 Microflow imaging analysis of microparticles  
 
To evaluate microflow imaging of microparticles (method 2.2.6), a control 
sample of brentuximab vedotin and photolytically degraded sample of brentuximab 
vedotin were compared. The particle counts were dramatically different between the 
control sample and photolytically degraded sample (Figure 7.3). The photolytically 
degraded sample had a concentration almost two orders of magnitude higher for both 
particles greater than 10 μm and particles greater than 20 μm micrometres. This 


















Particles 1 to 1000 nm 
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is also unaffected when testing brentuximab vedotin as opposed to trastuzumab 
emtansine or infliximab. 
 
Figure 7.3. Microflow imaging analysis of microparticles greater than 10 μm and 25 μm. Comparison of a 
control sample and photolytically degraded sample of brentuximab vedotin shows statistically significant 
increases in microparticle concentration after degradation. **** indicate p values less than 0.0001. 
 
7.2.6 Gel electrophoresis 
 
To evaluate gel electrophoresis analysis of brentuximab vedotin (method 2.2.7), 
a control sample of and antibody (Obinituzumab), a control sample of brentuximab 
vedotin and a photolytically degraded sample of brentuximab vedotin were compared 
(Figure 7.4).  
 
Reduced sample analysis appears unaffected. Comparison of photolytically 
degraded brentuximab vedotin to the control sample shows a feint but detectable band 
appearing around 75 kDa and a band at above 200 kDa (Figure 7.4 C1 & E1). This 
suggests aggregation and some resistance to the reduction of the interchain disulphide 
bonds on the brentuximab antibody. 
 
Intact sample analysis for the brentuximab vedotin control appears drastically 
different to the control sample of obinituzumab (Figure 7.4 B1 & D1). There are several 





















light chains. The bands are most likely to be due to various combinations of heavy and 
light chain. Light is approximately 25 kDa, Heavy is approximately 50 kDa, Heavy Light is 
approximately 75 kDa, Heavy-heavy is about 100 kDa, and Heavy-heavy-light is 
approximately 125 kDa. When attaching payloads to cysteine residues, the disulphide 
bonds are reduced to ensure the cysteine residues are available. This means the 
antibody for any brentuximab vedotin ADC can only have 3 or fewer intact inter-chain 
disulphide bonds. As part of intact analysis for gel electrophoresis, samples are 
denatured, causing the proteins to unfold and ensuring that protein mass, and not the 
three-dimensional shape, controls the distance travelled through the gel. When 
denatured for analysis via gel electrophoresis, the heavy and light chains likely do not 
have enough Van der Waals force left to hold them together and dissociate once without 
a disulphide bond holding them together. 
 
When comparing the intact analysis of the brentuximab vedotin control sample 
with the photolytically degraded sample can observe differences (Figure 7.4 D1 & F1). A 
strong band above 200 kDa is detectable and the intensity of bands below 150 kDa are 
much less intense than the band at 150 kDa. The band above 200 kDa suggests a lot of 
aggregation is present. The loss of band intensity for the ‘new’ bands below 150 kDa, 
may suggest that the DAR forms most susceptible to aggregation, may also be the DAR 
forms most likely to exhibit chain dissociation when denatured. Evidence from the 
literature can support this claim as the more payloads bound to a cysteine linked ADC 





Figure 7.4. Electrophoresis of brentuximab vedotin vs Obinituzumab. The digital ladder (A0), helps to 
identify band masses. (A1) and (B1) are the reduced and intact analysis of the model antibody 
obinituzumab. (C1) and (D1) are the reduced and intact analysis of brentuximab vedotin. (E1) and (F1) are 
the reduced and intact analysis of photolytically degraded brentuximab vedotin.  
 
7.2.7 Cellular MTT assay 
 
The figures for this experiment are in chapter six page 243, and were performed 
according to method 2.6.2 and 2.2.11 On target activity is antibody specific so using the 
cell line that works for trastuzumab emtansine or infliximab will not work for 
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brentuximab vedotin. However, the basic concept of the MTT assay is unaffected when 
using cells appropriate to brentuximab vedotin, such as GCT-27 cells that express the 
CD30 protein, (Figure 6.5). GCT-27 cells have previously been used by Schönberger et al 
to test brentuximab vedotin’s functional activity. 213  Furthermore, off target cellular 
assays using HepG2 are unaffected and dose response curves are easily generated 
(Figure 6.6). Furthermore, photolytic degradation of brentuximab vedotin causes a shift 
to the left, for both on target and off target cell lines (Figure 6.5 & 6.6). Against the on-
target cell line, the EC50s have shifted from 5.5 μg/mL to 2.6 μg/mL once photolytically 
degraded. Against the off-target cell line, the EC50s have shifted from 23.0 μg/mL to 10.4 
μg/mL once photolytically degraded.  This data indicates the cellular MTT assay will be 
stability indicating and is not negatively affected when measuring brentuximab vedotin 
as opposed to trastuzumab emtansine. These findings also indicate that brentuximab 
vedotin becomes more cytotoxic towards both target cells and off-target cells, unlike 
trastuzumab emtansine. 
 
7.2.8 Infrared spectroscopy structure determination 
 
To evaluate infrared spectroscopy structure determination of brentuximab 
vedotin, a control sample brentuximab vedotin and photolytically degraded sample of 
brentuximab vedotin were compared using method 2.2.9 (Figure 7.5). The photolytically 
degraded sample has an altered secondary structure, with a 7.9% increase in alpha helix 
and a 4.7% decrease in beta sheet. As this technique is able to predict a structure for 
brentuximab vedotin and measure a clear difference compared to the photolytically 
degraded sample, this preliminary investigation of infrared analysis suggests the method 
is both compatible and stability indicating in nature brentuximab vedotin.  Furthermore, 
the degree of structural change is significant enough that loss of binding would be 
expected, however the cellular assay did not demonstrate a loss of function, which may 
be explained by payload detachment. The technique is unaffected by testing 





Figure 7.5. Infrared spectroscopy structure determination of brentuximab vedotin’s secondary structure. 
Photolytic degradation has caused statistically significant changes to both alpha helix (7% increase) and 
beta sheet (5% decrease). *** and **** indicate a P value less than 0.001 and 0.0001 respectively. 
 
7.2.9 LC-MS chemical degradation and payload binding 
 
To evaluate LC-MS analysis of brentuximab vedotin, a control sample 
brentuximab vedotin and photolytically degraded sample of brentuximab vedotin were 
compared following methods 2.2.12 – 2.2.14 (Figure 7.6). Multiple peaks are detectable 
in the mass range of the light and heavy chains. While a pure brentuximab antibody was 
not available to establish the mass of naked chains, a previously published application 
note demonstrated analysis of reduced brentuximab vedotin on an  Agilent 6530 Q-TOF 
coupled with an ultra-high pressure LC system using a polymeric reverse phase protein 
column 214, the set-up is touted as having unmatched sensitivity  and mass accuracy. 
They identified the mass of brentuximab light and heavy chains. While the method used 
here does not use ultra-high-pressure liquid chromatography and is only performed on 
an Agilent 6420 Q-TOF, it is still possible to identify naked and single payload light and 
heavy chains (Figure 7.6). Naked light and heavy chain have masses around 23726 and 
50084 respectively. The mass of a single payload can be calculated as 1316 daltons, 
which identifies heavy chains with a single, double or triple payload attachment, as well 






 Furthermore, light chain with a linker but no warhead is detectable (Figure 7.6 
A). There are two peaks at 47451 and 48561 daltons (Figure 7.6 B) that do not 
correspond to any expected masses, these will require further investigation. 
 
Comparison of the control sample to the photolytically degraded sample shows 
a change in the peak heights of heavy chains. Specifically, photolytic degradation 
reduces the relative TICs of triple payload species, double payload species and single 
payload species, while increasing the relative TICs for naked heavy chain. This technique 
appears to be compatible with brentuximab vedotin and as it can distinguish between 





Figure 7.6. LC-MS analysis of (A & B) control samples and (C & D) photolytically degraded samples of 
brentuximab vedotin’s (A & C) light chains and (B & D) heavy chains. Y-axis = TICs, X-axis = Mass (Daltons). 
Signal loss of peaks corresponding to double payload band species is noted. 
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7.2.10   Size exclusion chromatography 
 
To evaluate size exclusion chromatography analysis of brentuximab vedotin, a 
control sample brentuximab vedotin and photolytically degraded sample of 
brentuximab vedotin were compared using method 2.2..17 (Figure 7.7). The monomer 
peak has an asymmetry of 1.26 which is an acceptable level to begin a full validation. 
Furthermore, the photolytically degraded sample had a drastically reduced absorbance 
corresponding to the monomer, a 92% loss of absorbance (Figure 7.7).  The dimer peak 
has also disappeared, likely due to further aggregation to nano or micro-scale 
particulates as detected via MFI and NTA analysis. Interestingly, there is a new peak at 
8.15 minutes, eluting after the monomer peak. This suggested photolytic degradation 
has caused fragmentation of the ADC, creating a fragment with a molecular weight 
between 10 and  
0.2 kDa, based on comparison to the BioSep-SEC-s4000 column quality control test 
report. It is possible that we are observing fragmented payloads, as MMAE, the warhead 
for brentuximab vedotin has a molecular weight of 718 daltons and the entire payloads 
has a molecular weight around 1.3. The presence of payload fragments can help explain 
why no loss of functional activity is noted even after large losses of monomer.  This data 
suggests that size exclusion chromatography method is compatible with brentuximab 
vedotin and as it can distinguish between the control sample and photolytically 
degraded sample method is it is likely to be stability indicating too. 
 
 
Figure 7.7. Size exclusion chromatography analysis of a brentuximab vedotin control sample (Black) vs a 
photolytically degraded sample (Blue). The X-axis is time (minutes). Degradation has caused a large 




7.2.11  Hydrophobic interaction chromatography analysis of DAR 
 
This experiment discusses data first presented in chapter 4, collected using 
method 2.2.15. To evaluate hydrophobic interaction chromatography analysis of 
brentuximab vedotin’s DAR, a control sample brentuximab vedotin was analysed (Figure 
4.32). It is possible to separate and integrate the peaks corresponding to DAR 0 – 8. This 
method works for brentuximab vedotin but not for trastuzumab emtansine due to the 
difference in their site of attachment. Due to the payloads being attached at cysteine 
residues, the variability of DAR and distribution of payload is greatly reduced. This 
creates a more restricted hydrophobicity profile, dominated by the DAR instead of the 
distribution of payload. This allows distinct peaks to be generated when using HIC, 
providing an alternative method of DAR characterisation to the LC-MS method. HIC 
results such as (Figure 4.32) can be used to calculate the DAR with the following data 
processing steps. 
 
1) Integrating the peaks corresponding to each DAR 
2) Calculating the relative peak area for each DAR peak 
3) Multiplying the relative peak areas of each DAR peak by its own DAR value 
4) Sum the DAR adjusted relative peak areas 
5) Divide the sum of DAR adjusted relative peak areas by 100 
 
Using the above process on the data from (Figure 4.32) It was calculated that 
brentuximab vedotin had a DAR of 4, matching multiple published independent LC-MS 
and HIC based determinations. 215-219 HIC work was not performed on the degraded 
samples due to time constraints. However, work by Hamblet et al and Wakanker et al 
used HIC to measure the DAR of cysteine linked ADCs. 173, 199  Thus, suggesting that HIC 
would be a viable method for determining DAR of brentuximab vedotin. 
 
7.3 Conclusion 
This preliminary investigation has demonstrated that all methods developed for 
the stability evaluation of trastuzumab emtansine appear to be compatible for a similar 
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evaluation of brentuximab vedotin. Furthermore, HIC analysis of DAR, which was 
incompatible with trastuzumab emtansine, is compatible with brentuximab vedotin. 
 
This work has also highlighted that the chemistry used to attach brentuximab’s 
payloads via cysteine residues destabilises the antibody as disulphide bonds are reduced 
and therefore the molecular forces holding the antibody component of the ADC 
together are weaker. Gel electrophoresis shows brentuximab vedotin is unable to 
remain fully intact when denatured, while trastuzumab emtansine and infliximab were 
(Figure 7.4). Furthermore, brentuximab vedotin was considerably more degraded than 
trastuzumab emtansine and infliximab when subjected to the same photolytic 
degradation conditions. Brentuximab vedotin exhibited a greater increase in 
nanoparticle concentrations, microparticle concentrations, the development of visible 
turbidity, a greater loss of monomer concentration, as well as loss of payload detectable 
via LC-MS and maybe as a low molecular weight fragment in SEC analysis. 
 
This preliminary work also demonstrated an increase in potency regarding on 
and off target activity upon photolytic degradation for brentuximab vedotin (Figure 6.6). 
The EC50s more than halved against both cell lines suggesting photolytic degradation had 
more than doubled brentuximab vedotin’s cytotoxic potential. This suggests 
brentuximab vedotin becomes more harmful and cytotoxic following degradation. While 
trastuzumab emtansine was demonstrated to be degraded by many common cleaning 
agents used in hospitals and ascetic compounding units, the degradation did not cause 
an increase in its off-target activity, and only reduced its on-target activity (Figure 4.7). 
As brentuximab vedotin has been demonstrated as more sensitive to photolytic 
degradation, most likely due to loss of 1 or more disulphide bonds, it may also be more 




8 Chapter 8 – Conclusions and Future Work 
 
The overall aim of this project was to develop methods, for the characterisation 
of the ADC trastuzumab emtansine, compliant with the guidelines set out in the NHS 
yellow cover documents for stability guidance. The purpose of developing these 
compliant methods was to enable a valid stability study to be performed to apply an 
extended shelf-life to Kadcyla. This would enable Bath ASU to offer UK hospitals Kadcyla 
in a ready to infuse presentation with more than 24 hours of shelf life. To accomplish 
this aim, much work was required to meet several objectives. During this work many 
obstacles were encountered, providing ample opportunity to use creative thinking. 
 
An understanding of what is required for a stability study was needed to ensure 
its results would be appropriate to apply a shelf life extension to the product and it was 
necessary to identify and understand all critical stability characteristics for a basic 
antibody and suitable analytical techniques for assessing them. Using the NHS yellow 
cover stability guidance documents, 101,102 as well multiple ICH guidance documents 
pertaining to drug stability, biopharmaceuticals and assay validation,  105,158,220-222  what 
is required of a stability study for its findings to be useable for a shelf life extension of 
aseptically prepared biopharmaceuticals was learnt. An understanding of the critical 
characteristics of biopharmaceuticals regarding their stability and safety was gained. 
Further literature research was required to understand the wealth of techniques that 
could be used to assess different caveats of the critical characterises, for example, the 
numerous methods of monitoring particles, 111,5.4,123,126-134 or investigating higher order 
structure. 135-157 The first major obstacle encountered was when reviewing the vast array 
of techniques that can be used for assessing the critical characteristics of a 
biopharmaceutical product. Justification of choosing one technique instead of another 
was needed. This was made easier by assessing which instruments were accessible at 
Bath University and Bath ASU. Then it was possible to rule out the techniques that 
required long periods of time or high levels of expertise, for example x-ray 
crystallography. Particle assessment has an incredible number of techniques, so the 




We wanted to demonstrate that a fully NHS compliant stability study could be 
designed and executed, using a simple antibody.  An issue found when designing the 
infliximab stability study was the NHS guidance states that study samples will ideally be 
exact replicates of the ready to use product, however to produce an appropriate number 
of samples at the required volumes and concentrations would have used a large volume 
of infliximab costing around £28,000. By scaling down the samples from 250 mL infusion 
containers, to 50 mL infusion containers we were able to save almost £25,000. This 
sample scale down approach was later applied to the trastuzumab emtansine study to 
save approximately £130,000. Another obstacle was the time dependent nature of the 
proposed antibody stability study. It is required that a full stability characterisation be 
performed within 24 hrs of compounding, and there are many benefits for doing this at 
the limit of its SPC shelf life as well. This means all techniques must be run separately on 
day 0 and 1. It would be impossible for the number of samples required for the stability 
study to be assessed by a single person during one working day. To that end three 
measures were employed. Firstly, samples for LC-MS analysis were processed, then 
frozen and submitted to be run Dr Shaun Reeksting in the Chemical Characterisation and 
Analysis Facility (CCAF) at Bath University. Secondly, the preparation of different 
concentrations of samples was staggered, thus reducing the workload on each sampling 
day. Thirdly, while the techniques and methods were chosen, developed and validated 
by me, staff at Bath ASU helped collect the data on each time point, with specific tasks 
assigned to an individual for the duration of the study. A fully NHS compliant stability 
study was designed and conducted on clinically relevant concentrations of Remsima 
brand infliximab stored in Fresenius Kabi Freeflex infusion bags. This published study 
demonstrates infliximab’s stability while refrigerated over a seven day period, and 
allows anyone operating under a Section 10 exemption or a Specials License  to be able 
to also apply a seven day shelf life to Remsima brand infliximab when manufactured 
according to the methods used in the published study 167. The publication also 
demonstrates the ability for a fully NHS compliant study to be performed and proving 
the study design was practicable,  and is cited by the NHS quality assurance committee 




Critical characteristics unique to ADCs (as compared to antibodies) needed to be 
identified. Through literature research regarding antibodies and ADCs, an understanding 
of ADC structure, stability and safety concerns was gained. 73, 90 For example the 
difference between: cleavable and non-cleavable linkers, 90 common types of ADC 
warheads and their mechanisms of action, 91 how potent the warheads of ADCs are 
when not conjugated, 92 how the site of attachment and linker chemistry controls the 
ratio of drug payloads to antibody, 88 the importance of DAR 90, and the locational 
distribution of the payloads  across the antibody, what has been referred to a positional 
-isomers. 90 This knowledge informed me that neither DAR, or off target toxicity were 
covered by any current guidance document, circa 2016. 
 
By testing control samples and degraded samples of trastuzumab emtansine via 
each method used during the infliximab study, it was discerned which methods had 
issues assessing ADCs. For example, circular dichroism spectra to secondary structure 
software ‘Circular Dichroism Neural Network’ was found to be incompatible with ADCs. 
 
One of the most significant obstacles encountered was discovering secondary 
structure analysis via CD, which is commonly used in biopharmaceutical stability studies, 
was unsuitable for assessing the ADC trastuzumab emtansine. Only minor issues with 
CD had been found in the literature suggesting some issues with signal magnitude at the 
near-UV region.  Though circular dichroism can still be used to assess conformational 
stability ADCs using thermal ramps and measuring the melting temperatures, that’s not 
a detailed enough analysis of higher order structure to satisfy the current requirements 
set out in the NHS yellow cover Part 2 guidance.   
However, it did provide an opportunity to explore alternative, and in many ways 
superior, methods of secondary structure determination, namely infrared spectroscopy 
analysis. Finding an IR method of determining secondary structure proved a challenge 
owing to the lack of an IR structure determination method that could work out of the 
box at clinically low concentrations for antibodies and ADCs. Equipment configurations 
able to predict structure that were sensitive at clinically high and supra clinical 
concentrations could were found to be insensitive at clinically low concentrations.  
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An original quantitative data set was designed, built and validated, which was 
compatible with infrared spectrometry equipment sensitive enough to detect clinical 
concentrations of ADCs and antibodies. This allows rapid, precise and accurate 
measurements of sub-clinical and supra-clinical concentrations of protein structures, 
including antibodies, fusion proteins, enzymes and antibody drug conjugates. By 
measuring the amide 1 and 2 bands and comparison to the QDS. 
After presenting data collected using this method on multiple antibodies and 
ADCs, and the validation of the quantitative data set, to members of the NHS 
pharmaceutical quality assurance committee (2017), infrared spectroscopy was added 
to their list of recommended techniques suitable for characterising physico-chemical 
changes. 
A mass spectroscopy-based method of assessing DAR was developed and 
validated, overcoming issues of low sensitivity at clinical constrictions, using the mass 
spectrometry equipment available at Bath University. This was achieved by using TCEP 
to reduce the antibody drug conjugate into its heavy and light chain components, which 
didn’t affect the amide or ester bonds of the ADCs. Comparing the relative change in 
peak ratios corresponding to heavy and light chains with varying numbers of payload 
bound to them provides sufficient knowledge of the payload binding. 
 
A stability study of trastuzumab emtansine in line with the NHS stability guidance 
was carried out, having had multiple meetings with members of the NHS quality 
assurance committee to facilitate regulatory approval of the proposed stability study. A 
stability study on Kadcyla brand trastuzumab emtansine was designed and performed 
which was subsequently reviewed by the chair of the NHS pharmaceutical quality 
assurance committee (2017) and deemed to be compliant with all requirements for a 
ADC stability study. The study enabled a 21-day shelf life extension to be applied to 
Kadcyla brand when diluted to clinical concentrations in Fresenius Kabi Freeflex sodium 
chloride infusion bags and refrigerated at 2-8 °C when protected from light. This is, to 
the authors knowledge, the world’s first shelf life extension of a ready to use ADC 
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product. This extension has contributed to an 80% increase in batches of Kadcyla 
manufactured by Bath ASU per annum between 2015 and 2017. 
 
It was also discovered that not all polyolefin infusion bags affect drug stability 
equally. While it has been known for some time that polyvinylchloride infusion bags 
generally cause increased adhesion and particle formation, with guidance such as the 
NHS yellow cover documents and even particular products summaries of product 
characteristics, stating that polyolefin infusion bags must be used instead of polyvinyl 
chloride ones. However, it was demonstrated that different methods of bag 
manufacture and types of polyolefin, affect aggregation and adhesion significantly 
differently. Furthermore, each bag type was not clearly better or worse for all drugs. 
This suggests stability study data is only applicable to products manufactured in the 
same bags type. It also raised the question of whether measurements made of a drug 
within its SPC shelf life in one bag type can be used as baselines of acceptability for 
studies in a different bag type, discussion with NHS quality assurance staff made it clear 
this was not acceptable and based on this research the NHS pharmaceutical quality 
assurance committee of 2017 amended their own guidance on container choice, adding 
“Data cannot be extrapolated to other container types and care should be taken when 
extrapolating to a different manufacturer’s container, there is some evidence that not 
all polyolefin bags behave the same with all biologicals”. 
 
Additionally, preliminary investigations to evaluate the in-use safety of 
trastuzumab emtansine, as well as to the further applicability of methods developed for 
the study of Kadcyla towards other ADCs such as Adcetris, were conducted. A final 
challenge that was encountered relates to the preliminary study into the in-use handling 
of trastuzumab emtansine. There is a lack of publicly accessible information regarding 
the policies of different NHS hospitals approaches to spills and how to classify spills, 
based on the substance, concentration, volume and location of spills. Although it was 
possible to find some information regarding spill procedures and use of different 
cleaning agents, 207,208 and have conversations with NHS hospitals nurses and 




Finally, it was also demonstrated that although trastuzumab emtansine can be 
easily degraded with common cleaning agents used around hospitals and aseptic 
compounding units, it does not appear to pose any more danger to staff when degraded 
as the payload fragments are unable to enter cells. However preliminary work on 
brentuximab vedotin shows this is not the case for all antibodies, suggesting that 
cleavable linker-based ADCs, like brentuximab vedotin, may become more toxic and less 




In the pursuit of the overarching aim of thesis, there were many interesting 
findings that were not fully investigated. One area of that would be of interest to return 
and expand upon would be the bag comparison study. The finding that the choice of 
different brands of polyolefin infusion bags had a significant impact on drug aggregation 
was both interesting and useful. A deeper understanding of this would be of value. Ideas 
include identifying the concentration of non-ionic surfactants used to help to control for 
that variable. As well as using drugs that have the same surfactants rather than three 
different ones. Furthermore, measurements of the zeta potential of the plastics inner 
surface would also be of interest as that was a possible driver of aggregation. Finally, we 
only tested three brands of bags while there are many bag manufacturers and suppliers 
on the market. It would be interesting compare the surface roughness and zeta potential 
of bags that have the same inner surface material and manufacturing process, this could 
help identify the extent the manufacturing process and surface roughness contribute to 
the aggregation. As well as zeta potential it may also be of value to measure the 
hydrophobicity of the materials, by measuring the contact angle of water. Highly 
hydrophobic materials may interact more strongly with exposed hydrophobic regions of 
proteins, such as the hinge region and areas exposed during conformational changes. 
  
Another area that was not fully explored was the inability for CDNN to 
adequately process CD spectra of trastuzumab emtansine to predicted secondary 
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structures. Further work here could expand upon the differences found by ourselves and 
Beckley et al (2013) that showed the near UV CD spectra of ADCs were affected, with 
regards to the signal intensity. 233 This is the exact region that CDNN uses to calculate 
the secondary structure. It would be interesting to make measurements of the other 
three licensed ADCs to see if they also have the same issues found with trastuzumab 
emtansine. 
 
There has also been interest in testing methods to determine the tertiary 
structure of ADCs. While there were issues identified with near UV CD analysis, no issues 
where found by Beckley regarding the far UV CD spectra, which can be used to 
characterise the tertiary structure of antibodies. 233 Tertiary structure characterisations 
can provide useful information regarding protein misfolding, and even predict early 
aggregation due to exposure of hydrophobic regions upon tertiary conformational 
changes. 243 
 
Measurements of payload bound to heavy and light chains were made but it 
would be interesting to see if these values could be used to calculate a total DAR. This 
calculated DAR could then be tracked, reducing the number of statistics being presented 
and increasing the relevance of the data presented. 
 
Ideally, it would be possible able to continue research about the in-use safety 
concerns of brentuximab vedotin. To do this would require a fully validation of the 
stability characterisation techniques on brentuximab vedotin. The preliminary research 
concerning brentuximab vedotin, suggests there should be no problems during 
validation. Even the unusual appearance during intact gel electrophoresis analysis and 
the two unidentified peaks identified in heavy chain LC-MS analysis, won’t stop an 
investigation int o the stability upon exposure to common cleaning agents, even if the 
total amount of MMAE may not be lethal it could certainly still be harmful based on 




Once that work is done, a stability study on brentuximab vedotin would be 
possible and has many of the same logistical and financial benefits that a stability study 
on trastuzumab emtansine does, however it arguably has more of an impact on staff 
safety than trastuzumab emtansine as brentuximab vedotin has been shown to have 
more harm potential than trastuzumab emtansine, thus enabling its manufacture to 
occur in aseptic compounding pharmacies can aid the NHS and private hospitals in their 
efforts to manage the risk of cytotoxic exposure of their staff and patients. 
 
 As preliminary brentuximab vedotin characterisation has already revealed 
differences to trastuzumab emtansine characterisation it would certainly be of interest 
to perform an investigation in to either the recently relicensed gemtuzumab ozagamicin 
or recently licensed inotozumab ozagamicin, as these use a different linker technology 
and warhead to both previously investigated ADCs.  
 
Furthermore, some techniques used during this project could be improved, for 
example gel electrophoresis is mainly used as a qualitative test, however the Agilent 
Tapestation 2200 produces electropherograms, not used in this thesis, which could be 




The main purpose of this PhD was to enable a shelf life extension of trastuzumab 
emtansine. This was achieved, in addition to discovering limitations of existing 
techniques, developing new methods for ADC characterisation, that are demonstrated 
to work on multiple types of ADC as well as normal antibodies. Also, novel information 
pertaining to container construction and material has been discovered which has 
affected NHS stability guidance. I am proud of the research that I have performed and 
pleased I was able to achieve all of the original aims and objectives, as well as being able 




Chapter 9. References 
 
1. Rettig, R.A. The war on cancer: An anatomy of failure, a blueprint for the future. 
Health Affairs 25, 1446-1447 (2006). 
2. Fenn, J.E. & Udelsman, R. First Use of Intravenous Chemotherapy Cancer Treatment: 
Rectifying the Record. Journal of the American College of Surgeons 212, 413-417 
(2011). 
3. Farber, S., Diamond, L.K., Mercer, R.D., Sylvester, R.F. & Wolff, J.A. Temporary 
Remissions In Acute Leukemia In Children Produced By Folic Acid Antagonist, 4-
Aminopteroyl-Glutamic Acid (Aminopterin). New England Journal of Medicine 238, 
787-793 (1948). 
4. Evans, A.E., Mariano, P.J., Farber, S. & Brunet, S. Vincristine In Treatment Of Acute 
Leukemia In Children. Cancer 16, 1302-1309 (1963). 
5. Djerassi, I., Farber, S., Abir, E. & Neikirk, W. Continuous Infusion Of Methotrexate In 
Children With Acute Leukemia. Cancer 20, 233-& (1967). 
6. Li, M.C., Hertz, R. & Bergenstal, D.M. Therapy Of Choriocarcinoma And Related 
Trophoblastic Tumors With Folic Acid And Purine Antagonists. New England Journal of 
Medicine 259, 66-74 (1958). 
7. Wilson, W.L. Chemotherapy Of Human Solid Tumors With 5-Fluorouracil. Cancer 13, 
1230-1239 (1960). 
8. Wolberg, W.H. & Curreri, A.R. Toxicity Studies Of 5-Fluorouracil Used As An Adjunct To 
Surgery. Archives of Surgery 81, 244-250 (1960). 
9. Ellison, R.R. Collateral Sensitivity To Methotrexate In 6-Mercaptopurine-Responsive 
Adult Acute Leukemics. Journal of Clinical Investigation 36, 887-887 (1957). 
10. Law, L.W. Differences Between Cancers In Terms Of Evolution Of Drug Resistance. 
Cancer Research 16, 698-716 (1956). 
11. Frei, E. Potential for eliminating leukemic cells in childhood acute leukemia. Proc Amer 
Assoc Cancer Res 5, 20 (1964). 
12. Thompson, I., Hall, T.C. & Moloney, W.C. Combination Therapy Of Adult Acute 
Myelogenous Leukemia - Experience With Simultaneous Use Of Vincristine 
Amethopterin 6-Mercaptopurine And Prednisone. New England Journal of Medicine 
273, 1302-1315 (1965). 
13. Luce, J.K. & Gamble, J.F. Combination Chemotherapy (Mopp) In Disseminated 
Hodgkins Disease (HD). Cancer Chemotherapy Reports Part 1 53, 89-& (1969). 
14. Lowenbraun, S., Devita, V.T. & Serpick, A.A. Combination Chemotherapy With Nitrogen 
Mustard, Vincristine, Procarbazine, And Prednisone In Lymphosarcoma And Reticulum 
Cell Sarcoma. Cancer 25, 1018-1023 (1970). 
15. Sitarz, A.L., et al. Induction Of Remission In Childhood Leukemia With Vincristine And 
6-Mercaptopurine And Methotrexate - Adminstration In Sequence After Prednisone. 
Cancer 21, 920-924 (1968). 
16. Welch, A.D. Problem Of Drug Resistance In Cancer Chemotherapy. Cancer Research 19, 
359-371 (1959). 
17. Skipper, H.E., Schabel, F., Trader, M.W. & Thompson, J.R. Experimental evaluation of 
potential anticancer agents. VI. Anatomical distribution of leukemic cells and failure of 
chemotherapy. Cancer Res 21, 1154-1164 (1961). 
18. Skipper, H.E. Cellular kinetics associated with "curability" of experimental leukemias. 
Perspectives in leukemia. Symposium of the Leukemia Society of America. December, 
1966, 187-216 (1968). 
270 
 
19. Skipper, H.E., et al. Implications of biochemical, cytokinetic, pharmacologic, and 
toxicologic relationships in design of optimal therapeutic schedules. Cancer 
Chemotherapy Reports Part 1 54, 431-439 (1970). 
20. Hajdu, S.I. & Vadmal, M. A Note From History: Landmarks in History of Cancer, Part 6. 
Cancer 119, 4058-4082 (2013). 
21. Ward, H.W.C. Antiestrogen therapy for breast-cancer - Trial of tamoxifen at 2 dose 
levels. Bmj-British Medical Journal 1, 13-14 (1973). 
22. Heel, R.C., Brogden, R.N., Speight, T.M. & Avery, G.S. Tamoxifen - review of its 
pharmacological properties and therapeutic use in treatment of breast-cancer. Drugs 
16, 1-24 (1978). 
23. Goustin, A.S., Leof, E.B., Shipley, G.D. & Moses, H.L. Growth-factors and cancer. Cancer 
Research 46, 1015-1029 (1986). 
24. Zhou, D.J., Battifora, H., Yokota, J., Yamamoto, T. & Cline, M.J. Association of multiple 
copies of the c-erbb-2 oncogene with spread of breast-cancer. Cancer Research 47, 
6123-6125 (1987). 
25. Lin, N.U. & Winer, E.P. Brain metastases: The HER2 paradigm. Clinical Cancer Research 
13, 1648-1655 (2007). 
26. Achkova, D. & Maher, J. Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis 
in cancer. Biochemical Society Transactions 44, 333-341 (2016). 
27. Druker, B.J., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the 
growth of Bcr-Abl positive cells. Nature Medicine 2, 561-566 (1996). 
28. Lin, N.U. & Winer, E.P. Brain metastases: The HER2 paradigm. in Clinical Cancer 
Research, Vol. 13 (2007) Accessed on 25/07/18 
From:  http://clincancerres.aacrjournals.org/content/clincanres/13/6/1648/F2.large.jp
g?width=800&height=600&carousel=1). 
29. Achkova, D. & Maher, J. Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis 




30. Prull, C.R. Part of a scientific master plan? - Paul Ehrlich and the origins of his receptor 
concept. Medical History 47, 332-356 (2003). 
31. Strebhardt, K. & μLlrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. 
Nature Reviews Cancer 8, 473-480 (2008). 
32. Dr Paul Ehrlich and diagrams of his receptor theory.  (Accessed on 25/07/18) 
Image from: http://tibbs.unc.edu/wp-content/uploads/2015/05/paul-ehrlich.jpg 
33. Waxdal, M.J., Konigsberg, W.H. & Edelman, G.M. Structure of a human gamma g 
immunoglobulin. Cold Spring Harbor Symposia on Quantitative Biology 32, 53-+ (1967). 
34. Edelman, G.M., et al. Covalent structure of an entire gammag immunoglobulin 
molecule. Proceedings of the National Academy of Sciences of the United States of 
America 63, 78-83 (1969). 
35. Cohen, S. & Porter, R.R. Structure and biological activity of immunoglobulins. Advances 
in Immunology 4, 287-349 (1964). 
36. Simple diagram of an antibody.  (Accessed on: 25/07/18 
Image from: https://www.progen.com/media/catalog/category/Antibodies_1.png 
37. Fab and Fc digram of an antibody.  (Accessed on 25/08/18 
Image from: https://static.bio-rad-antibodies.com/blog/blue-antibody-fab-blog.png 
38. Wu, T.T. & Kabat, E.A. An analysis of sequences of variable regions of bence jones 
proteins and myeloma light chains and their implications for antibody 
complementarity. Journal of Experimental Medicine 132, 211-232 (1970). 
39. Simple CDR diagram of an antibody.  (Accessed on 25/07/18) 
271 
 
Image from: http://escience.ws/b572/L14/images/CDRx.gif ). 
40. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of 
predefined specificity. Nature 256, 495-497 (1975). 
41. Ruigrok, V.J.B., Levisson, M., Eppink, M.H.M., Smidt, H. & van der Oost, J. Alternative 
affinity tools: more attractive than antibodies? Biochemical Journal 436, 1-13 (2011). 
42. Diagram of monoclonal antibody producing hybridoma cells.  (Image from: 
http://www.biochemj.org/content/436/1/1). 
43. Sgro, C. Side-effects of a monoclonal antibody, muromonab CD3 orthoclone OKT3: 
Bibliographic review. Toxicology 105, 23-29 (1995). 
44. Morrison, S.L., Johnson, M.J., Herzenberg, L.A. & Oi, V.T. Chimeric human-antibody 
molecules - mouse antigen-binding domains with human constant region domains. 
Proceedings of the National Academy of Sciences of the United States of America-
Biological Sciences 81, 6851-6855 (1984). 
45. Hwang, W.Y.K. & Foote, J. Immunogenicity of engineered antibodies. Methods 36, 3-10 
(2005). 
46. Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human-antibodies for 
therapy. Nature 332, 323-327 (1988). 
47. Simple diagram of antibodies, with murine protein in blue and human protein in 
orange.  (Accessed on: 25/07/18) 
Image from: http://modiquestresearch.nl/services/antibody-optimization/ ). 
48. Grillo-Lopez, A.J., et al. Overview of the clinical development of rituximab: First 
monoclonal antibody approved for the treatment of lymphoma. Seminars in Oncology 
26, 66-73 (1999). 
49. Falduto, A., et al. How gene polymorphisms can influence clinical response and toxicity 
following R-CHOP therapy in patients with diffuse large B cell lymphoma. Blood 
Reviews 31, 235-249 (2017). 




51. Nahta, R., Yu, D.H., Hung, M.C., Hortobagyi, G.N. & Esteva, F.J. Mechanisms of disease: 
understanding resistance to HER2-targeted therapy in human breast cancer. Nature 
Clinical Practice Oncology 3, 269-280 (2006). 
52. Pegram, M.D. & Slamon, D.J. Combination therapy with trastuzumab (Herceptin) and 
cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced 
chemosensitivity. Seminars in Oncology 26, 89-95 (1999). 
53. Burris, H.A. Docetaxel (Taxotere) in HER-2-positive patients and in combination with 
trastuzumab (Herceptin). Seminars in Oncology 27, 19-23 (2000). 
54. Umana, P., et al. Novel 3(rd) generation humanized type IICD20 antibody with 
glycoengineered fc and modified elbow hinge for enhanced ADCC and superior 
apoptosis induction. Blood 108, 72A-72A (2006). 
55. Umana, P., et al. Novel third generation humanized type IICD20 antibody with superior 
direct cell death induction and glycoengineered Fc region for enhanced ADCC 
induction. Molecular Cancer Therapeutics 6, 3353S-3353S (2007). 
56. Morschhauser, F., et al. Results of a phase I/II study of ocrelizumab, a fully humanized 
anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Annals of 
Oncology 21, 1870-1876 (2010). 
57. Lauc, G., Pezer, M., Rudan, I. & Campbell, H. Mechanisms of disease: The human N-
glycome. Biochimica Et Biophysica Acta-General Subjects 1860, 1574-1582 (2016). 






59. Steplewski, Z., et al. Biological-activity of human mouse IGG1, IGG2, IGG3, AND IGG4 
chimeric monoclonal-antibodies with antitumor specificity. Proceedings of the 
National Academy of Sciences of the United States of America 85, 4852-4856 (1988). 
60. Jefferis, R. Antibody therapeutics: isotype and glycoform selection. Expert Opinion on 
Biological Therapy 7, 1401-1413 (2007). 
61. Tao, M.H., Canfield, S.M. & Morrison, S.L. The differential ability of human IGG1 and 
IGG4 to activate complement is determined by the COOH-terminal sequence of the 
CH2 domain. Journal of Experimental Medicine 173, 1025-1028 (1991). 
62. Correia, I.R. Stability of IgG isotypes in serum. Mabs 2, 221-232 (2010). 
63. Diagrams of IgG isotypes.  (Accessed on: 25/07/18)  
  Image from: https://teaching.ncl.ac.uk/bms/wiki/images/3/33/Antibody.jpg  ). 
64. Janeway, C. Travers, P. Walport, M. & Schlomchik. Immunobiology:   The Immune 
System in Health and Disease. 5th Edition, (Garland Science, New York, 2001). 
65. Highly detailed diagram of an IgG1 antibody.  (Accessed on: 25/07/18 
Image from: https://www.tandfonline.com/doi/pdf/10.4161/mabs.2.3.5.488 ). 
66. Trail, P.A., et al. Cure of xenografted human carcinomas by br96-doxorubicin 
immunoconjugates. Science 261, 212-215 (1993). 
67. Trail, P.A., Willner, D. & Hellstrom, K.E. Site-directed delivery of anthracyclines for 
treatment of cancer. Drug Development Research 34, 196-209 (1995). 
68. Slichenmyer, W.J., et al. Phase I clinical trials with the immunoconjugate BR96-
doxorubicin. Abstracts of Papers of the American Chemical Society 211, 32-37 (1996). 
69. Trail, P.A., King, H.D. & Dubowchik, G.M. Monoclonal antibody drug 
immunoconjugates for targeted treatment of cancer. Cancer Immunology 
Immunotherapy 52, 328-337 (2003). 
70. Saleh, M.N., et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-
Doxorubicin in patients with Lewis Y-expressing epithelial tumors. Journal of Clinical 
Oncology 18, 2282-2292 (2000). 
71. Tijink, B.M., et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab 
mertansine in patients with incurable squamous cell carcinoma of the head and neck 
or esophagus. Clinical Cancer Research 12, 6064-6072 (2006). 
72. Becher, O.J. & Holland, E.C. Genetically engineered models have advantages over 
xenografts for preclinical studies. Cancer Research 66, 3355-3358 (2006). 
73. Bouchard, H., Viskov, C. & Garcia-Echeverria, C. Antibody-drug conjugates-A new wave 
of cancer drugs. Bioorganic & Medicinal Chemistry Letters 24, 5357-5363 (2014). 
74. Mechanism of ADC internalisation and drug release.  (Image accessed: 25/07/18 
Image from: https://ars-els-cdn-com.ezproxy1.bath.ac.uk/content/image/1-s2.0-
S0960894X1401066X-gr1.jpg ). 
75. Petersdorf, S.H., et al. A phase 3 study of gemtuzumab ozogamicin during induction 
and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 
121, 4854-4860 (2013). 
76. Castaigne, S., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with 
de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 
study. Lancet 379, 1508-1516 (2012). 
77. Sievers, E.L., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with 
CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology 19, 
3244-3254 (2001). 
78. Dinndorf, P.A., et al. Expression of myeloid differentiation antigens in acute 
nonlymphocytic leukemia - increased concentration of cd33-antigen predicts poor 
273 
 
outcome - A report from the childrens cancer study-group. Medical and Pediatric 
Oncology 20, 192-200 (1992). 
79. Hamblett, K.J., et al. SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent 
antitumor activity for the treatment of CD30(+) malignancies. Blood 106, 181A-181A 
(2005). 
80. Beljaards, R.C., et al. Prognostic-significance of CD30 (KI-1/BER-H2) expression in 
primary cutaneous large-cell lymphomas of t-cell origin - A clinicopathologic and 
immunohistochemical study in 20 patients. American Journal of Pathology 135, 1169-
5.48 (1989). 
81. Niculescu-Duvaz, I. Trastuzumab emtansine, an antibody-drug conjugate for the 
treatment of HER2+metastatic breast cancer. Current Opinion in Molecular 
Therapeutics 12, 350-360 (2010). 
82. Rosen, D.B., et al. AKT Signaling as a Novel Factor Associated with In Vitro Resistance 
of Human AML to Gemtuzumab Ozogamicin. Plos One 8(2013 
Accessed on 25/07/18  Image taken from: https://www.ncbi.nlm.nih.gov/pmc/articles 
/PMC3539972/figure/pone-0053518-g001/). 
83. Eyre, T.A., Khan, D., Hall, G.W. & Collins, G.P. Anaplastic lymphoma kinase-positive 
anaplastic large cell lymphoma: current and future perspectives in adult and paediatric 
disease. European Journal of Haematology 93, 455-468 (2014) 
Accessed on 25/07/18 Image from: https://onlinelibrary-wiley-com.ezproxy1.bath.ac 
.uk/doi/epdf/10.1111/ejh.12360). 
84. Gogia, A., et al. Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of 
Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer. Indian 
Journal of Medical and Paediatric Oncology 39, 79-87 (2018) Accessed on 25/08/18 
Image from: http://www.ijmpo.org/temp/IndianJMedPaediatrOncol 39179-2682634_ 
072706.pdf). 
85. Hoffmann, R.M., et al. Antibody structure and engineering considerations for the 
design and function of Antibody Drug Conjugates (ADCs). Oncoimmunology 7(2018). 
86. Chari, R.V.J. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. 
Accounts of Chemical Research 41, 98-107 (2008). 
87. Lu, J., Jiang, F., Lu, A.P. & Zhang, G. Linkers Having a Crucial Role in Antibody-Drug 
Conjugates. International Journal of Molecular Sciences 17(2016). 
88. Hollander, I., Kunz, A. & Hamann, P.R. Selection of reaction additives used in the 
preparation of monomeric antibody-calicheamicin conjugates. Bioconjugate Chemistry 
19, 358-361 (2008). 
89. Marcoux, J., et al. Native mass spectrometry and ion mobility characterization of 
trastuzumab emtansine, a lysine-linked antibody drug conjugate. Protein Science 24, 
1210-1223 (2015). 
90. McCombs, J.R. & Owen, S.C. Antibody Drug Conjugates: Design and Selection of Linker, 
Payload and Conjugation Chemistry. Aaps Journal 17, 339-351 (2015). 
91. Jackson, D. & Stover, D. Using the Lessons Learned From the Clinic to Improve the 
Preclinical Development of Antibody Drug Conjugates. Pharmaceutical Research 32, 
3458-3469 (2015). 
92. Kupchan, S.M., et al. Tumor inhibitors .73. Maytansine, a novel antileukemic ansa 
macrolide from maytenus-ovatus. Journal of the American Chemical Society 94, 1354-
1360 (1972). 
93. Annual Reports in Medicinal Chemistry, Vol 50: Platform Technologies in Drug 
Discovery and Validation. Annual Reports in Medicinal Chemistry, Vol 50: Platform 
Technologies in Drug Discovery and Validation 50, 1-675 (2017). 
274 
 
94. Lopus, M., et al. Maytansine and Cellular Metabolites of Antibody-Maytansinoid 
Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules. 
Molecular Cancer Therapeutics 9, 2689-2699 (2010). 
95. Li, F., et al. Intracellular Released Payload Influences Potency and Bystander-Killing 
Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Research 76, 2710-
2719 (2016). 
96. Shah, D.K., et al. A Priori Prediction of Tumor Payload Concentrations: Preclinical Case 
Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate. Aaps Journal 16, 
452-463 (2014). 
97. Lambert, J.M. & Berkenblit, A. Antibody-Drug Conjugates for Cancer Treatment. 
Annual Review of Medicine, Vol 69 69, 191-207 (2018). 
98. MHRA. Inspection Enforcement and Standards Division Medicines and Healthcare 
products Regulatory Agency (MHRA) London UK  Rules and Guidance for 
Pharmaceutical Manufacturers and Distributors 2017, (Pharmaceutical Press, a 
publishing division of the Royal Pharmaceutical Society, 66-68, East Smithfield, 
London, E1W 1AW, UK, 2017). 
99. Breckenridge, A. Report of the working party on the addition of drugs to intravenous 
infusion fluids.  (London : Department of Health and Social Security, 1976). 
100. Beaney, A., M. Preparing injectable medicines safely.  (Nursing Times 108 (3), 2012). 
101. National-Health-Service-Pharmaceutical-Quality-Assurance-Committee. Standard 
Protocol for Deriving and Assessment of Stability, Part 1: Aseptic Preparations (Small 
Molecules).  (2017). 
102. National-Health-Service-Pharmaceutical-Quality-Assurance-Committee. Standard 
Protocol for Deriving and Assessment of Stability, Part 2: Aseptic Preparations 
(Biopharmacuticals).  (2017). 
103. Krop, I.E., et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in 
patients with HER2-positive metastatic breast cancer and central nervous system 
metastases: a retrospective, exploratory analysis in EMILIA. Annals of Oncology 26, 
113-119 (2015). 
104. Krop, I.E., et al. Trastuzumab emtansine versus treatment of physician's choice in 
patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): 
final overall survival results from a randomised open-label phase 3 trial. Lancet 
Oncology 18, 743-754 (2017). 
105. ICH. Q2(R1) Validation of Analytical Procedures: Methodology. 
106. Khabar, K.S.A., Siddiqui, S. & Armstrong, J.A. WEHI-13VAR - a stable and sensitive 
variant of WEHI-164 clone-13 fibrosarcoma for tumor-necrosis-factor bioassay. 
Immunology Letters 46, 107-110 (1995). 
107. Austgulen, R., Hammerstrom, J., Espevik, T. & Nissenmeyer, J. Human monocyte 
cytotoxic factor mediates cytolysis of WEHI 164 cells. Cellular Immunology 98, 211-220 
(1986). 
108. Song, M.-Y., et al. Characterization of a novel anti-human TNF-alpha murine 
monoclonal antibody with high binding affinity and neutralizing activity. Experimental 
and Molecular Medicine 40, 35-42 (2008). 
109. Tawede, S., A. Particulate Matter in Injectables: Main cause for Recalls. in Journal of 
Pharmacovigilance, Vol. 3 (2015). 
110. BP. British Pharmacopoeia Appendix XIII Addendum 1996 - Particulate contamination.  
(1996). 
111. Sreedhara, A., et al. Stability of IgG1 monoclonal antibodies in intravenous infusion 




112. Psathas, P.A., Kuzmission, A., Ikeda, K. & Yasuo, S. Stability of Doripenem in Vitro in 
Representative Infusion Solutions and Infusion Bags. Clinical Therapeutics 30, 2075-
2087 (2008). 
113. Lebitasy, M., Hecq, J.D., Vanbeckbergen, D., Jamart, J. & Galanti, L. Long-term stability 
of tramadol hydrochloride and droperidol mixture in 5% dextrose infusion polyolefin 
bags at 5 +/- 3 degrees C. Annales Pharmaceutiques Francaises 67, 272-277 (2009). 
114. Karbownik, A., et al. The physical and chemical stability of cisplatin (Teva) in 
concentrate and diluted in sodium chloride 0.9%. Wspolczesna Onkologia-
Contemporary Oncology 16, 435-439 (2012). 
115. Nissen, K.B., Jorgensen, L.B., Berg, D.L. & Andersen, G. Stability study of methotrexate 
in 0.9% sodium chloride injection and 5% dextrose injection with limit tests for 
impurities. American Journal of Health-System Pharmacy 74, E211-E223 (2017). 
116. Spindeldreier, K.C., Thiesen, J. & Kraemer, I. Physicochemical stability of cabazitaxel 
containing premix solution and diluted infusion solutions. European Journal of Hospital 
Pharmacy-Science and Practice 22, 260-266 (2015). 
5.4. Paul, M., Vieillard, V., Lemos, R.D., Escalup, L. & Astier, A. Long-term physico-chemical 
stability of diluted trastuzumab. International Journal of Pharmaceutics 448, 101-104 
(2013). 
118. Lazzarini, R., et al. Physicochemical stability of cabazitaxel and docetaxel solutions. 
European Journal of Hospital Pharmacy-Science and Practice 22, 150-155 (2015). 
119. Joshi, V.S., Kumar, V. & Rathore, A.S. Enhanced product understanding in the QbD 
paradigm: linkage between charge heterogeneity and stability of monoclonal antibody 
therapeutic products. Journal of Chemical Technology and Biotechnology 93, 2102-
2110 (2018). 
120. Leblanc, Y., Ramon, C., Bihoreau, N. & Chevreux, G. Charge variants characterization of 
a monoclonal antibody by ion exchange chromatography coupled on-line to native 
mass spectrometry: Case study after a long-term storage at+5 degrees C. Journal of 
Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 1048, 
130-139 (2017). 
121. Parekh, B.S., et al. Correlating charge heterogeneity data generated by agarose gel 
isoelectric focusing and ion exchange chromatography methods. Journal of 
Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 1073, 1-
9 (2018). 
122. Kantner, T. & Watts, A.G. Characterization of Reactions between Water-Soluble 
Trialkylphosphines and Thiol Alkylating Reagents: Implications for Protein-Conjugation 
Reactions. Bioconjugate Chemistry 27, 2400-2406 (2016). 
123. Paul, M., Vieillard, V., Jaccoulet, E. & Astier, A. Long-term stability of diluted solutions 
of the monoclonal antibody rituximab. International Journal of Pharmaceutics 436, 
282-290 (2012). 
124. Glover, Z.W.K., et al. Compatibility and stability of pertuzumab and trastuzumab 
admixtures in i.v. infusion bags for coadministration. Journal of Pharmaceutical 
Sciences 102, 794-812 (2013). 
125. Hernandez-Jimenez, J., et al. The Effects of Light-Accelerated Degradation on the 
Aggregation of Marketed Therapeutic Monoclonal Antibodies Evaluated by Size-
Exclusion Chromatography With Diode Array Detection. Journal of Pharmaceutical 
Sciences 105, 1405-1418 (2016). 
126. Kumru, O.S., et al. Compatibility, physical stability, and characterization of an IgG4 
monoclonal antibody after dilution into different intravenous administration bags. 
Journal of Pharmaceutical Sciences 101, 3636-3650 (2012). 
276 
 
127. Kalonia, C., et al. Calculating the Mass of Subvisible Protein Particles with Improved 
Accuracy Using Microflow Imaging Data. Journal of Pharmaceutical Sciences 104, 536-
547 (2015). 
128. Randolph, T.W., et al. Do Not Drop: Mechanical Shock in Vials Causes Cavitation, 
Protein Aggregation, and Particle Formation. Journal of Pharmaceutical Sciences 104, 
602-611 (2015). 
129. Telikepalli, S., et al. Characterization of the Physical Stability of a Lyophilized IgG1 mAb 
after Accelerated Shipping-Like Stress. Journal of Pharmaceutical Sciences 104, 495-
507 (2015). 
130. Cordes, A.A., Carpenter, J.F. & Randolph, T.W. Accelerated Stability Studies of 
Abatacept Formulations: Comparison of Freeze-Thawing- and Agitation-Induced 
Stresses. Journal of Pharmaceutical Sciences 101, 2307-2315 (2012). 
131. Vlieland, N.D., et al. The Impact of Inadequate Temperature Storage Conditions on 
Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha 
Inhibitors. Pharmaceutical Research 35(2018). 
132. Vasudev, R., Mathew, S. & Afonina, N. Characterization of Submicron (0.1-1 mu m) 
Particles in Therapeutic Proteins by Nanoparticle Tracking Analysis. Journal of 
Pharmaceutical Sciences 104, 1622-1631 (2015). 
133. Patois, E., Capelle, M.A.H., Palais, C., Gurny, R. & Arvinte, T. Evaluation of nanoparticle 
tracking analysis (NTA) in the characterization of therapeutic antibodies and seasonal 
influenza vaccines: pros and cons. Journal of Drug Delivery Science and Technology 22, 
427-433 (2012). 
134. Tian, X.S., et al. A Comprehensive Evaluation of Nanoparticle Tracking Analysis 
(NanoSight) for Characterization of Proteinaceous Submicron Particles. Journal of 
Pharmaceutical Sciences 105, 3366-3375 (2016). 
135. Castellanos, M.M., Howell, S.C., Gallagher, D.T. & Curtis, J.E. Characterization of the 
NISTmAb Reference Material using small-angle scattering and molecular simulation. 
Analytical and Bioanalytical Chemistry 410, 2141-2159 (2018). 
136. Davies, A.M., Rispens, T., Ooijevaar-de Heer, P., Aalberse, R.C. & Sutton, B.J. Room 
temperature structure of human IgG4-Fc from crystals analysed in situ. Molecular 
Immunology 81, 85-91 (2017). 
137. Harris, L.J., Skaletsky, E. & McPherson, A. Crystallographic structure of an intact IgG1 
monoclonal antibody. Journal of Molecular Biology 275, 861-872 (1998). 
138. Saphire, E.O., et al. Contrasting IgG structures reveal extreme asymmetry and 
flexibility. Journal of Molecular Biology 319, 9-18 (2002). 
139. Singh, S.M., Bandi, S., Jones, D.N.M. & Mallela, K.M.G. Effect of Polysorbate 20 and 
Polysorbate 80 on the Higher-Order Structure of a Monoclonal Antibody and Its Fab 
and Fc Fragments Probed Using 2D Nuclear Magnetic Resonance Spectroscopy. Journal 
of Pharmaceutical Sciences 106, 3486-3498 (2017). 
140. Kiss, R., Fizil, A. & Szantay, C. What NMR can do in the biopharmaceutical industry. 
Journal of Pharmaceutical and Biomedical Analysis 147, 367-377 (2018). 
141. Brinson, R.G., et al. Application of 2D-NMR with room temperature NMR probes for 
the assessment of the higher order structure of filgrastim. Journal of Pharmaceutical 
and Biomedical Analysis 141, 229-233 (2017). 
142. Frueh, D.P., Goodrich, A.C., Mishra, S.H. & Nichols, S.R. NMR methods for structural 
studies of large monomeric and multimeric proteins. Current Opinion in Structural 
Biology 23, 734-739 (2013). 
143. Biswas, A., Ranjan, D., Zubair, M. & He, J. A Novel Computational Method for Deriving 
Protein Secondary Structure Topologies Using Cryo-EM Density Maps and Multiple 
Secondary Structure Predictions. Bioinformatics Research and Applications (Isbra 2015) 
9096, 60-71 (2015). 
277 
 
144. Bokori-Brown, M., et al. Cryo-EM structure of lysenin pore elucidates membrane 
insertion by an aerolysin family protein. Nature Communications 7(2016). 
145. Fibriansah, G., et al. Cryo-EM structure of an antibody that neutralizes dengue virus 
type 2 by locking E protein dimers. Science 349, 88-91 (2015). 
146. Long, F., et al. Cryo-EM structures elucidate neutralizing mechanisms of anti-
chikungunya human monoclonal antibodies with therapeutic activity. Proceedings of 
the National Academy of Sciences of the United States of America 112, 13898-13903 
(2015). 
147. Wang, R.Y.R., et al. De novo protein structure determination from near-atomic-
resolution cryo-EM maps. Nature Methods 12, 335-U384 (2015). 
148. Mason, B.I., Schoneich, C. & Kerwin, B.A. Effect of pH and Light on Aggregation and 
Conformation of an IgG1 mAb. Molecular Pharmaceutics 9, 774-790 (2012). 
149. Sousa, F., Sarrnento, B. & Neves-Petersen, M.T. Biophysical study of bevacizumab 
structure and bioactivity under thermal and pH-stresses. European Journal of 
Pharmaceutical Sciences 105, 127-136 (2017). 
150. Wang, S.J., et al. Stabilizing two IgG1 monoclonal antibodies by surfactants: Balance 
between aggregation prevention and structure perturbation. European Journal of 
Pharmaceutics and Biopharmaceutics 114, 263-277 (2017). 
151. Lim, J.Y., Kim, N.A., Lim, D.G., Kim, K.H. & Jeong, S.H. Effects of thermal and mechanical 
stress on the physical stability of human growth hormone and epidermal growth 
factor. Archives of Pharmacal Research 38, 1488-1498 (2015). 
152. Durowoju, I.B., Bhandal, K.S., Hu, J., Carpick, B. & Kirkitadze, M. Differential Scanning 
Calorimetry - A Method for Assessing the Thermal Stability and Conformation of 
Protein Antigen. Jove-Journal of Visualized Experiments (2017). 
153. Kubelka, J., Pancoska, P. & Keiderling, T.A. Novel use of a static modification of two-
dimensional correlation analysis. Part II: Hetero-spectral correlations of protein 
Raman, FT-IR, and circular dichroism spectra. Applied Spectroscopy 53, 666-671 (1999). 
154. Buddanavar, A.T. & Nandibewoor, S.T. Multi-spectroscopic characterization of bovine 
serum albumin upon interaction with atomoxetine. Journal of Pharmaceutical Analysis 
7, 148-155 (2017). 
155. Rahmelow, K. & Hubner, W. Secondary structure determination of proteins in aqueous 
solution by infrared spectroscopy: A comparison of multivariate data analysis 
methods. Analytical Biochemistry 241, 5-13 (1996). 
156. Zangooei, M.H. & Jalili, S. Protein secondary structure prediction using DWKF based on 
SVR-NSGAII. Neurocomputing 94, 87-101 (2012). 
157. Zhang, Y. & Sagui, C. Secondary structure assignment for conformationally irregular 
peptides: Comparison between DSSP, STRIDE and KAKSI. Journal of Molecular Graphics 
& Modelling 55, 72-84 (2015). 
158. ICH. Stability testing of Biotechnological/Biological products Q5C.  (Online, 1996). 
159. Sadavarte, R.H. & Ghosh, R. A Thermal-Cycling Method for Disaggregating Monoclonal 
Antibody Oligomers. Journal of Pharmaceutical Sciences 103, 870-878 (2014). 
160. Wang, B., Cicerone, M.T., Aso, Y. & Pikal, M.J. The Impact of Thermal Treatment on the 
Stability of Freeze-Dried Amorphous Pharmaceuticals: II. Aggregation in an IgG1 Fusion 
Protein. Journal of Pharmaceutical Sciences 99, 683-700 (2010). 
161. Coussot, G., Le Postollec, A., Faye, C. & Dobrijevic, M. A gold standard method for the 
evaluation of antibody-based materials functionality: Approach to forced degradation 
studies. Journal of Pharmaceutical and Biomedical Analysis 152, 17-24 (2018). 
162. Shah, D.D., Zhang, J.M., Maity, H. & Mallela, K.M.G. Effect of photo-degradation on the 
structure, stability, aggregation, and function of an IgG1 monoclonal antibody. 
International Journal of Pharmaceutics 547, 438-449 (2018). 
278 
 
163. Singh, S.R., et al. Effect of Polysorbate 80 Quality on Photostability of a Monoclonal 
Antibody. Aaps Pharmscitech 13, 422-430 (2012). 
164. Bane, J., et al. Photo-oxidation of IgG1 and Model Peptides: Detection and Analysis of 
Triply Oxidized His and Trp Side Chain Cleavage Products. Pharmaceutical Research 34, 
229-242 (2017). 
165. Zamani, L., Andersson, F.O., Edebrink, P., Yang, Y. & Jacobsson, S.P. Conformational 
studies of a monoclonal antibody, IgG1, by chemical oxidation: Structural analysis by 
ultrahigh-pressure LC-electrospray ionization tune-of-flight MS and multivariate data 
analysis. Analytical Biochemistry 380, 155-163 (2008). 
166. Usami, A., Ohtsu, A., Takahama, S. & Fujii, T. Effect of pH, hydrogen peroxide and 
temperature on the stability of human monoclonal antibody. Journal of 
Pharmaceutical and Biomedical Analysis 14, 1133-1140 (1996). 
167. Young, B.L., et al. Evaluation of the physicochemical and functional stability of diluted 
REMSIMA upon extended storage-A study compliant with NHS (UK) guidance. in Int J 
Pharm (2015 The Authors. Published by Elsevier B.V, 2015). 
168. Cockrell, G.M., Wolfe, M.S., Wolfe, J.L. & Schoneich, C. Photoinduced Aggregation of a 
Model Antibody-Drug Conjugate. Molecular Pharmaceutics 12, 1784-1797 (2015). 
169. Brockhoff, G., et al. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on 
BT474 and SK-BR-3 breast cancer cell proliferation. Cell Proliferation 40, 488-507 
(2007). 
170. Sumikawa, T., et al. Dexamethasone interferes with trastuzumab-induced cell growth 
inhibition through restoration of AKT activity in BT-474 breast cancer cells. 
International Journal of Oncology 32, 683-688 (2008). 
171. Vanslooten, H.J., et al. Outgrowth of bt-474 human breast-cancer cells in immune-
deficient mice - a new in-vivo model for hormone-dependent breast-cancer. British 
Journal of Cancer 72, 22-30 (1995). 
172. Lasfargues, E.Y., Coutinho, W.G. & Dion, A.S. Human-breast tumor-cell line (bt-474) 
that supports mouse mammary-tumor virus-replication. In Vitro-Journal of the Tissue 
Culture Association 15, 723-729 (1979). 
173. Wakankar, A., Chen, Y., Gokarn, Y. & Jacobson, F.S. Analytical methods for 
physicochemical characterization of antibody drug conjugates. Mabs 3, 161-172 
(2011). 
174. Goswami, S., Wang, W., Arakawa, T. & Ohtake, S. Developments and Challenges for 
mAb-Based Therapeutics. Antibodies 2, 452-500 (2013). 
175. Klein, M., Rivera, B. & McGinley, M. Analysis of Antibody Drug Conjugates using 
High  Efficiency Gel Filtration Columns   (TN 5.45).  (Phenomenex, 2015). 
176. Pinho, S.P. & Macedo, E.A. Solubility of NaCl, NaBr, and KCI in water, methanol, 
ethanol, and their mixed solvents. Journal of Chemical and Engineering Data 50, 29-32 
(2005). 
177. Renn, C.N. & Synovec, R.E. Effect of temperature on separation efficiency for high-
speed size exclusion chromatography. Analytical Chemistry 64, 479-484 (1992). 
178. Hong, P., Koza, S. & Bouvier, E.S.P. A review size-exclusion chromatography for the 
analysis of protein biotherapeutics and their aggregates. Journal of Liquid 
Chromatography & Related Technologies 35, 2923-2950 (2012). 
179. Kabsch, W. & Sander, C. Dictionary of protein secondary structure - pattern-
recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577-2637 
(1983). 
180. Frishman, D. & Argos, P. Knowledge-based protein secondary structure assignment. 
Proteins-Structure Function and Genetics 23, 566-579 (1995). 
181. Martin, J., et al. Protein secondary structure assignment revisited: a detailed analysis 
of different assignment methods. Bmc Structural Biology 5(2005). 
279 
 
182. Park, S.Y., Yokoyama, T., Shibayama, N., Shiro, Y. & Tame, J.R.H. 1.25 angstrom 
resolution crystal structures of human haemoglobin in the oxy, deoxy and 
carbonmonoxy forms. Journal of Molecular Biology 360, 690-701 (2006). 
183. Barends, T.R.M., et al. Direct observation of ultrafast collective motions in CO 
myoglobin upon ligand dissociation. Science 350, 445-450 (2015). 
184. Majorek, K.A., et al. Structural and immunologic characterization of bovine, horse, and 
rabbit serum albumins. Molecular Immunology 52, 174-182 (2012). 
185. Berglund, G.I., et al. The catalytic pathway of horseradish peroxidase at high 
resolution. Nature 417, 463-468 (2002). 
186. Sugahara, M., et al. Hydroxyethyl cellulose matrix applied to serial crystallography. 
Scientific Reports 7(2017). 
187. Maurady, A., Zdanov, A., de Moissac, D., Beaudry, D. & Sygusch, J. A conserved 
glutamate residue exhibits multifunctional catalytic roles in D-fructose-1,6-
bisphosphate aldolases. Journal of Biological Chemistry 277, 9474-9483 (2002). 
188. Chruszcz, M., Wlodawer, A. & Minor, W. Determination of protein structures - A series 
of fortunate events. Biophysical Journal 95, 1-9 (2008). 
189. Purwar, N., McGarry, J.M., Kostera, J., Pacheco, A.A. & Schmidt, M. Interaction of Nitric 
Oxide with Catalase: Structural and Kinetic Analysis. Biochemistry 50, 4491-4503 
(2011). 
190. Koch, C., Neumann, P., Valerius, O., Feussner, I. & Ficner, R. Crystal Structure of 
Alcohol Oxidase from Pichia pastoris. Plos One 11(2016). 
191. Wohlfahrt, G., et al. 1.8 and 1.9 angstrom resolution structures of the Penicillium 
amagasakiense and Aspergillus niger glucose oxidases as a basis for modelling 
substrate complexes. Acta Crystallographica Section D-Biological Crystallography 55, 
969-977 (1999). 
192. Raj, S.B., Ramaswamy, S. & Plapp, B.V. Yeast Alcohol Dehydrogenase Structure and 
Catalysis. Biochemistry 53, 5791-5803 (2014). 
193. Vergara, A., Caterino, M. & Merlino, A. Raman-markers of X-ray radiation damage of 
proteins. International Journal of Biological Macromolecules 111, 1194-1205 (2018). 
194. Transue, T.R., Krahn, J.M., Gabel, S.A., DeRose, E.F. & London, R.E. X-ray and NMR 
characterization of covalent complexes of trypsin, borate, and alcohols. Biochemistry 
43, 2829-2839 (2004). 
195. Parkin, S., Rupp, B. & Hope, H. Atomic resolution structure of concanavalin A at 120 K. 
Acta Crystallographica Section D-Biological Crystallography 52, 1161-1168 (1996). 
196. Bruker-Optik-GMbH. OPUS Spectroscopy software Version 7 User Manual QUANT.  
(Bruker, 2011). 
197. Kim, M.T., Chen, Y., Marhoul, J. & Jacobson, F. Statistical Modeling of the Drug Load 
Distribution on Trastuzumab Emtansine (Kadcyla), a Lysine-Linked Antibody Drug 
Conjugate. Bioconjugate Chemistry 25, 1223-1232 (2014). 
198. Quiles, S., Raisch, K.P., Sanford, L.L., Bonner, J.A. & Safavy, A. Synthesis and Preliminary 
Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-
Targeted Chemotherapy. Journal of Medicinal Chemistry 53, 586-594 (2010). 
199. Hamblett, K.J., et al. Effects of drug loading on the antitumor activity of a monoclonal 
antibody drug conjugate. Clinical Cancer Research 10, 7063-7070 (2004). 
200. Dieras, V., et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients 
with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive 
analysis of final overall survival results from a randomised, open-label, phase 3 trial. 
Lancet Oncology 18, 732-742 (2017). 
201. The Lancet. Trastuzumab emtansine and cost-based decision making (vol 389, pg 2, 
2017). Lancet 389, E2-E2 (2017). 
280 
 
202. Factsheet: Freeflex: The Innovative IV-Bag. Fresenius Kabi UK, Runcorn, 
Ches.  Available at:  http://www.freseniuskabi-productpartnering.com/files 
/Factsheet_5_Freeflex.pdf  
203. McLeod, A.G., Walker, I.R., Zheng, S. & Hayward, C.P.M. Loss of factor VIII activity 
during storage in PVC containers due to adsorption. Haemophilia 6, 89-92 (2000). 
204. Hill, H.R., Oliver, C.K., Lippert, L.E., Greenwalt, T.J. & Hess, J.R. The effects of polyvinyl 
chloride and polyolefin blood bags on red blood cells stored in a new additive solution. 
Vox Sanguinis 81, 161-166 (2001). 
205. Jin, S.E., Jeon, S., Byon, H.J. & Hwang, S.J. Evaluation of tacrolimus sorption to PVC- 
and non-PVC-based tubes in administration sets: Pump method vs. drip method. 
International Journal of Pharmaceutics 528, 172-179 (2017). 
206. Langille, S.E. Particulate matter in injectable drug products. PDA journal of 
pharmaceutical science and technology 67, 186-200 (2013). 
207. Murtough, S.H., S. Palmer, M. Russell, A. A survey of disinfectant use in hospital 
pharmacy aseptic preparation areas. Vol. 264 (Pharmacutical Journal, Pharmacutical 
Journal, 2000). 
208. Hunt, J. Decontamination of Medical Devices, Infection Prevention and Control Policy: 
Appendix 12 - Version 3.  (2017). 
209. Erickson, H.K., et al. Antibody-maytansinoid conjugates are activated in targeted 
cancer cells by lysosomal degradation and linker-dependent intracellular processing. 
Cancer Research 66, 4426-4433 (2006). 
210. Kovtun, Y.V., et al. Antibody-drug conjugates designed to eradicate tumors with 
homogeneous and heterogeneous expression of the target antigen. Cancer Research 
66, 3214-3221 (2006). 
211. Valliere-Douglass, J.F., Lewis, P., Salas-Solano, O. & Jiang, S. Solid-State mAbs and ADCs 
Subjected to Heat-Stress Stability Conditions can be Covalently Modified with Buffer 
and Excipient Molecules. Journal of Pharmaceutical Sciences 104, 652-665 (2015). 
212. Adem, Y.T., et al. Auristatin Antibody Drug Conjugate Physical Instability and the Role 
of Drug Payload. Bioconjugate Chemistry 25, 656-664 (2014). 
213. Schonberger, S., et al. Brentuximab vedotin exerts profound antiproliferative and pro-
apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell 
tumour cell lines. Journal of Cellular and Molecular Medicine 22, 568-575 (2018). 
214. Zuo, S.B., T. Babu, S. Measuring Drug-to-Antibody Ratio (DAR) for Antibody-Drug 
Conjugates (ADCs) with UHPLC/Q-TOF.  (2016). 
215. Li, H., Han, T.H., Hunder, N.N., Jang, G. & Zhao, B.T. Population Pharmacokinetics of 
Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies. 
Journal of Clinical Pharmacology 57, 1148-1158 (2017). 
216. Debaene, F., et al. Innovative Native MS Methodologies for Antibody Drug Conjugate 
Characterization: High Resolution Native MS and IM-MS for Average DAR and DAR 
Distribution Assessment. Analytical Chemistry 86, 10674-10683 (2014). 
217. Sochaj, A.M., Swiderska, K.W. & Otlewski, J. Current methods for the synthesis of 
homogeneous antibody-drug conjugates. Biotechnology Advances 33, 775-784 (2015). 
218. Lhospice, F., et al. Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 
Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. 
Molecular Pharmaceutics 12, 1863-1871 (2015). 
219. Sassoon, I. & Blanc, V. Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review. 
Antibody-Drug Conjugates 1045, 1-27 (2013). 
220. ICH. Quality of biotechnological products:  Stability testing of biotechnological / 
biological   products   Q5C (1995). 
221. ICH. Specifications: Test Procedures and Acceptance Criteria for New Drug Substances 
and New Drug Products: Biotechnological/Biological Products Q6B.  (Online, 1999). 
281 
 
222. ICH. Stability testing of new drug substances and products Q1A (R2).  (Online, 2003). 
223. NHS England. Pharmacy Aseptic Services Review: Summary of Key Findings. (Online 
2018) 
224. Amin, S., et al. Protein aggregation, particle formation, characterization & rheology. 
Current Opinion in Colloid & Interface Science 19, p438-449 (2014). 
225. Ahmadi, M., et al. Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic 
Potential of Monoclonal Antibody Therapeutics. Pharmacuetical Research 32, p1383-
1394 (2015). 
226. Davydova, N., et al. The VD1 Neutralizing Antibody to Vascular Endothelial Growth 
Factor-D: Binding Epitope and Relationship to Receptor Binding. Journal of Molecular 
Biology 407, p581-593 (2011). 
227.  Fu, X., et al. Hla-Dr-Alpha Chain Residues Located On The Outer Loops Are Involved In 
Nonpolymorphic And Polymorphic Antibody-Binding Epitopes 39. p253-260 (1994). 
228. Tan, YH., et al. A Nanoengineering Approach for Investigation and Regulation of Protein 
Immobilization. American Chemical Society Nano 2. p2374-2384 (2008). 
229. Ikeda, R., et al. Stability of Infliximab in polyvinylchloride bags. American Journal of 
Health-System Pharmacy 69, 1509-1512 (2012). 
230. Alley, SC., et al. Contribution of Linker Stability to the Activities of Anticancer 
Immunoconjugates. Bioconjugate Chemistry 19, p759-765 (2008). 
231. Li, J., et al. Analysis of phthalates via HPLC-UV in environmental water samples after 
concentration by solid-phase extraction using ionic liquid mixed hemimicelles. Talanta 
74, p498–504 (2008). 
232. Guo, Z., Wei, D., Wang, M., Wang, S. Determination of Six Phthalic Acid Esters in Orange 
Juice Packaged by PVC Bottle Using SPE and HPLC–UV. Journal of Chromatographic 
Science 48, p760-765 (2009). 
233. Beckley, NS., et al. Investigation into Temperature-Induced Aggregation of an Antibody 
Drug Conjugate. Bioconjugate Chemistry 24, p1674-1683 (2013). 
234. Arakawa, T., et al. Biophysical characterization of a model antibody drug conjugate. Drug 
Discoveries and Therapeutics 10, p211-217 (2016). 
235. Ricker, RD., Sandoval, LA., Fast, reproducible size-exclusion chromatography of 
biological macromolecules. Journal of Analytical Chromatography 743, p43-50 (1996). 
236. Napp Pharmaceuticals Limited., Remsima 100 mg powder for concentrate for solution 
for infusion – SmPC. Electronic Medicines Compendium. [Accessed on: 14/03/2019] 
https://www.medicines.org.uk/emc/product/3709#DOCREVISION. 
237. Bee, JS., et al, Effects of Surfaces and Leachables on the Stability of Biopharmaceuticals. 
Journal of Pharmaceutical Sciences 100, p4158-4170 (2011) 
238. Oliveira, R., et al, Understanding Adhesion: A Means for Preventing Fouling. 
Experimental Thermal and Fluidic Science 14, p316-322 (1997) 
239. Lameiras, F.S., et al, Measurement of the zeta potential of planar surfaces with a 
rotating disk. Materials Research 11, p217-219 (2008) 
240. McAuley, A., et al, Modulation of Protein Adsorption by Poloxamer 188 in Relation to 
Polysorbates 80 and 20 at Solid Surfaces. Journal of Pharmaceutical Sciences 103, p1043-
1049 (2014) 
241. Petrul, H., et al. In vitro and in vivo efficacy of the anti-MN immunoconjugate BAY 79-
4620, MN-IC, in MN (CAIX) expressing preclinical tumor models. Experimental and 
Molecular Therapeutics 70, p2577-2577 (2011) 
282 
 
242. Hospira. Vincristine Sulphate Injection Safety Data Sheet. Pfizer MSDS Archive. 2016. 
Accessed from: https://www.pfizer.com/sites/default/files/products/material_safety_ 
data/Vincristine_Sulfate_Injection(Hospira)_13-Sep-2016_0.pdf Accessed on: 20/03/19 
243. Vermeer, AWP., et al.  The thermal stability of immunoglobulin: Unfolding and 
aggregation of a multi-domain protein. Biophysical Journal 78, p394-404 (2000) 
244. Hanahan, D., Weinberg, R.A., Hallmarks of Cancer: The Next Generation. Cell 144, p646-
674 (2011) 
245. Neubauer, A., Wollmer, E., Side Effects of tumor pharmacotherapy. Der Internist 52, 
p1429-1446 (2011) 
246. van der Kuip, H., et al. Mechanisms of clinical resistance to small molecule tyrosine 
kinase inhibitors targeting oncogenic tyrosine kinases. American Journal of 
Pharmacogenomics 5, p101-112 (2005) 
247. Rosa, D.D., Ismael, G., Lago, L.D., Awada, A., Molecular-targeted therapies: Lessons from 
years of clinical development. Cancer Treatment Reviews 34, p61-80 (2008) 
248. Saijo, N., Present Status and Problems on Molecular Targeted Therapy of Cancer. Cancer 
Research and Treatment 44, p1-10 (2012) 
249. Schroeder, H.W., Cavacini, L., Structure and Function of Immunoglobulins. Journal of 
Allergy and Clinical Immunology 125, p41-52 (2010) 
250. Alberts, B., Johnson, A., Lewis, J., et al. Molecular Biology of the Cell. 4th edition. Garland 
Science. (2002) 
251. Meyer, S,. et al. Regulation of complement and modulation of its activity in monoclonal 
antibody therapy of cancer. MABs 6, p1133-1144 (2014) 
252. Seidel, U.J., et al. Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity 
in Tumor Immunotherapy with Therapeutic Antibodies. Frontiers in Immunology 4, 
(2013) 
253. Vidarsson, G., et al. IgG Subclasses and Allotypes: From Structure to Effector Functions 
Frontiers in Immunology 5, (2014) 
254. Tiezheng, L., et al. Modulating IgG effector function by Fc glycan engineering. 
Proceedings of the National Academy of Sciences of the United States of America 114, 
p3485-3490 (2017) 
255. Hafeez, U., Gan, H.K., Scott, A.M., Monoclonal antibodies as immunomodulatory 
therapy against cancer and autoimmune diseases. Current Opinion in Pharmacology 41, 
p114-121 (2018) 
256. Trotman, J., et al. Prognostic value of end-of-induction PET response after first-line 
immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a 
randomised, phase 3 trial. Lancet  Oncology 19, p1530-1542 (2018) 
257. Joint Formulary Committee. British National Formulary London: Pharmaceutical Press 
and BMJ Group     <http://www.medicinescomplete.com>     [Accessed on 26/03/2019] 
258. Reslan, L., et al, Understanding and circumventing resistance to anticancer monoclonal 
antibodies. MAbs 1, p222-229 (2009) 
259. Rubleski, J., Prescription Drug Prices Will Drive Health Insurance Premium Increases in 
2017. Seidman Business Review 23, p9-10 (2017) 
260. Romley, J.A., et al. Survey Results Show That Adults Are Willing To Pay Higher Insurance 
Premiums For Generous Coverage Of Specialty Drugs. Health Affairs 31, P683-690 (2012) 
283 
 
261. Mulero, P., et al. Ocrelizumab: a new milestone in multiple sclerosis therapy. 
Therapeutic Advances in Neurological Disorders 11, p1-10 (2018) 
262. Salles, G., et al, Atezolizumab in Combination with Obinutuzumab and Lenalidomide 
Demonstrates Favorable Activity and Manageable Toxicity in Patients with 
Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial. 
Blood 132, p1603 (2018) 
263. Hawe, A., et al, Forced Degradation of Therapeutic Proteins. Journal of Pharmaceutical 
Sciences 101, p895-913 (2012) 
234. Wang, W., et al. Protein aggregation—Pathways and influencing factors. International 
Journal of Pharmaceutics 390, p89-99 (2010) 
265. Schmid, I., et al. Assessment of susceptible chemical modification sites of trastuzumab 
and endogenous human immunoglobulins at physiological conditions. Communication 
Biology 1, p1-10 (2018) 
266. Yan, Q., et al. Structure Based Prediction of Asparagine Deamidation Propensity in 
Monoclonal Antibodies. mAbs 10, p901-912 (2017) 
267. Gerhardt, A., et al. Surfactant Effects on Particle Generation in Antibody Formulations 
in Pre-filled Syringes. Journal of Pharmaceutical Science 104, p4056-4064 (2015) 
268. Wang, W., et al. Antibody structure, instability, and formulation. Journal of 
Pharmaceutical Sciences 96, p1-26 (2006) 
269. Mesink, M.A., et al.  How sugars protect proteins in the solid state and during drying 
(review): Mechanisms of stabilization in relation to stress conditions. European Journal 
of Pharmaceutics and Biopharmaceutics 114, p288-295 (2017) 
270. Wakankar, A.A., et al. The effect of cosolutes on the isomerization of aspartic acid 
residues and conformational stability in a monoclonal antibody. Journal of 
Pharmaceutical Sciences 96, p1708-1718 (2007) 
271. Motomiya, Y., et al.  An in vitro evaluation of the glycation potential of a natural 
disaccharide, trehalose. Journal of Clinical and Experimental Nephrology 7, p195-200 
(2003) 
272. Wei, B., et al. Glycation of antibodies: Modification, methods and potential effects on 
biological functions. mAbs 9, p586-594 (2017) 
273. Zheng, K., et al. Characterization of Ring-Opening Reaction of Succinimide Linkers in 
ADCs. Journal of Pharmaceutical Sciences 108, p133-141 (2019) 
274. Tsuchikama, K., et al. Antibody-drug conjugates: recent advances in conjugation and 
linker chemistries. Protein Cell 9, p33-46 (2018) 
275. Lyon. R.P., et al. Self-hydrolyzing maleimides improve the stability and pharmacological 
properties of antibody-drug conjugates. Nature Biotechnology 32, p1059-1062 (2014) 
276. Vijayan, S., et al. Establishment of the first at-home natalizumab infusion service for the 
treatment of relapsing remitting multiple sclerosis. Journal of Neurology, Neurosurgery 
and Psychiatry 88, (2017) 
277. Orange, J.S., Improved clinical outcomes for patients receiving immunoglobulin therapy 
through speciality pharmacy or home infusion services. Annals of Allergy, Asthma & 
Immunology 115, p18 (2015) 
278. Bach, P.B., et al. Overspending driven by oversized single dose vials of cancer drugs. The 
Bristish Medical Journal 352, (2016) 
284 
 
279. Fuentes, S., et al.  Why is intravenous chemotherapy cancelled and how often? Could it 






Appendix I: Abatacept size exclusion chromatography method validation data 
 
Figure 1A. Size exclusion linearity plot for abatacept. 
 









Table 1A. Repeat injection precision for abatacept. 
 
Figure 1B. SEC chromatogram overlay of abatacept control (Blue) and Photolytically degraded (Green). 



























Appendix II: Rituximab size exclusion chromatography method validation data 
 
Figure 2A. Size exclusion linearity plot for abatacept. 
 









Table 2A. Repeat injection precision for rituximab. 
 
Figure 2B. SEC chromatogram overlay of rituximab control (Black) and base hydrolysed (Blue). The X-

























Appendix III: Trastuzumab size exclusion chromatography method validation data 
 
Figure 3A. Size exclusion linearity plot for trastuzumab. 
 









Table 3A. Repeat injection precision for abatacept. 
 
Figure 3B. SEC chromatogram overlay of trastuzmab control (Black) and base hydrolysed (Blue). The X-


























Appendix IV: Infliximab (Remsima) representative sample photographs 
 











Appendix V: Trastuzumab emtansine (Kadcyla) representative sample photographs 
 
 







Figure 5B. Day 24 sample photographs. 
